PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20737414-9	2011	A reverse transcription-polymerase chain reaction analysis, nevertheless, revealed developmental stage-dependent expression of mRNAs encoding SULT3 ST1 and SULT3 ST3, two enzymes previously shown to be capable of sulfating dextrorphan, an active metabolite of dextromethorphan.	Dextromethorphan	260-276	sulfotransferase family 3, cytosolic sulfotransferase 1	Danio rerio	142-151
20737414-9	2011	A reverse transcription-polymerase chain reaction analysis, nevertheless, revealed developmental stage-dependent expression of mRNAs encoding SULT3 ST1 and SULT3 ST3, two enzymes previously shown to be capable of sulfating dextrorphan, an active metabolite of dextromethorphan.	Dextromethorphan	260-276	sulfotransferase family 3, cytosolic sulfotransferase 3	Danio rerio	156-165
21542294-9	2011	The Km and Vmax are 111.36 +/- 10.89 micromol x L(-1) (n=3) and 222.2 +/- 20.12 pmol x nmol(-1) (CYP2D6) x min(-1) (n=3) for CYP2D6*10 to catalyze dextromethorphan.	Dextromethorphan	147-163	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
20881352-10	2011	In the caruncles, the Clone and PG groups showed significantly higher GLUT1 and GLUT3 mRNA levels than the SP group, and the GLUT3 mRNA level was significantly higher in the Clone group than in the DEX group.	Dextromethorphan	198-201	solute carrier family 2, facilitated glucose transporter member 3	Bos taurus	125-130
20881352-11	2011	The glucocorticoid receptor alpha mRNA level was significantly lower in the SP group than in the DEX group.	Dextromethorphan	97-100	nuclear receptor subfamily 3 group C member 1	Bos taurus	4-33
21121944-5	2011	The Phase I metabolism of the established marker drugs: midazolam, bupropion and dextromethorphan were measured by LC-MS and confirmed the activities of the 3A, 2B and 2D families of CYP isoforms, respectively.	Dextromethorphan	81-97	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	183-186
21146468-6	2011	The results showed: 1) a subset of IBS patients, but not controls, showed TSSP in response to a series of noxious heat pulses; and 2) TSSP was blocked by administration of dextromethorphan, an NMDA receptor antagonist.	Dextromethorphan	172-188	serine protease 16	Homo sapiens	74-78
21146468-6	2011	The results showed: 1) a subset of IBS patients, but not controls, showed TSSP in response to a series of noxious heat pulses; and 2) TSSP was blocked by administration of dextromethorphan, an NMDA receptor antagonist.	Dextromethorphan	172-188	serine protease 16	Homo sapiens	134-138
21542294-9	2011	The Km and Vmax are 111.36 +/- 10.89 micromol x L(-1) (n=3) and 222.2 +/- 20.12 pmol x nmol(-1) (CYP2D6) x min(-1) (n=3) for CYP2D6*10 to catalyze dextromethorphan.	Dextromethorphan	147-163	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	125-131
21542297-3	2011	Phenotypes of CYP2D6 in all subjects were determined using dextromethorphan as probe drug by HPLC methods.	Dextromethorphan	59-75	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
21403895-7	2011	Additionally, DEX pre-treatment only decreased P-gp expression level without inhibition of NF-kappaB activation, suggesting NF-kappaB independent pathway may also participate in regulating seizure induced P-gp over-expression.	Dextromethorphan	14-17	phosphoglycolate phosphatase	Rattus norvegicus	47-51
21114979-0	2011	Effect of dextromethorphan on human K(v)1.3 channel activity: involvement of C-type inactivation.	Dextromethorphan	10-26	potassium voltage-gated channel subfamily A member 3	Homo sapiens	36-43
21114979-9	2011	Dextromethorphan treatment induced a slight inhibition of peak currents in human K(v)1.2 and K(v)1.3 channels, whereas dextromethorphan profoundly inhibited the steady-state currents of human K(v)1.3 channels compared to K(v)1.2 channel currents.	Dextromethorphan	0-16	potassium voltage-gated channel subfamily A member 2	Homo sapiens	81-88
21114979-9	2011	Dextromethorphan treatment induced a slight inhibition of peak currents in human K(v)1.2 and K(v)1.3 channels, whereas dextromethorphan profoundly inhibited the steady-state currents of human K(v)1.3 channels compared to K(v)1.2 channel currents.	Dextromethorphan	0-16	potassium voltage-gated channel subfamily A member 3	Homo sapiens	93-100
21114979-9	2011	Dextromethorphan treatment induced a slight inhibition of peak currents in human K(v)1.2 and K(v)1.3 channels, whereas dextromethorphan profoundly inhibited the steady-state currents of human K(v)1.3 channels compared to K(v)1.2 channel currents.	Dextromethorphan	0-16	potassium voltage-gated channel subfamily A member 2	Homo sapiens	221-228
21114979-9	2011	Dextromethorphan treatment induced a slight inhibition of peak currents in human K(v)1.2 and K(v)1.3 channels, whereas dextromethorphan profoundly inhibited the steady-state currents of human K(v)1.3 channels compared to K(v)1.2 channel currents.	Dextromethorphan	119-135	potassium voltage-gated channel subfamily A member 3	Homo sapiens	192-199
21114979-10	2011	Dextromethorphan"s action on steady-state currents of human K(v)1.3 channels was in a concentration-dependent manner.	Dextromethorphan	0-16	potassium voltage-gated channel subfamily A member 3	Homo sapiens	60-67
21114979-13	2011	These results indicate that dextromethorphan accelerates C-type inactivation of human K(v)1.3 channels and acts as an open-channel blocker.	Dextromethorphan	28-44	potassium voltage-gated channel subfamily A member 3	Homo sapiens	86-93
21114979-14	2011	These results further suggest the possibility that dextromethorphan-mediated acceleration of C-type inactivation of human K(v)1.3 channels might be one of the cellular bases of dextromethorphan-mediated protection against inflammation-mediated neurodegeneration.	Dextromethorphan	51-67	potassium voltage-gated channel subfamily A member 3	Homo sapiens	122-129
21114979-14	2011	These results further suggest the possibility that dextromethorphan-mediated acceleration of C-type inactivation of human K(v)1.3 channels might be one of the cellular bases of dextromethorphan-mediated protection against inflammation-mediated neurodegeneration.	Dextromethorphan	177-193	potassium voltage-gated channel subfamily A member 3	Homo sapiens	122-129
21228393-9	2011	We suspected that myoclonus was due to dextromethorphan-related symptoms induced by CYP2D6, which primarily metabolizes dextromethorphan.	Dextromethorphan	39-55	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	84-90
21228393-9	2011	We suspected that myoclonus was due to dextromethorphan-related symptoms induced by CYP2D6, which primarily metabolizes dextromethorphan.	Dextromethorphan	120-136	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	84-90
21228393-17	2011	CONCLUSIONS: Myoclonus and other symptoms in this patient may have been caused by a prolonged high concentration of dextromethorphan due to CYP2D6 polymorphisms and drug interactions.	Dextromethorphan	116-132	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	140-146
21198441-2	2011	The specific CYP substrates used in this cocktail assay included phenacetin (CYP1A2), bupropion (CYP2B6), amodiaquine (CYP2C8), tolbutamide (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4/5).	Dextromethorphan	175-191	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-16
21403895-7	2011	Additionally, DEX pre-treatment only decreased P-gp expression level without inhibition of NF-kappaB activation, suggesting NF-kappaB independent pathway may also participate in regulating seizure induced P-gp over-expression.	Dextromethorphan	14-17	phosphoglycolate phosphatase	Rattus norvegicus	205-209
22132117-11	2011	Compared to the DEX/CRH test before the start of the treatment, a considerable and significant increase in all CRH-stimulated ACTH and cortisol parameters could be detected in the second DEX/CRH test.	Dextromethorphan	16-19	corticotropin releasing hormone	Homo sapiens	111-114
22167136-6	2011	The dextromethorphan/dextrorphan (DEM/DEX) metabolic ratios were determined as a sign of inhibitory influences on CYP2D2.	Dextromethorphan	4-20	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	114-120
22132117-11	2011	Compared to the DEX/CRH test before the start of the treatment, a considerable and significant increase in all CRH-stimulated ACTH and cortisol parameters could be detected in the second DEX/CRH test.	Dextromethorphan	16-19	corticotropin releasing hormone	Homo sapiens	111-114
22132117-11	2011	Compared to the DEX/CRH test before the start of the treatment, a considerable and significant increase in all CRH-stimulated ACTH and cortisol parameters could be detected in the second DEX/CRH test.	Dextromethorphan	187-190	corticotropin releasing hormone	Homo sapiens	111-114
22132117-11	2011	Compared to the DEX/CRH test before the start of the treatment, a considerable and significant increase in all CRH-stimulated ACTH and cortisol parameters could be detected in the second DEX/CRH test.	Dextromethorphan	187-190	corticotropin releasing hormone	Homo sapiens	111-114
21083986-7	2010	The immune histochemiscal analysis showed that the expression of BMP4, BMPR-II, Phospho-Smad1 (pSmad1) and ATF-2 in the 1D-BEX, 3D-BEX and 3D-DEX groups was significantly higher than that in the control group (P<0.01).	Dextromethorphan	142-145	bone morphogenetic protein 4	Rattus norvegicus	65-69
20940534-7	2010	Support of CYP2D6 was measured by metabolism of EOMCC (2H-1-benzopyran-3-carbonitrile,7-(ethoxy-methoxy)-2-oxo-(9Cl)), dextromethorphan and bufuralol.	Dextromethorphan	119-135	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	11-17
20940534-9	2010	RESULTS: Compared with WT POR, disease-causing POR mutants A287P and R457H supported no detectable CYP2D6 activity with EOMCC, but A287P supported approximately 25% activity with dextromethorphan and bufuralol.	Dextromethorphan	179-195	cytochrome p450 oxidoreductase	Homo sapiens	47-50
20940534-10	2010	Q153R had increased function with CYP2D6 (128% with EOMCC, 198% with dextromethorphan, 153% with bufuralol).	Dextromethorphan	69-85	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	34-40
21083986-6	2010	RESULTS: The levels of BMP4, BMPR-II and Smad1 mRNA expression were up-regulated in the 1D-BEX, 3D-BEX and 3D-DEX groups compared with those in the control group (P<0.05).	Dextromethorphan	110-113	bone morphogenetic protein 4	Rattus norvegicus	23-27
20456283-6	2010	Islets from DEX rats secreted more insulin in response to increasing concentrations of glucose and other metabolic and non-metabolic stimuli, compared with that in the CTL group.	Dextromethorphan	12-15	insulin	Homo sapiens	35-42
20456283-7	2010	The insulin secretion for the most compounds studied returned to CTL values in DEX(10) islets.	Dextromethorphan	79-82	insulin	Homo sapiens	4-11
20456283-8	2010	Increased insulin secretion correlated well with the augmentation in beta-cell proliferation and mass in DEX rats, and these morphological alterations were normalized in islets from DEX(10) rats.	Dextromethorphan	105-108	insulin	Homo sapiens	10-17
20456283-8	2010	Increased insulin secretion correlated well with the augmentation in beta-cell proliferation and mass in DEX rats, and these morphological alterations were normalized in islets from DEX(10) rats.	Dextromethorphan	182-185	insulin	Homo sapiens	10-17
20456283-9	2010	In parallel, the increased levels of proteins involved in beta-cell proliferation such as Cd2 and Cdk4 observed in DEX islets were also normalized in DEX(10) islets.	Dextromethorphan	115-118	Cd2 molecule	Rattus norvegicus	90-93
20456283-9	2010	In parallel, the increased levels of proteins involved in beta-cell proliferation such as Cd2 and Cdk4 observed in DEX islets were also normalized in DEX(10) islets.	Dextromethorphan	115-118	cyclin-dependent kinase 4	Rattus norvegicus	98-102
20881950-0	2010	Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.	Dextromethorphan	108-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	34-40
20881950-1	2010	The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms.	Dextromethorphan	24-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	72-91
20881950-1	2010	The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms.	Dextromethorphan	24-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	93-99
21083986-6	2010	RESULTS: The levels of BMP4, BMPR-II and Smad1 mRNA expression were up-regulated in the 1D-BEX, 3D-BEX and 3D-DEX groups compared with those in the control group (P<0.05).	Dextromethorphan	110-113	bone morphogenetic protein receptor type 2	Rattus norvegicus	29-36
21083986-7	2010	The immune histochemiscal analysis showed that the expression of BMP4, BMPR-II, Phospho-Smad1 (pSmad1) and ATF-2 in the 1D-BEX, 3D-BEX and 3D-DEX groups was significantly higher than that in the control group (P<0.01).	Dextromethorphan	142-145	bone morphogenetic protein receptor type 2	Rattus norvegicus	71-78
21083986-7	2010	The immune histochemiscal analysis showed that the expression of BMP4, BMPR-II, Phospho-Smad1 (pSmad1) and ATF-2 in the 1D-BEX, 3D-BEX and 3D-DEX groups was significantly higher than that in the control group (P<0.01).	Dextromethorphan	142-145	SMAD family member 1	Rattus norvegicus	88-93
21083986-6	2010	RESULTS: The levels of BMP4, BMPR-II and Smad1 mRNA expression were up-regulated in the 1D-BEX, 3D-BEX and 3D-DEX groups compared with those in the control group (P<0.05).	Dextromethorphan	110-113	SMAD family member 1	Rattus norvegicus	41-46
21083986-7	2010	The immune histochemiscal analysis showed that the expression of BMP4, BMPR-II, Phospho-Smad1 (pSmad1) and ATF-2 in the 1D-BEX, 3D-BEX and 3D-DEX groups was significantly higher than that in the control group (P<0.01).	Dextromethorphan	142-145	activating transcription factor 2	Rattus norvegicus	107-112
21083986-8	2010	The results of Western blot demonstrated that the expression of BMP4 and BMPR-II protein increased significantly in the 1D-BEX, 3D-BEX and 3D-DEX groups when compared with the control group (P<0.01).	Dextromethorphan	142-145	bone morphogenetic protein 4	Rattus norvegicus	64-68
21083986-8	2010	The results of Western blot demonstrated that the expression of BMP4 and BMPR-II protein increased significantly in the 1D-BEX, 3D-BEX and 3D-DEX groups when compared with the control group (P<0.01).	Dextromethorphan	142-145	bone morphogenetic protein receptor type 2	Rattus norvegicus	73-80
20716633-4	2010	CYP1A2, CYP2D6, CYP2C9, and CYP3A4 enzyme activities were measured by the metabolism of caffeine, dextromethorphan, losartan, and buspirone, respectively.	Dextromethorphan	98-114	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-6
20700584-0	2010	Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population.	Dextromethorphan	79-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	28-34
20637185-7	2010	Of note, some commercially available inhibitors for iNOS and/or COX-2, such as ibuprofen, dextromethorphan, and N(G)-methyl-l-arginine (l-NMA), show negligible effects on microglial Abeta phagocytosis.	Dextromethorphan	90-106	nitric oxide synthase 2, inducible	Mus musculus	52-56
20637185-7	2010	Of note, some commercially available inhibitors for iNOS and/or COX-2, such as ibuprofen, dextromethorphan, and N(G)-methyl-l-arginine (l-NMA), show negligible effects on microglial Abeta phagocytosis.	Dextromethorphan	90-106	prostaglandin-endoperoxide synthase 2	Mus musculus	64-69
20700584-8	2010	CONCLUSIONS: CYP2D6*36 in tandem with CYP2D6*10 plays a minor role in interindividual variation of dextromethorphan metabolism in vivo.	Dextromethorphan	99-115	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
20700584-8	2010	CONCLUSIONS: CYP2D6*36 in tandem with CYP2D6*10 plays a minor role in interindividual variation of dextromethorphan metabolism in vivo.	Dextromethorphan	99-115	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	38-44
20716633-4	2010	CYP1A2, CYP2D6, CYP2C9, and CYP3A4 enzyme activities were measured by the metabolism of caffeine, dextromethorphan, losartan, and buspirone, respectively.	Dextromethorphan	98-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
20473659-9	2010	One Spanish individual with a CYP2D6 4/31 genotype was phenotyped as a poor metabolizer with the CYP2D6 probe drug dextromethorphan (urinary ratio DM/DX=0.71).	Dextromethorphan	115-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	30-36
20501912-0	2010	Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan.	Dextromethorphan	80-96	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	18-25
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	172-188	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	24-31
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	172-188	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	36-43
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	172-188	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	113-120
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	172-188	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	139-145
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	172-188	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	283-290
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	221-237	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	24-31
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	221-237	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	36-43
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	221-237	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	113-120
20501912-7	2010	Metabolic assays of the CYP2D17 and CYP2D44 proteins heterologously expressed in Escherichia coli indicated that CYP2D44 metabolized human CYP2D6 substrates, bufuralol and dextromethorphan (bufuralol 1"-hydroxylation and dextromethorphan O-demethylation) but to a lesser extent than CYP2D17.	Dextromethorphan	221-237	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	139-145
20501912-8	2010	Kinetic analysis of dextromethorphan metabolism indicated that the apparent K(m) and V(max) of CYP2D17 and CYP2D44 catalyzed O-demethylation were similar, and, the V(max) values of CYP2D17 and CYP2D44 catalyzed N-demethylation (which human CYP2D6 catalyzes much less effectively) were similar, but the apparent K(m) of the CYP2D44 reaction was higher.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	95-102
20501912-8	2010	Kinetic analysis of dextromethorphan metabolism indicated that the apparent K(m) and V(max) of CYP2D17 and CYP2D44 catalyzed O-demethylation were similar, and, the V(max) values of CYP2D17 and CYP2D44 catalyzed N-demethylation (which human CYP2D6 catalyzes much less effectively) were similar, but the apparent K(m) of the CYP2D44 reaction was higher.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	107-114
20501912-8	2010	Kinetic analysis of dextromethorphan metabolism indicated that the apparent K(m) and V(max) of CYP2D17 and CYP2D44 catalyzed O-demethylation were similar, and, the V(max) values of CYP2D17 and CYP2D44 catalyzed N-demethylation (which human CYP2D6 catalyzes much less effectively) were similar, but the apparent K(m) of the CYP2D44 reaction was higher.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	181-188
20473659-9	2010	One Spanish individual with a CYP2D6 4/31 genotype was phenotyped as a poor metabolizer with the CYP2D6 probe drug dextromethorphan (urinary ratio DM/DX=0.71).	Dextromethorphan	115-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
20501912-8	2010	Kinetic analysis of dextromethorphan metabolism indicated that the apparent K(m) and V(max) of CYP2D17 and CYP2D44 catalyzed O-demethylation were similar, and, the V(max) values of CYP2D17 and CYP2D44 catalyzed N-demethylation (which human CYP2D6 catalyzes much less effectively) were similar, but the apparent K(m) of the CYP2D44 reaction was higher.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	193-200
20501912-8	2010	Kinetic analysis of dextromethorphan metabolism indicated that the apparent K(m) and V(max) of CYP2D17 and CYP2D44 catalyzed O-demethylation were similar, and, the V(max) values of CYP2D17 and CYP2D44 catalyzed N-demethylation (which human CYP2D6 catalyzes much less effectively) were similar, but the apparent K(m) of the CYP2D44 reaction was higher.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	240-246
20473659-12	2010	CONCLUSIONS: CYP2D6 31 was associated with poor metabolism of dextromethorphan in vivo, which is consistent with a previous report classifying this allelic variant as nonfunctional.	Dextromethorphan	62-78	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
20501912-8	2010	Kinetic analysis of dextromethorphan metabolism indicated that the apparent K(m) and V(max) of CYP2D17 and CYP2D44 catalyzed O-demethylation were similar, and, the V(max) values of CYP2D17 and CYP2D44 catalyzed N-demethylation (which human CYP2D6 catalyzes much less effectively) were similar, but the apparent K(m) of the CYP2D44 reaction was higher.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	193-200
20086201-6	2010	In the DIO and DEX groups, circulating levels of MCP-1, MIP-1alpha, IL-15, and IL-18 were decreased, and adiponectin was increased (P < 0.05 for all).	Dextromethorphan	15-18	C-C motif chemokine ligand 2	Homo sapiens	49-54
20528625-4	2010	Metabolism of phenacetin to paracetamol and dextromethorphan to dextrorphan (metabolic reactions catalyzed by CYP 1A2 and 2D6 in humans respectively) were observed in the zebrafish larvae.	Dextromethorphan	44-60	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	110-125
20382755-5	2010	Both dog CYP2A13 and CYP2A25 exhibited little or no catalytic activity toward other common cytochrome P450 probe substrates, including bupropion, amodiaquine, diclofenac, S-mephenytoin, bufuralol, dextromethorphan, midazolam, and testosterone.	Dextromethorphan	197-213	cytochrome P450 family 2 subfamily A polypeptide 13	Canis lupus familiaris	9-16
20382755-5	2010	Both dog CYP2A13 and CYP2A25 exhibited little or no catalytic activity toward other common cytochrome P450 probe substrates, including bupropion, amodiaquine, diclofenac, S-mephenytoin, bufuralol, dextromethorphan, midazolam, and testosterone.	Dextromethorphan	197-213	cytochrome P450, family 2, subfamily A, polypeptide 7	Canis lupus familiaris	21-28
20047716-8	2010	In the subpopulation of 110 patients, diagnosis-related alleles were also associated with the reduction of cortisol secretion in the Dex/CRH test during a 4-wk treatment period, while psychopathological changes were not associated.	Dextromethorphan	133-136	corticotropin releasing hormone	Homo sapiens	137-140
20047716-10	2010	This study extends the replicated association of a promoter SNP with antidepressant response on a biological level by demonstrating normalization of the cortisol response under Dex/CRH stimulation during treatment.	Dextromethorphan	177-180	corticotropin releasing hormone	Homo sapiens	181-184
20086201-6	2010	In the DIO and DEX groups, circulating levels of MCP-1, MIP-1alpha, IL-15, and IL-18 were decreased, and adiponectin was increased (P < 0.05 for all).	Dextromethorphan	15-18	C-C motif chemokine ligand 3	Homo sapiens	56-66
20086201-6	2010	In the DIO and DEX groups, circulating levels of MCP-1, MIP-1alpha, IL-15, and IL-18 were decreased, and adiponectin was increased (P < 0.05 for all).	Dextromethorphan	15-18	interleukin 15	Homo sapiens	68-73
20086201-6	2010	In the DIO and DEX groups, circulating levels of MCP-1, MIP-1alpha, IL-15, and IL-18 were decreased, and adiponectin was increased (P < 0.05 for all).	Dextromethorphan	15-18	interleukin 18	Homo sapiens	79-84
20086201-6	2010	In the DIO and DEX groups, circulating levels of MCP-1, MIP-1alpha, IL-15, and IL-18 were decreased, and adiponectin was increased (P < 0.05 for all).	Dextromethorphan	15-18	adiponectin, C1Q and collagen domain containing	Homo sapiens	105-116
21386204-4	2010	In this paper, we describe three simple, noninvasive phenotype breath tests using [13C]-dextromethorphan and [13C]-pantoprazole for assessing polymorphic CYP2D6 and CYP2C19 enzyme activity and [13C]-uracil to assess the enzyme activity of DPD, DPHD and beta-ureidopropionase for identifying pyrimidine metabolic disorder.	Dextromethorphan	88-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	154-160
21386204-4	2010	In this paper, we describe three simple, noninvasive phenotype breath tests using [13C]-dextromethorphan and [13C]-pantoprazole for assessing polymorphic CYP2D6 and CYP2C19 enzyme activity and [13C]-uracil to assess the enzyme activity of DPD, DPHD and beta-ureidopropionase for identifying pyrimidine metabolic disorder.	Dextromethorphan	88-104	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	165-172
21386204-4	2010	In this paper, we describe three simple, noninvasive phenotype breath tests using [13C]-dextromethorphan and [13C]-pantoprazole for assessing polymorphic CYP2D6 and CYP2C19 enzyme activity and [13C]-uracil to assess the enzyme activity of DPD, DPHD and beta-ureidopropionase for identifying pyrimidine metabolic disorder.	Dextromethorphan	88-104	dihydropyrimidine dehydrogenase	Homo sapiens	239-242
21386204-4	2010	In this paper, we describe three simple, noninvasive phenotype breath tests using [13C]-dextromethorphan and [13C]-pantoprazole for assessing polymorphic CYP2D6 and CYP2C19 enzyme activity and [13C]-uracil to assess the enzyme activity of DPD, DPHD and beta-ureidopropionase for identifying pyrimidine metabolic disorder.	Dextromethorphan	88-104	beta-ureidopropionase 1	Homo sapiens	253-274
20045184-12	2010	DEX treatment was associated with morphological (accelerated apical microvilli formation, nuclear maturation, and increased cell organelle number) and functional (elevated hCG secretion, increased 11beta-HSD2 mRNA expression and reduced cytotrophoblast proliferation (p<0.05 for all)) markers of syncytiotrophoblast differentiation.	Dextromethorphan	0-3	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	197-208
19996310-5	2010	RESULTS: The mRNA expression of AdipoR1 and -2 in SM was increased significantly in the exercise-only and DEX groups (both P < 0.05).	Dextromethorphan	106-109	adiponectin receptor 1	Homo sapiens	32-46
19996310-6	2010	The mRNA expression of adiponectin and AdipoRs in AT was increased significantly in all three groups (all P < 0.01), whereas serum total circulating adiponectin was significantly increased only in the DEX and hypocaloric diet groups (both P < 0.01).	Dextromethorphan	204-207	adiponectin, C1Q and collagen domain containing	Homo sapiens	152-163
19962776-6	2010	In CTL DEX islets, M3R and PLCbeta1 and phosphorylated PKCalpha, but not PKCalpha, protein content was significantly higher compared with each respective control.	Dextromethorphan	7-10	phospholipase C beta 1	Rattus norvegicus	27-35
19962776-6	2010	In CTL DEX islets, M3R and PLCbeta1 and phosphorylated PKCalpha, but not PKCalpha, protein content was significantly higher compared with each respective control.	Dextromethorphan	7-10	protein kinase C, alpha	Rattus norvegicus	55-63
20201775-1	2010	OBJECTIVE: To investigate the effects of black seed on the metabolic activities of CYP3A4 and CYP2D6 in human liver microsomes and in human subjects using dextromethorphan as a probe drug.	Dextromethorphan	155-171	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
20201775-1	2010	OBJECTIVE: To investigate the effects of black seed on the metabolic activities of CYP3A4 and CYP2D6 in human liver microsomes and in human subjects using dextromethorphan as a probe drug.	Dextromethorphan	155-171	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	94-100
20201775-2	2010	METHODS: CYP2D6-mediated O-demethylation and CYP3A4-mediated N-demethylation of dextromethorphan (DEX) to dextrorphan (DOR) and 3-methoxymorphinan (3-MM), respectively, were utilized to assess the metabolic activities of the two enzymatic pathways.	Dextromethorphan	80-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
20201775-2	2010	METHODS: CYP2D6-mediated O-demethylation and CYP3A4-mediated N-demethylation of dextromethorphan (DEX) to dextrorphan (DOR) and 3-methoxymorphinan (3-MM), respectively, were utilized to assess the metabolic activities of the two enzymatic pathways.	Dextromethorphan	98-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
20201775-10	2010	CONCLUSION: Black seed significantly inhibited CYP2D6 and CYP3A4 mediated metabolism of DEX in human liver microsomes and healthy human volunteers indicating that it has the potential to interact with CYP2D6 and CYP3A4 substrates.	Dextromethorphan	88-91	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
20201775-10	2010	CONCLUSION: Black seed significantly inhibited CYP2D6 and CYP3A4 mediated metabolism of DEX in human liver microsomes and healthy human volunteers indicating that it has the potential to interact with CYP2D6 and CYP3A4 substrates.	Dextromethorphan	88-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
20201775-10	2010	CONCLUSION: Black seed significantly inhibited CYP2D6 and CYP3A4 mediated metabolism of DEX in human liver microsomes and healthy human volunteers indicating that it has the potential to interact with CYP2D6 and CYP3A4 substrates.	Dextromethorphan	88-91	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	201-207
20201775-10	2010	CONCLUSION: Black seed significantly inhibited CYP2D6 and CYP3A4 mediated metabolism of DEX in human liver microsomes and healthy human volunteers indicating that it has the potential to interact with CYP2D6 and CYP3A4 substrates.	Dextromethorphan	88-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	212-218
20814160-5	2010	mfCYP3A5 was efficient at dextromethorphan O-demethylation, although human CYP3A5 was unable to catalyze this reaction.	Dextromethorphan	26-42	cytochrome P450 family 3 subfamily A member 5	Macaca fascicularis	0-8
20814160-5	2010	mfCYP3A5 was efficient at dextromethorphan O-demethylation, although human CYP3A5 was unable to catalyze this reaction.	Dextromethorphan	26-42	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	2-8
20041473-1	2010	OBJECTIVE: Variation in the activity of cytochrome P450 2D6 (CYP2D6) affects the pharmacokinetics and effectiveness of dextromethorphan (DM), because it controls the production of dextrorphan, an active metabolite, with higher affinity for the NMDA receptor than the parent compound.	Dextromethorphan	119-135	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
20041473-1	2010	OBJECTIVE: Variation in the activity of cytochrome P450 2D6 (CYP2D6) affects the pharmacokinetics and effectiveness of dextromethorphan (DM), because it controls the production of dextrorphan, an active metabolite, with higher affinity for the NMDA receptor than the parent compound.	Dextromethorphan	137-139	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-59
20041473-1	2010	OBJECTIVE: Variation in the activity of cytochrome P450 2D6 (CYP2D6) affects the pharmacokinetics and effectiveness of dextromethorphan (DM), because it controls the production of dextrorphan, an active metabolite, with higher affinity for the NMDA receptor than the parent compound.	Dextromethorphan	119-135	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-59
20041473-1	2010	OBJECTIVE: Variation in the activity of cytochrome P450 2D6 (CYP2D6) affects the pharmacokinetics and effectiveness of dextromethorphan (DM), because it controls the production of dextrorphan, an active metabolite, with higher affinity for the NMDA receptor than the parent compound.	Dextromethorphan	137-139	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
19679463-3	2009	Anti-cancer effects of a selective sigma-1 agonist, 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP), in glioblastoma were shown previously, leading to the present work where the effects on glioblastoma cells of 17 agonists or antagonists of sigma-1 receptors were studied, including currently marketed drugs fluvoxamine, dextromethorphan, donepezil, memantine and haloperidol.	Dextromethorphan	324-340	translocator protein	Homo sapiens	98-101
20117981-7	2010	Compared with LPS group, the 3 Lianggesan groups and DEX group showed significantly decreased expressions of STAT1 and p-STAT1 at 2, 4 and 8 h after LPS injection (P<0.05 or 0.01).	Dextromethorphan	53-56	signal transducer and activator of transcription 1	Rattus norvegicus	109-114
20117981-7	2010	Compared with LPS group, the 3 Lianggesan groups and DEX group showed significantly decreased expressions of STAT1 and p-STAT1 at 2, 4 and 8 h after LPS injection (P<0.05 or 0.01).	Dextromethorphan	53-56	signal transducer and activator of transcription 1	Rattus norvegicus	121-126
19444798-0	2009	A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.	Dextromethorphan	67-83	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	214-220
19444798-0	2009	A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.	Dextromethorphan	67-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	225-231
19444798-1	2009	Dextromethorphan is used as a probe drug for assessing CYP2D6 and CYP3A4 activity in vivo and in vitro.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
19444798-1	2009	Dextromethorphan is used as a probe drug for assessing CYP2D6 and CYP3A4 activity in vivo and in vitro.	Dextromethorphan	0-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
19444798-7	2009	The method has been successfully applied for the in vitro inhibition of metabolism of dextromethorphan by CYP2D6 and CYP3A4 using known inhibitors of CYPs such as quinidine and verapamil.	Dextromethorphan	86-102	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	106-112
19444798-7	2009	The method has been successfully applied for the in vitro inhibition of metabolism of dextromethorphan by CYP2D6 and CYP3A4 using known inhibitors of CYPs such as quinidine and verapamil.	Dextromethorphan	86-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
19727527-2	2009	Glucocorticoid treatment (dexamethasone, or Dex) has been reported to amplify IL-2-mediated selective in vivo expansion of Treg cells.	Dextromethorphan	44-47	interleukin 2	Mus musculus	78-82
19727527-5	2009	Results showed that short-term simultaneous administration of Dex and IL-2 markedly expanded functional suppressive CD4(+)CD25(+)FOXP3(+) T cells in the murine spleen.	Dextromethorphan	62-65	CD4 antigen	Mus musculus	116-119
19727527-5	2009	Results showed that short-term simultaneous administration of Dex and IL-2 markedly expanded functional suppressive CD4(+)CD25(+)FOXP3(+) T cells in the murine spleen.	Dextromethorphan	62-65	forkhead box P3	Mus musculus	129-134
19727527-8	2009	This study demonstrated that co-stimulation with Dex and IL-2 selectively expanded functional CD4(+)CD25(+)FOXP3(+) T cells in vivo, and that grafts from donors pre-treated with Dex and IL-2 led to longer survival time and greater suppression of GVHD after allogeneic transplantation.	Dextromethorphan	49-52	CD4 antigen	Mus musculus	94-97
19727527-8	2009	This study demonstrated that co-stimulation with Dex and IL-2 selectively expanded functional CD4(+)CD25(+)FOXP3(+) T cells in vivo, and that grafts from donors pre-treated with Dex and IL-2 led to longer survival time and greater suppression of GVHD after allogeneic transplantation.	Dextromethorphan	49-52	forkhead box P3	Mus musculus	107-112
19727527-8	2009	This study demonstrated that co-stimulation with Dex and IL-2 selectively expanded functional CD4(+)CD25(+)FOXP3(+) T cells in vivo, and that grafts from donors pre-treated with Dex and IL-2 led to longer survival time and greater suppression of GVHD after allogeneic transplantation.	Dextromethorphan	178-181	forkhead box P3	Mus musculus	107-112
19727527-8	2009	This study demonstrated that co-stimulation with Dex and IL-2 selectively expanded functional CD4(+)CD25(+)FOXP3(+) T cells in vivo, and that grafts from donors pre-treated with Dex and IL-2 led to longer survival time and greater suppression of GVHD after allogeneic transplantation.	Dextromethorphan	49-52	interleukin 2	Mus musculus	186-190
19012965-4	2009	Treatments that directly or indirectly reduced phosphorylated JNK and ERK resulted in Dex sensitivity in five resistant lymphoid cell lines.	Dextromethorphan	86-89	mitogen-activated protein kinase 8	Homo sapiens	62-65
19389455-8	2009	Significantly blunted plasma cortisol and ACTH responses in response to dex/CRH administration were found in the trauma exposed compared to the non-exposed women (F(1,20)=5.08, p=0.04 and F(1,20)=5.23, p=0.03 respectively).	Dextromethorphan	72-75	proopiomelanocortin	Homo sapiens	42-46
19202320-5	2009	Serum FSH and LH were assayed at 12, 24 and 48 h following eCG and did not differ between dexamethasone-treated and control animals, but prolactin showed a prolonged pattern of elevation in DEX-treated females.	Dextromethorphan	190-193	prolactin	Rattus norvegicus	137-146
19012965-4	2009	Treatments that directly or indirectly reduced phosphorylated JNK and ERK resulted in Dex sensitivity in five resistant lymphoid cell lines.	Dextromethorphan	86-89	mitogen-activated protein kinase 1	Homo sapiens	70-73
19013499-2	2009	Here we demonstrate that Dex (1 microM for 24h) inhibits basal and insulin (1 nM) stimulated glucose uptake in human and murine adipocytes by 50% with a concomitant reduction in the levels of GLUT1/4 at the plasma membrane but no change in total GLUT1/4 levels.	Dextromethorphan	25-28	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	192-199
19013499-2	2009	Here we demonstrate that Dex (1 microM for 24h) inhibits basal and insulin (1 nM) stimulated glucose uptake in human and murine adipocytes by 50% with a concomitant reduction in the levels of GLUT1/4 at the plasma membrane but no change in total GLUT1/4 levels.	Dextromethorphan	25-28	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	192-197
19013499-5	2009	Co-treatment with the glucocorticoid receptor antagonist RU486 (10 microM) abrogated the Dex effect on AS160-T642 phosphorylation and restored glucose uptake by 80%.	Dextromethorphan	89-92	TBC1 domain family member 4	Homo sapiens	103-108
19013499-6	2009	These data suggest Dex inhibits glucose uptake in adipocytes, at least in part, by reducing AS160 phosphorylation and interaction with 14-3-3.	Dextromethorphan	19-22	TBC1 domain family member 4	Homo sapiens	92-97
19158320-8	2009	Activation of the insulin receptor substrate 2/phosphatidylinositol 3-kinase/serine-threonine kinase/ribosomal protein S6 kinase pathway, as well as protein retinoblastoma in islets from DEX 1.0 and DEX 0.5, but not in DEX 0.1, rats was also observed.	Dextromethorphan	187-190	insulin receptor substrate 2	Rattus norvegicus	18-46
19189960-5	2009	Dextromethorphan pretreatment significantly suppressed the production of tumour necrosis factor-alpha, monocyte chemoattractant protein-1, interleukin-6, interleukin-10, and superoxide in macrophage cell culture after stimulation.	Dextromethorphan	0-16	chemokine (C-C motif) ligand 2	Mus musculus	103-137
19189960-5	2009	Dextromethorphan pretreatment significantly suppressed the production of tumour necrosis factor-alpha, monocyte chemoattractant protein-1, interleukin-6, interleukin-10, and superoxide in macrophage cell culture after stimulation.	Dextromethorphan	0-16	interleukin 6	Mus musculus	139-152
18710466-13	2009	After DST, SAF(dex) significantly correlated with F(dex) (r = 0.61, P < 0.0001).	Dextromethorphan	15-18	FAS antisense RNA 1	Homo sapiens	11-14
19189960-5	2009	Dextromethorphan pretreatment significantly suppressed the production of tumour necrosis factor-alpha, monocyte chemoattractant protein-1, interleukin-6, interleukin-10, and superoxide in macrophage cell culture after stimulation.	Dextromethorphan	0-16	interleukin 10	Mus musculus	154-168
19189960-6	2009	Indeed, DXM reduced macrophage nicotinamide adenine dinucleotide phosphate oxidase activity by decreasing membrane translocation of p47(phox) and p67(phox) through the inhibition of protein kinase C and extracellular signal-regulated kinase activation.	Dextromethorphan	8-11	NSFL1 (p97) cofactor (p47)	Mus musculus	132-141
19189960-6	2009	Indeed, DXM reduced macrophage nicotinamide adenine dinucleotide phosphate oxidase activity by decreasing membrane translocation of p47(phox) and p67(phox) through the inhibition of protein kinase C and extracellular signal-regulated kinase activation.	Dextromethorphan	8-11	methionine aminopeptidase 2	Mus musculus	146-149
19189960-6	2009	Indeed, DXM reduced macrophage nicotinamide adenine dinucleotide phosphate oxidase activity by decreasing membrane translocation of p47(phox) and p67(phox) through the inhibition of protein kinase C and extracellular signal-regulated kinase activation.	Dextromethorphan	8-11	NSFL1 (p97) cofactor (p47)	Mus musculus	136-140
19189960-8	2009	Dextromethorphan treatment (10-40 mg/kg/day) for 10 weeks in apoE-deficient mice significantly reduced superoxide production in their polymorphonuclear leukocytes and aortas.	Dextromethorphan	0-16	apolipoprotein E	Mus musculus	61-65
18710466-14	2009	A cut-off value of SAF(dex) > 2.0 nM and F(dex) > 50.0 nM detected CS with 100% sensitivity and specificity.	Dextromethorphan	23-26	FAS antisense RNA 1	Homo sapiens	19-22
18710466-16	2009	CONCLUSIONS: SAF(23) and SAF(dex) seem to be good screening tools based on their noninvasive nature, remarkable reproducibility and diagnostic performances.	Dextromethorphan	29-32	FAS antisense RNA 1	Homo sapiens	25-28
19059219-1	2009	The capacity to oxidize bufuralol (BF) and dextromethorphan (DEX) was compared kinetically between human CYP2D6 and four rat CYP2D (CYP2D1, -2D2, -2D3 and -2D4) isoenzymes in a yeast cell expression system.	Dextromethorphan	61-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	105-111
19158312-3	2009	To clarify the effects of these novel CYP2D6*10 haplotypes on the functions of CYP2D6, kinetic analysis for dextromethorphan O-demethylation was performed using the Escherichia coli expression system and human liver microsomes.	Dextromethorphan	108-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	38-44
19158312-3	2009	To clarify the effects of these novel CYP2D6*10 haplotypes on the functions of CYP2D6, kinetic analysis for dextromethorphan O-demethylation was performed using the Escherichia coli expression system and human liver microsomes.	Dextromethorphan	108-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
19158312-4	2009	The V(max)/K(m) values for dextromethorphan O-demethylation catalyzed by recombinant CYP2D6 forms encoded by CYP2D6*10, CYP2D6*49, and CYP2D6*72 were 3.0, 0.5, and 1.3%, respectively, compared with that catalyzed by CYP2D6.1.	Dextromethorphan	27-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	85-91
19158312-4	2009	The V(max)/K(m) values for dextromethorphan O-demethylation catalyzed by recombinant CYP2D6 forms encoded by CYP2D6*10, CYP2D6*49, and CYP2D6*72 were 3.0, 0.5, and 1.3%, respectively, compared with that catalyzed by CYP2D6.1.	Dextromethorphan	27-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-115
19158312-4	2009	The V(max)/K(m) values for dextromethorphan O-demethylation catalyzed by recombinant CYP2D6 forms encoded by CYP2D6*10, CYP2D6*49, and CYP2D6*72 were 3.0, 0.5, and 1.3%, respectively, compared with that catalyzed by CYP2D6.1.	Dextromethorphan	27-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-115
19158312-4	2009	The V(max)/K(m) values for dextromethorphan O-demethylation catalyzed by recombinant CYP2D6 forms encoded by CYP2D6*10, CYP2D6*49, and CYP2D6*72 were 3.0, 0.5, and 1.3%, respectively, compared with that catalyzed by CYP2D6.1.	Dextromethorphan	27-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-115
19158312-4	2009	The V(max)/K(m) values for dextromethorphan O-demethylation catalyzed by recombinant CYP2D6 forms encoded by CYP2D6*10, CYP2D6*49, and CYP2D6*72 were 3.0, 0.5, and 1.3%, respectively, compared with that catalyzed by CYP2D6.1.	Dextromethorphan	27-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-115
19059219-0	2009	The mechanism causing the difference in kinetic properties between rat CYP2D4 and human CYP2D6 in the oxidation of dextromethorphan and bufuralol.	Dextromethorphan	115-131	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	71-77
19059219-0	2009	The mechanism causing the difference in kinetic properties between rat CYP2D4 and human CYP2D6 in the oxidation of dextromethorphan and bufuralol.	Dextromethorphan	115-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-94
19059219-1	2009	The capacity to oxidize bufuralol (BF) and dextromethorphan (DEX) was compared kinetically between human CYP2D6 and four rat CYP2D (CYP2D1, -2D2, -2D3 and -2D4) isoenzymes in a yeast cell expression system.	Dextromethorphan	61-64	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	105-110
19059219-3	2009	In DEX N-demethylation, rat CYP2D2 did not show any detectable activity under the conditions used, whereas the other four enzymes yielded linear Eadie-Hofstee plots.	Dextromethorphan	3-6	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	28-34
19059219-7	2009	These results suggest that the introduction of phenylalanine in the active-site cavity of CYP2D4 simplifies complicated interactions between the substrates and the amino acid residues, but the mechanisms causing the simplification differ between BF and DEX.	Dextromethorphan	253-256	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	90-96
19182377-1	2009	Combined treatment with dexamethasone and oncostatin M (DEX/OSM) or interleukin-6 (DEX/IL-6) resulted in the appearance of numerous large vacuoles in human fetal liver (HFL) cells and showed synergistic effects on the formation of vacuoles.	Dextromethorphan	56-59	oncostatin M	Homo sapiens	42-54
19036432-6	2009	In addition, results demonstrated that Dex-loaded CMCht/PAMAM dendrimer nanoparticles combined with the HA enhance osteogenesis by increasing ALP activity and mineralization of the extra-cellular matrix.	Dextromethorphan	39-42	PDZ and LIM domain 3	Rattus norvegicus	142-145
19182377-5	2009	Expression of IL-6R mRNA was induced by DEX.	Dextromethorphan	40-43	interleukin 6 receptor	Homo sapiens	14-19
19339774-3	2009	RESULTS: LPL mRNA levels in muscle tissue were increased in the DEX group and in the CLA group (240% increase) compared with the SUC group.	Dextromethorphan	64-67	lipoprotein lipase	Mus musculus	9-12
18543297-1	2009	Cytochrome P450 2D6 (CYP2D6) mediated formation of dextrorphan (DOR) from dextromethorphan (DEX) is widely used as a marker to assess the activity of this enzyme both in vitro and in vivo.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-19
18543297-1	2009	Cytochrome P450 2D6 (CYP2D6) mediated formation of dextrorphan (DOR) from dextromethorphan (DEX) is widely used as a marker to assess the activity of this enzyme both in vitro and in vivo.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	21-27
18543297-1	2009	Cytochrome P450 2D6 (CYP2D6) mediated formation of dextrorphan (DOR) from dextromethorphan (DEX) is widely used as a marker to assess the activity of this enzyme both in vitro and in vivo.	Dextromethorphan	92-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-19
18543297-1	2009	Cytochrome P450 2D6 (CYP2D6) mediated formation of dextrorphan (DOR) from dextromethorphan (DEX) is widely used as a marker to assess the activity of this enzyme both in vitro and in vivo.	Dextromethorphan	92-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	21-27
18591960-8	2009	CYP2D6 phenotype was determined by assessing urinary elimination of dextromethorphan and its metabolite dextrorphan and compared to the array prediction (n=165).	Dextromethorphan	68-84	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
18838503-7	2009	In contrast, CYP2D6.24, CYP2D6.26, and CYP2D6.27 allelic isoforms all showed active drug-metabolizing activities toward both codeine and dextromethorphan O-demethylation.	Dextromethorphan	137-153	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
19817501-19	2009	For example, CYP2D6*17 is generally considered as an allele with reduced function, but it displays remarkable variability in its activity towards substrates such as dextromethorphan, risperidone, codeine and haloperidol.	Dextromethorphan	165-181	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
19133059-3	2009	CYP2D6 activity [3 h plasma metabolic ratio of dextromethorphan (DEX) to dextrorphan (DOR)] was determined in 44 patients (29 male; 24-55 years), CYP1A2 activity (salivary caffeine elimination half-life) in 44 patients (21 male; 24-55 years) and CYP3A activity (oral clearance of midazolam) in 49 patients (33 male; 23-55 years).	Dextromethorphan	47-63	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
19133059-3	2009	CYP2D6 activity [3 h plasma metabolic ratio of dextromethorphan (DEX) to dextrorphan (DOR)] was determined in 44 patients (29 male; 24-55 years), CYP1A2 activity (salivary caffeine elimination half-life) in 44 patients (21 male; 24-55 years) and CYP3A activity (oral clearance of midazolam) in 49 patients (33 male; 23-55 years).	Dextromethorphan	65-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
18838503-7	2009	In contrast, CYP2D6.24, CYP2D6.26, and CYP2D6.27 allelic isoforms all showed active drug-metabolizing activities toward both codeine and dextromethorphan O-demethylation.	Dextromethorphan	137-153	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
18838503-7	2009	In contrast, CYP2D6.24, CYP2D6.26, and CYP2D6.27 allelic isoforms all showed active drug-metabolizing activities toward both codeine and dextromethorphan O-demethylation.	Dextromethorphan	137-153	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
18838503-8	2009	Whereas CYP2D6.24 exhibited the highest intrinsic clearance in dextromethorphan O-demethylation (approximately 6-fold higher than that by CYP2D6.1), it had the lowest enzyme efficiency in codeine O-demethylation (approximately 50% lower than that by CYP2D6.1).	Dextromethorphan	63-79	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	8-14
18806696-2	2008	She was genotyped as a CYP2D6 poor metabolizer (PM): CYP2D6-4*/*6, which was confirmed by a dextromethorphan (DM) test (metabolic ratio = 5.8).	Dextromethorphan	92-108	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	23-29
19356111-1	2009	The potential of various microbes to metabolize the dextromethorphan (DXM) , a CYP 2D6 substrate was studied to investigate similarities between microbial and mammalian metabolism.	Dextromethorphan	52-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-86
19356111-1	2009	The potential of various microbes to metabolize the dextromethorphan (DXM) , a CYP 2D6 substrate was studied to investigate similarities between microbial and mammalian metabolism.	Dextromethorphan	70-73	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-86
19684420-9	2009	Our finding could reflect the elevation of DEX/CRH results by lithium, independent of clinical course.	Dextromethorphan	43-46	corticotropin releasing hormone	Homo sapiens	47-50
19034038-3	2008	The compounds clobutinol, pentoxyverine, dextromethorphan, and codeine inhibited the outward current in hERG transfected cells with half-maximal inhibition concentrations (IC50) of 1.9 microM, 3.0 microM, 5.1 microM, and 97 microM, respectively.	Dextromethorphan	41-57	ETS transcription factor ERG	Homo sapiens	104-108
20027150-10	2009	RES produced inhibition of CYP2D2, expressed by significant changes of both DEM and DEX levels in males and significant increase of only DEM levels in females.	Dextromethorphan	76-79	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	27-33
19094027-8	2008	We observed generally that GIP-producing K cells were augmented in all parts of SI and decreased in the LI of DEX rats.	Dextromethorphan	110-113	gastric inhibitory polypeptide	Rattus norvegicus	27-30
18806696-2	2008	She was genotyped as a CYP2D6 poor metabolizer (PM): CYP2D6-4*/*6, which was confirmed by a dextromethorphan (DM) test (metabolic ratio = 5.8).	Dextromethorphan	92-108	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	53-59
18634893-3	2008	METHODS: The assay consisted of human liver microsomes and a cocktail of probe substrates metabolized by the five major CYP isoforms (tacrine for CYP1A2, diclofenac for CYP2C9, (S)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4).	Dextromethorphan	206-222	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-123
18640775-5	2008	We conclude that the direct lipolytic effect of GH is accompanied by an increase in HSL mRNA in the presence of DEX, but GH also increased the mRNAs for other proteins that could explain all or part of its lipolytic action.	Dextromethorphan	112-115	growth hormone 1	Homo sapiens	48-50
18640775-5	2008	We conclude that the direct lipolytic effect of GH is accompanied by an increase in HSL mRNA in the presence of DEX, but GH also increased the mRNAs for other proteins that could explain all or part of its lipolytic action.	Dextromethorphan	112-115	lipase E, hormone sensitive type	Homo sapiens	84-87
18723411-2	2008	The results indicate that chiral recognition on the alpha3beta4 nAChR is a process involving initial tethering of dextromethorphan and levomethorphan at hydrophobic pockets within the central lumen followed by hydrogen bonding interactions favoring dextromethorphan.	Dextromethorphan	114-130	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	64-69
18723411-2	2008	The results indicate that chiral recognition on the alpha3beta4 nAChR is a process involving initial tethering of dextromethorphan and levomethorphan at hydrophobic pockets within the central lumen followed by hydrogen bonding interactions favoring dextromethorphan.	Dextromethorphan	135-149	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	64-69
18723411-2	2008	The results indicate that chiral recognition on the alpha3beta4 nAChR is a process involving initial tethering of dextromethorphan and levomethorphan at hydrophobic pockets within the central lumen followed by hydrogen bonding interactions favoring dextromethorphan.	Dextromethorphan	249-265	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	64-69
18728242-0	2008	Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype.	Dextromethorphan	22-38	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
18692486-6	2008	The nucleotide sequence of CYP2D50 was highly homologous to that of human CYP2D6 and therefore the activity of the enzyme was characterized using dextromethorphan and debrisoquine, two isoform selective substrates for the human orthologue.	Dextromethorphan	146-162	cytochrome P450 family 2 subfamily D member 50	Equus caballus	27-34
18692486-6	2008	The nucleotide sequence of CYP2D50 was highly homologous to that of human CYP2D6 and therefore the activity of the enzyme was characterized using dextromethorphan and debrisoquine, two isoform selective substrates for the human orthologue.	Dextromethorphan	146-162	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	74-80
18692486-7	2008	CYP2D50 displayed optimal catalytic activity with dextromethorphan using molar ratios of CYP2D50 to NADPH CYP450 reductase of 1:15.	Dextromethorphan	50-66	cytochrome P450 family 2 subfamily D member 50	Equus caballus	0-7
18692486-7	2008	CYP2D50 displayed optimal catalytic activity with dextromethorphan using molar ratios of CYP2D50 to NADPH CYP450 reductase of 1:15.	Dextromethorphan	50-66	cytochrome P450 family 2 subfamily D member 50	Equus caballus	89-96
18794647-5	2008	The pharmacokinetics of DEX and its metabolites were used to evaluate changes in CYP2D6 activity.	Dextromethorphan	24-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	81-87
18794647-6	2008	The urinary metabolic ratio of DEX and dextrorphan was used to calculate a recovery half-life of CYP2D6.	Dextromethorphan	31-34	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
19051610-2	2008	The purpose of the present study was to determine the distribution of CYP2D6 metabolizer status in subjects from central Poland, using dextromethorphan as the probe drug.	Dextromethorphan	135-151	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	70-76
18728242-3	2008	CYP2D6 phenotype was determined by (13)CO(2) enrichment measured by infrared spectrometry (delta-over-baseline [DOB] value) in expired breath samples collected before and up to 240 minutes after [(13)C]-DM ingestion and by 4-hour urinary metabolite ratio.	Dextromethorphan	203-205	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
18183034-5	2008	In CYP2D6 extensive metabolizers, the plasma ratio AUC(dextromethorphan)/AUC(dextrorphan) increased to 2.92-fold (2.31-3.69).	Dextromethorphan	55-71	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	3-9
18458004-7	2008	Our results show that an optimized procedure not only identified the known DEX metabolites as predictors of CYP2D6-specific metabolic pathways but also indicated the presence of additional, so far unknown path-specific glucuronide metabolites.	Dextromethorphan	75-78	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	108-114
18831921-8	2008	These observations suggest that cPLA2 inhibition may have a role in Dex-induced thymocyte apoptosis and highlight the importance of cPLA2 activity in thymocyte survival.	Dextromethorphan	68-71	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	32-37
18423379-7	2008	These data demonstrate that S1P upregulates the expression of Mcl-1 and protects MM cells from Dex-induced apoptosis, providing the preclinical framework for novel therapeutics targeting at both Mcl-1 and/or S1P to improve the patient outcome in MM.	Dextromethorphan	95-98	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	62-67
18359183-0	2008	Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study.	Dextromethorphan	17-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	104-110
18359183-15	2008	In conclusion, it is probably wise to recommend avoiding dextromethorphan in patients taking tricyclic antidepressants or another inhibitor of CYP2D6.	Dextromethorphan	57-73	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	143-149
18342837-3	2008	The intrinsic clearance of dextromethorphan O-demethylation, a measure of Cyp2d2 activity, was decreased 80% at both days 9 and 19 of gestation when compared to non-pregnant controls.	Dextromethorphan	27-43	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	74-80
18096693-8	2008	RU486, a glucocorticoid receptor antagonist, canceled the DEX-dependent blocking effect on the action of BDNF.	Dextromethorphan	58-61	brain derived neurotrophic factor	Homo sapiens	105-109
18261979-6	2008	Treatment with FL had no effect on GR location and Dex induced translocation of GR was unaffected by FL.	Dextromethorphan	51-54	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	80-82
18096693-3	2008	In this study, we investigated the effect of glucocorticoid (dexamethasone, DEX) on synaptic maturation and function enhanced by BDNF in early developing hippocampal neurons.	Dextromethorphan	76-79	brain derived neurotrophic factor	Homo sapiens	129-133
18096693-5	2008	Pretreatment with DEX significantly inhibited the BDNF-dependent up-regulation of both dendritic outgrowth and synaptic proteins.	Dextromethorphan	18-21	brain derived neurotrophic factor	Homo sapiens	50-54
18294637-11	2008	A significant interaction of time with harm avoidance and novelty seeking (F(4, 53)=3.37, p<.05) revealed that participants with both high levels of harm avoidance and low levels of novelty seeking had the highest cortisol responses to the Dex/CRH test.	Dextromethorphan	243-246	corticotropin releasing hormone	Homo sapiens	247-250
18056254-8	2008	To our surprise, only CYP2D6-expressing microsomes could catalyze the reaction, and omega-1 oxidation was strongly correlated with the CYP2D6 marker reaction, dextromethorphan O-demethylation (r(2) = 0.90), in human hepatic microsomes.	Dextromethorphan	159-175	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	22-28
18056254-8	2008	To our surprise, only CYP2D6-expressing microsomes could catalyze the reaction, and omega-1 oxidation was strongly correlated with the CYP2D6 marker reaction, dextromethorphan O-demethylation (r(2) = 0.90), in human hepatic microsomes.	Dextromethorphan	159-175	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	135-141
18096693-6	2008	In the more mature stage, the BDNF-reinforced postsynaptic Ca(2+) influx was decreased by DEX.	Dextromethorphan	90-93	brain derived neurotrophic factor	Homo sapiens	30-34
18096693-10	2008	Interestingly, the BDNF-activated MAPK/ERK pathway, which is an essential intracellular signaling pathway for the BDNF-increased synaptic proteins, was reduced by DEX.	Dextromethorphan	163-166	brain derived neurotrophic factor	Homo sapiens	19-23
18096693-10	2008	Interestingly, the BDNF-activated MAPK/ERK pathway, which is an essential intracellular signaling pathway for the BDNF-increased synaptic proteins, was reduced by DEX.	Dextromethorphan	163-166	brain derived neurotrophic factor	Homo sapiens	114-118
18048490-4	2008	Constitutive CYP2D6 expression resulted in 2- to 3-fold higher dextromethorphan O-demethylase activity in Tg-CYP2D6/CYP3A4 mouse liver microsomes compared with wild-type mice.	Dextromethorphan	63-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
18281903-6	2008	Antidyskinetic effects of dextromethorphan may be mediated via mechanisms other than NMDA, including the sigma-1 receptor and other binding sites common to dextromethorphan and BMY-14802.	Dextromethorphan	26-42	sigma non-opioid intracellular receptor 1	Rattus norvegicus	105-121
18279363-0	2008	Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain.	Dextromethorphan	0-16	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	50-79
18279363-4	2008	Dextromethorphan (DM), a low-affinity NMDAR antagonist with anti-inflammatory properties, may be neuroprotective against excitotoxic and inflammation-enhanced excitotoxic brain injury, without the associated stimulation of apoptotic degeneration.	Dextromethorphan	0-16	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	38-43
17971818-5	2008	The ability of genotype and AS to accurately predict phenotype using the CYP2D6 probe substrate dextromethorphan was evaluated using linear regression and clustering methods.	Dextromethorphan	96-112	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	73-79
18065299-1	2008	Dextromethorphan (DEM) is a widely used probe drug for human cytochrome P450 2D6 isozyme activity assessment by measuring the ratio between DEM and its N-demethylated metabolite dextrorphan (DOR).	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-80
17899220-3	2008	Moreover, the spectral changes detected in the presence of dextromethorphan (a CYP2D6 substrate) and imidazole (an exogenous heme axial ligand) indicated that the immobilized enzyme also preserved its ability to reversibly bind a substrate and form a heme-imidazole complex.	Dextromethorphan	59-75	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
18551885-1	2008	Coricidin HBP, a cold medication containing dextromethorphan, has become a popular agent abused among adolescents.	Dextromethorphan	44-60	heme binding protein 1	Homo sapiens	10-13
18065299-1	2008	Dextromethorphan (DEM) is a widely used probe drug for human cytochrome P450 2D6 isozyme activity assessment by measuring the ratio between DEM and its N-demethylated metabolite dextrorphan (DOR).	Dextromethorphan	18-21	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-80
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	18-34	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	226-232
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	47-63	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	237-243
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	18-34	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	237-243
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	47-63	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	245-263
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	18-34	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	245-263
17651725-6	2007	The inhibitory effect of sodium ozagrel on CYP2D6 activity was noncompetitive with dextromethorphan with a K(i) of 324.94 microM.	Dextromethorphan	83-99	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	43-49
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	47-63	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	226-232
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	47-63	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	237-243
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	47-63	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	245-263
17651725-3	2007	The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC).	Dextromethorphan	47-63	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	226-232
18024393-2	2007	The aim of this study was to characterize the involvement of Bcl-2 family members and caspase activation in dexamethasone(Dex)-induced apoptosis in ALL.	Dextromethorphan	122-125	BCL2 apoptosis regulator	Homo sapiens	61-66
17910620-3	2007	c-DNA baculovirus expressed CYP2D6 was used with dextromethorphan as substrate.	Dextromethorphan	49-65	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	28-34
18024393-2	2007	The aim of this study was to characterize the involvement of Bcl-2 family members and caspase activation in dexamethasone(Dex)-induced apoptosis in ALL.	Dextromethorphan	122-125	caspase 2	Homo sapiens	86-93
18024393-7	2007	RESULTS: Dex induced significant down-regulation of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, differential activation of the pro-apoptotic Bak and Bax, loss of Delta psi m and cytochrome c release.	Dextromethorphan	9-12	BCL2 apoptosis regulator	Homo sapiens	71-76
18024393-7	2007	RESULTS: Dex induced significant down-regulation of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, differential activation of the pro-apoptotic Bak and Bax, loss of Delta psi m and cytochrome c release.	Dextromethorphan	9-12	BCL2 apoptosis regulator	Homo sapiens	92-97
18024393-7	2007	RESULTS: Dex induced significant down-regulation of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, differential activation of the pro-apoptotic Bak and Bax, loss of Delta psi m and cytochrome c release.	Dextromethorphan	9-12	BCL2 like 1	Homo sapiens	102-108
18024393-7	2007	RESULTS: Dex induced significant down-regulation of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, differential activation of the pro-apoptotic Bak and Bax, loss of Delta psi m and cytochrome c release.	Dextromethorphan	9-12	BCL2 antagonist/killer 1	Homo sapiens	155-158
18024393-7	2007	RESULTS: Dex induced significant down-regulation of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, differential activation of the pro-apoptotic Bak and Bax, loss of Delta psi m and cytochrome c release.	Dextromethorphan	9-12	BCL2 associated X, apoptosis regulator	Homo sapiens	163-166
18024393-7	2007	RESULTS: Dex induced significant down-regulation of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL, differential activation of the pro-apoptotic Bak and Bax, loss of Delta psi m and cytochrome c release.	Dextromethorphan	9-12	cytochrome c, somatic	Homo sapiens	192-204
18024393-8	2007	Dex-induced apoptosis also involved early activation of caspases 2 and -3.	Dextromethorphan	0-3	caspase 2	Homo sapiens	56-73
18024393-10	2007	In 12 primary ALL samples Dex-induced apoptosis was associated with activation of Bax (p=0.045) and down-regulation of Bcl-2 (p=0.016) and/or Bcl-xL (p=0.004).	Dextromethorphan	26-29	BCL2 associated X, apoptosis regulator	Homo sapiens	82-85
18024393-10	2007	In 12 primary ALL samples Dex-induced apoptosis was associated with activation of Bax (p=0.045) and down-regulation of Bcl-2 (p=0.016) and/or Bcl-xL (p=0.004).	Dextromethorphan	26-29	BCL2 apoptosis regulator	Homo sapiens	119-124
18024393-10	2007	In 12 primary ALL samples Dex-induced apoptosis was associated with activation of Bax (p=0.045) and down-regulation of Bcl-2 (p=0.016) and/or Bcl-xL (p=0.004).	Dextromethorphan	26-29	BCL2 like 1	Homo sapiens	142-148
18024393-12	2007	INTERPRETATION AND CONCLUSIONS: The differential regulation of pro- and anti-apoptotic Bcl-2 family members appears to be a key event in the execution of Dex-induced apoptosis in ALL cell lines, and also indicates a role for these proteins in primary ALL cells.	Dextromethorphan	154-157	BCL2 apoptosis regulator	Homo sapiens	87-92
18195464-3	2007	The aim of this study was to identify the CYP2D6 oxidation phenotype with dextromethorphan (DM) as a probe drug.	Dextromethorphan	92-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
18195464-0	2007	CYP2D6 phenotyping with dextromethorphan.	Dextromethorphan	24-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
18007217-1	2007	An 18-year-old male developed a severe serotonin syndrome after recreational ingestion of Coricidin HBP (chlorpheniramine 4 mg and dextromethorphan hydrobromide 30 mg).	Dextromethorphan	131-160	heme binding protein 1	Homo sapiens	100-103
18195464-3	2007	The aim of this study was to identify the CYP2D6 oxidation phenotype with dextromethorphan (DM) as a probe drug.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
17590365-7	2007	IGF-I induced ATDC5 proliferation was further decreased when Dex (24%; P < 0.01) or IL-1beta (33%; P < 0.001) were added to PD but not LY cultures.	Dextromethorphan	61-64	insulin-like growth factor 1	Mus musculus	0-5
17542019-2	2007	Probe substrates were phenacetin, diclofenac, S-mephenytoin, and dextromethorphan for CYP1A2, CYP2C9, CYP2C19, and CYP2D6, respectively.	Dextromethorphan	65-81	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	86-92
17542019-2	2007	Probe substrates were phenacetin, diclofenac, S-mephenytoin, and dextromethorphan for CYP1A2, CYP2C9, CYP2C19, and CYP2D6, respectively.	Dextromethorphan	65-81	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	94-100
17542019-2	2007	Probe substrates were phenacetin, diclofenac, S-mephenytoin, and dextromethorphan for CYP1A2, CYP2C9, CYP2C19, and CYP2D6, respectively.	Dextromethorphan	65-81	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	102-109
17542019-2	2007	Probe substrates were phenacetin, diclofenac, S-mephenytoin, and dextromethorphan for CYP1A2, CYP2C9, CYP2C19, and CYP2D6, respectively.	Dextromethorphan	65-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	115-121
17768383-14	2007	Pretreatment of GR siRNA followed by DEX treatment caused a reduction of the MYOC and CDT6 gene expressions when compared with eyes pretreated with scramble-control (percent silencing: 99.3% +/- 0.005 and 97.3% +/- 0.25, respectively, for individual 5 and 98.2% +/- 0.06 and 85.6% +/- 0.88, respectively, for individual 6).	Dextromethorphan	37-40	myocilin	Homo sapiens	77-81
17768383-14	2007	Pretreatment of GR siRNA followed by DEX treatment caused a reduction of the MYOC and CDT6 gene expressions when compared with eyes pretreated with scramble-control (percent silencing: 99.3% +/- 0.005 and 97.3% +/- 0.25, respectively, for individual 5 and 98.2% +/- 0.06 and 85.6% +/- 0.88, respectively, for individual 6).	Dextromethorphan	37-40	angiopoietin like 7	Homo sapiens	86-90
17092767-1	2007	A simple, accurate and highly sensitive spectrophotometric method is proposed for the rapid determination of pipazethate hydrochloride, dextromethorphan hydrobromide and drotaverine hydrochloride using chromotrope 2B (C2B) and chromotrope 2R (C2R).	Dextromethorphan	136-165	secretoglobin family 2B member 3, pseudogene	Homo sapiens	218-221
17537407-3	2007	Study of a panel of 20 different cell types showed the effect of (Dex) upon caveolin-1 expression to be highly cell selective for lung alveolar epithelial cells.	Dextromethorphan	66-69	caveolin 1	Homo sapiens	76-86
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Dextromethorphan	141-144	caveolin 1	Homo sapiens	35-45
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Dextromethorphan	141-144	caveolin 1	Homo sapiens	166-176
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Dextromethorphan	141-144	caveolin 1	Homo sapiens	166-176
17537407-5	2007	Treatment with actinomycin D (ACD) revealed that the effects of Dex are also, at least in part, mediated by stabilisation of caveolin-1 mRNA.	Dextromethorphan	64-67	caveolin 1	Homo sapiens	125-135
17612897-6	2007	PBM CD80 expression was significantly inhibited in CSA-treated animals, but increased in Dex-treated animals.	Dextromethorphan	89-92	Cd80 molecule	Rattus norvegicus	4-8
17452028-0	2007	Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma.	Dextromethorphan	48-64	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	25-40
17452028-2	2007	Consequently dextromethorphan, flurbiprofen, midazolam and other compounds are commonly used as probe substrates to evaluate cytochrome P450 function in humans.	Dextromethorphan	13-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	125-140
17409567-1	2007	The capability of Cunninghamella blakesleeana AS 3.153 to transform CYP2D6 probe drug dextromethorphan was investigated.	Dextromethorphan	86-102	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	68-74
17660178-7	2007	Overall, these results support greater pain relief attained over the first 3 d in patients with acute otitis externa treated with CIP/DEX compared with NPH and a rapid reduction in severe pain after initiation of treatment.	Dextromethorphan	134-137	muscular LMNA interacting protein	Homo sapiens	130-133
17386960-0	2007	Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats.	Dextromethorphan	0-16	sigma non-opioid intracellular receptor 1	Rattus norvegicus	67-82
17719518-0	2007	Dextromethorphan-induced near-fatal suicide attempt in a slow metabolizer at cytochrome P450 2D6.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	77-96
17392730-1	2007	A 5-year-old African-American girl presented with a CYP2D6*4xN/*10 genotype that was discordant with her poor metabolizer phenotype determined with the probe drug dextromethorphan.	Dextromethorphan	163-179	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	52-58
17236099-3	2007	Induction of NtMEK2 (DD) by DEX in the hybrid cells induced the activation of SIPK, the generation of hydrogen peroxide (H (2)O (2)), and cell death at 37 degrees C. The activation of SIPK, generation of H (2)O (2), and cell death at 26 degrees C were compromised by DEX treatment in hybrid cells harbouring NtMEK2 (KR).	Dextromethorphan	28-31	mitogen-activated protein kinase kinase 5-like	Nicotiana tabacum	13-19
17236099-3	2007	Induction of NtMEK2 (DD) by DEX in the hybrid cells induced the activation of SIPK, the generation of hydrogen peroxide (H (2)O (2)), and cell death at 37 degrees C. The activation of SIPK, generation of H (2)O (2), and cell death at 26 degrees C were compromised by DEX treatment in hybrid cells harbouring NtMEK2 (KR).	Dextromethorphan	28-31	mitogen-activated protein kinase kinase 5-like	Nicotiana tabacum	308-314
17236099-3	2007	Induction of NtMEK2 (DD) by DEX in the hybrid cells induced the activation of SIPK, the generation of hydrogen peroxide (H (2)O (2)), and cell death at 37 degrees C. The activation of SIPK, generation of H (2)O (2), and cell death at 26 degrees C were compromised by DEX treatment in hybrid cells harbouring NtMEK2 (KR).	Dextromethorphan	267-270	mitogen-activated protein kinase kinase 5-like	Nicotiana tabacum	13-19
17273835-11	2007	CONCLUSION: Application of the validation criteria suggests that dextromethorphan and debrisoquine are the best CYP2D6 phenotyping drugs, with debrisoquine having the problem of very limited availability as a therapeutic drug.	Dextromethorphan	65-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
17371531-4	2007	Urine samples (0-8 hr) were collected after administration of 30 mg of oral dextromethorphan (probe drug for CYP2D6) for analysis of dextromethorphan and dextrorphan.	Dextromethorphan	76-92	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-115
17273835-12	2007	However, the assessment of the best dextromethorphan CYP2D6 phenotyping metric/procedure is still ongoing.	Dextromethorphan	36-52	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	53-59
17118450-11	2007	We also show that upon MTX treatment PBMC from normal volunteers exhibit a higher sensitivity to DEX inhibition on LPS-induced TNF alpha release.	Dextromethorphan	97-100	metaxin 1	Homo sapiens	23-26
17498391-1	2007	PURPOSE: The purpose of this study was to quantify the intestinal metabolism of midazolam, a CYP P450 substrate, usually used as a probe for the activity of the isoform CYP3A4/1 and to compare it with previous results obtained for other P450 substrates such as testosterone, dextromethorphan and bupropion, which show some specificities for different CYP isoforms.	Dextromethorphan	275-291	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	169-177
17244768-0	2007	Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.	Dextromethorphan	172-188	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-116
17244768-1	2007	In vitro-in vivo extrapolation of clearance, embedded in a clinical trial simulation, was used to investigate differences in the pharmacokinetics and pharmacodynamics of dextromethorphan between CYP2D6 poor and extensive metabolizer phenotypes.	Dextromethorphan	170-186	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	195-201
17163453-5	2007	Compared with BLyS/LPS/TGF-beta alone, treatment with BLyS/LPS/TGF-beta/IL-4/IL-5/alpha delta Dex increased AcH3 at S alpha fourfold, and also increased GL alpha RNA levels more than eightfold.	Dextromethorphan	94-97	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	54-58
17163453-5	2007	Compared with BLyS/LPS/TGF-beta alone, treatment with BLyS/LPS/TGF-beta/IL-4/IL-5/alpha delta Dex increased AcH3 at S alpha fourfold, and also increased GL alpha RNA levels more than eightfold.	Dextromethorphan	94-97	transforming growth factor, beta 1	Mus musculus	63-71
17163453-5	2007	Compared with BLyS/LPS/TGF-beta alone, treatment with BLyS/LPS/TGF-beta/IL-4/IL-5/alpha delta Dex increased AcH3 at S alpha fourfold, and also increased GL alpha RNA levels more than eightfold.	Dextromethorphan	94-97	interleukin 5	Mus musculus	77-81
17163453-5	2007	Compared with BLyS/LPS/TGF-beta alone, treatment with BLyS/LPS/TGF-beta/IL-4/IL-5/alpha delta Dex increased AcH3 at S alpha fourfold, and also increased GL alpha RNA levels more than eightfold.	Dextromethorphan	94-97	galactosidase, alpha	Mus musculus	153-161
17498391-1	2007	PURPOSE: The purpose of this study was to quantify the intestinal metabolism of midazolam, a CYP P450 substrate, usually used as a probe for the activity of the isoform CYP3A4/1 and to compare it with previous results obtained for other P450 substrates such as testosterone, dextromethorphan and bupropion, which show some specificities for different CYP isoforms.	Dextromethorphan	275-291	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	169-172
16891616-8	2006	Pharmacophore analysis revealed that GIF shares common chemical properties (hydrogen bond acceptor, positive ionizable, and hydrophobic regions) with other subpicomolar-acting compounds known to inhibit NADPH oxidase: naloxone, dextromethorphan, and Gly-Gly-Phe.	Dextromethorphan	228-244	cobalamin binding intrinsic factor	Rattus norvegicus	37-40
17556849-2	2007	OBJECTIVE: SLEs influence the TRH and DEX/CRH tests in major depressive disorder when administered at the time of admission and improvement.	Dextromethorphan	38-41	corticotropin releasing hormone	Homo sapiens	42-45
17587180-9	2007	The inhibitory effects of DEX on somatic growth was paralleled by decreased 24 h food intake (FI), decreased food efficiency (FE) and lower plasma IGF-1 levels versus vehicle-treated rats.	Dextromethorphan	26-29	insulin-like growth factor 1	Rattus norvegicus	147-152
17083955-1	2006	Previous work in our laboratory has shown that acute exposure of primary rat hepatocyte cultures to non-toxic concentrations of arsenite causes major decreases in the DEX-mediated induction of CYP3A23 protein, with minor decreases in CYP3A23 mRNA.	Dextromethorphan	167-170	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	193-200
17083955-5	2006	This result, suggesting that the action of lactacystin is similar to arsenite and was post-transcriptional, was confirmed by the finding that lactacystin decreased association of DEX-induced CYP3A23 mRNA with polyribosomes.	Dextromethorphan	179-182	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	191-198
17077009-6	2006	CONCLUSION: CI-I and DEX can inhibit the decrease of ikappaBalpha expression and prevent TNF-alpha and IL-6 secretion in RAW264.7 cells attacked with LPS, which contributes to the alleviation of cellular injury.	Dextromethorphan	21-24	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	53-65
17046241-4	2006	In this study, we provided novel evidence that Dex induced the expressions of small GTPase RhoB mRNA and protein, but not RhoA and RhoC mRNA in a dose- and time-dependent fashion via glucocorticoid receptor (GR).	Dextromethorphan	47-50	ras homolog family member B	Homo sapiens	91-95
17046241-4	2006	In this study, we provided novel evidence that Dex induced the expressions of small GTPase RhoB mRNA and protein, but not RhoA and RhoC mRNA in a dose- and time-dependent fashion via glucocorticoid receptor (GR).	Dextromethorphan	47-50	nuclear receptor subfamily 3 group C member 1	Homo sapiens	183-206
17046241-4	2006	In this study, we provided novel evidence that Dex induced the expressions of small GTPase RhoB mRNA and protein, but not RhoA and RhoC mRNA in a dose- and time-dependent fashion via glucocorticoid receptor (GR).	Dextromethorphan	47-50	nuclear receptor subfamily 3 group C member 1	Homo sapiens	208-210
17046241-5	2006	Over-expression of RhoB increased while inhibition of RhoB expression by RNA interference reversed Dex-induced growth arrest, indicating that RhoB signaling is involved in Dex-induced proliferation inhibition.	Dextromethorphan	99-102	ras homolog family member B	Homo sapiens	19-23
17046241-5	2006	Over-expression of RhoB increased while inhibition of RhoB expression by RNA interference reversed Dex-induced growth arrest, indicating that RhoB signaling is involved in Dex-induced proliferation inhibition.	Dextromethorphan	99-102	ras homolog family member B	Homo sapiens	54-58
17046241-5	2006	Over-expression of RhoB increased while inhibition of RhoB expression by RNA interference reversed Dex-induced growth arrest, indicating that RhoB signaling is involved in Dex-induced proliferation inhibition.	Dextromethorphan	99-102	ras homolog family member B	Homo sapiens	54-58
17046241-5	2006	Over-expression of RhoB increased while inhibition of RhoB expression by RNA interference reversed Dex-induced growth arrest, indicating that RhoB signaling is involved in Dex-induced proliferation inhibition.	Dextromethorphan	172-175	ras homolog family member B	Homo sapiens	19-23
17046241-5	2006	Over-expression of RhoB increased while inhibition of RhoB expression by RNA interference reversed Dex-induced growth arrest, indicating that RhoB signaling is involved in Dex-induced proliferation inhibition.	Dextromethorphan	172-175	ras homolog family member B	Homo sapiens	54-58
17046241-5	2006	Over-expression of RhoB increased while inhibition of RhoB expression by RNA interference reversed Dex-induced growth arrest, indicating that RhoB signaling is involved in Dex-induced proliferation inhibition.	Dextromethorphan	172-175	ras homolog family member B	Homo sapiens	54-58
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	72-75	ras homolog family member B	Homo sapiens	23-27
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	72-75	nuclear factor kappa B subunit 1	Homo sapiens	79-88
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	ras homolog family member B	Homo sapiens	117-121
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	nuclear factor kappa B subunit 1	Homo sapiens	168-177
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	ras homolog family member B	Homo sapiens	117-121
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	nuclear factor kappa B subunit 1	Homo sapiens	168-177
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	nuclear factor kappa B subunit 1	Homo sapiens	168-177
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	ras homolog family member B	Homo sapiens	117-121
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	nuclear factor kappa B subunit 1	Homo sapiens	168-177
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	ras homolog family member B	Homo sapiens	117-121
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	nuclear factor kappa B subunit 1	Homo sapiens	168-177
17046241-7	2006	Furthermore, elevating RhoB signaling enhanced the inhibitory effect of Dex on NF-kappaB activity, while attenuating RhoB signaling almost abrogated Dex suppression of NF-kappaB signaling, indicating that RhoB pathway is involved in the regulation of NF-kappaB activity and is essential for Dex transcriptional repression on NF-kappaB signaling in HO-8910 cells.	Dextromethorphan	149-152	nuclear factor kappa B subunit 1	Homo sapiens	168-177
17191579-7	2006	The expression of EGF was weaker and weaker and that of EGFR was stronger and stronger as following order: NS, TET, DEX, T+D and control groups; showing significant differences between them (P<0.05).	Dextromethorphan	116-119	epidermal growth factor like 1	Rattus norvegicus	18-21
17191579-7	2006	The expression of EGF was weaker and weaker and that of EGFR was stronger and stronger as following order: NS, TET, DEX, T+D and control groups; showing significant differences between them (P<0.05).	Dextromethorphan	116-119	epidermal growth factor receptor	Rattus norvegicus	56-60
17050794-3	2006	CEE significantly decreased CYP1A2 (caffeine metabolic ratio: 0.57 +/- 0.20 before, 0.40 +/- 0.20 after, P = .001) and significantly increased CYP2D6 (dextromethorphan/dextrorphan ratio: 0.0116 +/- 0.0143 before, 0.0084 +/- 0.0135 after, P = .022) metabolism.	Dextromethorphan	151-167	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	143-149
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	Dextromethorphan	155-158	tumor necrosis factor	Mus musculus	22-31
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	Dextromethorphan	155-158	interleukin 6	Mus musculus	36-40
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	Dextromethorphan	208-211	tumor necrosis factor	Mus musculus	22-31
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	Dextromethorphan	208-211	interleukin 6	Mus musculus	36-40
17077009-6	2006	CONCLUSION: CI-I and DEX can inhibit the decrease of ikappaBalpha expression and prevent TNF-alpha and IL-6 secretion in RAW264.7 cells attacked with LPS, which contributes to the alleviation of cellular injury.	Dextromethorphan	21-24	tumor necrosis factor	Mus musculus	89-98
17077009-6	2006	CONCLUSION: CI-I and DEX can inhibit the decrease of ikappaBalpha expression and prevent TNF-alpha and IL-6 secretion in RAW264.7 cells attacked with LPS, which contributes to the alleviation of cellular injury.	Dextromethorphan	21-24	interleukin 6	Mus musculus	103-107
16595712-4	2006	The activity of this purified enzyme was directly compared with purified human CYP2D6 toward codeine, dextromethorphan, and methadone as substrates.	Dextromethorphan	102-118	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
16989778-4	2006	RESULTS: On admission, TNF-alpha levels were inversely associated with the ACTH response to the combined dex/CRH test.	Dextromethorphan	105-108	tumor necrosis factor	Homo sapiens	23-32
16989778-4	2006	RESULTS: On admission, TNF-alpha levels were inversely associated with the ACTH response to the combined dex/CRH test.	Dextromethorphan	105-108	proopiomelanocortin	Homo sapiens	75-79
16989778-5	2006	Changes in TNF-alpha, sTNF-R p55, and sTNF-R p75 plasma levels from admission to discharge were positively correlated with the dex/CRH test outcome at discharge.	Dextromethorphan	127-130	tumor necrosis factor	Homo sapiens	11-20
16989778-5	2006	Changes in TNF-alpha, sTNF-R p55, and sTNF-R p75 plasma levels from admission to discharge were positively correlated with the dex/CRH test outcome at discharge.	Dextromethorphan	127-130	TNF receptor superfamily member 1B	Homo sapiens	45-48
16989778-5	2006	Changes in TNF-alpha, sTNF-R p55, and sTNF-R p75 plasma levels from admission to discharge were positively correlated with the dex/CRH test outcome at discharge.	Dextromethorphan	127-130	corticotropin releasing hormone	Homo sapiens	131-134
16340958-6	2006	Drugs that are known to inhibit cortical spreading depression (CSD), such as N-methyl-D-aspartate receptor antagonists MK-801 and 7-chlorokynurenic acid, and sigma-1 receptor agonists dextromethorphan and carbetapentane, did not reduce the frequency of PIDs, but did diminish the severity of episodic hypoperfusions, and prevented the expansion of severely hypoperfused cortex, thus improving CBF during 90 mins of acute focal ischemia.	Dextromethorphan	184-200	sigma non-opioid intracellular receptor 1	Mus musculus	158-174
16621933-4	2006	As for DEM, both NO donors increased (up to 3.5-fold) the recovery of the CYP2D1-mediated metabolite dextrorphan (DOR) in the outlet perfusate.	Dextromethorphan	7-10	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	74-80
17102541-3	2006	AIM: To study the influence of some CYP2D6 genotypes on the metabolism of its substrate dextromethorphan in healthy South Indian volunteers and to assess the contribution of the CYP2D6*10 and CYP2D6*4 alleles.	Dextromethorphan	88-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
17102541-6	2006	Volunteers were phenotyped for the CYP2D6 enzyme using dextromethorphan as probe drug.	Dextromethorphan	55-71	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	35-41
16621933-7	2006	Additionally, both SNP and ISDN significantly reduced the metabolism of DEM to 3-hydroxymorphinan, which is mostly regulated by CYP3A2.	Dextromethorphan	72-75	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	128-134
16595712-5	2006	Purified Cyp2d22 was found to catalyze the O-demethylation of dextromethorphan with significantly higher K(m) values (250 microM) than that (4.2 microM) exhibited by purified human CYP2D6.	Dextromethorphan	62-78	cytochrome P450, family 2, subfamily d, polypeptide 22	Mus musculus	9-16
16595712-5	2006	Purified Cyp2d22 was found to catalyze the O-demethylation of dextromethorphan with significantly higher K(m) values (250 microM) than that (4.2 microM) exhibited by purified human CYP2D6.	Dextromethorphan	62-78	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	181-187
16630563-3	2006	Calcium chelators EGTA and BAPTA reduced [Ca2+]i levels and protected CEM-C7-14 cells from Dex-evoked E4BP4 upregulation as well as apoptosis.	Dextromethorphan	91-94	nuclear factor, interleukin 3 regulated	Homo sapiens	102-107
16913391-10	2006	Dextromethorphan, with and without effector, was incubated with pooled human liver and recombinant CYP 2D6-containing microsomes.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	99-106
16219421-5	2006	Mecamylamine, dextromethorphan and 18-methoxycoronaridine inhibited nicotine-induced ERK phosphorylation with much higher affinity than dihydro-beta-erythroidine and alpha-conotoxin MII.	Dextromethorphan	14-30	Eph receptor B1	Rattus norvegicus	85-88
16414224-1	2006	Thirty samples of Indonesian medicinal plants were tested for their mechanism-based inhibition on cytochrome P450 3A4 (CYP3A4) and CYP2D6 via erythromycin N-demethylation and dextromethorphan O-demethylation activities in human liver microsomes.	Dextromethorphan	175-191	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-117
16414224-1	2006	Thirty samples of Indonesian medicinal plants were tested for their mechanism-based inhibition on cytochrome P450 3A4 (CYP3A4) and CYP2D6 via erythromycin N-demethylation and dextromethorphan O-demethylation activities in human liver microsomes.	Dextromethorphan	175-191	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-125
16414224-1	2006	Thirty samples of Indonesian medicinal plants were tested for their mechanism-based inhibition on cytochrome P450 3A4 (CYP3A4) and CYP2D6 via erythromycin N-demethylation and dextromethorphan O-demethylation activities in human liver microsomes.	Dextromethorphan	175-191	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137
16563352-0	2006	Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy.	Dextromethorphan	22-38	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-129
16563352-2	2006	Resonance Raman data, reported for the first time for CYP2D6, show that the CYP2D6 heme is found to be in a six-coordinated low-spin state in the absence of substrates, and it is perturbed to different extents by bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine (MDMA).	Dextromethorphan	224-240	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
16563352-2	2006	Resonance Raman data, reported for the first time for CYP2D6, show that the CYP2D6 heme is found to be in a six-coordinated low-spin state in the absence of substrates, and it is perturbed to different extents by bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine (MDMA).	Dextromethorphan	224-240	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	76-82
16563352-3	2006	Dextromethorphan and MDMA induce in CYP2D6 a significant amount of five-coordinated high-spin heme species and reduce the polarity of its heme-pocket, whereas bufuralol does not.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
16563352-4	2006	Spectra of the F120A mutant CYP2D6 suggest that Phe120 is involved in substrate-binding of dextromethorphan and MDMA, being responsible for the spectral differences observed between these two compounds and bufuralol.	Dextromethorphan	91-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	28-34
16563352-5	2006	These differences could be explained postulating a different substrate mobility for each compound in the CYP2D6 active site, consistently with the role previously suggested for Phe120 in binding dextromethorphan and MDMA.	Dextromethorphan	195-211	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	105-111
16984212-6	2006	CYP2D6 phenotype was assigned following single-dose dextromethorphan administration.	Dextromethorphan	52-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
16364007-8	2006	DEX treatment reduced IL-8 levels in control and LPS-treated cultures by 70-90%.	Dextromethorphan	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	22-26
16368922-5	2006	Changes in the dextromethorphan/dextrorphan urine metabolic ratio (MRDX) measured the effect on CYP2D6 metabolism following a 30 mg dose of dextromethorphan in the absence and presence of lasofoxifene (days 2 and 7).	Dextromethorphan	15-31	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	96-102
16368922-5	2006	Changes in the dextromethorphan/dextrorphan urine metabolic ratio (MRDX) measured the effect on CYP2D6 metabolism following a 30 mg dose of dextromethorphan in the absence and presence of lasofoxifene (days 2 and 7).	Dextromethorphan	140-156	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	96-102
16315033-1	2005	OBJECTIVE: Dextromethorphan (DEM) shares part of the adverse event profile of opioids and is widely used as a probe drug for CYP2D6 phenotyping and for the assessment of CYP2D6 activity.	Dextromethorphan	11-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	125-131
16269134-2	2005	The T309V mutant of CYP2D6 displayed a strong shift from O-dealkylation to N-dealkylation reactions in oxidation of dextromethorphan and 3,4-methylenedioxymethylamphetamine.	Dextromethorphan	116-132	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	20-26
16125735-3	2005	The substrates used in this study were tolbutamide (CYP2C6), dextromethorphan (CYP2D2) and midazolam (CYP3A2).	Dextromethorphan	61-77	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	79-85
16315033-0	2005	Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.	Dextromethorphan	55-71	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	15-21
17003573-0	2006	Additive effect of dextromethorphan on the inhibitory effect of anti-NT4 on morphine tolerance.	Dextromethorphan	19-35	neurotrophin 4	Rattus norvegicus	69-72
17003573-13	2006	Dextromethorphan in both doses (10 or 30 mg/kg) has an additive effect on the inhibitory effect of anti-NT4 on the reversal of morphine tolerance (7 mg/kg).	Dextromethorphan	0-16	neurotrophin 4	Rattus norvegicus	104-107
16283274-2	2005	METHODS: CYP2D6 gene sequence variations associated with *6, *7, *8, *9, *11, *14, *29, *41, *45, and *46 alleles as well as the 2988G>A SNP were examined in 264 Mexican Americans; 236 had previously been phenotyped with dextromethorphan.	Dextromethorphan	224-240	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	9-15
16283274-10	2005	CONCLUSIONS: The CYP2D6*4, *5, and *6 null alleles along the reduced function alleles *9, *10, and *41 are the major cause for diminished dextromethorphan oxidative capacity in Mexican Americans.	Dextromethorphan	138-154	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	17-23
16315033-1	2005	OBJECTIVE: Dextromethorphan (DEM) shares part of the adverse event profile of opioids and is widely used as a probe drug for CYP2D6 phenotyping and for the assessment of CYP2D6 activity.	Dextromethorphan	11-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	170-176
16315033-1	2005	OBJECTIVE: Dextromethorphan (DEM) shares part of the adverse event profile of opioids and is widely used as a probe drug for CYP2D6 phenotyping and for the assessment of CYP2D6 activity.	Dextromethorphan	29-32	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	125-131
16315033-1	2005	OBJECTIVE: Dextromethorphan (DEM) shares part of the adverse event profile of opioids and is widely used as a probe drug for CYP2D6 phenotyping and for the assessment of CYP2D6 activity.	Dextromethorphan	29-32	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	170-176
16315033-5	2005	CYP2D6 and CYP3A4 metabolic ratios were measured as the log of the ratios of the amount of DEM to the amount of dextrorphan (DOR) and of the amount of DEM to the amount of 3-methoxy-morphinan (MET) excreted in urine during a 12-h time period, respectively, following the oral administration of 80 mg of dextromethorphan hydrobromide.	Dextromethorphan	91-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
16315033-5	2005	CYP2D6 and CYP3A4 metabolic ratios were measured as the log of the ratios of the amount of DEM to the amount of dextrorphan (DOR) and of the amount of DEM to the amount of 3-methoxy-morphinan (MET) excreted in urine during a 12-h time period, respectively, following the oral administration of 80 mg of dextromethorphan hydrobromide.	Dextromethorphan	91-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
16315033-5	2005	CYP2D6 and CYP3A4 metabolic ratios were measured as the log of the ratios of the amount of DEM to the amount of dextrorphan (DOR) and of the amount of DEM to the amount of 3-methoxy-morphinan (MET) excreted in urine during a 12-h time period, respectively, following the oral administration of 80 mg of dextromethorphan hydrobromide.	Dextromethorphan	151-154	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
16315033-5	2005	CYP2D6 and CYP3A4 metabolic ratios were measured as the log of the ratios of the amount of DEM to the amount of dextrorphan (DOR) and of the amount of DEM to the amount of 3-methoxy-morphinan (MET) excreted in urine during a 12-h time period, respectively, following the oral administration of 80 mg of dextromethorphan hydrobromide.	Dextromethorphan	151-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
16315033-5	2005	CYP2D6 and CYP3A4 metabolic ratios were measured as the log of the ratios of the amount of DEM to the amount of dextrorphan (DOR) and of the amount of DEM to the amount of 3-methoxy-morphinan (MET) excreted in urine during a 12-h time period, respectively, following the oral administration of 80 mg of dextromethorphan hydrobromide.	Dextromethorphan	303-332	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
16315033-5	2005	CYP2D6 and CYP3A4 metabolic ratios were measured as the log of the ratios of the amount of DEM to the amount of dextrorphan (DOR) and of the amount of DEM to the amount of 3-methoxy-morphinan (MET) excreted in urine during a 12-h time period, respectively, following the oral administration of 80 mg of dextromethorphan hydrobromide.	Dextromethorphan	303-332	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
16315033-11	2005	CONCLUSIONS: Dextromethorphan can be used for CYP2D6 phenotyping, but the CYP2D6 and CYP3A4 metabolic ratios are not strictly independent one from each other.	Dextromethorphan	13-29	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
16222729-7	2005	Microsomes containing human CPR and CYP2D6 converted different substrates, such as 3-cyano-7-ethoxycoumarin, parathion and dextrometorphan.	Dextromethorphan	123-138	cytochrome p450 oxidoreductase	Homo sapiens	28-31
16182522-12	2005	Furthermore, we show that an increase in GR levels under certain circumstances could considerably potentiate the effects of glucocorticoids on the cAspAT promoter via synergistic activation of both GRU, To the opposite, an enhancement in GR levels did not further potentiate Dex-activation of the GS promoter, showing a differential mechanism of action of GR in the context of both promoters.	Dextromethorphan	275-278	glutamic-oxaloacetic transaminase 1, soluble	Mus musculus	147-153
16182522-12	2005	Furthermore, we show that an increase in GR levels under certain circumstances could considerably potentiate the effects of glucocorticoids on the cAspAT promoter via synergistic activation of both GRU, To the opposite, an enhancement in GR levels did not further potentiate Dex-activation of the GS promoter, showing a differential mechanism of action of GR in the context of both promoters.	Dextromethorphan	275-278	nuclear receptor subfamily 3, group C, member 1	Mus musculus	41-43
16222729-7	2005	Microsomes containing human CPR and CYP2D6 converted different substrates, such as 3-cyano-7-ethoxycoumarin, parathion and dextrometorphan.	Dextromethorphan	123-138	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
16222729-8	2005	The kinetic parameters of dextrometorphan conversion closely matched those of CYP2D6 from other recombinant expression systems and human microsomes.	Dextromethorphan	26-41	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
16151560-7	2005	Recipe-like extraction procedures are quickly available on the Internet for seemingly simple and inexpensive home manufacture of concentrated dextromethorphan powder from Coricidin HBP Cough & Cold tablets (street name triple C).	Dextromethorphan	142-158	heme binding protein 1	Homo sapiens	181-184
16239355-0	2005	The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.	Dextromethorphan	38-54	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
16239355-4	2005	The objectives of the present study were to assess the metabolic activity of CYP2D6 in a Mexican American population using dextromethorphan and to correlate this metabolic activity with a genotypic analysis.	Dextromethorphan	123-139	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	77-83
16079895-6	2005	Thal/Dex administration resulted in a significant reduction of sRANKL/OPG ratio, and bone resorption.	Dextromethorphan	5-8	TNF receptor superfamily member 11b	Homo sapiens	70-73
16079895-13	2005	These results suggest that the combination of intermediate dose of Thal/Dex is effective in patients with refractory/relapsed myeloma and improves abnormal bone remodeling through the reduction of sRANKL/OPG ratio.	Dextromethorphan	72-75	TNF receptor superfamily member 11b	Homo sapiens	204-207
15964599-0	2005	Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil.	Dextromethorphan	24-40	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	97-101
16176333-10	2005	On the contrary, a low correlation with CYP2D6 activity as determined by dextrometorphan O-demethylation (r(2)=0.31) was established.	Dextromethorphan	73-88	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-46
16207427-1	2005	OBJECTIVE: To study the expression levels of endothelin-1(ET-1) and nuclear factor-kappaB (NF-kappaB) in lung vascular endothelium, bronchial and alveolar epithelia in acute pulmonary thromboembolism (APTE), and to explore the effects of thrombolytic (urokinase, UK) or ant-inflammatory therapy (dexamethasone, Dex) on their expressions.	Dextromethorphan	311-314	endothelin-1	Oryctolagus cuniculus	45-57
16081774-5	2005	In this study, we show that LNFPIII-Dex stimulation of APCs induces rapid, but transient NF-kappaB translocation and activity in the nucleus, in comparison with the persistent activation induced by LPS.	Dextromethorphan	36-39	amyloid P component, serum	Homo sapiens	55-59
16081774-5	2005	In this study, we show that LNFPIII-Dex stimulation of APCs induces rapid, but transient NF-kappaB translocation and activity in the nucleus, in comparison with the persistent activation induced by LPS.	Dextromethorphan	36-39	nuclear factor kappa B subunit 1	Homo sapiens	89-98
16207427-14	2005	In the UK + Dex group, the ET-1 expression was 0.186 +/- 0.033, 0.107 +/- 0.012 and 0.098 +/- 0.026 respectively, significantly different from the PTE group (all P < 0.05); the NF-kappaB P65 expression was 0.109 +/- 0.018, 0.062 +/- 0.023 and 0.093 +/- 0.019 respectively, significantly lower as compared with the PTE and the UK groups (all P < 0.	Dextromethorphan	12-15	endothelin-1	Oryctolagus cuniculus	27-31
15979871-5	2005	DEX and HCT in the submicromolar concentration range caused a 2-fold induction of transcriptional activity at the MRP3 promoter construct, while MRP2 expression was not activated.	Dextromethorphan	0-3	ATP binding cassette subfamily C member 3	Homo sapiens	114-118
15723099-9	2005	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	Dextromethorphan	29-45	sigma non-opioid intracellular receptor 1	Mus musculus	106-121
15870909-7	2005	Dex down-regulated CD10/NEP expression on immature B cell line NALM-6 in a concentration- and time-dependent fashion.	Dextromethorphan	0-3	membrane metalloendopeptidase	Homo sapiens	19-23
15870909-7	2005	Dex down-regulated CD10/NEP expression on immature B cell line NALM-6 in a concentration- and time-dependent fashion.	Dextromethorphan	0-3	membrane metalloendopeptidase	Homo sapiens	24-27
15870909-9	2005	Dex-induced CD10/NEP down-regulation was mediated via glucocorticoid receptors (GR), as it was fully abrogated by a GR antagonist, RU 38486.	Dextromethorphan	0-3	membrane metalloendopeptidase	Homo sapiens	12-16
15870909-9	2005	Dex-induced CD10/NEP down-regulation was mediated via glucocorticoid receptors (GR), as it was fully abrogated by a GR antagonist, RU 38486.	Dextromethorphan	0-3	membrane metalloendopeptidase	Homo sapiens	17-20
15970126-1	2005	We analyzed cytochrome P450 2D6 polymorphism by determining phenotype as the metabolic ratio between dextromethorphan and its main metabolite, dextrorphan.	Dextromethorphan	101-117	cytochrome P450 2D6	Homo sapiens	12-31
15907323-7	2005	These results suggest that DEX ameliorate the impairments of arterial relaxation induced by proliferative stimuli and that these beneficial effects may be mediated by maintaining the adhesion of endothelial cells to the vascular wall and/or by recovering eNOS mRNA expression.	Dextromethorphan	27-30	nitric oxide synthase, endothelial	Oryctolagus cuniculus	255-259
15777360-3	2005	RESULTS: The cortisol response to the dex/CRH test correlated significantly between the 2 tests (r = 0.997; p < 0.0005).	Dextromethorphan	38-41	corticotropin releasing hormone	Homo sapiens	42-45
15821042-1	2005	Dextromethorphan urinary metabolic ratio is widely used to determine the CYP2D6 phenotype, but its utility to reflect subtle differences in catalytic activity is unclear.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	73-79
15821042-3	2005	Data from 10 healthy extensive metabolizers of CYP2D6 were given 30 mg of dextromethorphan hydrobromide orally on two occasions.	Dextromethorphan	74-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
16053268-5	2005	This indicates that dextromethorphan induces the behavioural syndrome by releasing 5-HT from serotonergic neurons with resultant activation of the postsynaptic 5-HT1A receptors by the released 5-HT.	Dextromethorphan	20-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	160-166
15988119-0	2005	Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.	Dextromethorphan	14-30	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
15988119-3	2005	The results of low formations of dextrorphan (DXO) and 3-hydroxymorphinan (3-HM) in CYP2D6 PM hepatocytes incubated with dextromethorphan reflected the clinical data.	Dextromethorphan	121-137	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	84-90
15723099-9	2005	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	Dextromethorphan	29-45	sigma non-opioid intracellular receptor 1	Mus musculus	251-266
15723099-9	2005	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	Dextromethorphan	187-203	sigma non-opioid intracellular receptor 1	Mus musculus	106-121
15723099-9	2005	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	Dextromethorphan	187-203	sigma non-opioid intracellular receptor 1	Mus musculus	251-266
15797796-1	2005	A direct injection LC/MS/MS method involving a novel incubation technique was developed for the inhibition screening of CYP 2D6 and CYP 3A4 isoenzymes using dextromethorphan and midazolam as probe substrates.	Dextromethorphan	157-173	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	120-127
15797796-1	2005	A direct injection LC/MS/MS method involving a novel incubation technique was developed for the inhibition screening of CYP 2D6 and CYP 3A4 isoenzymes using dextromethorphan and midazolam as probe substrates.	Dextromethorphan	157-173	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-139
16089243-3	2005	Methadone has been found to inhibit CYP2D6, indicating a potential for interaction with dextromethorphan.	Dextromethorphan	88-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
15754397-13	2005	RESULTS: There were significant differences in ALT of the five groups (F = 23.164 P = 0.000), and ALT in Dex-SpC group was significantly higher than that in blank control, control, Dex, and SpC groups (P = 0.000), and ALT in SpC group was significantly higher than that in blank control (P = 0.000), control (P = 0.004), and Dex groups (P = 0.02).	Dextromethorphan	105-108	surfactant protein C	Rattus norvegicus	109-112
15792399-1	2005	OBJECTIVE: To determine the CYP2D6 phenotype in a Greek population by using dextromethorphan (DM) as a probe drug.	Dextromethorphan	76-92	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	28-34
15754397-13	2005	RESULTS: There were significant differences in ALT of the five groups (F = 23.164 P = 0.000), and ALT in Dex-SpC group was significantly higher than that in blank control, control, Dex, and SpC groups (P = 0.000), and ALT in SpC group was significantly higher than that in blank control (P = 0.000), control (P = 0.004), and Dex groups (P = 0.02).	Dextromethorphan	105-108	surfactant protein C	Rattus norvegicus	190-193
15754397-13	2005	RESULTS: There were significant differences in ALT of the five groups (F = 23.164 P = 0.000), and ALT in Dex-SpC group was significantly higher than that in blank control, control, Dex, and SpC groups (P = 0.000), and ALT in SpC group was significantly higher than that in blank control (P = 0.000), control (P = 0.004), and Dex groups (P = 0.02).	Dextromethorphan	105-108	surfactant protein C	Rattus norvegicus	190-193
15754397-15	2005	T bili in Dex-SpC group was significantly higher than that in blank control, control, Dex, and SpC groups.	Dextromethorphan	10-13	surfactant protein C	Rattus norvegicus	14-17
15716633-9	2005	Both tSD and subsequent damage were blocked by the NMDA receptor antagonist MK-801 (100 microM) or the sigma-1 receptor (sigma1R) ligands dextromethorphan (30 microM) or BD-1063 (100 microM).	Dextromethorphan	138-154	sigma non-opioid intracellular receptor 1	Homo sapiens	103-119
15716633-9	2005	Both tSD and subsequent damage were blocked by the NMDA receptor antagonist MK-801 (100 microM) or the sigma-1 receptor (sigma1R) ligands dextromethorphan (30 microM) or BD-1063 (100 microM).	Dextromethorphan	138-154	sigma non-opioid intracellular receptor 1	Homo sapiens	121-128
15869321-1	2005	Avanir Pharmaceuticals in the US is developing a fixed-dose combination of dextromethorphan (30 mg), a weak NMDA antagonist/sigma 1 agonist, and quinidine (30 mg), a cytochrome P450-2D6 (CYP2D6) enzyme inhibitor [AVP 923, Neurodextrade mark].	Dextromethorphan	75-91	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	187-193
15537648-7	2005	An inward membrane current activated by subnanomolar concentrations of orexin-A and the currents activated upon transient expression of trpc3 channels were also sensitive to Mg(2+), dextromethorphan, and tetraethylammonium.	Dextromethorphan	182-198	transient receptor potential cation channel subfamily C member 3	Homo sapiens	136-141
15356218-5	2005	In oocytes expressing various neuronal acetylcholine nicotinic receptors (nAChR), dextrometorphan and dextrorphan blocked nicotine activation of expressed alpha(3)beta(4), alpha(4)beta(2), and alpha(7) subtypes with a small degree of selectivity.	Dextromethorphan	82-97	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	74-79
15356218-8	2005	In that respect, dextrometorphan seems to behave as another mecamylamine, a noncompetitive nicotinic receptor antagonist with a preferential activity to alpha(3)beta(4)(*) neuronal nAChR subtypes.	Dextromethorphan	17-32	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	181-186
15627475-9	2005	Real-time RT-PCR analysis revealed that DM administration suppressed the expression of a variety of inflammation-related genes such as macrophage inflammatory protein-2, CXC chemokine, thrombospondin-1, intercellular adhesion molecular-1 and interleukin-6.	Dextromethorphan	40-42	chemokine (C-X-C motif) ligand 2	Mus musculus	135-168
15627475-9	2005	Real-time RT-PCR analysis revealed that DM administration suppressed the expression of a variety of inflammation-related genes such as macrophage inflammatory protein-2, CXC chemokine, thrombospondin-1, intercellular adhesion molecular-1 and interleukin-6.	Dextromethorphan	40-42	thrombospondin 1	Mus musculus	185-237
15627475-9	2005	Real-time RT-PCR analysis revealed that DM administration suppressed the expression of a variety of inflammation-related genes such as macrophage inflammatory protein-2, CXC chemokine, thrombospondin-1, intercellular adhesion molecular-1 and interleukin-6.	Dextromethorphan	40-42	interleukin 6	Mus musculus	242-255
15591770-6	2004	Meanwhile, DM (5 mg/kg) significantly inhibited the elevation of plasma tumor necrosis factor-alpha and interleukin-10 levels, as well as values of GOT and GPT (as an index of liver function), and BUN and creatinine (as an index of renal function) caused by LPS.	Dextromethorphan	11-13	tumor necrosis factor	Rattus norvegicus	72-99
15664414-12	2005	In 5 and 50 ng DEX-treated groups, p27kip1 mRNA was dramatically increased in comparison with control groups.	Dextromethorphan	15-18	cyclin dependent kinase inhibitor 1B	Homo sapiens	35-42
15664414-14	2005	This result shows that p27kip1 may play a role in late period of mouse placental development and p57kip2 may play a role in middle period of mouse placental development, and that p27kip1 may play a role in growth inhibition of human choriocarcinoma cells and could be up-regulated by DEX in human choriocarcinoma.	Dextromethorphan	284-287	cyclin-dependent kinase inhibitor 1C (P57)	Mus musculus	97-104
15664414-14	2005	This result shows that p27kip1 may play a role in late period of mouse placental development and p57kip2 may play a role in middle period of mouse placental development, and that p27kip1 may play a role in growth inhibition of human choriocarcinoma cells and could be up-regulated by DEX in human choriocarcinoma.	Dextromethorphan	284-287	cyclin-dependent kinase inhibitor 1B	Mus musculus	179-186
15556536-0	2004	LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation.	Dextromethorphan	21-37	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-94
15556536-1	2004	In order to establish a fast screening method for the determination of the CYP2D6 metabolic phenotype a sensitive LC-MS/MS assay to quantify dextromethorphan (DEX) and its O-demethylated metabolite dextrorphan (DOR) in human saliva was developed with limits of quantitation of 1 pmol/ml.	Dextromethorphan	141-157	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	75-81
15556536-1	2004	In order to establish a fast screening method for the determination of the CYP2D6 metabolic phenotype a sensitive LC-MS/MS assay to quantify dextromethorphan (DEX) and its O-demethylated metabolite dextrorphan (DOR) in human saliva was developed with limits of quantitation of 1 pmol/ml.	Dextromethorphan	159-162	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	75-81
15556536-8	2004	The three poor CYP2D6 metabolizers excreted relatively high amounts of the parent compound DEX (up to 7 micromol), but only low amounts of glucuronides (DORGlu: 0.4-1.0 micromol; HOMGlu: 0.2-0.7 micromol).	Dextromethorphan	91-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	15-21
15383492-6	2004	CYP3A5 exhibited comparable metabolic activity as CYP3A4 (90-110%) toward dextromethorphan N-demethylation and carbamazepine epoxidation.	Dextromethorphan	74-90	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
15383492-6	2004	CYP3A5 exhibited comparable metabolic activity as CYP3A4 (90-110%) toward dextromethorphan N-demethylation and carbamazepine epoxidation.	Dextromethorphan	74-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
16416672-2	2005	Dextrometorphan (DM) has been used as a test compound to evaluate the in vivo activity of CYP2D6.	Dextromethorphan	0-15	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	90-96
15582917-0	2004	P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6.	Dextromethorphan	44-60	phosphoglycolate phosphatase	Mus musculus	0-14
15582917-0	2004	P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6.	Dextromethorphan	44-60	phosphoglycolate phosphatase	Mus musculus	163-167
15582917-1	2004	In this study, the role of P-glycoprotein (P-gp) for the pharmacokinetics of dextromethorphan, a CYP2D6 substrate, and of melperone, a CYP2D6 inhibitor, was investigated.	Dextromethorphan	77-93	phosphoglycolate phosphatase	Mus musculus	27-41
15582917-1	2004	In this study, the role of P-glycoprotein (P-gp) for the pharmacokinetics of dextromethorphan, a CYP2D6 substrate, and of melperone, a CYP2D6 inhibitor, was investigated.	Dextromethorphan	77-93	phosphoglycolate phosphatase	Mus musculus	43-47
15582917-5	2004	The concentration of dextromethorphan in the brain was more than twice as high in abcb1ab (-/-) mice compared to wild-type mice.	Dextromethorphan	21-37	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	82-87
15582917-6	2004	Therefore, P-gp appears to be a factor in the uptake of dextromethorphan into the mouse brain, and abcb1-polymorphisms need to be considered for CYP2D6 phenotyping experiments with this drug.	Dextromethorphan	56-72	phosphoglycolate phosphatase	Mus musculus	11-15
15582917-8	2004	P-gp is a factor in the uptake of dextromethorphan, but not of melperone.	Dextromethorphan	34-50	phosphoglycolate phosphatase	Mus musculus	0-4
15591770-6	2004	Meanwhile, DM (5 mg/kg) significantly inhibited the elevation of plasma tumor necrosis factor-alpha and interleukin-10 levels, as well as values of GOT and GPT (as an index of liver function), and BUN and creatinine (as an index of renal function) caused by LPS.	Dextromethorphan	11-13	interleukin 10	Rattus norvegicus	104-118
15591770-6	2004	Meanwhile, DM (5 mg/kg) significantly inhibited the elevation of plasma tumor necrosis factor-alpha and interleukin-10 levels, as well as values of GOT and GPT (as an index of liver function), and BUN and creatinine (as an index of renal function) caused by LPS.	Dextromethorphan	11-13	glutamic--pyruvic transaminase	Rattus norvegicus	156-159
15458850-3	2004	The main result is a statistically significant difference concerning the delta value for cortisol plasma value on the DEX/CRH test for depressed patients with two or more previous episodes compared to healthy controls.	Dextromethorphan	118-121	corticotropin releasing hormone	Homo sapiens	122-125
15364549-4	2004	The monotonic concentration response for repression of QOR gene products up to 100 microM DEX concentration demonstrated that the glucocorticoid receptor (GR) was most likely involved in this process.	Dextromethorphan	90-93	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	130-153
15555450-1	2004	AIM: To explore the expression of IL-18 in patients with active lupus nephritis(LN) and the inhibitory effects of immunosupressive agents FK506, cyclosporin A (CsA) and dexamethasone(DEX).	Dextromethorphan	183-186	interleukin 18	Homo sapiens	34-39
15336363-0	2004	Development of a chromatographic bioreactor based on immobilized beta-glucuronidase on monolithic support for the determination of dextromethorphan and dextrorphan in human urine.	Dextromethorphan	131-147	glucuronidase beta	Homo sapiens	65-83
15336363-1	2004	We here reported the development and application of an immobilized enzyme reactor (IMER) based on beta-glucuronidase to the on-line determination of urinary molar ratios of dextromethorphan (DOMe)/dextrorphan (DOH) for the assessment of the metabolic activity of CYP2D6, a genetically variable isoform of cytochrome P-450 (CYP).	Dextromethorphan	173-189	glucuronidase beta	Homo sapiens	98-116
15555450-5	2004	FK506, CsA and DEX suppressed significantly the expressions of IL-18 mRNA and its protein (P<0.001) in LPS/PHA-stimulated whole blood cell from LN patients.	Dextromethorphan	15-18	interleukin 18	Homo sapiens	63-68
15555450-6	2004	The inhibitory effects of FK506, CsA and DEX on the IL-18 protein expression in LN patients were stronger than that in normal control group (P<0.01 or P<0.05).	Dextromethorphan	41-44	interleukin 18	Homo sapiens	52-57
15364549-4	2004	The monotonic concentration response for repression of QOR gene products up to 100 microM DEX concentration demonstrated that the glucocorticoid receptor (GR) was most likely involved in this process.	Dextromethorphan	90-93	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	155-157
15149890-0	2004	Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity.	Dextromethorphan	22-38	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	106-112
14992686-0	2004	Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.	Dextromethorphan	110-126	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-65
15252821-5	2004	The CYP2D6 phenotype (dextromethorphan test) was determined in 56 genotyped (PCR-SSCP) depressed caucasian inpatients with a heterozygous genotype.	Dextromethorphan	22-38	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
15149890-1	2004	BACKGROUND: This study was designed to assess the metabolic activities of dextromethorphan O-demethylation in healthy Japanese subjects carrying duplicated CYP2D6 alleles, CYP2D6*1 x 2, CYP2D6*2 x 2 or CYP2D6*10 x 2.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	156-162
15149890-1	2004	BACKGROUND: This study was designed to assess the metabolic activities of dextromethorphan O-demethylation in healthy Japanese subjects carrying duplicated CYP2D6 alleles, CYP2D6*1 x 2, CYP2D6*2 x 2 or CYP2D6*10 x 2.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	172-178
15149890-1	2004	BACKGROUND: This study was designed to assess the metabolic activities of dextromethorphan O-demethylation in healthy Japanese subjects carrying duplicated CYP2D6 alleles, CYP2D6*1 x 2, CYP2D6*2 x 2 or CYP2D6*10 x 2.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	172-178
15149890-1	2004	BACKGROUND: This study was designed to assess the metabolic activities of dextromethorphan O-demethylation in healthy Japanese subjects carrying duplicated CYP2D6 alleles, CYP2D6*1 x 2, CYP2D6*2 x 2 or CYP2D6*10 x 2.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	172-178
15010261-7	2004	These data suggest that the 3"-UTR of the COX-2 gene is involved in not only the induction by LPS but also the suppression by DEX of COX-2 expression at the post-transcriptional level.	Dextromethorphan	126-129	prostaglandin-endoperoxide synthase 2	Homo sapiens	42-47
15018793-1	2004	Dextromethorphan, the innocuous non-narcotic antitussive agent, is the most widely used probe drug to assess CYP2D6 function both in vivo and in vitro.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-115
15025748-6	2004	The corresponding ratios using dextromethorphan as the probe for CYP2D6 were 0.9 (95% CI 0.5, 2.1) for males and 1.9 (1.3, 3.2) for females.	Dextromethorphan	31-47	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
15010261-7	2004	These data suggest that the 3"-UTR of the COX-2 gene is involved in not only the induction by LPS but also the suppression by DEX of COX-2 expression at the post-transcriptional level.	Dextromethorphan	126-129	prostaglandin-endoperoxide synthase 2	Homo sapiens	133-138
12869505-6	2003	While Epo and SCF never showed opposite effects on gene expression, Dex either enhanced or attenuated the effect of Epo and/or SCF.	Dextromethorphan	68-71	erythropoietin	Homo sapiens	116-119
15096107-4	2004	PROCEDURE: The dogs were treated for 2 weeks each with dextromethorphan (2 mg/kg BID) and placebo in a randomized, double blind, crossover designed study.	Dextromethorphan	55-71	BH3 interacting domain death agonist	Canis lupus familiaris	81-84
15096109-2	2004	Several authors have suggested the concomitant administration of DM and a CYP2D6 reversible inhibitor in order to enhance the exposure of DM and limit the exposure to total dextrorphan (DX).	Dextromethorphan	138-140	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	74-80
15001615-3	2004	We have extended these studies by evaluating the salivary cortisol response to awakening and plasma ACTH and cortisol responses to CRH stimulation and a dexamethasone-suppressed CRH (DEX/CRH) test in a group of low birth weight [LBW; <3.18 kg (7 lb), n = 58] and high birth weight [>3.86 kg (8.5 lb), n = 65] men aged 60-69 yr.	Dextromethorphan	183-186	corticotropin releasing hormone	Homo sapiens	178-181
15001615-3	2004	We have extended these studies by evaluating the salivary cortisol response to awakening and plasma ACTH and cortisol responses to CRH stimulation and a dexamethasone-suppressed CRH (DEX/CRH) test in a group of low birth weight [LBW; <3.18 kg (7 lb), n = 58] and high birth weight [>3.86 kg (8.5 lb), n = 65] men aged 60-69 yr.	Dextromethorphan	183-186	corticotropin releasing hormone	Homo sapiens	178-181
15036602-4	2004	Consistently, ERK5 activation was significantly suppressed by genistein (protein-tyrosine kinase inhibitor), PP2 (specific inhibitor of Src family kinases), nifedipine (L-VGCC blocker) and dextromethorphan (NMDA receptor antagonist), but not 6,7-dinitroquinoxaline-2, 3(1H, 4H)-dione (AMPA receptor antagonist).	Dextromethorphan	189-205	mitogen-activated protein kinase 7	Rattus norvegicus	14-18
14630163-0	2003	Enantioselective interactions of dextromethorphan and levomethorphan with the alpha 3 beta 4-nicotinic acetylcholine receptor: comparison of chromatographic and functional data.	Dextromethorphan	33-49	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	93-125
14630163-0	2003	Enantioselective interactions of dextromethorphan and levomethorphan with the alpha 3 beta 4-nicotinic acetylcholine receptor: comparison of chromatographic and functional data.	Dextromethorphan	54-68	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	93-125
15060507-5	2004	RESULTS: As a CYP2D6-specific catalytic probe, R-568 offers a 20-fold higher sensitivity compared with that of dextromethorphan.	Dextromethorphan	111-127	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
16680870-5	2004	Dextromethorphan O-demethylation was used as a probe of CYP2D6 activity.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	56-62
14689465-0	2003	Single-point plasma or urine dextromethorphan method for determining CYP3A activity.	Dextromethorphan	29-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-74
14689465-1	2003	Dextromethorphan is used widely in vivo to phenotype the polymorphically expressed cytochrome P450 (CYP) 2D6.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	83-108
14689465-2	2003	Also dextromethorphan is N-demethylated in vivo to 3-methoxymorphinan by human CYP3A4/5.	Dextromethorphan	5-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
12869505-6	2003	While Epo and SCF never showed opposite effects on gene expression, Dex either enhanced or attenuated the effect of Epo and/or SCF.	Dextromethorphan	68-71	KIT ligand	Homo sapiens	127-130
12869505-7	2003	Several glucocorticoid receptor (GR)-target genes were regulated by Dex only in the presence of Epo and/or SCF, suggesting that the GR functions in the context of a larger transactivation complex to regulate these genes.	Dextromethorphan	68-71	nuclear receptor subfamily 3 group C member 1	Homo sapiens	8-31
12869505-7	2003	Several glucocorticoid receptor (GR)-target genes were regulated by Dex only in the presence of Epo and/or SCF, suggesting that the GR functions in the context of a larger transactivation complex to regulate these genes.	Dextromethorphan	68-71	nuclear receptor subfamily 3 group C member 1	Homo sapiens	33-35
12869505-7	2003	Several glucocorticoid receptor (GR)-target genes were regulated by Dex only in the presence of Epo and/or SCF, suggesting that the GR functions in the context of a larger transactivation complex to regulate these genes.	Dextromethorphan	68-71	erythropoietin	Homo sapiens	96-99
12869505-7	2003	Several glucocorticoid receptor (GR)-target genes were regulated by Dex only in the presence of Epo and/or SCF, suggesting that the GR functions in the context of a larger transactivation complex to regulate these genes.	Dextromethorphan	68-71	KIT ligand	Homo sapiens	107-110
12869505-7	2003	Several glucocorticoid receptor (GR)-target genes were regulated by Dex only in the presence of Epo and/or SCF, suggesting that the GR functions in the context of a larger transactivation complex to regulate these genes.	Dextromethorphan	68-71	nuclear receptor subfamily 3 group C member 1	Homo sapiens	132-134
14620514-5	2003	Catalytic activities were measured through O-demethylation (CYP2D) and N-demethylation of dextromethorphan (CYP3A) and O-deethylation of 7-ethoxyresorufin (CYP1A2).	Dextromethorphan	90-106	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	108-113
14677084-8	2003	In contrast to the established decline of HPA system activity during treatment with tricyclic antidepressants, neuroendocrine studies on the effects of lithium augmentation on the HPA system showed an unexpected and marked increase in the ACTH and cortisol response in the combined DEX/CRH test.	Dextromethorphan	282-285	proopiomelanocortin	Homo sapiens	239-243
14746803-7	2003	Furthermore, regulation of ANT3 expression by IL-4 and IFN-gamma correlated with the modulation T cell survival by these cytokines from dex-induced apoptosis.	Dextromethorphan	136-139	solute carrier family 25 member 6	Homo sapiens	27-31
14746803-7	2003	Furthermore, regulation of ANT3 expression by IL-4 and IFN-gamma correlated with the modulation T cell survival by these cytokines from dex-induced apoptosis.	Dextromethorphan	136-139	interleukin 4	Homo sapiens	46-50
14746803-7	2003	Furthermore, regulation of ANT3 expression by IL-4 and IFN-gamma correlated with the modulation T cell survival by these cytokines from dex-induced apoptosis.	Dextromethorphan	136-139	interferon gamma	Homo sapiens	55-64
12936703-9	2003	The IC50 values of typical substrates of CYP2D6 (bufuralol and dextromethorphan at lower substrate concentration) in inhibition studies using HLM, were similar to those in the case of recombinant CYP2D6, but the values of the compounds that are metabolized by multiple CYP forms (perphenazine and chlorpromazine) in HLM were much larger.	Dextromethorphan	63-79	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	41-47
12920172-3	2003	CYP2B11 and CYP3A12 effectively catalyzed the N1-demethylation and C3-hydroxylation of diazepam (and its derivatives), whereas CYP3A12 and CYP2D15 catalyzed exclusively the N- and O-demethylation, respectively, of dextromethorphan.	Dextromethorphan	214-230	cytochrome P450 2B11	Canis lupus familiaris	0-7
12920172-3	2003	CYP2B11 and CYP3A12 effectively catalyzed the N1-demethylation and C3-hydroxylation of diazepam (and its derivatives), whereas CYP3A12 and CYP2D15 catalyzed exclusively the N- and O-demethylation, respectively, of dextromethorphan.	Dextromethorphan	214-230	cytochrome P450 3A12	Canis lupus familiaris	12-19
12920172-3	2003	CYP2B11 and CYP3A12 effectively catalyzed the N1-demethylation and C3-hydroxylation of diazepam (and its derivatives), whereas CYP3A12 and CYP2D15 catalyzed exclusively the N- and O-demethylation, respectively, of dextromethorphan.	Dextromethorphan	214-230	cytochrome P450 3A12	Canis lupus familiaris	127-134
12920172-3	2003	CYP2B11 and CYP3A12 effectively catalyzed the N1-demethylation and C3-hydroxylation of diazepam (and its derivatives), whereas CYP3A12 and CYP2D15 catalyzed exclusively the N- and O-demethylation, respectively, of dextromethorphan.	Dextromethorphan	214-230	cytochrome P450 2D15	Canis lupus familiaris	139-146
12920172-5	2003	In contrast to CYP3A12, the CYP2D15-dependent O-demethylation of dextromethorphan was a low Km process (Km = 0.7 microM), similar to that in dog liver microsomes (Km = 2.3 microM).	Dextromethorphan	65-81	cytochrome P450 3A12	Canis lupus familiaris	15-22
12920172-5	2003	In contrast to CYP3A12, the CYP2D15-dependent O-demethylation of dextromethorphan was a low Km process (Km = 0.7 microM), similar to that in dog liver microsomes (Km = 2.3 microM).	Dextromethorphan	65-81	cytochrome P450 2D15	Canis lupus familiaris	28-35
12920165-6	2003	In this study, human lymphocyte activity was assessed with a CYP2D6-specific, high-turnover probe substrate that is severalfold more sensitive than traditional markers of CYP2D6 (e.g., dextromethorphan).	Dextromethorphan	185-201	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
12950260-5	2003	For this, we developed an assay suitable for rapid analysis of CYP-mediated drug interactions in both systems, using radiolabelled dextromethorphan, a well-characterized probe substrate for enzymes of the CYP2D family.	Dextromethorphan	131-147	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	63-66
14571354-2	2003	Ninety drug-free, healthy volunteers and 14 patients undergoing psychotropic drug treatment were phenotyped for their individual CYP2D6 activity using dextromethorphan as a probe, and then the metabolic ratio (MR) was calculated.	Dextromethorphan	151-167	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	129-135
15169672-5	2003	1 x 10(-4), 1 x 10(-3) g/L of lumbricus abstracts could increase TNF-alpha level and also antagonize the inhibition of Dex on the secretion of TNF-alpha by Mphi s and splenic cells.	Dextromethorphan	119-122	tumor necrosis factor	Mus musculus	143-152
15169672-6	2003	CONCLUSION: The abstracts of lumbricus can activate Mphi s and splenic cells to secrete NO and TNF-alpha and antagonize the inhibition effect of Dex on these cells.	Dextromethorphan	145-148	tumor necrosis factor	Mus musculus	95-104
12936703-9	2003	The IC50 values of typical substrates of CYP2D6 (bufuralol and dextromethorphan at lower substrate concentration) in inhibition studies using HLM, were similar to those in the case of recombinant CYP2D6, but the values of the compounds that are metabolized by multiple CYP forms (perphenazine and chlorpromazine) in HLM were much larger.	Dextromethorphan	63-79	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	41-44
12773140-16	2003	LIPID+DEX elevated leptin levels by 112.5+/-35.8% at 480 min (P=0.037), however, the Intralipid/heparin infusion did not blunt the rise of leptin under these conditions.	Dextromethorphan	6-9	leptin	Homo sapiens	19-25
12900870-2	2003	Mephenytoin (MEPH), dextromethorphan, diclofenac, caffeine, and methadone (MET) were successfully applied as test substrates for CYP2C19, CYP2D6*1, CYP2C9*1, CYP1A2, and CYP3A4, respectively.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	129-136
12900870-2	2003	Mephenytoin (MEPH), dextromethorphan, diclofenac, caffeine, and methadone (MET) were successfully applied as test substrates for CYP2C19, CYP2D6*1, CYP2C9*1, CYP1A2, and CYP3A4, respectively.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	138-144
12900870-2	2003	Mephenytoin (MEPH), dextromethorphan, diclofenac, caffeine, and methadone (MET) were successfully applied as test substrates for CYP2C19, CYP2D6*1, CYP2C9*1, CYP1A2, and CYP3A4, respectively.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	148-154
12711372-1	2003	We investigated the ability of dextromethorphan, a clinically available NMDA receptor antagonist, to attenuate the behaviors and the expression of c-fos mRNA associated with acute morphine withdrawal in the 7-day-old rat.	Dextromethorphan	31-47	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	147-152
12711372-2	2003	The intensity of the acute morphine withdrawal behaviors and the elevation in c-fos mRNA expression in the brain induced by acute morphine withdrawal were reduced by dextromethorphan.	Dextromethorphan	166-182	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	78-83
12704799-10	2003	Dex induced mRNA osteoblastic markers expression like bone sialoprotein (BSP) and osteocalcin (OC) and an adipocyte marker expression, the fatty acid binding protein aP2.	Dextromethorphan	0-3	integrin-binding sialoprotein	Rattus norvegicus	54-71
12704799-10	2003	Dex induced mRNA osteoblastic markers expression like bone sialoprotein (BSP) and osteocalcin (OC) and an adipocyte marker expression, the fatty acid binding protein aP2.	Dextromethorphan	0-3	integrin-binding sialoprotein	Rattus norvegicus	73-76
12485954-6	2003	A significant correlation was observed between activities of NE-100 metabolism and dextromethorphan O-demethylation (a specific activity for CYP2D6) or testosterone 6beta-hydroxylation (a specific activity for CYP3A4) in HLM.	Dextromethorphan	83-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	141-147
12704799-10	2003	Dex induced mRNA osteoblastic markers expression like bone sialoprotein (BSP) and osteocalcin (OC) and an adipocyte marker expression, the fatty acid binding protein aP2.	Dextromethorphan	0-3	bone gamma-carboxyglutamate protein	Rattus norvegicus	82-93
12704799-10	2003	Dex induced mRNA osteoblastic markers expression like bone sialoprotein (BSP) and osteocalcin (OC) and an adipocyte marker expression, the fatty acid binding protein aP2.	Dextromethorphan	0-3	fatty acid binding protein 4	Rattus norvegicus	166-169
12887795-9	2003	VitB(12) can not inhibit DEX"s enhancing effect on the expression level of Annexin I, but it can antagonize DEX"s inhibiting effect on expression level of cPLA(2), which is probably one of the mechanisms why VitB(12) antagonize glucocorticoid"s deforming effect.	Dextromethorphan	108-111	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	155-162
12576146-10	2003	MK-801, ketamine and dextrometorphan decreased significantly Fos immunoreactivity also in area CA3.	Dextromethorphan	21-36	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	61-64
12576146-10	2003	MK-801, ketamine and dextrometorphan decreased significantly Fos immunoreactivity also in area CA3.	Dextromethorphan	21-36	carbonic anhydrase 3	Rattus norvegicus	95-98
12799527-5	2003	Dextromethorphan (weakly NR2A-selective) (10 and 30 mg/kg, i.p.)	Dextromethorphan	0-16	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	25-29
12684690-8	2003	Expression of anti-apoptotic genes, such as nucleophosmin/B23, Rab2, MAP kinase kinase and CREB binding protein, was up-regulated by dextromethorphan.	Dextromethorphan	133-149	RAB2A, member RAS oncogene family	Rattus norvegicus	63-67
12684690-8	2003	Expression of anti-apoptotic genes, such as nucleophosmin/B23, Rab2, MAP kinase kinase and CREB binding protein, was up-regulated by dextromethorphan.	Dextromethorphan	133-149	CREB binding protein	Rattus norvegicus	91-111
12637241-18	2003	Correlation analysis suggested that CYP2B11 catalyses the N-demethylation of dextromethorphan (mediated in humans by CYP3A) and the 4"-hydroxylation of mephenytoin (mediated in humans by CYP2C19) in the dog, and that this enzyme and CYP3A12 contribute to S-warfarin 7-hydroxylation (mediated in humans by CYP2C9).	Dextromethorphan	77-93	cytochrome P450 2B11	Canis lupus familiaris	36-43
12637241-18	2003	Correlation analysis suggested that CYP2B11 catalyses the N-demethylation of dextromethorphan (mediated in humans by CYP3A) and the 4"-hydroxylation of mephenytoin (mediated in humans by CYP2C19) in the dog, and that this enzyme and CYP3A12 contribute to S-warfarin 7-hydroxylation (mediated in humans by CYP2C9).	Dextromethorphan	77-93	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	187-194
12637241-18	2003	Correlation analysis suggested that CYP2B11 catalyses the N-demethylation of dextromethorphan (mediated in humans by CYP3A) and the 4"-hydroxylation of mephenytoin (mediated in humans by CYP2C19) in the dog, and that this enzyme and CYP3A12 contribute to S-warfarin 7-hydroxylation (mediated in humans by CYP2C9).	Dextromethorphan	77-93	cytochrome P450 3A12	Canis lupus familiaris	233-240
12637241-18	2003	Correlation analysis suggested that CYP2B11 catalyses the N-demethylation of dextromethorphan (mediated in humans by CYP3A) and the 4"-hydroxylation of mephenytoin (mediated in humans by CYP2C19) in the dog, and that this enzyme and CYP3A12 contribute to S-warfarin 7-hydroxylation (mediated in humans by CYP2C9).	Dextromethorphan	77-93	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	305-311
12392820-7	2002	CYP2D6.1 and CYP2D6.2 displayed similar kinetics with all probe drugs except for dextromethorphan O-demethylation with the intrinsic clearance value of CYP2D6.2 being half that of CYP2D6.1.	Dextromethorphan	81-97	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
12433806-5	2002	incubations of (-)-OSU6162 (5 micro M) with hepatic microsomes from a panel of human donors showed that (-)-OSU6162 N-depropylase activity correlated well with CYP2D6-catalyzed dextromethorphan O-demethylase activity but not with other p450 enzyme-specific activities; 2).	Dextromethorphan	177-193	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	160-166
12438554-6	2002	The CYP2D6.10 enzyme was the most impaired, exhibiting an estimated enzyme efficiency (as V(max)/K(m)) 50-fold lower for DXM O-demethylation and 100-fold lower for fluoxetine N-demethylation when compared with CYP2D6.1, whereas no measurable catalytic activity was observed for this variant toward codeine.	Dextromethorphan	121-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
12438554-6	2002	The CYP2D6.10 enzyme was the most impaired, exhibiting an estimated enzyme efficiency (as V(max)/K(m)) 50-fold lower for DXM O-demethylation and 100-fold lower for fluoxetine N-demethylation when compared with CYP2D6.1, whereas no measurable catalytic activity was observed for this variant toward codeine.	Dextromethorphan	121-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	210-216
12649767-6	2003	The effect of melperone on CYP2D6 was further assessed in seven patients by means of the dextromethorphan O-demethylation, which serves as a CYP2D6 probe reaction.	Dextromethorphan	89-105	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	141-147
12649769-14	2003	The ACTH and cortisol area under the curve in the Dex/CRH tests decreased significantly, reflecting a decrease of activity in the HPA system.	Dextromethorphan	50-53	corticotropin releasing hormone	Homo sapiens	54-57
12460693-5	2002	RESULTS: Chronically abused BPD patients had a significantly enhanced corticotropin (ACTH) and cortisol response to the DEX/CRH challenge compared with nonabused subjects.	Dextromethorphan	120-123	corticotropin releasing hormone	Homo sapiens	124-127
12460693-9	2002	Possibly due to an enhanced efficacy of HPA suppression by dexamethasone, PTSD attenuates the ACTH response to DEX/CRH.	Dextromethorphan	111-114	corticotropin releasing hormone	Homo sapiens	115-118
12433801-7	2002	The formation of 6 beta-hydroxy and 21-hydroxy metabolites in human liver microsomes was best correlated with CYP3A-selective dextromethorphan N-demethylation and testosterone 6 beta-hydroxylation activities.	Dextromethorphan	126-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-115
12472684-8	2002	In contrast, diverse auxin-related physiological processes including gravitropism and phototropism were impaired by DEX treatment in roots, hypocotyls, stems, and leaves in iaa1-GR transgenic plants.	Dextromethorphan	116-119	indole-3-acetic acid inducible	Arabidopsis thaliana	173-180
12472684-9	2002	Auxin induction of seven Aux/IAA mRNAs including IAA1 itself was repressed by DEX treatment, suggesting that IAA1 functions in the nucleus by mediating auxin response and might act as a negative feedback regulator for the expression of Aux/IAA genes including IAA1 itself.	Dextromethorphan	78-81	indole-3-acetic acid inducible	Arabidopsis thaliana	49-53
12472684-9	2002	Auxin induction of seven Aux/IAA mRNAs including IAA1 itself was repressed by DEX treatment, suggesting that IAA1 functions in the nucleus by mediating auxin response and might act as a negative feedback regulator for the expression of Aux/IAA genes including IAA1 itself.	Dextromethorphan	78-81	indole-3-acetic acid inducible	Arabidopsis thaliana	109-113
12472684-9	2002	Auxin induction of seven Aux/IAA mRNAs including IAA1 itself was repressed by DEX treatment, suggesting that IAA1 functions in the nucleus by mediating auxin response and might act as a negative feedback regulator for the expression of Aux/IAA genes including IAA1 itself.	Dextromethorphan	78-81	indole-3-acetic acid inducible	Arabidopsis thaliana	109-113
12472684-10	2002	Auxin induction of Aux/IAA genes in the presence of cycloheximide can be repressed by DEX treatment, showing that the repression of transcription of the Aux/IAAs by the iaa1 mutant protein is primary.	Dextromethorphan	86-89	indole-3-acetic acid inducible	Arabidopsis thaliana	169-173
12392820-7	2002	CYP2D6.1 and CYP2D6.2 displayed similar kinetics with all probe drugs except for dextromethorphan O-demethylation with the intrinsic clearance value of CYP2D6.2 being half that of CYP2D6.1.	Dextromethorphan	81-97	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
12392820-7	2002	CYP2D6.1 and CYP2D6.2 displayed similar kinetics with all probe drugs except for dextromethorphan O-demethylation with the intrinsic clearance value of CYP2D6.2 being half that of CYP2D6.1.	Dextromethorphan	81-97	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
12392820-7	2002	CYP2D6.1 and CYP2D6.2 displayed similar kinetics with all probe drugs except for dextromethorphan O-demethylation with the intrinsic clearance value of CYP2D6.2 being half that of CYP2D6.1.	Dextromethorphan	81-97	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
12530471-8	2002	On the other hand positive correlations were found between dextromethorphan and bufuralol metabolism and the CYP2B immunochemical protein level, indicating that the CYP2B isoenzyme may be involved in the metabolism of these substrates.	Dextromethorphan	59-75	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	109-114
12424306-10	2002	Pretreatment with the sigma-one receptor (sigma(1)R) agonists dextromethorphan (10-100 microM), carbetapentane (100 microM), or 4-IBP (30 microM) blocked SD, even when KCl exposure was extended beyond 5 min.	Dextromethorphan	62-78	sigma non-opioid intracellular receptor 1	Rattus norvegicus	22-51
12487724-8	2002	For CYP3A4-mediated metabolism of DEM, MDZ and DZ, the V(max) for hBl microsomes were generally 2-9-fold higher than the respective yeast and human liver microsomes and E. coli membrane preparations, resulting in greater CL(int) or CL(max).	Dextromethorphan	34-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
12487724-8	2002	For CYP3A4-mediated metabolism of DEM, MDZ and DZ, the V(max) for hBl microsomes were generally 2-9-fold higher than the respective yeast and human liver microsomes and E. coli membrane preparations, resulting in greater CL(int) or CL(max).	Dextromethorphan	34-37	galectin 1	Homo sapiens	66-69
12234625-17	2002	Dex stimulated ALP activity and increased ALP mRNA expression whilst RA had an inhibitory effect.	Dextromethorphan	0-3	alkaline phosphatase, placental	Homo sapiens	15-18
12234625-17	2002	Dex stimulated ALP activity and increased ALP mRNA expression whilst RA had an inhibitory effect.	Dextromethorphan	0-3	alkaline phosphatase, placental	Homo sapiens	42-45
12234625-18	2002	Dex treatment led to an increase in PTH/PTH-rp receptor mRNA and PTH-induced cAMP accumulation with a peak response at 24 h and this effect was sustained for up to 14 days.	Dextromethorphan	0-3	parathyroid hormone	Homo sapiens	36-39
12234625-18	2002	Dex treatment led to an increase in PTH/PTH-rp receptor mRNA and PTH-induced cAMP accumulation with a peak response at 24 h and this effect was sustained for up to 14 days.	Dextromethorphan	0-3	parathyroid hormone	Homo sapiens	40-43
12234625-18	2002	Dex treatment led to an increase in PTH/PTH-rp receptor mRNA and PTH-induced cAMP accumulation with a peak response at 24 h and this effect was sustained for up to 14 days.	Dextromethorphan	0-3	parathyroid hormone	Homo sapiens	40-43
12530471-8	2002	On the other hand positive correlations were found between dextromethorphan and bufuralol metabolism and the CYP2B immunochemical protein level, indicating that the CYP2B isoenzyme may be involved in the metabolism of these substrates.	Dextromethorphan	59-75	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	165-170
12530471-15	2002	These results indicate that dextromethorphan and bufuralol metabolism may be catalysed by CYP2B and not CYP2D.	Dextromethorphan	28-44	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	90-95
12065442-4	2002	The reactions examined were CYP2C9-catalyzed diclofenac 4"-hydroxylation, CYP2D6-catalyzed dextromethorphan O-demethylation and thioridazine S-oxidation, CYP2C19-catalyzed imipramine N-demethylation, CYP3A4-catalyzed midazolam 1"-hydroxylation, and CYP1A2-catalyzed tacrine 1-hydroxylation.	Dextromethorphan	91-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	74-80
12151071-0	2002	A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.	Dextromethorphan	52-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	162-167
12151071-0	2002	A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.	Dextromethorphan	52-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	172-178
12151071-1	2002	The commonly used antitussive dextromethorphan can be used to simultaneously assess potential cytochrome P450 3A (CYP3A) and CYP2D6 inhibition during drug development.	Dextromethorphan	30-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-112
12151071-1	2002	The commonly used antitussive dextromethorphan can be used to simultaneously assess potential cytochrome P450 3A (CYP3A) and CYP2D6 inhibition during drug development.	Dextromethorphan	30-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119
12151071-1	2002	The commonly used antitussive dextromethorphan can be used to simultaneously assess potential cytochrome P450 3A (CYP3A) and CYP2D6 inhibition during drug development.	Dextromethorphan	30-46	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	125-131
12151071-10	2002	The method described herein is suitable for the rapid and efficient measurement of dextromethorphan and different metabolites to estimate potential CYP3A inhibition by drug candidates and for screening of extensive and poor metabolizers of CYP2D6 in the heterogeneous population.	Dextromethorphan	83-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-153
12151071-10	2002	The method described herein is suitable for the rapid and efficient measurement of dextromethorphan and different metabolites to estimate potential CYP3A inhibition by drug candidates and for screening of extensive and poor metabolizers of CYP2D6 in the heterogeneous population.	Dextromethorphan	83-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	240-246
12601911-3	2002	RESULTS: The inhibition function of ISO and DEX and high concentration of TNFgamma on lymphocyte proliferation was decreased with CDPS at higher concentration.	Dextromethorphan	44-47	calpain, small subunit 1	Mus musculus	130-134
12006904-8	2002	Quinidine > fluoxetine > placebo inhibited CYP2D6 as reflected in the change of the O-demethylation of dextromethorphan, a specific CYP2D6 probe.	Dextromethorphan	109-125	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	49-55
12152006-2	2002	METHODS: CYP2D6 activity was assessed with dextromethorphan in 283 black American subjects and correlated with their genotype (2D6*2 to *12, 2D6*14, 2D6*15, 2D6*17, 2D6*18, and 2D6*29 and gene duplications).	Dextromethorphan	43-59	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	9-15
12152006-4	2002	RESULTS: The median urinary dextromethorphan/dextrorphan metabolic ratio (MR) indicated significantly lower CYP2D6 activity in the black American group (0.016) than in a white control population (0.0044; P =.0001) studied previously.	Dextromethorphan	28-44	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	108-114
12087352-5	2002	CYP3A4, CYP2D6, and NAT2 activities were assessed by use of urinary metabolic ratios of 3-methoxymorphinan/dextromethorphan, dextrorphan/dextromethorphan, and 5-acetylamino-6-formylamino-3-methyluracil (AFMU)/1-methylxanthine(1X).	Dextromethorphan	107-123	N-acetyltransferase 2	Homo sapiens	20-24
12006904-8	2002	Quinidine > fluoxetine > placebo inhibited CYP2D6 as reflected in the change of the O-demethylation of dextromethorphan, a specific CYP2D6 probe.	Dextromethorphan	109-125	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	138-144
11910262-5	2002	CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine.	Dextromethorphan	39-55	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
11979343-8	2002	Dexamethasone aggravated proteinuria (protein, 0.4 +/- 0.1 mg/mg creatinine in the NC group, 6.3 +/- 2.0 mg/mg creatinine in the DC group, and 21.1 +/- 1.9 mg/mg creatinine in the D-Dex group; P < 0.05) and diminished VEGF release (22 +/- 3 pg/mg total protein in the NC group, 292 +/- 26 pg/mg total protein in the DC group, and 198 +/- 23 pg/mg total protein in the D-Dex group; P < 0.05).	Dextromethorphan	0-3	vascular endothelial growth factor A	Rattus norvegicus	221-225
11950793-0	2002	Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.	Dextromethorphan	120-136	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	43-49
11950793-0	2002	Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.	Dextromethorphan	120-136	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
11950793-0	2002	Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.	Dextromethorphan	120-136	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
11950793-0	2002	Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.	Dextromethorphan	120-136	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
11950793-5	2002	Relative to the wild-type CYP2D6.1 protein expressed in COS-7 cells, CYP2D6.17 exhibited a 2-fold higher K(m) and a 50% reduction in V(max) using dextromethorphan as the substrate.	Dextromethorphan	146-162	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
11950793-7	2002	When expressed in the baculovirus expression system, CYP2D6.17 exhibited a 6-fold increase in K(m) but no change in V(max) with dextromethorphan as the substrate, a 2-fold higher K(m) and 50% reduction in V(max) with bufuralol, and a 3-fold increase in K(m) and no change in V(max) with debrisoquine relative to CYP2D6.1.	Dextromethorphan	128-144	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	53-59
11983493-7	2002	Addition of GH+DEX to OVXHX rats restored the ER to levels above those seen in intact rats, whereas simultaneous oral treatment with E2 significantly decreased ER levels again.	Dextromethorphan	15-18	estrogen receptor 1	Rattus norvegicus	46-48
11818173-8	2002	In patients with high cortisol secretion patterns during the Dex/CRH test there was a decrease in HPA system activity after successful antidepressant treatment that was reflected by both the saliva and the serum Dex/CRH test.Thus, the saliva based combined Dex/CRH test appears to be a suitable tool for monitoring HPA system activity during the course of depressive illness.	Dextromethorphan	61-64	corticotropin releasing hormone	Homo sapiens	65-68
11818173-8	2002	In patients with high cortisol secretion patterns during the Dex/CRH test there was a decrease in HPA system activity after successful antidepressant treatment that was reflected by both the saliva and the serum Dex/CRH test.Thus, the saliva based combined Dex/CRH test appears to be a suitable tool for monitoring HPA system activity during the course of depressive illness.	Dextromethorphan	61-64	corticotropin releasing hormone	Homo sapiens	216-219
11818173-8	2002	In patients with high cortisol secretion patterns during the Dex/CRH test there was a decrease in HPA system activity after successful antidepressant treatment that was reflected by both the saliva and the serum Dex/CRH test.Thus, the saliva based combined Dex/CRH test appears to be a suitable tool for monitoring HPA system activity during the course of depressive illness.	Dextromethorphan	61-64	corticotropin releasing hormone	Homo sapiens	216-219
12023534-8	2002	The CYP2D6 specificity, judged by the CYP2D6/CYP1A1 activity ratios was 18.5, 7.0, 6.0, and 1.6 for dextromethorphan, bufuralol, sparteine, and debrisoquine, respectively.	Dextromethorphan	100-116	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
12023534-8	2002	The CYP2D6 specificity, judged by the CYP2D6/CYP1A1 activity ratios was 18.5, 7.0, 6.0, and 1.6 for dextromethorphan, bufuralol, sparteine, and debrisoquine, respectively.	Dextromethorphan	100-116	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	38-44
12023534-8	2002	The CYP2D6 specificity, judged by the CYP2D6/CYP1A1 activity ratios was 18.5, 7.0, 6.0, and 1.6 for dextromethorphan, bufuralol, sparteine, and debrisoquine, respectively.	Dextromethorphan	100-116	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	45-51
12021638-4	2002	His CYP2D6 phenotype was assessed using the test drug dextromethorphan before, during, and after treatment with bupropion.	Dextromethorphan	54-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
12051754-3	2002	To confirm this hypothesis, the kinetic parameters of CYP2D6.1 and CYP2D6.10 were compared for bufuralol 1"-hydroxylation and dextromethorphan O-demethylation using microsomes prepared from yeast transformed with plasmids carrying CYP2D6 cDNAs (*1A and *10B).	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
12051754-3	2002	To confirm this hypothesis, the kinetic parameters of CYP2D6.1 and CYP2D6.10 were compared for bufuralol 1"-hydroxylation and dextromethorphan O-demethylation using microsomes prepared from yeast transformed with plasmids carrying CYP2D6 cDNAs (*1A and *10B).	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	67-73
12051754-3	2002	To confirm this hypothesis, the kinetic parameters of CYP2D6.1 and CYP2D6.10 were compared for bufuralol 1"-hydroxylation and dextromethorphan O-demethylation using microsomes prepared from yeast transformed with plasmids carrying CYP2D6 cDNAs (*1A and *10B).	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	67-73
11818173-8	2002	In patients with high cortisol secretion patterns during the Dex/CRH test there was a decrease in HPA system activity after successful antidepressant treatment that was reflected by both the saliva and the serum Dex/CRH test.Thus, the saliva based combined Dex/CRH test appears to be a suitable tool for monitoring HPA system activity during the course of depressive illness.	Dextromethorphan	212-215	corticotropin releasing hormone	Homo sapiens	65-68
11818173-8	2002	In patients with high cortisol secretion patterns during the Dex/CRH test there was a decrease in HPA system activity after successful antidepressant treatment that was reflected by both the saliva and the serum Dex/CRH test.Thus, the saliva based combined Dex/CRH test appears to be a suitable tool for monitoring HPA system activity during the course of depressive illness.	Dextromethorphan	212-215	corticotropin releasing hormone	Homo sapiens	65-68
15618695-7	2002	In contrast, the inhibitory effects of phenacetin, diclofenac, S-mephenytoin, dextromethorphan, bufuralol and terfenadine, typical substrates for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, respectively, on each recombinant CYP activity decreased after preincubation.	Dextromethorphan	78-94	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	146-152
11818173-9	2002	The easier performance of the saliva Dex/CRH test in comparison to the standard test procedure for both patients and hospital staff opens the door for routine clinical use of the Dex/CRH test for treatment monitoring and estimation of relapse risk.	Dextromethorphan	37-40	corticotropin releasing hormone	Homo sapiens	183-186
11911841-2	2002	Among the metabolic reactions studied, diclofenac 4-hydroxylation (DFH), dextromethorphan O-demethylation (DMOD) and midazolam 4-hydroxylation were specifically catalyzed by CYP2C6, CYP2D2 and CYP3A1/3A2, respectively.	Dextromethorphan	73-89	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	174-180
11911841-2	2002	Among the metabolic reactions studied, diclofenac 4-hydroxylation (DFH), dextromethorphan O-demethylation (DMOD) and midazolam 4-hydroxylation were specifically catalyzed by CYP2C6, CYP2D2 and CYP3A1/3A2, respectively.	Dextromethorphan	73-89	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	182-188
11911841-2	2002	Among the metabolic reactions studied, diclofenac 4-hydroxylation (DFH), dextromethorphan O-demethylation (DMOD) and midazolam 4-hydroxylation were specifically catalyzed by CYP2C6, CYP2D2 and CYP3A1/3A2, respectively.	Dextromethorphan	73-89	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	193-199
12071430-1	2002	The present study evaluates the usefulness of dextromethorphan N-demethylation activity indices to reflect cytochrome P450 (CYP) 3A activity in man.	Dextromethorphan	46-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-131
12513834-4	2002	DEX and VP-16 could promote apoptosis of RMA cells while upregulating the expression of Fas and FasL without affecting the expression of Bcl-2.	Dextromethorphan	0-3	Fas ligand (TNF superfamily, member 6)	Mus musculus	96-100
12513834-12	2002	Fas-FasL system participated in the apoptosis induced by DEX and VP-16; different drugs induce apoptosis by different pathway of signal transduction.	Dextromethorphan	57-60	Fas ligand (TNF superfamily, member 6)	Mus musculus	4-8
11911841-3	2002	These results suggest that diclofenac 4-hydroxylation, dextromethorphan O-demethylation and midazolam 4-hydroxylation are useful as catalytic markers of CYP2C6, CYP2D2 and CYP3A1/3A2, respectively.	Dextromethorphan	55-71	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	153-159
11996177-7	2002	Moreover, fibronectin (FN) gene expression and secretion of the protein was increased by high doses of dex (> or = 10(-8) M), whereas low doses of dex (10(-10)M) showed no effect.	Dextromethorphan	103-106	fibronectin 1	Homo sapiens	10-21
11996177-7	2002	Moreover, fibronectin (FN) gene expression and secretion of the protein was increased by high doses of dex (> or = 10(-8) M), whereas low doses of dex (10(-10)M) showed no effect.	Dextromethorphan	103-106	fibronectin 1	Homo sapiens	23-25
11996177-7	2002	Moreover, fibronectin (FN) gene expression and secretion of the protein was increased by high doses of dex (> or = 10(-8) M), whereas low doses of dex (10(-10)M) showed no effect.	Dextromethorphan	150-153	fibronectin 1	Homo sapiens	10-21
11996177-7	2002	Moreover, fibronectin (FN) gene expression and secretion of the protein was increased by high doses of dex (> or = 10(-8) M), whereas low doses of dex (10(-10)M) showed no effect.	Dextromethorphan	150-153	fibronectin 1	Homo sapiens	23-25
11816009-1	2002	Dextromethorphan is a probe substrate to determine CYP2D6 phenotype.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	51-57
11816009-2	2002	The conversion of dextromethorphan to dextrorphan by CYP2D6 accounts for approximately 60% of total metabolism.	Dextromethorphan	18-34	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	53-59
12463319-8	2002	All adhesion molecule expression and plasma MIP-1alpha levels were comparable at days 5-7, with the exception of monocyte L-selectin expression levels, which remained lower in the DEX group.	Dextromethorphan	180-183	selectin L	Homo sapiens	122-132
11823760-5	2002	Tanzanian subjects homozygous for the CYP2D6*17 allele were slower metabolizers when debrisoquine or dextromethorphan was used as the probe drug than when codeine or metoprolol was used, showing a different substrate specificity of CYP2D6.17 than of CYP2D6.1 and CYP2D6.2.	Dextromethorphan	101-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	38-44
11823760-5	2002	Tanzanian subjects homozygous for the CYP2D6*17 allele were slower metabolizers when debrisoquine or dextromethorphan was used as the probe drug than when codeine or metoprolol was used, showing a different substrate specificity of CYP2D6.17 than of CYP2D6.1 and CYP2D6.2.	Dextromethorphan	101-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	232-238
11823760-5	2002	Tanzanian subjects homozygous for the CYP2D6*17 allele were slower metabolizers when debrisoquine or dextromethorphan was used as the probe drug than when codeine or metoprolol was used, showing a different substrate specificity of CYP2D6.17 than of CYP2D6.1 and CYP2D6.2.	Dextromethorphan	101-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	232-238
11823760-5	2002	Tanzanian subjects homozygous for the CYP2D6*17 allele were slower metabolizers when debrisoquine or dextromethorphan was used as the probe drug than when codeine or metoprolol was used, showing a different substrate specificity of CYP2D6.17 than of CYP2D6.1 and CYP2D6.2.	Dextromethorphan	101-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	232-238
11823760-7	2002	The metabolic ratios of dextromethorphan and metoprolol differed significantly among Tanzanian subjects homozygous for the CYP2D6*29 allele compared with those with CYP2D6*1 or *2 alleles.	Dextromethorphan	24-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	123-129
11602530-1	2001	Dextromethorphan (DXM) is a widely used probe drug for human CYP2D6 activity both in vitro and in vivo.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
16200774-10	2001	Dex inhibited the expression of HSP90 and GR mRNA of T lymphocytes from asthmatic patients (1.23 +/- 0.16 vs 1.68 +/- 0.38 and 0.42 +/- 0.06 vs 0.54 +/- 0.07, respectively, P all < 0.05).	Dextromethorphan	0-3	heat shock protein 90 alpha family class A member 1	Homo sapiens	32-37
16200774-11	2001	GA could interrupt the inhibiting effect of Dex on the expression of HSP90 and GR mRNA but had no effect on it.	Dextromethorphan	44-47	heat shock protein 90 alpha family class A member 1	Homo sapiens	69-74
16200774-12	2001	CONCLUSION: The low ratio of HSP90/GR could reduce the inducing apoptosis effect of Dex.	Dextromethorphan	84-87	heat shock protein 90 alpha family class A member 1	Homo sapiens	29-34
16200774-13	2001	Dex could down-regulate the mRNA expression of HSP90 and GR and GA could interrupt the inhibiting effect of Dex.	Dextromethorphan	0-3	heat shock protein 90 alpha family class A member 1	Homo sapiens	47-52
16200774-13	2001	Dex could down-regulate the mRNA expression of HSP90 and GR and GA could interrupt the inhibiting effect of Dex.	Dextromethorphan	108-111	heat shock protein 90 alpha family class A member 1	Homo sapiens	47-52
11602510-1	2001	The O-demethylation of dextromethorphan to dextrorphan in humans is catalyzed primarily by cytochrome P450 2D6 (CYP2D6).	Dextromethorphan	23-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	91-110
11602510-1	2001	The O-demethylation of dextromethorphan to dextrorphan in humans is catalyzed primarily by cytochrome P450 2D6 (CYP2D6).	Dextromethorphan	23-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
11602510-2	2001	However, contrary to conventional wisdom, preparations of recombinant cytochrome P450 (P450) expressed from CYP2D6*1 cDNA also appear to produce significant amounts of 3-methoxymorphinan, the N-demethylated metabolite of dextromethorphan, when assayed in vitro.	Dextromethorphan	221-237	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	108-114
11602510-7	2001	These results indicate that at least two distinct binding orientations exist for dextromethorphan within the active site of CYP2D6.	Dextromethorphan	81-97	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	124-130
11808821-2	2002	This study evaluated the association between CYP2D6 activity, as determined by dextromethorphan (DM) urinary metabolite ratio, and tramadol biotransformation in 13 children (7-16 years).	Dextromethorphan	79-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	45-51
11955301-7	2002	Comparison of A means of FN induced by Dex and RU38486 was 10(-6) mol/L dex (12 days) > 10(-7) mol/L Dex (12 d) > 10(-7) mol/L Dex (5 d) > Control group = 10(-7) mol/L Dex (5 d) + 10(-8) mol/L RU38486 (7 d).	Dextromethorphan	72-75	fibronectin 1	Homo sapiens	25-27
11716842-3	2001	In the present study, we performed c-Fos immunohistochemistry in the dopaminergic terminal regions of adolescent rat brain after the intraperitoneal administration of dextromethorphan at different doses (0, 10, 20, and 40 mg/kg), and also examined the effects on nocturnal behavior.	Dextromethorphan	167-183	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	35-40
11716842-4	2001	The results showed that dextromethorphan increased c-Fos expression dose dependently in the anterior cingulate cortex, caudate putamen, nucleus accumbens, and central amygdala.	Dextromethorphan	24-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-56
11602530-1	2001	Dextromethorphan (DXM) is a widely used probe drug for human CYP2D6 activity both in vitro and in vivo.	Dextromethorphan	18-21	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
11602530-3	2001	The formation of MEM has been attributed primarily to CYP3A4, and the use of DXM has been debated as a simultaneous probe for CYP3A4 and CYP2D6 activities.	Dextromethorphan	77-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
11602530-3	2001	The formation of MEM has been attributed primarily to CYP3A4, and the use of DXM has been debated as a simultaneous probe for CYP3A4 and CYP2D6 activities.	Dextromethorphan	77-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	137-143
11602530-4	2001	Recently, we found that highly purified CYP2D6 has significant DXM N-demethylase activity in addition to its well known DXM O-demethylase activity.	Dextromethorphan	63-66	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-46
11602530-4	2001	Recently, we found that highly purified CYP2D6 has significant DXM N-demethylase activity in addition to its well known DXM O-demethylase activity.	Dextromethorphan	120-123	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-46
11602530-10	2001	All of our in vitro results are consistent and indicate that DXM as a marker for monitoring both CYP2D6 and CYP3A activities is practical in an average human or human liver microsomal preparation.	Dextromethorphan	61-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
11602530-10	2001	All of our in vitro results are consistent and indicate that DXM as a marker for monitoring both CYP2D6 and CYP3A activities is practical in an average human or human liver microsomal preparation.	Dextromethorphan	61-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-113
11502894-5	2001	When PXR was expressed, both basal and t-Bu-DEX-dependent gene expression was increased over 2-fold, respectively.	Dextromethorphan	44-47	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	5-8
11673545-5	2001	Examination of spontaneous cytokine production showed that this Gr1(+)/F4/80(+) population of cells spontaneously produced low levels of proinflammatory cytokines, but higher levels of IL-10 and TGF-beta ex vivo, compared to peritoneal cells from mice injected with Dex.	Dextromethorphan	266-269	glutathione reductase	Mus musculus	64-73
11502351-0	2001	Dextromethorphan increases tyrosine hydroxylase mRNA in the mesencephalon of adolescent rats.	Dextromethorphan	0-16	tyrosine hydroxylase	Rattus norvegicus	27-47
11304901-0	2001	Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.	Dextromethorphan	57-73	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	77-83
11408369-6	2001	In the case of CYP2D6, the dextromethorphan to dextrorphan urinary ratio was not significantly different before (0.021 +/- 0.04) and after (0.024 +/- 0.06) clarithromycin dosing.	Dextromethorphan	27-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	15-21
11452704-0	2001	Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.	Dextromethorphan	119-135	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-80
11452704-4	2001	CYP3A4 and CYP2D6 activities were phenotyped with dextromethorphan (DM) on study days 7, 14, 21, and 28 using urinary ratios of DM:3-methoxymorphinan (3MM) and DM:dextrorphan (DX), respectively.	Dextromethorphan	50-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
11452704-4	2001	CYP3A4 and CYP2D6 activities were phenotyped with dextromethorphan (DM) on study days 7, 14, 21, and 28 using urinary ratios of DM:3-methoxymorphinan (3MM) and DM:dextrorphan (DX), respectively.	Dextromethorphan	50-66	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	11-17
11452704-11	2001	High inter- and intrasubject variability in DM:3MM and DM:DX were clearly demonstrated and limit the use of dextromethorphan to phenotype endogenous CYP3A4 and CYP2D6 activity.	Dextromethorphan	108-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-155
11452704-11	2001	High inter- and intrasubject variability in DM:3MM and DM:DX were clearly demonstrated and limit the use of dextromethorphan to phenotype endogenous CYP3A4 and CYP2D6 activity.	Dextromethorphan	108-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	160-166
11360030-6	2001	Although dextromethorphan metabolic ratio is significantly increased by risperidone (median urinary dextromethorphan/dextrorphan ratios before and after risperidone: 0.010, 0.018; p = 0.042), risperidone can be considered a weak in vivo CYP2D6 inhibitor, as this increase is modest and none of the eight patients was changed from an extensive to a poor metabolizer.	Dextromethorphan	9-25	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	237-243
11417446-3	2001	CYP2D6 was probed with dextromethorphan and metoprolol and CYP2C19 was probed with omeprazole.	Dextromethorphan	23-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
11334347-6	2001	The DI/GCE-MS-MS method demonstrates acceptable accuracy and precision for the quantification of dextrorphan, a marker metabolite of dextromethorphan mediated by CYP2D6, in microsomal incubations.	Dextromethorphan	133-149	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	162-168
11304901-1	2001	Two antidepressants, venlafaxine and fluoxetine, were evaluated in vivo for their effect on cytochrome P450 2D6 (CYP2D6) activity, measured by the ratio of dextromethorphan, a sensitive CYP2D6 marker, to its metabolite dextrorphan (i.e., DM:DT) excreted in urine after DM coadministration.	Dextromethorphan	156-172	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	113-119
11505218-9	2001	Using DEX as the substrate, the ratios of Ki(*10)/Ki(*1) for inhibitors were: budipine (1.3), sparteine (1.6), debrisoquine (8.1), fluoxetine (16), norfluoxetine (30), paroxetine (14), MDMA (21) and MMDA-2 (7.1), indicating that CYP2D6.10 shows drug-specific altered susceptibility to inhibition.	Dextromethorphan	6-9	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	229-235
11318417-10	2001	The validated assay proved to be suitable for the determination of DEM metabolic indexes reported to reflect the enzymatic activity of the cytochrome P450s, CYP2D6 and CYP3A, both in vivo, when applied to urine samples from patients, and in vitro, when applied to samples from the incubation of liver microsomes with dextromethorphan.	Dextromethorphan	317-333	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	157-163
11318417-10	2001	The validated assay proved to be suitable for the determination of DEM metabolic indexes reported to reflect the enzymatic activity of the cytochrome P450s, CYP2D6 and CYP3A, both in vivo, when applied to urine samples from patients, and in vitro, when applied to samples from the incubation of liver microsomes with dextromethorphan.	Dextromethorphan	317-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	168-173
11411376-7	2001	Some recent reports about interactions (involving hepatic cytochrome P450 enzymes) between dextromethorphan and other drugs are also noteworthy.	Dextromethorphan	91-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
11122451-6	2000	Naive splenocytes or M phi + NK cell co-cultures incubated with HMW-DEX or HMW-DEX-BSA produced higher IFN-gamma levels than splenocytes or co-cultures incubated with BSA alone.	Dextromethorphan	78-83	interferon gamma	Mus musculus	103-112
11377437-8	2001	An elevated cortisol response in the DEX/CRH test was correlated with a four- to six-fold higher risk for relapse than in individuals with a normal cortisol response.	Dextromethorphan	37-40	corticotropin releasing hormone	Homo sapiens	41-44
11225566-5	2001	CYP2D6 phenotype was assessed during each study period using dextromethorphan (30 mg).	Dextromethorphan	61-77	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
11095574-8	2000	The correlation between the contribution of CYP2D6 to NAPQI formation in human liver microsomes and the CYP2D6 activity probed by the O-demethylation of dextromethorphan was studied, and found to be strong (r(2) = 0.85), and significant (P <.0001).	Dextromethorphan	153-169	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
11095574-8	2000	The correlation between the contribution of CYP2D6 to NAPQI formation in human liver microsomes and the CYP2D6 activity probed by the O-demethylation of dextromethorphan was studied, and found to be strong (r(2) = 0.85), and significant (P <.0001).	Dextromethorphan	153-169	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	104-110
11256478-2	2001	The differential effects of 1alpha,25(OH)2D3 and 1alpha,25(OH)2-16-ene-D3 and the modulation by E2 on ALP activity in HOB-DEX and HOB+DEX cells were small but significant.	Dextromethorphan	122-125	ATHS	Homo sapiens	102-105
11256478-2	2001	The differential effects of 1alpha,25(OH)2D3 and 1alpha,25(OH)2-16-ene-D3 and the modulation by E2 on ALP activity in HOB-DEX and HOB+DEX cells were small but significant.	Dextromethorphan	134-137	ATHS	Homo sapiens	102-105
11256478-5	2001	Osteocalcin (OC) production in HOB-DEX cells was stimulated 1.3 to 1.4-fold by 1alpha,25(OH)2D3 and 1alpha,25(OH)2-16-ene-D3 at a concentration of 0.01 nM, with E2 inhibiting the effect of 1alpha,25(OH)2-16-ene-D3.	Dextromethorphan	35-38	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
11256478-7	2001	Western blot analysis of 1alpha,25(OH)2D3 receptor (VDR) levels showed that in SaOS+DEX cells, the effect of 1alpha,25(OH)2D3 was larger than that of 1alpha,25(OH)2-16-ene-D3.	Dextromethorphan	84-87	vitamin D receptor	Homo sapiens	52-55
12567591-1	2001	PURPOSE: Dexamethasone(DEX) was tested for its ability to modulate human retinal pigment epithelium(hRPE) cell proliferation in cell culture.	Dextromethorphan	23-26	ribulose-5-phosphate-3-epimerase	Homo sapiens	100-104
12567591-2	2001	METHODS: DEX in different concentrations was added to cultured hRPE cells.	Dextromethorphan	9-12	ribulose-5-phosphate-3-epimerase	Homo sapiens	63-67
12567591-4	2001	RESULTS: DEX increased survival rate and DNA synthesis from 32 mg/L to 320 mg/L under hRPE culture conditions, but paradoxically reduced them at 1,000 mg/L and 3,200 mg/L in dose and time dependent fashion by both MTT assay and 3H-TdR incorporation.	Dextromethorphan	9-12	ribulose-5-phosphate-3-epimerase	Homo sapiens	86-90
11165039-1	2001	Recently, pregnane X receptor (PXR) has been described to mediate the genomic effects of several steroid hormones, such as progesterone (P), glucocorticoid (Dex), pregnenolone (Preg), and xenobiotics through the cytochrome P-450 3A gene family (CYP3A), which are monooxygenases, responsible for the oxidative metabolism of some endogenous substrates and xenobiotics.	Dextromethorphan	157-160	nuclear receptor subfamily 1, group I, member 2	Mus musculus	10-29
11165039-1	2001	Recently, pregnane X receptor (PXR) has been described to mediate the genomic effects of several steroid hormones, such as progesterone (P), glucocorticoid (Dex), pregnenolone (Preg), and xenobiotics through the cytochrome P-450 3A gene family (CYP3A), which are monooxygenases, responsible for the oxidative metabolism of some endogenous substrates and xenobiotics.	Dextromethorphan	157-160	nuclear receptor subfamily 1, group I, member 2	Mus musculus	31-34
11165039-2	2001	In the present study, we used a transient transfection reporter gene expression assay of COS-7 cells to demonstrate that P, Dex and Preg significantly stimulate PXR-mediated transcription at relatively high concentration comparable with that of progesterone near term pregnancy.	Dextromethorphan	124-127	nuclear receptor subfamily 1, group I, member 2	Mus musculus	161-164
11144999-0	2001	Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation.	Dextromethorphan	34-50	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
11122451-8	2000	DEX-induced IFN-gamma production by NK cells was dependent upon the presence of IL-12, and IL-12 production by M phi was dependent upon the presence of IFN-gamma in these co-cultures.	Dextromethorphan	0-3	interferon gamma	Mus musculus	12-21
11133003-2	2000	Nifedipine oxidation (CYP3A) activity correlated significantly with N-dealkylation rates of haloperidol and bromperidol and oxidation rates of their reduced forms, while neither ethoxyresorufin O-deethylation (CYP1A2) activity nor dextromethorphan O-deethylation (CYP2D6) activity did.	Dextromethorphan	231-247	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-27
11095593-3	2000	Competition experiments using heterologously expressed CYP2D6 demonstrated that the introduction and elongation of alkyl substituents strongly decreased the IC(50) values toward dextromethorphan O-demethylation.	Dextromethorphan	178-194	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
11038161-8	2000	Metoprolol and dextromethorphan were primarily CYP2D6 substrates and propranolol was metabolized by CYP2D6 (59%), CYP1A2 (26%), and CYP2C19 (15%).	Dextromethorphan	15-31	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Dextromethorphan	111-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-9
11061577-6	2000	RESULTS: The median CYP1A2 metabolic ratio after administration of caffeine + dextromethorphan was not significantly different from that obtained with the cocktail (P = .84).	Dextromethorphan	78-94	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	20-26
11034254-3	2000	Dextromethorphan was used as the probe for CYP2D6 activity and mephenytoin was used for CYP2C19 activity.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	43-49
11034254-5	2000	The CYP2D6 phenotype was determined from the ratio of dextromethorphan conversion to dextrorphan and the CYP2C19 phenotype from the ratio of S-mephenytoin and R-mephenytoin.	Dextromethorphan	54-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
11034254-9	2000	The prevalence of poor metabolizer phenotype of dextromethorphan (CYP2D6) in the Yemenite (0%) and Ethiopian groups (0%) was significantly different from the prevalence in the Russian (17%) and Israeli Arab (9%) groups.	Dextromethorphan	48-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	66-72
10942192-1	2000	A bioanalytical method for the determination of dextromethorphan (DEX) and its metabolites dextrorphan (DTX), 3-methoxymorphinan (3MM), and 3-hydroxymorphinan (3HM) in human urine was developed for CYP2D6 phenotyping and CYP3A4 activity measurements in clinical pharmacology studies using dextromethorphan administered in a drinking solution as substrate.	Dextromethorphan	48-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	198-204
10942192-1	2000	A bioanalytical method for the determination of dextromethorphan (DEX) and its metabolites dextrorphan (DTX), 3-methoxymorphinan (3MM), and 3-hydroxymorphinan (3HM) in human urine was developed for CYP2D6 phenotyping and CYP3A4 activity measurements in clinical pharmacology studies using dextromethorphan administered in a drinking solution as substrate.	Dextromethorphan	48-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	221-227
10997936-9	2000	IC(50) values for inhibition of a CYP2D6 index reaction (dextromethorphan O-demethylation) by bupropion and hydroxybupropion were 58 and 74 microM, respectively.	Dextromethorphan	57-73	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	34-40
10942192-9	2000	For CYP3A4 activity determinations it was concluded that in general a change in dextromethorphan/3-methoxymorphinan (DEX/3MM) ratios of 10% or more as detected with the current method, is a significant increase or decrease in the activity of CYP3A4.	Dextromethorphan	80-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
10942192-9	2000	For CYP3A4 activity determinations it was concluded that in general a change in dextromethorphan/3-methoxymorphinan (DEX/3MM) ratios of 10% or more as detected with the current method, is a significant increase or decrease in the activity of CYP3A4.	Dextromethorphan	80-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	242-248
10942192-9	2000	For CYP3A4 activity determinations it was concluded that in general a change in dextromethorphan/3-methoxymorphinan (DEX/3MM) ratios of 10% or more as detected with the current method, is a significant increase or decrease in the activity of CYP3A4.	Dextromethorphan	117-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
10942192-9	2000	For CYP3A4 activity determinations it was concluded that in general a change in dextromethorphan/3-methoxymorphinan (DEX/3MM) ratios of 10% or more as detected with the current method, is a significant increase or decrease in the activity of CYP3A4.	Dextromethorphan	117-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	242-248
10942192-10	2000	The authors concluded that they had obtained an analytically valid and clinically reliable bioanalytical method for the determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan, and 3-hydroxymorphinan in human urine for CYP2D6 phenotyping and CYP3A4 activity measurements for clinical pharmacology studies.	Dextromethorphan	137-153	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	249-255
10942192-10	2000	The authors concluded that they had obtained an analytically valid and clinically reliable bioanalytical method for the determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan, and 3-hydroxymorphinan in human urine for CYP2D6 phenotyping and CYP3A4 activity measurements for clinical pharmacology studies.	Dextromethorphan	137-153	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	272-278
11037108-5	2000	Human CYP probe substrates used for characterization of mouse CYP activities included bufuralol, testosterone, dextromethorphan, phenacetin, diclofenac and S-mephenytoin.	Dextromethorphan	111-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
10876080-3	2000	An weak NR2A antagonist, dextromethorphan, did not show such effects while it significantly suppressed the manifestation of AS in already susceptible post-weaning (primed) rats.	Dextromethorphan	25-41	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	8-12
10848718-3	2000	METHODS: Metoprolol and dextromethorphan (DM) were selected as probe drugs because they are well-studied and widely used test substrates of CYP2D6.	Dextromethorphan	24-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	140-146
10886115-0	2000	Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.	Dextromethorphan	95-111	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	141-147
10848718-3	2000	METHODS: Metoprolol and dextromethorphan (DM) were selected as probe drugs because they are well-studied and widely used test substrates of CYP2D6.	Dextromethorphan	42-44	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	140-146
10895987-7	2000	A moderate effect was observed for high affinity dextromethorphan metabolism (CYP2D6) in one of the microsomes samples tested only (IC50=173 microM).	Dextromethorphan	49-65	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
10923858-6	2000	CYP2D subfamily mRNA and protein levels were correlated with brain dextromethorphan O-demethylation (DOD), a measure of human CYP2D6 and rat CYP2D1 activities.	Dextromethorphan	67-83	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-5
10806376-0	2000	Evidence for the catalysis of dextromethorphan O-demethylation by a CYP2D6-like enzyme in pig liver.	Dextromethorphan	30-46	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	68-74
10806376-7	2000	We investigated the ability of pig liver microsomes to catalyse dextromethorphan O-demethylation, a widely-used marker enzyme activity for CYP2D6.	Dextromethorphan	64-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	139-145
10806376-10	2000	We conclude that dextromethorphan O-demethylation is catalysed by a CYP2D enzyme which is remarkably similar to human CYP2D6, suggesting potential value of the pig as a model for predicting human metabolism of xenobiotics which undergo CYP2D6-dependent biotransformation.	Dextromethorphan	17-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	68-73
10806376-10	2000	We conclude that dextromethorphan O-demethylation is catalysed by a CYP2D enzyme which is remarkably similar to human CYP2D6, suggesting potential value of the pig as a model for predicting human metabolism of xenobiotics which undergo CYP2D6-dependent biotransformation.	Dextromethorphan	17-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	118-124
10806376-10	2000	We conclude that dextromethorphan O-demethylation is catalysed by a CYP2D enzyme which is remarkably similar to human CYP2D6, suggesting potential value of the pig as a model for predicting human metabolism of xenobiotics which undergo CYP2D6-dependent biotransformation.	Dextromethorphan	17-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	236-242
10837520-4	2000	Twenty-nine subjects out of 42 intermediate metabolizers(70%) of dextromethorphan were homozygous for CYP2D6*10B.	Dextromethorphan	65-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-108
10837520-7	2000	CONCLUSION: The CYP2D6*10B allele containing the C(188)--> T mutation is the major cause of CYP2D6 polymorphism in relation to diminished dextromethorphan oxidative capacity in Chinese subjects.	Dextromethorphan	141-157	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	16-22
10837520-7	2000	CONCLUSION: The CYP2D6*10B allele containing the C(188)--> T mutation is the major cause of CYP2D6 polymorphism in relation to diminished dextromethorphan oxidative capacity in Chinese subjects.	Dextromethorphan	141-157	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	95-101
10802201-7	2000	The dextromethorphan/dextrorphan concentration ratio of 2.5 found in this toddler was compatible with a slow CYP2D6 metabolizer phenotype.	Dextromethorphan	4-20	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	109-115
10764440-2	2000	Particular emphasis is placed on describing the newer information on the cytochrome P450 (CYP) system and the interactions of opioids, antidepressants, and the antitussive, dextromethorphan.	Dextromethorphan	173-189	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-93
10967711-2	2000	The CYP2D6 metabolizer phenotype (dextromethorphan test) of 31 drug treated psychiatric adult patients suffering from extrapyramidal side-effects (group 1) and of 31 matched patients without drug side effects (group 2) were compared.	Dextromethorphan	34-50	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
10677595-6	2000	Dextromethorphan was metabolized to dextrorphan in rat brain microsomes and was inhibited by quinidine and by a polyclonal antibody against CYP2D6.	Dextromethorphan	0-16	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	140-146
11343579-1	2000	In an open trial 11 in-patients with a major depressive episode (ICD-10), extensive metabolizers of mephenytoin (CYP2C19) and dextromethorphan (CYP2D6) and who were non-responders to a 3-wk pretreatment with 40 mg/d citalopram (Cit), were co-medicated for 7 wk (days 0-49) with fluoxetine (Fluox) (10 mg/d).	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	144-150
10753054-0	2000	Insulin-dependent diabetes mellitus induced by the antitussive agent dextromethorphan.	Dextromethorphan	69-85	insulin	Homo sapiens	0-7
11013424-3	2000	A highly efficient direct injection on-line guard cartridge extraction/tandem mass spectrometry (DI-GCE/MS/MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 3A4, 2D6 and 2E1 inhibition potential via cassette dosing of midazolam, dextromethorphan and chlorzoxazone using human hepatic microsomes and 96-well microtiter plates.	Dextromethorphan	265-281	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	188-191
10771453-2	2000	METHODS: Twenty-four healthy young subjects aged 18-45 years were screened for CYP2D6 metabolizing activity and shown to be extensive metabolizers of dextromethorphan.	Dextromethorphan	150-166	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
11741249-5	2000	In addition, we identified 2 subjects with CYP2D6 genotypes indicative of poor metabolizers who had extensive metabolizer phenotypes as determined by dextromethorphan/dextrorphan ratios.	Dextromethorphan	150-166	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	43-49
10911933-6	2000	Using in vitro studies, we have identified drugs of abuse that are substrates of the polymorphic enzymes CYP2D6 (codeine, amphetamines, dextromethorphan), CYP2A6 (nicotine) and CYP2C19 (flunitrazepam).	Dextromethorphan	136-152	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	105-111
10911933-8	2000	In addition, we inhibited CYP2D6 and decreased individuals" risk of dependence experimentally (codeine, dextromethorphan) and treated codeine dependence.	Dextromethorphan	104-120	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	26-32
11013424-3	2000	A highly efficient direct injection on-line guard cartridge extraction/tandem mass spectrometry (DI-GCE/MS/MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 3A4, 2D6 and 2E1 inhibition potential via cassette dosing of midazolam, dextromethorphan and chlorzoxazone using human hepatic microsomes and 96-well microtiter plates.	Dextromethorphan	265-281	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	171-186
10613613-1	1999	OBJECTIVES: Dextromethorphan and chloroguanide (INN, proguanil) are used as prototypic phenotyping substrates of polymorphically expressed CYP2D6 and CYP2C19 in humans.	Dextromethorphan	12-28	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	139-145
10659949-10	2000	Western blotting provided additional evidence for the expression of CYP1A1 and CYP3A4 at the protein level and treatment of cultured enterocytes with 30 microM Aroclor 1254 or 50 microM beta-NF resulted in enhanced expression of the CYP1A protein, and CYP3A4 protein expression was induced following treatment with 50 microM DEX, 2 mM PB, 30 microM Aroclor 1254 or 50 microM beta-NF.	Dextromethorphan	325-328	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	68-74
10659949-10	2000	Western blotting provided additional evidence for the expression of CYP1A1 and CYP3A4 at the protein level and treatment of cultured enterocytes with 30 microM Aroclor 1254 or 50 microM beta-NF resulted in enhanced expression of the CYP1A protein, and CYP3A4 protein expression was induced following treatment with 50 microM DEX, 2 mM PB, 30 microM Aroclor 1254 or 50 microM beta-NF.	Dextromethorphan	325-328	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
10613613-12	1999	CYP2D6 and CYP2C19 activity can be determined from a blood sample drawn 3 hours after oral administration of dextromethorphan and chloroguanide, respectively.	Dextromethorphan	109-125	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
10613613-1	1999	OBJECTIVES: Dextromethorphan and chloroguanide (INN, proguanil) are used as prototypic phenotyping substrates of polymorphically expressed CYP2D6 and CYP2C19 in humans.	Dextromethorphan	12-28	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	150-157
10613613-12	1999	CYP2D6 and CYP2C19 activity can be determined from a blood sample drawn 3 hours after oral administration of dextromethorphan and chloroguanide, respectively.	Dextromethorphan	109-125	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	11-18
10613613-9	1999	Inhibition of CYP3A-dependent biotransformation of dextromethorphan to methoxymorphinan did not appear to be responsible for this change because the log(dextromethorphan/methoxymorphinan) urinary ratio, an index of CYP3A activity, did not significantly change during chloroguanide coadministration.	Dextromethorphan	51-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-19
10657736-7	1999	In the DEX-CRH test, plasma cortisol concentrations showed higher values before (DEX-pretreated) and after CRH stimulation in the MS patients than in the controls (AUC(cortisol) 738.3 +/- 154.5 vs. 295.7 +/- 55.8; p < 0.05), this finding was more pronounced in chronic progressive patients.	Dextromethorphan	7-10	corticotropin releasing hormone	Homo sapiens	11-14
10562433-7	1999	Recombinant CYP2D17 catalyzed the oxidation of bufuralol to 1"-hydroxybufuralol and dextromethorphan to dextrorphan, reactions shown to be mediated by CYP2D6 in humans; the apparent K(m) values for bufuralol and dextromethorphan were 1 and 0.8 microM, respectively.	Dextromethorphan	84-100	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	12-19
10562433-7	1999	Recombinant CYP2D17 catalyzed the oxidation of bufuralol to 1"-hydroxybufuralol and dextromethorphan to dextrorphan, reactions shown to be mediated by CYP2D6 in humans; the apparent K(m) values for bufuralol and dextromethorphan were 1 and 0.8 microM, respectively.	Dextromethorphan	84-100	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	151-157
10562433-7	1999	Recombinant CYP2D17 catalyzed the oxidation of bufuralol to 1"-hydroxybufuralol and dextromethorphan to dextrorphan, reactions shown to be mediated by CYP2D6 in humans; the apparent K(m) values for bufuralol and dextromethorphan were 1 and 0.8 microM, respectively.	Dextromethorphan	212-228	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	12-19
10562433-7	1999	Recombinant CYP2D17 catalyzed the oxidation of bufuralol to 1"-hydroxybufuralol and dextromethorphan to dextrorphan, reactions shown to be mediated by CYP2D6 in humans; the apparent K(m) values for bufuralol and dextromethorphan were 1 and 0.8 microM, respectively.	Dextromethorphan	212-228	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	151-157
10628907-7	1999	The only clear inhibition was seen for the CYP2D6-dependent high-affinity O-demethylation of dextromethorphan, where IC50 values of 27 microM and 44 microM were observed.	Dextromethorphan	93-109	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	43-49
10657736-7	1999	In the DEX-CRH test, plasma cortisol concentrations showed higher values before (DEX-pretreated) and after CRH stimulation in the MS patients than in the controls (AUC(cortisol) 738.3 +/- 154.5 vs. 295.7 +/- 55.8; p < 0.05), this finding was more pronounced in chronic progressive patients.	Dextromethorphan	7-10	corticotropin releasing hormone	Homo sapiens	107-110
10508187-4	1999	In this manuscript we show that when B cells are stimulated in vitro with dextran-conjugated anti-IgD antibodies (anti-IgD-dex), as the multivalent mIg ligand, their proliferation is enhanced and they can be induced to secrete Ig in response to ODN containing various non-optimal motifs, both methylated and non-methylated.	Dextromethorphan	74-77	chemokine (C-X-C motif) ligand 9	Mus musculus	148-151
10597902-2	1999	The most pronounced effects were observed with terfenadine, astemizole and loratadine which inhibited CYP3A4-mediated testosterone 6beta-hydroxylation (IC50 of 23, 21 and 32 microM, respectively) and CYP2D6-mediated dextromethorphan O-demethylation (IC50 of 18, 36 and 15 microM, respectively).	Dextromethorphan	216-232	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
10760842-0	1999	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes.	Dextromethorphan	65-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
10579479-6	1999	RESULTS: Mean CYP2D6 dextromethorphan metabolic ratios before and after fluoxetine therapy were 0.028 +/- 0.031 and 0.080 +/- 0.058, respectively (P = .001), indicating that a strong inhibition of CYP2D6 by fluoxetine activity was observed in Chinese subjects.	Dextromethorphan	21-37	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
10579479-12	1999	CONCLUSION: We conclude that fluoxetine may cause significant inhibition of the CYP2D6 activity as determined by dextromethorphan phenotyping.	Dextromethorphan	113-129	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
10579482-0	1999	Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.	Dextromethorphan	19-35	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-59
10579482-0	1999	Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.	Dextromethorphan	19-35	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
10579482-1	1999	Most dextromethorphan CYP2D6 phenotyping studies use a 30-mg dose, but data that show superiority of any particular dose are lacking.	Dextromethorphan	5-21	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	22-28
10599932-3	1999	The CYP2D6 phenotype, determined when the patient received the antidepressant comedication, characterized a poor metabolizer status (dextromethorphan metabolic ratio >0.3), despite a heterozygous genotype containing a wild-type allele with extensive metabolic capacity and a mutant non-functional allele (CYP2D6*1A/CYP2D6*4A).	Dextromethorphan	133-149	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
10508187-4	1999	In this manuscript we show that when B cells are stimulated in vitro with dextran-conjugated anti-IgD antibodies (anti-IgD-dex), as the multivalent mIg ligand, their proliferation is enhanced and they can be induced to secrete Ig in response to ODN containing various non-optimal motifs, both methylated and non-methylated.	Dextromethorphan	74-77	chemokine (C-X-C motif) ligand 9	Mus musculus	98-100
10460803-11	1999	Terbinafine, however, is a competitive inhibitor of the CYP2D6 reaction, dextromethorphan O-demethylation (K(i) = 0.03 microM).	Dextromethorphan	73-89	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	56-62
10460801-2	1999	The dealkylation of ethoxyresorufin, dextromethorphan, and erythromycin were all shown to be specific reactions for CYP1A2, CYP2D6, and CYP3A4 that allowed direct comparison with kinetic data for HLM.	Dextromethorphan	37-53	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	116-122
10464173-3	1999	Dex-treated DC showed an enhancement of mannose receptor (MR)-mediated endocytosis (measured as uptake of FITC-dextran) and of fluid-phase endocytosis [measured as uptake of Lucifer yellow (LY)] The effect was dose dependent and correlated with the length of exposure to Dex.	Dextromethorphan	0-3	mannose receptor C-type 1	Homo sapiens	40-56
10460810-3	1999	All antipsychotic drugs tested competitively inhibited dextromethorphan O-demethylation, a selective marker for CYP2D6, in a concentration-dependent manner.	Dextromethorphan	55-71	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
10510150-0	1999	The antitussive effect of dextromethorphan in relation to CYP2D6 activity.	Dextromethorphan	26-42	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-64
10510150-1	1999	AIMS: To test the hypothesis that inhibition of cytochrome P450 2D6 (CYP2D6) by quinidine increases the antitussive effect of dextromethorphan (DEX) in an induced cough model.	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-67
10510150-1	1999	AIMS: To test the hypothesis that inhibition of cytochrome P450 2D6 (CYP2D6) by quinidine increases the antitussive effect of dextromethorphan (DEX) in an induced cough model.	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
10464173-6	1999	After maturation with tumor necrosis factor-alpha or CD40 ligand in Dex-treated DC, despite a reduction induced by maturation the endocytic activity of FITC-dextran and LY, the expression of MR, CD16 and CD32 remained higher than in control DC.	Dextromethorphan	68-71	mannose receptor C-type 1	Homo sapiens	191-193
10464173-3	1999	Dex-treated DC showed an enhancement of mannose receptor (MR)-mediated endocytosis (measured as uptake of FITC-dextran) and of fluid-phase endocytosis [measured as uptake of Lucifer yellow (LY)] The effect was dose dependent and correlated with the length of exposure to Dex.	Dextromethorphan	0-3	mannose receptor C-type 1	Homo sapiens	58-60
10464173-6	1999	After maturation with tumor necrosis factor-alpha or CD40 ligand in Dex-treated DC, despite a reduction induced by maturation the endocytic activity of FITC-dextran and LY, the expression of MR, CD16 and CD32 remained higher than in control DC.	Dextromethorphan	68-71	Fc gamma receptor IIIa	Homo sapiens	195-199
10510150-1	1999	AIMS: To test the hypothesis that inhibition of cytochrome P450 2D6 (CYP2D6) by quinidine increases the antitussive effect of dextromethorphan (DEX) in an induced cough model.	Dextromethorphan	144-147	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-67
10510150-1	1999	AIMS: To test the hypothesis that inhibition of cytochrome P450 2D6 (CYP2D6) by quinidine increases the antitussive effect of dextromethorphan (DEX) in an induced cough model.	Dextromethorphan	144-147	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
10464173-5	1999	Dex up-regulates MR, CD16 and CD32 expression on DC.	Dextromethorphan	0-3	mannose receptor C-type 1	Homo sapiens	17-19
10510150-4	1999	RESULTS: Inhibition of CYP2D6 by quinidine caused a significant increase in the mean ratio of DEX to dextrorphan (DEX:DOR) plasma AUC(96) (0.04 vs 1.81, P<0.001).	Dextromethorphan	94-97	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	23-29
10464173-5	1999	Dex up-regulates MR, CD16 and CD32 expression on DC.	Dextromethorphan	0-3	Fc gamma receptor IIIa	Homo sapiens	21-25
10464173-6	1999	After maturation with tumor necrosis factor-alpha or CD40 ligand in Dex-treated DC, despite a reduction induced by maturation the endocytic activity of FITC-dextran and LY, the expression of MR, CD16 and CD32 remained higher than in control DC.	Dextromethorphan	68-71	Fc gamma receptor IIa	Homo sapiens	204-208
10464173-5	1999	Dex up-regulates MR, CD16 and CD32 expression on DC.	Dextromethorphan	0-3	Fc gamma receptor IIa	Homo sapiens	30-34
10464173-6	1999	After maturation with tumor necrosis factor-alpha or CD40 ligand in Dex-treated DC, despite a reduction induced by maturation the endocytic activity of FITC-dextran and LY, the expression of MR, CD16 and CD32 remained higher than in control DC.	Dextromethorphan	68-71	tumor necrosis factor	Homo sapiens	22-49
10464173-6	1999	After maturation with tumor necrosis factor-alpha or CD40 ligand in Dex-treated DC, despite a reduction induced by maturation the endocytic activity of FITC-dextran and LY, the expression of MR, CD16 and CD32 remained higher than in control DC.	Dextromethorphan	68-71	CD40 molecule	Homo sapiens	53-57
10421620-0	1999	Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan.	Dextromethorphan	91-107	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	20-40
10421620-9	1999	These data characterize CYP2D1-mediated dextromethorphan metabolism in rat brain and suggest that localized metabolism of other CYP2D1 substrates (drugs, neurotoxins, and possibly endogenous compounds) within the brain will occur.	Dextromethorphan	40-56	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	24-30
10691018-1	1999	Dextromethorphan, a constituent of many over-the-counter cough syrups, is used as a probe drug for phenotyping subjects for their cytochrome P450 2D6 (CYP2D6) enzyme activity and for measuring CYP2D6 activity of preparations such as microsomes.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	130-149
10691018-1	1999	Dextromethorphan, a constituent of many over-the-counter cough syrups, is used as a probe drug for phenotyping subjects for their cytochrome P450 2D6 (CYP2D6) enzyme activity and for measuring CYP2D6 activity of preparations such as microsomes.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	151-157
10691018-1	1999	Dextromethorphan, a constituent of many over-the-counter cough syrups, is used as a probe drug for phenotyping subjects for their cytochrome P450 2D6 (CYP2D6) enzyme activity and for measuring CYP2D6 activity of preparations such as microsomes.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	193-199
10448923-7	1999	The mixed dopamine D1/D2 receptor agonist apomorphine (0.5 and 1 mg/kg, s.c.) reduced the response induced by dextromethorphan.	Dextromethorphan	110-126	dopamine receptor D1	Mus musculus	19-33
10780265-0	1999	Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.	Dextromethorphan	15-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-69
10780265-7	1999	Intraindividual variability in baseline CYP3A activity (median, 25-75th percentile), as determined by coefficients of variation, was 48.3% (36.8-68.8%) for 3MM/DM and 10.3% (8.3-11.8%) for MDZ CL.	Dextromethorphan	160-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-45
10383919-0	1999	Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.	Dextromethorphan	51-67	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	21-41
10391422-7	1999	All subjects were extensive metabolizers of CYP2D6 as determined by metabolic ratios of DM:DT (mean+/-SD 0.0255+/-0.048).	Dextromethorphan	88-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
10445392-4	1999	The present study was undertaken to investigate the influence of immunosuppressants cyclophosphamide and dexamethasone on the CYP2D 1-dependent metabolism of dextromethorphan (DEM) in the isolated perfused liver from male rat donors (Wistar albino, 250-310 g).	Dextromethorphan	158-174	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	126-133
10733338-6	1999	When C1 cells were induced to differentiate into chondrocytes in aggregate cultures in the presence of dexamethasone(dex), noggin expression was significantly increased.	Dextromethorphan	103-106	noggin	Mus musculus	123-129
10391422-0	1999	A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.	Dextromethorphan	27-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-87
10391422-1	1999	Dextromethorphan (DM) is metabolized in the body to dextrophan (DT) and 3-methoxymorphinan (3-MM) by cytochrome P450 (CYP) 2D6 and 3A4, respectively, and cyclosporine (CsA) is a known substrate of CYP3A4.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	101-126
10381760-0	1999	Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.	Dextromethorphan	64-80	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	22-27
10348802-8	1999	CYP2C9, 2C19, 2D6, and 3A4 activities were determined from the tolbutamide metabolic ratio, 4"-hydroxymephenytoin excretion, and dextromethorphan/dextrorphan ratios in urine and midazolam systemic clearance, respectively.	Dextromethorphan	129-145	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
10471059-3	1999	A recent study of the effects of renal impairment has found discrepancies between different indices used to mark CYP2D6 activity based on sparteine and dextromethorphan urinary recoveries.	Dextromethorphan	152-168	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	113-119
10340923-0	1999	Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population.	Dextromethorphan	43-59	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	16-22
10391422-1	1999	Dextromethorphan (DM) is metabolized in the body to dextrophan (DT) and 3-methoxymorphinan (3-MM) by cytochrome P450 (CYP) 2D6 and 3A4, respectively, and cyclosporine (CsA) is a known substrate of CYP3A4.	Dextromethorphan	0-16	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	168-171
10391422-1	1999	Dextromethorphan (DM) is metabolized in the body to dextrophan (DT) and 3-methoxymorphinan (3-MM) by cytochrome P450 (CYP) 2D6 and 3A4, respectively, and cyclosporine (CsA) is a known substrate of CYP3A4.	Dextromethorphan	0-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	197-203
10391422-1	1999	Dextromethorphan (DM) is metabolized in the body to dextrophan (DT) and 3-methoxymorphinan (3-MM) by cytochrome P450 (CYP) 2D6 and 3A4, respectively, and cyclosporine (CsA) is a known substrate of CYP3A4.	Dextromethorphan	18-20	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	101-126
10391422-1	1999	Dextromethorphan (DM) is metabolized in the body to dextrophan (DT) and 3-methoxymorphinan (3-MM) by cytochrome P450 (CYP) 2D6 and 3A4, respectively, and cyclosporine (CsA) is a known substrate of CYP3A4.	Dextromethorphan	18-20	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	168-171
10391422-1	1999	Dextromethorphan (DM) is metabolized in the body to dextrophan (DT) and 3-methoxymorphinan (3-MM) by cytochrome P450 (CYP) 2D6 and 3A4, respectively, and cyclosporine (CsA) is a known substrate of CYP3A4.	Dextromethorphan	18-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	197-203
10340911-5	1999	The change in CYP2D6 enzyme activity before (x 3) and after (monthly x 6 months) administration of terbinafine (250 mg once daily x 14 days) was evaluated with the dextromethorphan to dextrorphan urinary metabolite ratios.	Dextromethorphan	164-180	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
10223772-2	1999	In this study we investigated the inhibition profiles of CYP1A2 (substrate: caffeine) CYP2D6 (substrate: dextromethorphan), and CYP3A4/5 (substrate: dextrorphan) by cimetidine, ranitidine, and the novel H2-receptor antagonist ebrotidine in human liver microsomes.	Dextromethorphan	105-121	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	57-63
10095051-5	1999	Paradoxically, dextromethorphan itself caused an elevated activator protein-1 DNA-binding activity and Fos-related antigen-immunoreactive protein in the CA1 region which lasted for at least 4 days.	Dextromethorphan	15-31	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	58-77
10095051-5	1999	Paradoxically, dextromethorphan itself caused an elevated activator protein-1 DNA-binding activity and Fos-related antigen-immunoreactive protein in the CA1 region which lasted for at least 4 days.	Dextromethorphan	15-31	carbonic anhydrase 1	Rattus norvegicus	153-156
10095051-6	1999	The results suggest that the CA1 area is the critical site for mediating the putative neuroprotective effect induced by dextromethorphan.	Dextromethorphan	120-136	carbonic anhydrase 1	Rattus norvegicus	29-32
9877254-12	1998	The results showed a satisfactory fit (goodness-of-fit index: 0.945 - 1.0) for the path diagrams: Dex --> T/IGF-I --> WHR or D --> insulin --> triglycerides with additional direct input of blunted Dex on insulin values (see Figure 1).	Dextromethorphan	98-101	insulin like growth factor 1	Homo sapiens	111-116
10101136-1	1999	A higher throughput method of screening for the inhibition of recombinant CYP2D6 using a microtiter plate (MTP) assay was evaluated using 62 new chemical entities and compared to data from the dextromethorphan O-demethylase assay in human liver microsomes (HLM).	Dextromethorphan	193-209	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	74-80
9918565-2	1999	In humans, DEM is metabolized into DOR by the polymorphic enzyme CYP2D6.	Dextromethorphan	11-14	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
10073750-2	1999	METHODS: The CYP2D6 phenotype of 154 healthy Gabonese subjects was assessed by giving the subject a single dose of 30 mg dextromethorphan, and collecting their urine for the next 8 h. The CYP2D6 genotype was determined for 50 individuals of the EM phenotypic group by Southern blotting and various PCR-based procedures aimed at identifying different CYP2D6 alleles.	Dextromethorphan	121-137	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
10073750-5	1999	We found that the CYP2D6*17 and CYP2D6*2 alleles, prevalent in this black population, are characterised by their low capacity for dextromethorphan demethylation.	Dextromethorphan	130-146	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	18-24
10073750-5	1999	We found that the CYP2D6*17 and CYP2D6*2 alleles, prevalent in this black population, are characterised by their low capacity for dextromethorphan demethylation.	Dextromethorphan	130-146	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-38
9974119-1	1999	Photochemical thrombotic ischemia model was used to study the possible roles of excision repair cross-complementing group 6 (ERCC6), a DNA repair gene, in the neuroprotection of dextromethorphan (DM), a NMDA antagonist, in ischemic brain injury.	Dextromethorphan	178-194	ERCC excision repair 6, chromatin remodeling factor	Rattus norvegicus	80-123
9974119-1	1999	Photochemical thrombotic ischemia model was used to study the possible roles of excision repair cross-complementing group 6 (ERCC6), a DNA repair gene, in the neuroprotection of dextromethorphan (DM), a NMDA antagonist, in ischemic brain injury.	Dextromethorphan	178-194	ERCC excision repair 6, chromatin remodeling factor	Rattus norvegicus	125-130
10200551-3	1999	In this paper, we have further characterized the sensitive and resistant phenotypes and investigated whether a different expression of the apoptotic genes Fas, FasL, Bcl-2, Bcl-x and Bax is involved in the regulation of Dex-mediated apoptosis.	Dextromethorphan	220-223	BCL2 associated X, apoptosis regulator	Homo sapiens	183-186
10200551-4	1999	The results show that the amount of Bcl-2 expression, that changes during cell cycle phases, determines susceptibility or resistance to apoptosis induced by Dex.	Dextromethorphan	157-160	BCL2 apoptosis regulator	Homo sapiens	36-41
10200551-5	1999	In fact, undetectable expression of Bcl-2 in sensitive cells favors Dex-mediated apoptosis while high expression of Bcl-2 in proliferating cells counterbalances apoptosis induction.	Dextromethorphan	68-71	BCL2 apoptosis regulator	Homo sapiens	36-41
10200551-6	1999	Moreover, the addition of exogenous IL-2, in the presence of Dex, fails to up-regulate Bcl-2 expression and to revert Dex-mediated apoptotic phenomena.	Dextromethorphan	61-64	interleukin 2	Homo sapiens	36-40
10200551-6	1999	Moreover, the addition of exogenous IL-2, in the presence of Dex, fails to up-regulate Bcl-2 expression and to revert Dex-mediated apoptotic phenomena.	Dextromethorphan	118-121	interleukin 2	Homo sapiens	36-40
9877254-12	1998	The results showed a satisfactory fit (goodness-of-fit index: 0.945 - 1.0) for the path diagrams: Dex --> T/IGF-I --> WHR or D --> insulin --> triglycerides with additional direct input of blunted Dex on insulin values (see Figure 1).	Dextromethorphan	98-101	insulin	Homo sapiens	140-147
9877254-12	1998	The results showed a satisfactory fit (goodness-of-fit index: 0.945 - 1.0) for the path diagrams: Dex --> T/IGF-I --> WHR or D --> insulin --> triglycerides with additional direct input of blunted Dex on insulin values (see Figure 1).	Dextromethorphan	98-101	insulin	Homo sapiens	216-223
9877254-12	1998	The results showed a satisfactory fit (goodness-of-fit index: 0.945 - 1.0) for the path diagrams: Dex --> T/IGF-I --> WHR or D --> insulin --> triglycerides with additional direct input of blunted Dex on insulin values (see Figure 1).	Dextromethorphan	209-212	insulin like growth factor 1	Homo sapiens	111-116
9823980-4	1998	Eleven prostate specimens were analysed for genotype and enzymatic activities NAT2, CYP2D6 and CYP3A by using the enzyme-specific substrates sulphamethazine and dextromethorphan.	Dextromethorphan	161-177	N-acetyltransferase 2	Homo sapiens	78-82
9861783-7	1998	We then tested the effect of these antidepressants on the Dex stimulation of TRH content.	Dextromethorphan	58-61	thyrotropin releasing hormone	Rattus norvegicus	77-80
9823980-4	1998	Eleven prostate specimens were analysed for genotype and enzymatic activities NAT2, CYP2D6 and CYP3A by using the enzyme-specific substrates sulphamethazine and dextromethorphan.	Dextromethorphan	161-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-100
9860112-5	1998	The female Dark Agouti lacks CYP2D1, the cytochrome P450 enzyme which catalyses the oxidative O-demethylation of dextromethorphan to dextrorphan.	Dextromethorphan	113-129	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	29-35
10763411-4	1998	We show that DEX induced cell proliferation is paralleled by a decrease in Cdkn2a gene transcripts, suggesting a mechanism for hormone promotion.	Dextromethorphan	13-16	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	75-81
9795195-5	1998	Examination of the effects of mutation of the AP-2 or Egr-1 binding sites on PNMT promoter activation by DEX and the factor binding to the remaining intact site or by all three transcriptional activators showed changes in luciferase reporter gene expression which suggest that DNA structure may be altered thereby reducing or enhancing synergistic activation.	Dextromethorphan	105-108	transcription factor AP-2 alpha	Homo sapiens	46-50
9795195-5	1998	Examination of the effects of mutation of the AP-2 or Egr-1 binding sites on PNMT promoter activation by DEX and the factor binding to the remaining intact site or by all three transcriptional activators showed changes in luciferase reporter gene expression which suggest that DNA structure may be altered thereby reducing or enhancing synergistic activation.	Dextromethorphan	105-108	early growth response 1	Homo sapiens	54-59
9795195-5	1998	Examination of the effects of mutation of the AP-2 or Egr-1 binding sites on PNMT promoter activation by DEX and the factor binding to the remaining intact site or by all three transcriptional activators showed changes in luciferase reporter gene expression which suggest that DNA structure may be altered thereby reducing or enhancing synergistic activation.	Dextromethorphan	105-108	phenylethanolamine N-methyltransferase	Homo sapiens	77-81
9795195-7	1998	When the glucocorticoid response element (GRE) within the PNMT promoter was mutated, PNMT promoter activation by Egr-1 and DEX, AP-2 and DEX or all three showed both inhibition and enhancement, even when the GRE was completely eliminated.	Dextromethorphan	123-126	phenylethanolamine N-methyltransferase	Homo sapiens	58-62
9795195-7	1998	When the glucocorticoid response element (GRE) within the PNMT promoter was mutated, PNMT promoter activation by Egr-1 and DEX, AP-2 and DEX or all three showed both inhibition and enhancement, even when the GRE was completely eliminated.	Dextromethorphan	123-126	phenylethanolamine N-methyltransferase	Homo sapiens	85-89
9795195-7	1998	When the glucocorticoid response element (GRE) within the PNMT promoter was mutated, PNMT promoter activation by Egr-1 and DEX, AP-2 and DEX or all three showed both inhibition and enhancement, even when the GRE was completely eliminated.	Dextromethorphan	137-140	phenylethanolamine N-methyltransferase	Homo sapiens	58-62
9851668-5	1998	ATP citrate lyase activity was measured in M.GLAND, liver and PARA of SO, ADX and ADX + DEX.	Dextromethorphan	88-91	ATP citrate lyase	Rattus norvegicus	0-17
9851668-10	1998	However, the therapy with DEX elevated lipid content, in vivo lipogenesis rate and ATP citrate lyase activity to levels similar to those in SO.	Dextromethorphan	26-29	ATP citrate lyase	Rattus norvegicus	83-100
9825832-0	1998	Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.	Dextromethorphan	123-139	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-98
9825832-1	1998	Intraindividual variability and the effects of menstrual cycle phase on CYP2D6 activity were evaluated by dextromethorphan phenotyping in 20 Caucasian normal volunteers.	Dextromethorphan	106-122	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	72-78
9825832-10	1998	Because baseline metabolic ratios may fluctuate an average of 37%, repeat baseline and treatment phenotyping assessments should be obtained for accurate determination of a given drug"s effect on CYP2D6 activity when measured by dextromethorphan.	Dextromethorphan	228-244	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	195-201
9825834-8	1998	Dexfenfluramine was a specific inhibitor (IC50 46 microM) of CYP2D6-mediated dextromethorphan O-demethylation in human liver microsomes but did not appreciably inhibit six other cytochrome P450 isoform-selective activities for CYP1A2, 2A6, 2C9, 2C19, 2E1 and 3A activities in human liver microsomes.	Dextromethorphan	77-93	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
9690700-0	1998	Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.	Dextromethorphan	24-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-66
9757149-10	1998	Mean CYP2D6 molar urinary dextromethorphan ratios before and after fluvoxamine therapy were 0.00780 +/- 0.00694 and 0.0153 +/- 0.0127, respectively (P = .011).	Dextromethorphan	26-42	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	5-11
9733666-3	1998	An overlay of terfenadine and dextromethorphan, a known substrate of CYP2D6, showed that it was possible to superimpose the site of hydroxylation (t-butyl group) and the nitrogen atom of terfenadine with similar regions in dextromethorphan.	Dextromethorphan	30-46	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
9733666-3	1998	An overlay of terfenadine and dextromethorphan, a known substrate of CYP2D6, showed that it was possible to superimpose the site of hydroxylation (t-butyl group) and the nitrogen atom of terfenadine with similar regions in dextromethorphan.	Dextromethorphan	223-239	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
9848131-6	1998	Dex significantly attenuated the postexposure neutrophilic cellular response in BAL 1 day after exposure (15.8 +/- 4.9% neutrophils in the dex group vs 49.8 +/- 2.7% neutrophils in the saline group) (P < or = 0.001).	Dextromethorphan	0-3	solute carrier family 27 member 5	Rattus norvegicus	80-85
9811160-0	1998	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.	Dextromethorphan	62-78	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	97-103
9811160-0	1998	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.	Dextromethorphan	62-78	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	105-112
9811160-0	1998	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.	Dextromethorphan	62-78	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	114-120
9811160-0	1998	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.	Dextromethorphan	62-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-131
9811160-11	1998	After adjustment for relative abundance, CYP3A4 was identified as the dominant enzyme mediating 3-methoxymorphinan formation from dextromethorphan, although CYP2C9 and -2C19 were estimated to contribute to 3-methoxymorphinan formation, particularly at low substrate concentrations.	Dextromethorphan	130-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
9690700-1	1998	Dextromethorphan is a nonopioid antitussive metabolized by cytochrome P450 2D6 (CYP2D6) to an active metabolite, dextrorphan.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	59-78
9690700-1	1998	Dextromethorphan is a nonopioid antitussive metabolized by cytochrome P450 2D6 (CYP2D6) to an active metabolite, dextrorphan.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
9690701-4	1998	However, D- and L-fenfluramine significantly inhibited P450-2D6 activity as measured by dextromethorphan O-demethylation, with mean 50% inhibitory concentrations (15.1 microM) within one order of magnitude of that for fluoxetine (2.7 microM).	Dextromethorphan	88-104	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	55-59
9731719-1	1998	The ability to metabolize CYP2D6 substrates sparteine, debrisoquine, and dextromethorphan was studied in healthy Caucasian (n = 20), Ghanaian (n = 21), and Chinese (n = 22) CYP2D6 extensive metabolizers.	Dextromethorphan	73-89	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	26-32
9679644-2	1998	Since the promoter in iNOS gene contains binding motifs for NF-kappa B/Rel, NF-IL6, and Oct which appear to be important for LPS-mediated iNOS induction, the effects of DEX on the activation of these transcription factors were examined.	Dextromethorphan	169-172	nitric oxide synthase 2, inducible	Mus musculus	22-26
9679644-3	1998	Treatment of DEX to RAW 264.7 cells induced a dose-related inhibition of NF-kappa B/Rel in chloramphenicol acetyltransferase activity, while NF-IL6 or Oct activation was not affected by DEX.	Dextromethorphan	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	73-83
9679644-3	1998	Treatment of DEX to RAW 264.7 cells induced a dose-related inhibition of NF-kappa B/Rel in chloramphenicol acetyltransferase activity, while NF-IL6 or Oct activation was not affected by DEX.	Dextromethorphan	13-16	plexin A2	Mus musculus	151-154
9679644-4	1998	Treatment of RAW 264.7 cells with DEX inhibited DNA binding of NF-kappa B/Rel proteins to their cognate DNA site as measured by electrophoretic mobility shift assay.	Dextromethorphan	34-37	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	63-73
9679644-5	1998	In addition, DEX treatment caused a significant reduction in nuclear c-rel, p65, and p50 protein contents, and these decreases were paralleled by the accumulation of cytoplasmic c-rel, p65, and p50.	Dextromethorphan	13-16	reticuloendotheliosis oncogene	Mus musculus	69-74
9679644-5	1998	In addition, DEX treatment caused a significant reduction in nuclear c-rel, p65, and p50 protein contents, and these decreases were paralleled by the accumulation of cytoplasmic c-rel, p65, and p50.	Dextromethorphan	13-16	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	76-79
9679644-5	1998	In addition, DEX treatment caused a significant reduction in nuclear c-rel, p65, and p50 protein contents, and these decreases were paralleled by the accumulation of cytoplasmic c-rel, p65, and p50.	Dextromethorphan	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	85-88
9679644-5	1998	In addition, DEX treatment caused a significant reduction in nuclear c-rel, p65, and p50 protein contents, and these decreases were paralleled by the accumulation of cytoplasmic c-rel, p65, and p50.	Dextromethorphan	13-16	reticuloendotheliosis oncogene	Mus musculus	178-183
9679644-5	1998	In addition, DEX treatment caused a significant reduction in nuclear c-rel, p65, and p50 protein contents, and these decreases were paralleled by the accumulation of cytoplasmic c-rel, p65, and p50.	Dextromethorphan	13-16	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	185-188
9679644-5	1998	In addition, DEX treatment caused a significant reduction in nuclear c-rel, p65, and p50 protein contents, and these decreases were paralleled by the accumulation of cytoplasmic c-rel, p65, and p50.	Dextromethorphan	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	194-197
9679644-6	1998	These results suggest that DEX may inhibit iNOS gene expression by a mechanism involving the blockade of LPS-induced nuclear translocation of NF-kappa B/Rel.	Dextromethorphan	27-30	nitric oxide synthase 2, inducible	Mus musculus	43-47
9679644-6	1998	These results suggest that DEX may inhibit iNOS gene expression by a mechanism involving the blockade of LPS-induced nuclear translocation of NF-kappa B/Rel.	Dextromethorphan	27-30	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	142-152
9593857-3	1998	Even more striking increases in AADC were noted with 40 mg/kg amantadine (3.8-fold for CS, 9.0-fold for SN), 40 mg/kg memantine (3.4-fold for CS, 3.1-fold for SN; 20 mg/kg no effect) and 40 mg/kg dextromethorphan (3.4-fold for CS, 6.2-fold for SN, in 6/10 "responders").	Dextromethorphan	196-212	dopa decarboxylase	Rattus norvegicus	32-36
9626121-4	1998	Dex induced not only a significant suppression of serum cortisol (to 8% of baseline) but also of DHEA (18%), DHEA(S) (16%), and androstenedione (26%), as well as of testosterone (28%), dihydrotestosterone (43%), and estrone (54%).	Dextromethorphan	0-3	sulfotransferase family 2A member 1	Homo sapiens	109-116
9618394-0	1998	Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.	Dextromethorphan	36-52	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	76-82
9618394-1	1998	O-Demethylation of dextromethorphan co-segregates with 4-hydroxylation of debrisoquin and is used for CYP2D6 phenotyping.	Dextromethorphan	19-35	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-108
10375730-5	1998	Pretreatment with Dex at a dose of 50 mg.kg-1 improved the postischemic hypoperfusion compared with the control at 20 and 30 min after lesion (both 31% increase), and also upregulated the expression of anti-apoptosis gene bcl-2.	Dextromethorphan	18-21	BCL2, apoptosis regulator	Rattus norvegicus	222-227
9630843-8	1998	Similarly, the liver microsomes isolated from rats pretreated with dexamethasone (DEX-microsomes) had a normal level of FMO activity but had enhanced rates of forming 6 beta-and 2 beta-hydroxytestosterone (Cyp3A1) as well as androstenedione (CYP3A1).	Dextromethorphan	82-85	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	206-212
9630843-8	1998	Similarly, the liver microsomes isolated from rats pretreated with dexamethasone (DEX-microsomes) had a normal level of FMO activity but had enhanced rates of forming 6 beta-and 2 beta-hydroxytestosterone (Cyp3A1) as well as androstenedione (CYP3A1).	Dextromethorphan	82-85	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	242-248
9548563-6	1998	Transcriptional modifications in response to Dex are reflected by quantitative differences between proliferating and mature osteoblasts in the formation of glucocorticoid receptor binding complexes at the proximal OC glucocorticoid response element.	Dextromethorphan	45-48	bone gamma-carboxyglutamate protein	Rattus norvegicus	214-216
10923431-5	1998	In Dex-treated group, compared with the control group of ischemia reperfusion, the expression of iNOS mRNA was downregulated, NO and iNOS were reduced, the recovery of myocardial dysfunction was ameliorated and MDA, CPK reduced.	Dextromethorphan	3-6	nitric oxide synthase 2	Rattus norvegicus	97-101
10375730-6	1998	CONCLUSION: Dex protects against ischemic neuronal damage in this model and its effects on CBF and bcl-2 expression may contribute to its neuroprotective action.	Dextromethorphan	12-15	BCL2, apoptosis regulator	Rattus norvegicus	99-104
10923431-5	1998	In Dex-treated group, compared with the control group of ischemia reperfusion, the expression of iNOS mRNA was downregulated, NO and iNOS were reduced, the recovery of myocardial dysfunction was ameliorated and MDA, CPK reduced.	Dextromethorphan	3-6	nitric oxide synthase 2	Rattus norvegicus	133-137
9540144-6	1998	Dextromethorphan shows clear antinociceptive as well as neuromodulary effects, both depending heavily on the cytochrome P450 2D6 phenotype (CYP2D6).	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-128
12501679-3	1998	A small dosage of Dex rapidly attenuated or even abolished the cardiovascular responses to NA/NPY microinjected into NTS, and this effect continued for a longer period.	Dextromethorphan	18-21	neuropeptide Y	Rattus norvegicus	94-97
12501679-4	1998	It indicates that the effect of Dex on cardiovascular responses to NA/NPY is mediated through both the genomic and non-genomic pathways.	Dextromethorphan	32-35	neuropeptide Y	Rattus norvegicus	70-73
9555014-7	1998	These findings show that the dex-mediated down-regulation of the L-FABP expression found in vivo is not due to a direct endocrine effect, but is likely secondary to changes in cellular lipid metabolism.	Dextromethorphan	29-32	fatty acid binding protein 1	Rattus norvegicus	65-71
9591930-3	1998	METHOD: The CYP2D6 phenotype was assessed in 48 patients before and after LT with debrisoquine or dextromethorphan.	Dextromethorphan	98-114	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	12-18
9525337-9	1998	Dex plus IBMX-induced adipogenesis can be inhibited by interleukin-1beta, tumor necrosis factor-alpha, and transforming growth factor-beta.	Dextromethorphan	0-3	interleukin 1 beta	Homo sapiens	55-101
9540144-6	1998	Dextromethorphan shows clear antinociceptive as well as neuromodulary effects, both depending heavily on the cytochrome P450 2D6 phenotype (CYP2D6).	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	140-146
9625265-8	1998	The results show that urinary analysis of dextrorphan and dextromethorphan omitting the enzymatic deconjugation step is a fast, reliable and sensitive method and could be used for studying CYP2D6 type genetic polymorphism in man.	Dextromethorphan	58-74	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	189-195
9538932-5	1998	Treatment of smooth muscle cells with dexamethasone (0.01-0.1 microM Dex) and with the protein kinase C activator, phorbol myristate acetate (0.1 microM PMA), increased NEP mRNA by 3-4 fold and two fold, respectively.	Dextromethorphan	69-72	membrane metalloendopeptidase	Homo sapiens	169-172
9871440-3	1998	The NMDA receptor-ion channel antagonists MK 801, budipine, amantadine, memantine and dextromethorphan all caused a pronounced in creased in AADC activity, more especially in the SNr than CS.	Dextromethorphan	86-102	dopa decarboxylase	Rattus norvegicus	141-145
9429230-0	1997	CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.	Dextromethorphan	52-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
9440469-5	1998	Dex treatment reduced maximal insulin-stimulated 2-[3H]DG uptake by 48% +/- 4% (mean +/- SEM) and decreased cell-surface (ATB-[2-3H]BMPA-photolabeled) GLUT4 by 48% +/- 3%, despite an increase in total muscle GLUT4 content of 26% +/- 7%.	Dextromethorphan	0-3	solute carrier family 2 member 4	Rattus norvegicus	151-156
9440469-5	1998	Dex treatment reduced maximal insulin-stimulated 2-[3H]DG uptake by 48% +/- 4% (mean +/- SEM) and decreased cell-surface (ATB-[2-3H]BMPA-photolabeled) GLUT4 by 48% +/- 3%, despite an increase in total muscle GLUT4 content of 26% +/- 7%.	Dextromethorphan	0-3	solute carrier family 2 member 4	Rattus norvegicus	208-213
10513455-4	1998	In the present pilot study, there was a high frequency of CYP2D6*17, and about one-third of the African-American participants showed a reduced capacity to metabolize dextromethorphan, a CYP2D6 probe drug.	Dextromethorphan	166-182	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-64
10513455-4	1998	In the present pilot study, there was a high frequency of CYP2D6*17, and about one-third of the African-American participants showed a reduced capacity to metabolize dextromethorphan, a CYP2D6 probe drug.	Dextromethorphan	166-182	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	186-192
11596190-0	1997	[Distinguishing CYP2D6 homozygous and heterozygous extensive metabolizers by dextromethorphan phenotyping].	Dextromethorphan	77-93	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	16-22
9489930-1	1998	This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine.	Dextromethorphan	173-189	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	137-143
9389570-6	1997	PCR and RT-PCR analysis illustrated the integration and activation of the dexamethasone(dex)-inducible MMTV-LTR promoter linked to the complete AS-c-myc fragment in GLC4cDDP/AS cells, but not in GLC4cDDP/C cells.	Dextromethorphan	74-77	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	147-152
9389570-7	1997	Dex-induced AS-c-myc RNA resulted in 50% growth inhibition during the first 48 hr, which declined to 25% at 72 hr.	Dextromethorphan	0-3	steroid sulfatase	Homo sapiens	12-16
9402947-6	1997	For CYP1A measured as ethoxyresorufin O-deethylase activity, CYP2C8/9 measured as tolbutamide 4-hydroxylation activity, CYP2D6 measured as dextromethorphan O-demethylation, and AZT glucuronidation, there is either no effect or, where induction is found to be statistically significant in these other endpoints, the maximum induction values are consistently < 100% of the control.	Dextromethorphan	139-155	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	120-126
9429230-1	1997	Fourteen drug free healthy volunteers and 22 psychiatric patients under psychotropic medication were phenotyped for their individual CYP2D6 activity using dextromethorphan as a probe drug.	Dextromethorphan	155-171	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	133-139
9429230-4	1997	The CYP2D6 phenotype was determined from the ratio of dextromethorphan to dextrorphan.	Dextromethorphan	54-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
9429230-13	1997	Therefore the determination of dextromethorphan and metabolites in serum could be advantageous to measure individual CYP2D6 activities in vivo and thus optimize the dosing of drugs metabolized by CYP2D6.	Dextromethorphan	31-47	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	117-123
9429230-13	1997	Therefore the determination of dextromethorphan and metabolites in serum could be advantageous to measure individual CYP2D6 activities in vivo and thus optimize the dosing of drugs metabolized by CYP2D6.	Dextromethorphan	31-47	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	196-202
9359413-2	1997	Insulin in combination with dexamethasone (INS/DEX) increased heparin-releasable LPL activity by 71% over the control level (566+/-85 versus 331+/-48 nmol/h.mg cell protein).	Dextromethorphan	47-50	lipoprotein lipase	Rattus norvegicus	81-84
9348244-3	1997	After 6-h of incubation in treated cells, dexamethasone(Dex) and triiodo-L-thyronine(T3) significantly increased GH pre-mRNA levels(3.2- and 2.2-fold compared to non-treated cells, respectively).	Dextromethorphan	56-59	gonadotropin releasing hormone receptor	Rattus norvegicus	113-115
9348244-5	1997	After 24-h incubation with Dex and T3, significant increases in GH mRNA levels were detected on Northern blots, but GH pre-mRNA levels did not differ between treated and non-treated cells.	Dextromethorphan	27-30	gonadotropin releasing hormone receptor	Rattus norvegicus	64-66
9348244-5	1997	After 24-h incubation with Dex and T3, significant increases in GH mRNA levels were detected on Northern blots, but GH pre-mRNA levels did not differ between treated and non-treated cells.	Dextromethorphan	27-30	gonadotropin releasing hormone receptor	Rattus norvegicus	116-118
9359413-5	1997	LPL protein mass, quantified by ELISA, was the same in both control and INS/DEX-treated cells (27.7 versus 28.6 ng/mg cell protein, respectively), thus LPL specific activity in cardiomyocytes was increased by INS/DEX treatment (0.113 versus 0.069 mU/ng LPL protein).	Dextromethorphan	76-79	lipoprotein lipase	Rattus norvegicus	0-3
9359413-5	1997	LPL protein mass, quantified by ELISA, was the same in both control and INS/DEX-treated cells (27.7 versus 28.6 ng/mg cell protein, respectively), thus LPL specific activity in cardiomyocytes was increased by INS/DEX treatment (0.113 versus 0.069 mU/ng LPL protein).	Dextromethorphan	213-216	lipoprotein lipase	Rattus norvegicus	0-3
9357391-5	1997	During pregnancy the dextromethorphan/dextrorphan metabolic ratio was significantly reduced (p = 0.0015) among homozygous and heterozygous extensive metabolizers, indicating increased CYP2D6 activity.	Dextromethorphan	21-37	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	184-190
9264312-8	1997	This reaction was negligible in CYP2D6-deficient liver microsomes, was inhibited stereoselectively by the quinidine/quinine enantiomer pair, and was cosegregated with dextromethorphan O-demethylation (r = 0.975).	Dextromethorphan	167-183	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-38
9300912-3	1997	Proguanil and cycloguanil are assayed in separate aliquots of urine to that used for dextromethorphan/dextrorphan as pretreatment with beta-glucuronidase is required for the analysis of dextrorphan.	Dextromethorphan	85-101	glucuronidase beta	Homo sapiens	135-153
9224780-6	1997	Both drugs were competitive inhibitors of CYP2C9-catalyzed conversion of tolbutamide to 4-hydroxytolbutamide (K(i) = 40.1 +/- 14.8 microM for omeprazole, K(i) = 52.1 +/- 1.4 microM for lansoprazole) and were noncompetitive inhibitors of CYP3A-catalyzed conversion of dextromethorphan to 3-methoxymorphinan (K(i) = 84.4 +/- 4.0 microM for omeprazole, K(i) = 170.4 +/- 7.1 microM for lansoprazole).	Dextromethorphan	267-283	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	42-48
9134975-2	1997	Injection of dexamethasone (DEX 5-50 microg/kg BW) 3.5 h prior to the electrical stimuli inhibited the serum ACTH and corticosterone (CS) responses in a dose dependent manner.	Dextromethorphan	28-31	proopiomelanocortin	Homo sapiens	109-113
9152607-2	1997	DEX (0.01-4.0 microM inhibited DEXTROase activity (IC50 = 1.8 +/- 0.25 microM; mean +/- SD; N = 5 livers) and was less potent than quinidine (QND), prototypical and clinically relevant CYP2D6 inhibitor (IC50 = 0.22 +/- 0.02 microM; mean Ki = 0.07 microM).	Dextromethorphan	0-3	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	185-191
9152607-3	1997	Similar results were obtained with human B-lymphoblast microsomes containing cDNA-expressed CYP2D6 (DEX, IC50 = 2.2 microM; QND, IC50 0.15 microM).	Dextromethorphan	100-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-98
9152607-5	1997	In addition, DEX elicited a Type IIb difference spectrum (lambda max approximately 436 nm; lambda min approximately 414 nm) when added to cDNA-expressed CYP2D6 under aerobic (oxidized) conditions.	Dextromethorphan	13-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	153-159
9152607-6	1997	These data indicated that DEX was able to bind reversibly to the heme (ferric) iron of CYP2D6.	Dextromethorphan	26-29	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	87-93
9088003-5	1997	As expected, increasing DEX doses were associated with decreasing amounts of adrenocorticotropin (ACTH) and cortisol being released after CRH injection.	Dextromethorphan	24-27	corticotropin releasing hormone	Homo sapiens	138-141
9089691-3	1997	The channel blockers dizocilpine, memantine and phencyclidine (PCP) were equally potent antagonists at both receptor subtypes whereas dextromethorphan was four times more potent at NR1A/NR2A receptors.	Dextromethorphan	134-150	nodal homolog 1 L homeolog	Xenopus laevis	181-185
9164697-2	1997	Phenotyping was based on HPLC determination of the CYP2D6-related dextromethorphan metabolic ratio in overnight urine samples after oral administration of 30 mg dextromethorphan hydrobromide.	Dextromethorphan	66-82	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	51-57
9164697-2	1997	Phenotyping was based on HPLC determination of the CYP2D6-related dextromethorphan metabolic ratio in overnight urine samples after oral administration of 30 mg dextromethorphan hydrobromide.	Dextromethorphan	161-190	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	51-57
9164697-5	1997	PCR-based analyses of DNA for variants of the CYP2D6 gene demonstrated that the PMs of dextromethorphan had the defective allele CYP2D6*4.	Dextromethorphan	87-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
9164697-5	1997	PCR-based analyses of DNA for variants of the CYP2D6 gene demonstrated that the PMs of dextromethorphan had the defective allele CYP2D6*4.	Dextromethorphan	87-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	129-135
9089691-3	1997	The channel blockers dizocilpine, memantine and phencyclidine (PCP) were equally potent antagonists at both receptor subtypes whereas dextromethorphan was four times more potent at NR1A/NR2A receptors.	Dextromethorphan	134-150	glutamate receptor ionotropic, NMDA 2A-like	Xenopus laevis	186-190
9020523-5	1997	Treatment of the cells with the corticosteroid DEX at 10(-5) M but not 10(-6) M significantly reduced the ionomycin-induced expression of IL-3 but not IL-4 or IL-8 mRNA.	Dextromethorphan	47-50	interleukin 3	Homo sapiens	138-142
9069041-4	1997	CYP2D6 phenotype, assigned using dextromethorphan urinary ratios, was assessed in 25 unrelated parents of SIDS victims.	Dextromethorphan	33-49	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
9020523-5	1997	Treatment of the cells with the corticosteroid DEX at 10(-5) M but not 10(-6) M significantly reduced the ionomycin-induced expression of IL-3 but not IL-4 or IL-8 mRNA.	Dextromethorphan	47-50	interleukin 4	Homo sapiens	151-155
9020523-5	1997	Treatment of the cells with the corticosteroid DEX at 10(-5) M but not 10(-6) M significantly reduced the ionomycin-induced expression of IL-3 but not IL-4 or IL-8 mRNA.	Dextromethorphan	47-50	C-X-C motif chemokine ligand 8	Homo sapiens	159-163
9020523-7	1997	In conclusion, this study shows that cytokine expression, particularly of IL-3, is inhibited in a human mast cell line by CsA and DEX.	Dextromethorphan	130-133	interleukin 3	Homo sapiens	74-78
8986013-2	1996	All patients were extensive metabolizers of mephenytoin (CYP2C19) and dextromethorphan (CYP2D6), except one patient, who had a genetic deficiency of CYP2D6.	Dextromethorphan	70-86	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-94
8995308-6	1997	NR1/2A responses were inhibited by the noncompetitive antagonists MK-801 and dextromethorphan and were dependent on extracellular calcium but not on intracellular calcium stores.	Dextromethorphan	77-93	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	0-3
8968029-2	1996	SaOS+DEX cells have been previously shown to express higher PTH-stimulated adenylate cyclase (PTH-AC) and basal alkaline phosphatase (ALP) activities compared with SaOS-DEX cells.	Dextromethorphan	5-8	parathyroid hormone	Homo sapiens	60-63
8968029-2	1996	SaOS+DEX cells have been previously shown to express higher PTH-stimulated adenylate cyclase (PTH-AC) and basal alkaline phosphatase (ALP) activities compared with SaOS-DEX cells.	Dextromethorphan	5-8	parathyroid hormone	Homo sapiens	94-97
8968029-2	1996	SaOS+DEX cells have been previously shown to express higher PTH-stimulated adenylate cyclase (PTH-AC) and basal alkaline phosphatase (ALP) activities compared with SaOS-DEX cells.	Dextromethorphan	5-8	alkaline phosphatase, placental	Homo sapiens	112-132
8968029-2	1996	SaOS+DEX cells have been previously shown to express higher PTH-stimulated adenylate cyclase (PTH-AC) and basal alkaline phosphatase (ALP) activities compared with SaOS-DEX cells.	Dextromethorphan	5-8	alkaline phosphatase, placental	Homo sapiens	134-137
8968029-3	1996	ALP: In SaOS+DEX cells, 0.1 nmol/L analog, but not 1alpha,25(OH)2D3, increased ALP activity 1.7-fold (p < 0.05).	Dextromethorphan	13-16	alkaline phosphatase, placental	Homo sapiens	0-3
8968029-8	1996	Osteocalcin (OC): 1alpha,25(OH)2D3 and its analog stimulated OC production in SaOS-DEX cells with smaller effects in SaOS+DEX cells.	Dextromethorphan	83-86	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
8968029-8	1996	Osteocalcin (OC): 1alpha,25(OH)2D3 and its analog stimulated OC production in SaOS-DEX cells with smaller effects in SaOS+DEX cells.	Dextromethorphan	122-125	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
8968029-11	1996	In SaOS+DEX cells, both compounds inhibited PTH-AC approximately 35%.	Dextromethorphan	8-11	parathyroid hormone	Homo sapiens	44-47
9265947-10	1997	Various probe drugs may be used for phenotyping CYP2D6 (debrisoquine, dextromethorphan and sparteine) and CYP2C19 (mephenytoin and omeprazole).	Dextromethorphan	70-86	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
9001717-13	1996	Neuronal damage in the CA1 sector of the hippocampus and in the dorsolateral striatum produced by 4VO was significantly attenuated by dextromethorphan.	Dextromethorphan	134-150	carbonic anhydrase 1	Rattus norvegicus	23-26
8794469-0	1996	Metabolism of dextromethorphan in human liver microsomes: a rapid HPCL assay to monitor cytochrome P450 2D6 activity.	Dextromethorphan	14-30	2-hydroxyacyl-CoA lyase 1	Homo sapiens	66-70
8941025-3	1996	The determination of the CYP2D6 A, B, D, E, and T alleles was used to identify the deficiency in CYP2D6 expression in 161 individuals phenotyped for CYP2D6 activity with dextromethorphan.	Dextromethorphan	170-186	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
8941025-3	1996	The determination of the CYP2D6 A, B, D, E, and T alleles was used to identify the deficiency in CYP2D6 expression in 161 individuals phenotyped for CYP2D6 activity with dextromethorphan.	Dextromethorphan	170-186	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
8937133-1	1996	UNLABELLED: To investigate the effects of disease modifying antirheumatic drugs (DMARDs) and DEX on production of IL-1 beta, IL-6 and TNF-alpha, synovial cells were observed after IL-1 beta administration in vitro.	Dextromethorphan	93-96	interleukin 1 beta	Homo sapiens	114-123
8937133-1	1996	UNLABELLED: To investigate the effects of disease modifying antirheumatic drugs (DMARDs) and DEX on production of IL-1 beta, IL-6 and TNF-alpha, synovial cells were observed after IL-1 beta administration in vitro.	Dextromethorphan	93-96	interleukin 6	Homo sapiens	125-129
8937133-6	1996	RESULTS: DEX inhibited the production of IL-6.	Dextromethorphan	9-12	interleukin 6	Homo sapiens	41-45
8841152-0	1996	The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.	Dextromethorphan	96-112	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	17-23
8841152-15	1996	CONCLUSION: The disposition of dextromethorphan was substantially influenced by CYP2D6 status.	Dextromethorphan	31-47	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
9863163-0	1996	Inhibitory effects of dextromethorphan on c-fos protein expression during focal cerebral ischemia in rats.	Dextromethorphan	22-38	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	42-47
8873685-1	1996	Dextromethorphan is used widely in vivo to phenotype the polymorphically expressed cytochrome P450 (CYP) 2D6.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	83-108
8873685-2	1996	Dextromethorphan is N-demethylated in vitro to 3-methoxymorphinan by human CYP3A4/5.	Dextromethorphan	0-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
8873685-5	1996	The urine excretion of dextromethorphan and 3-methoxymorphinan was delayed in poor metabolizers of CYP2D6 but appeared to be formation rate-limited.	Dextromethorphan	23-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	99-105
8873685-8	1996	for 7 days) significantly reduced the 0- to 72-hour dextromethorphan/3-methoxymorphinan MR consistent with an 830% (+/- 1808%) induction of CYP3A activity (n = 8), whereas erythromycin (250 mg q.i.d.	Dextromethorphan	52-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-145
8873685-12	1996	We conclude that the commonly used antitussive dextromethorphan can be used as an in vivo marker of CYP3A and CYP2D6 activity.	Dextromethorphan	47-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
8873685-12	1996	We conclude that the commonly used antitussive dextromethorphan can be used as an in vivo marker of CYP3A and CYP2D6 activity.	Dextromethorphan	47-63	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-116
8874133-7	1996	Furthermore, the effects of (+)-SKF-10,047 or dextromethorphan in combination with phenytoin were blocked by the dopamine D1 receptor antagonist.	Dextromethorphan	46-62	dopamine receptor D1	Mus musculus	113-133
8690157-10	1996	We conclude that dex/GH treatment in mice TG for human IAPP induces IAPP-derived islet amyloid, hyperglycemia, and islet dysfunction.	Dextromethorphan	17-20	islet amyloid polypeptide	Homo sapiens	55-59
8690157-10	1996	We conclude that dex/GH treatment in mice TG for human IAPP induces IAPP-derived islet amyloid, hyperglycemia, and islet dysfunction.	Dextromethorphan	17-20	islet amyloid polypeptide	Homo sapiens	68-72
8794469-0	1996	Metabolism of dextromethorphan in human liver microsomes: a rapid HPCL assay to monitor cytochrome P450 2D6 activity.	Dextromethorphan	14-30	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-107
8794469-1	1996	A new HPLC assay was developed to study dextromethorphan O-demethylation to dextrorphan in vitro using human liver microsomes to investigate the activity of the polymorphic monooxygenase cytochrome P450 2D6 (CYP 2D6).	Dextromethorphan	40-56	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	187-206
8794469-1	1996	A new HPLC assay was developed to study dextromethorphan O-demethylation to dextrorphan in vitro using human liver microsomes to investigate the activity of the polymorphic monooxygenase cytochrome P450 2D6 (CYP 2D6).	Dextromethorphan	40-56	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	208-215
8794469-2	1996	The separation of dextromethorphan and its main metabolite dextrorphan was performed on a polymeric C18 reversed-phase column with UV-detection using levallorphan as an internal standard.	Dextromethorphan	18-34	Bardet-Biedl syndrome 9	Homo sapiens	100-103
8762084-6	1996	Treatment of mice with dexamethasone (Dex; 0.5-5 micrograms per mouse corresponding to approximately 0.015-1.5 mg kg-1) increased LC1 levels in neutrophils and monocytes.	Dextromethorphan	38-41	annexin A1	Mus musculus	130-133
8797187-2	1996	After DEX pretreatment, this group of patients had higher CRH-induced adrenocorticotrophic hormone (ACTH) and cortisol levels than the control group, but lower than a reference group of depressed patients.	Dextromethorphan	6-9	corticotropin releasing hormone	Homo sapiens	58-61
8738772-10	1996	The method is suitable for in vivo phenotyping of CYP2D6 activity, which catalyzes the O-demethylation of dextromethorphan to dextrorphan, and is also applicable to pharmacokinetic studies in man.	Dextromethorphan	106-122	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	50-56
8784647-7	1996	CYP2D6, but not CYP3A3/4, is subject to genetic polymorphism, which has been identified through the administration of a probe drug (sparteine, debrisoquin, or dextromethorphan).	Dextromethorphan	159-175	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
8818046-5	1996	This method can be used to measure dextromethorphan and its metabolites to phenotype individuals as poor or extensive metabolizers of drugs metabolized by CYP2D6.	Dextromethorphan	35-51	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	155-161
8730981-3	1996	To investigate the potential of NEF and its metabolites to interfere with the metabolism of other drugs, we tested these compounds for their ability to alter dextromethorphan (DMO) O-demethylation to dextrorphan (DOP; an index reaction for CYP2D6) and N-demethylation to 3-methoxy morphinan (MEM, a recently proposed index reaction of CYP3A3/4).	Dextromethorphan	176-179	S100 calcium binding protein B	Homo sapiens	32-35
8646830-11	1996	CONCLUSION: Assessment of CYP2D6 activity by use of dextromethorphan and sparteine is possible in extensive metabolizer patients with chronic renal failure.	Dextromethorphan	52-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	26-32
8730981-3	1996	To investigate the potential of NEF and its metabolites to interfere with the metabolism of other drugs, we tested these compounds for their ability to alter dextromethorphan (DMO) O-demethylation to dextrorphan (DOP; an index reaction for CYP2D6) and N-demethylation to 3-methoxy morphinan (MEM, a recently proposed index reaction of CYP3A3/4).	Dextromethorphan	158-174	S100 calcium binding protein B	Homo sapiens	32-35
8666241-7	1996	Based on this observation, we examined the effect of a glucocorticoid (dexamethasone, Dex) on 24p3 expression.	Dextromethorphan	86-89	lipocalin 2	Mus musculus	94-98
8666241-8	1996	Dex induced the expression of 24p3 dramatically in the absence of de novo protein synthesis.	Dextromethorphan	0-3	lipocalin 2	Mus musculus	30-34
8666241-12	1996	Furthermore, we have identified a 43-bp region of the 24p3 promoter required for the Dex responsiveness.	Dextromethorphan	85-88	lipocalin 2	Mus musculus	54-58
8786303-12	1996	In transfer experiments, irradiated recipients of spleen cells or purified 8 cells from animals suppressed with Dex(low)LPL(high) did not respond to LPL-OVA.	Dextromethorphan	112-115	lipoprotein lipase	Mus musculus	120-123
8726395-1	1996	We have previously shown that the combination of estrogen (E2) and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] enhanced alkaline phosphatase (ALP) activity in human osteosarcoma SaOS-2 cells which had been grown in the presence of 10 nmol/L dexamethasone (SaOS + DEX cells).	Dextromethorphan	258-261	alkaline phosphatase, placental	Homo sapiens	137-140
8726395-12	1996	Thus changes in ALP activity are associated with changes in ER levels in SaOS + DEX cells.	Dextromethorphan	80-83	alkaline phosphatase, placental	Homo sapiens	16-19
7587952-9	1995	There was a significant correlation between the quantity of immunoreactive CYP2D6 as determined by immunoblotting with anti-peptide 2 antiserum and dextromethorphan O-demethylation in a panel of 10 human liver microsomes (r = 0.95).	Dextromethorphan	148-164	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	75-81
8591998-8	1996	Dex also reduced the synthesis of both latent and mature forms of TGF-beta protein by approximately four-fold as determined by the mink lung epithelial cell growth inhibition bioassay.	Dextromethorphan	0-3	transforming growth factor, beta 1	Mus musculus	66-74
8615885-7	1996	With the addition of ketoconazole (CYP3A4 inhibitor) to the incubation mixtures, the residual rate of formation of DCL correlated (r2 = 0.81) with that for dextromethorphan O-demethylation, a CYP2D6 reaction.	Dextromethorphan	156-172	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
8719909-14	1995	Hydroxylation of gliclazide was related to the activity of CYP2D1 as assessed by dextrorphan production from dextromethorphan (rs = 0.83, p = 0.01).	Dextromethorphan	109-125	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	59-65
7593709-1	1995	Dextromethorphan is primarily metabolized to dextrorphan by cytochrome P450 2D6 (CYP2D6), a genetically polymorphic enzyme in humans.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-79
7593709-1	1995	Dextromethorphan is primarily metabolized to dextrorphan by cytochrome P450 2D6 (CYP2D6), a genetically polymorphic enzyme in humans.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	81-87
7593709-6	1995	Pretreatment of these subjects with 100 mg of quinidine, a selective inhibitor of CYP2D6, significantly suppressed the formation of dextrorphan and elevated the concentrations of dextromethorphan (t1/2, 16.4 hours).	Dextromethorphan	179-195	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	82-88
7593709-7	1995	In poor metabolizers (N = 4) given the same dose, dextromethorphan was the major component in the plasma with a t1/2 of 29.5 hours.	Dextromethorphan	50-66	CD5 molecule	Homo sapiens	112-124
7593709-9	1995	Urinary recovery studies indicated that the inhibition by quinidine was reversible and that the elimination of dextromethorphan primarily depends on CYP2D6 activity rather than renal elimination.	Dextromethorphan	111-127	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	149-155
7593709-10	1995	These data demonstrated that the CYP2D6 phenotype and the concurrent administration of quinidine significantly affect the disposition of dextromethorphan and the formation of the active metabolite dextrorphan and are important factors to be considered in studies of the pharmacologic and behavioral effects of dextromethorphan.	Dextromethorphan	137-153	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	33-39
7593709-10	1995	These data demonstrated that the CYP2D6 phenotype and the concurrent administration of quinidine significantly affect the disposition of dextromethorphan and the formation of the active metabolite dextrorphan and are important factors to be considered in studies of the pharmacologic and behavioral effects of dextromethorphan.	Dextromethorphan	310-326	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	33-39
8861658-4	1996	Dextromethorphan, debrisoquine and sparteine are good substrates for CYP2D6, whereas the S-enantiomer of mephenytoin is a good substrate for CYP2C19, both being two isozymes of cytochrome P-450.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
8861658-4	1996	Dextromethorphan, debrisoquine and sparteine are good substrates for CYP2D6, whereas the S-enantiomer of mephenytoin is a good substrate for CYP2C19, both being two isozymes of cytochrome P-450.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	141-148
8861658-4	1996	Dextromethorphan, debrisoquine and sparteine are good substrates for CYP2D6, whereas the S-enantiomer of mephenytoin is a good substrate for CYP2C19, both being two isozymes of cytochrome P-450.	Dextromethorphan	0-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	177-193
8861660-0	1996	Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity.	Dextromethorphan	18-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-100
8861660-7	1996	The frequency distribution of the CYP2D6 metabolic ratio (DTM/DT) illustrated a bimodal distribution whereas, the CYP3A metabolic ratio (DTM/3MM) exhibited a unimodal distribution in overnight urine samples of volunteers who ingested 30 mg dextromethorphan hydrobromide.	Dextromethorphan	58-61	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	34-40
8861660-7	1996	The frequency distribution of the CYP2D6 metabolic ratio (DTM/DT) illustrated a bimodal distribution whereas, the CYP3A metabolic ratio (DTM/3MM) exhibited a unimodal distribution in overnight urine samples of volunteers who ingested 30 mg dextromethorphan hydrobromide.	Dextromethorphan	137-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119
8861660-7	1996	The frequency distribution of the CYP2D6 metabolic ratio (DTM/DT) illustrated a bimodal distribution whereas, the CYP3A metabolic ratio (DTM/3MM) exhibited a unimodal distribution in overnight urine samples of volunteers who ingested 30 mg dextromethorphan hydrobromide.	Dextromethorphan	240-269	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119
8861660-8	1996	The CYP2D6 metabolic ratio significantly correlated with 3MM/3OH (r=0.82) and DTM/3OH (r=0.95) but did not correlate with the CYP3A metabolic ratio (r=0.27).	Dextromethorphan	78-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
8861661-0	1996	Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	75-81
8861661-0	1996	Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.	Dextromethorphan	0-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-91
8861661-1	1996	Dextromethorphan (DM) is O-demethylated into dextrorphan (DEX) in humans by the cytochrome P450 designated as CYP2D6 and N-demethylated into 3-methoxymorphinan (3MM) via CYP3As.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-116
8838442-6	1996	The average apparent Ki values determined using CYP2D6-dependent dextromethorphan O-demethylation were: 33, 52 and 22 microM for rac-venlafaxine, R(+)-venlafaxine and S(-)-venlafaxine, respectively, vs 0.065 to 1.8 microM for paroxetine, fluoxetine, norfluoxetine, fluvoxamine and sertraline.	Dextromethorphan	65-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
8528270-10	1995	Similar Ki values (within a factor of three) were observed for perhexiline and (R,S)-propranolol while quinidine and dextromethorphan were 8.5-fold and 21-fold more effective inhibitors of CYP2D6-Val relative to CYP2D6-Met.	Dextromethorphan	117-133	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	189-195
8528270-10	1995	Similar Ki values (within a factor of three) were observed for perhexiline and (R,S)-propranolol while quinidine and dextromethorphan were 8.5-fold and 21-fold more effective inhibitors of CYP2D6-Val relative to CYP2D6-Met.	Dextromethorphan	117-133	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	212-218
7626468-8	1995	As expected, nocturnal DEX administration inhibited the GH response to GHRH.	Dextromethorphan	23-26	growth hormone 1	Homo sapiens	56-58
7558935-4	1995	In addition, IL-7 but not IL-4 was consistently able to suppress the cell death of IL-2-dependent T cells triggered by DEX, a synthetic GC.	Dextromethorphan	119-122	interleukin 7	Homo sapiens	13-17
7558935-4	1995	In addition, IL-7 but not IL-4 was consistently able to suppress the cell death of IL-2-dependent T cells triggered by DEX, a synthetic GC.	Dextromethorphan	119-122	interleukin 2	Homo sapiens	83-87
7558935-6	1995	Interestingly, IL-7 inhibited the downregulation of bcl-2 gene product expression that appeared on TCCs after IL-2 withdrawal and also shared with IL-2 the ability to induce the upregulation of CD25 antigen on activated T lymphocytes in the presence of DEX.	Dextromethorphan	253-256	interleukin 7	Homo sapiens	15-19
7558935-6	1995	Interestingly, IL-7 inhibited the downregulation of bcl-2 gene product expression that appeared on TCCs after IL-2 withdrawal and also shared with IL-2 the ability to induce the upregulation of CD25 antigen on activated T lymphocytes in the presence of DEX.	Dextromethorphan	253-256	BCL2 apoptosis regulator	Homo sapiens	52-57
7558935-6	1995	Interestingly, IL-7 inhibited the downregulation of bcl-2 gene product expression that appeared on TCCs after IL-2 withdrawal and also shared with IL-2 the ability to induce the upregulation of CD25 antigen on activated T lymphocytes in the presence of DEX.	Dextromethorphan	253-256	interleukin 2 receptor subunit alpha	Homo sapiens	194-198
7626468-8	1995	As expected, nocturnal DEX administration inhibited the GH response to GHRH.	Dextromethorphan	23-26	growth hormone releasing hormone	Homo sapiens	71-75
7626468-9	1995	In this situation of hypercortisolism, both PRO and CLO, but not PD, were able to reverse the inhibitory effect of DEX on GHRH-elicited release.	Dextromethorphan	115-118	growth hormone releasing hormone	Homo sapiens	122-126
7896902-4	1995	Dex caused a continuous increase in the Ca(II) level in dex-sensitive CEM-C7 cells, while in CEM-C1 cells dex caused an initial increase in the Ca(II) level which in approximately 36 h was restored to its normal value.	Dextromethorphan	0-3	carbonic anhydrase 2	Homo sapiens	40-46
7478683-0	1995	Dextromethorphan suppresses both formalin-induced nociceptive behavior and the formalin-induced increase in spinal cord c-fos mRNA.	Dextromethorphan	0-16	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	120-125
7478683-5	1995	Pretreatment with dextromethorphan at 60 mg/kg s.c., 30 min prior to formalin resulted in a suppression of c-fos induction, so that c-fos mRNA levels in the ipsilateral spinal dorsal horn of animals receiving dextromethorphan prior to formalin did not differ from controls.	Dextromethorphan	18-34	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	107-112
7478683-5	1995	Pretreatment with dextromethorphan at 60 mg/kg s.c., 30 min prior to formalin resulted in a suppression of c-fos induction, so that c-fos mRNA levels in the ipsilateral spinal dorsal horn of animals receiving dextromethorphan prior to formalin did not differ from controls.	Dextromethorphan	18-34	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	132-137
7478683-5	1995	Pretreatment with dextromethorphan at 60 mg/kg s.c., 30 min prior to formalin resulted in a suppression of c-fos induction, so that c-fos mRNA levels in the ipsilateral spinal dorsal horn of animals receiving dextromethorphan prior to formalin did not differ from controls.	Dextromethorphan	209-225	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	132-137
7478683-6	1995	These data indicate that dextromethorphan suppresses formalin nociceptive behavior and one of the biochemical consequences of formalin nociception, i.e., induction of c-fos mRNA.	Dextromethorphan	25-41	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-172
7663527-6	1995	HPLC analysis confirmed that heterologously expressed CYP2D6 catalysed the oxidation of debrisoquine and dextromethorphan, two prototype substrates for CYP2D6.	Dextromethorphan	105-121	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
7663527-6	1995	HPLC analysis confirmed that heterologously expressed CYP2D6 catalysed the oxidation of debrisoquine and dextromethorphan, two prototype substrates for CYP2D6.	Dextromethorphan	105-121	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	152-158
7663527-8	1995	Dextromethorphan O-demethylase activity in CYP2D6-containing microsomes was characterized by Km 8.5 microM and Vmax 700 pmol mg-1 min-1.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	43-49
7663530-0	1995	The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos.	Dextromethorphan	44-60	cytochrome P450 2D6	Homo sapiens	62-81
7758836-7	1995	Here, we investigated the regulation of protease (cathepsin B, cathepsin D, proteasome C2 subunit and m-calpain) mRNA concentrations by Dex in cultured L8 muscle cells.	Dextromethorphan	136-139	cathepsin B	Rattus norvegicus	50-61
7624897-3	1995	CYP2D6 activity was also assessed in vitro on microsomes from the liver of the recipients and the donors, using dextromethorphan.	Dextromethorphan	112-128	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
7900830-10	1995	In tissues treated with dexamethasone the half-life (t1/2) of SP-B mRNA increased > 2.5-fold (t1/2 control = 9 h; t1/2 dex-treated = 25 h).	Dextromethorphan	24-27	pulmonary surfactant-associated protein B	Oryctolagus cuniculus	62-66
7648511-3	1995	PMN adhesion was increased prominently when Dex and RU 38486 were given after TNF pretreatment.	Dextromethorphan	44-47	tumor necrosis factor	Homo sapiens	78-81
7624898-0	1995	Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
7758836-7	1995	Here, we investigated the regulation of protease (cathepsin B, cathepsin D, proteasome C2 subunit and m-calpain) mRNA concentrations by Dex in cultured L8 muscle cells.	Dextromethorphan	136-139	cathepsin D	Rattus norvegicus	63-74
7758836-7	1995	Here, we investigated the regulation of protease (cathepsin B, cathepsin D, proteasome C2 subunit and m-calpain) mRNA concentrations by Dex in cultured L8 muscle cells.	Dextromethorphan	136-139	calpain 2	Rattus norvegicus	76-111
7758836-8	1995	Cathepsin B mRNA concentration was enhanced 3.3-fold by Dex.	Dextromethorphan	56-59	cathepsin B	Rattus norvegicus	0-11
7758836-11	1995	Concentrations of cathepsin D and m-calpain mRNAs were also increased by Dex.	Dextromethorphan	73-76	cathepsin D	Rattus norvegicus	18-29
7554919-5	1995	Our studies, using the osteoblastic cell lines ROS 17/2.8 and UMR 106-06, have revealed that the glucocorticoid (10(-8) M dexamethasone; dex) effect on BSP mRNA involves both direct and indirect pathways.	Dextromethorphan	122-125	integrin binding sialoprotein	Homo sapiens	152-155
7529792-5	1995	In contrast, concentrations as low as 3 pg/ml of multivalent, dextran-conjugated, anti-IgD (alpha delta-dex) or anti-IgM (alpha mu-dex) were strongly synergistic with CD40L for induction of B cell proliferation, viable cell outgrowth, Ig isotype switching, and maturation to Ig secretion.	Dextromethorphan	62-65	CD40 ligand	Mus musculus	167-172
7756104-2	1995	The O-deethylation reaction was previously shown in vivo to co-segregate with the O-demethylation of dextromethorphan indicating that ethylmorphine is a substrate of polymorphic cytochrome P450(CYP)2D6.	Dextromethorphan	101-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	189-201
7532779-7	1995	The response to galanin + GHRH was similar to galanin + saline in chronically vehicle-treated rats, but was significantly enhanced in chronically dex-treated rats.	Dextromethorphan	146-149	growth hormone releasing hormone	Rattus norvegicus	26-30
7893267-1	1995	The polymorphism of dextromethorphan (CAS 125-71-3) metabolism is dependent on hepatic cytochrom P4502D6 (CYP2D6) activity.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	106-112
7893267-2	1995	The relationship between the CYP2D6 genotype and the dextromethorphan phenotype was studied in 83 healthy unrelated subjects.	Dextromethorphan	53-69	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	29-35
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine > fluoxetine identical to norfluoxetine > or = sertraline > or = fluvoxamine > venlafaxine.	Dextromethorphan	221-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine > fluoxetine identical to norfluoxetine > or = sertraline > or = fluvoxamine > venlafaxine.	Dextromethorphan	221-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine > fluoxetine identical to norfluoxetine > or = sertraline > or = fluvoxamine > venlafaxine.	Dextromethorphan	221-237	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	165-171
8477556-3	1993	The O-demethylation ratio of dextromethorphan that expressed CYP2D6 activity in 19 patients receiving fluoxetine fell in the region of the antimode separating the O-demethylation ratio values observed in 208 extensive metabolizers from 15 poor metabolizers of a control group of healthy subjects.	Dextromethorphan	29-45	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
7896253-4	1994	The treatment of HL-60 cells with 10(-6) mol/L led to a decrease in the affinity of whole cell GCR for [3H]Dex, but vincristine had no that effect.	Dextromethorphan	107-110	nuclear receptor subfamily 3 group C member 1	Homo sapiens	95-98
7522859-24	1994	Local administration of Dex at a dose which was ineffective when given systemically (1 microg) also reduced neutrophil migration induced by IL-8, either alone or in combination with histamine.	Dextromethorphan	24-27	chemokine (C-X-C motif) ligand 15	Mus musculus	140-144
7523333-1	1994	The kinetics of DEX-induced changes in lymphocytes from the thymus and spleen of normal mice were examined in relation to cell numbers, programmed cell death (PCD), in vitro proliferative response to anti-CD3 antibodies or Con-A, and changes in lymphocyte subsets by flow cytometry.	Dextromethorphan	16-19	CD3 antigen, epsilon polypeptide	Mus musculus	205-208
7523333-6	1994	Thymocytes from mice exposed to DEX (48 or 24 h) proliferated vigorously when cultured in the presence of anti-CD3 or Con-A, thereby suggesting that the remaining thymocytes can transduce activation signals.	Dextromethorphan	32-35	CD3 antigen, epsilon polypeptide	Mus musculus	111-114
8345201-7	1993	Because PMN and monocytes share the same stem cell, and monocyte-derived IL-8 is regulated by prostaglandin E2 (PGE2), glucocorticoids (dexamethasone; DEX) and the T-Lymphocyte-derived IL-4, we postulated that PMN-derived IL-8 production may be regulated in a similar manner.	Dextromethorphan	151-154	C-X-C motif chemokine ligand 8	Homo sapiens	73-77
8345201-11	1993	DEX and IL-4 in concentrations of 10(-6) M and 10 ng/ml resulted in maximal inhibition of LPS-induced PMN-derived IL-8, respectively.	Dextromethorphan	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	114-118
8345201-12	1993	Moreover, both DEX and IL-4 administration could be delayed 4 hr post-stimulation with LPS and result in significant suppression of PMN-derived IL-8.	Dextromethorphan	15-18	C-X-C motif chemokine ligand 8	Homo sapiens	144-148
8220439-0	1993	CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.	Dextromethorphan	42-58	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
8220439-0	1993	CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.	Dextromethorphan	42-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-17
8220439-1	1993	The metabolism of dextromethorphan, a drug used to probe genetically determined CYP2D6 activity has been investigated in vivo and in vitro.	Dextromethorphan	18-34	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
8220439-10	1993	These data clearly suggest that the N-demethylation of dextromethorphan is dependent on CYP3A and that both CYP2D6 and CYP3A are involved in the overall metabolism of dextromethorphan.	Dextromethorphan	55-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-93
8220439-10	1993	These data clearly suggest that the N-demethylation of dextromethorphan is dependent on CYP3A and that both CYP2D6 and CYP3A are involved in the overall metabolism of dextromethorphan.	Dextromethorphan	167-183	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	108-114
8220439-10	1993	These data clearly suggest that the N-demethylation of dextromethorphan is dependent on CYP3A and that both CYP2D6 and CYP3A are involved in the overall metabolism of dextromethorphan.	Dextromethorphan	167-183	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-124
8477651-6	1993	This allowed us to deduce the primary structure of ovine CBG and to demonstrate that hepatic CBG mRNA abundance (single transcript of 1.8 kilobases) rose from 0.9 +/- 0.2 to 3.6 +/- 1.6 arbitrary units after 96 h of DEX treatment.	Dextromethorphan	216-219	corticosteroid-binding globulin	Ovis aries	93-96
8477651-7	1993	Fetal DEX treatment produced a significant increase (7.1 +/- 1.2% to 13.1 +/- 1.4%) in the Concanavalin-A-binding forms of CBG that predominate in adult sheep plasma.	Dextromethorphan	6-9	corticosteroid-binding globulin	Ovis aries	123-126
7876334-8	1994	This was paralleled by DEX inhibition of the Con A-induced increase in soluble PLC activity measured in vitro and cytosolic Gi alpha immunoreactivity.	Dextromethorphan	23-26	heparan sulfate proteoglycan 2	Homo sapiens	79-82
7530886-5	1994	When mice were immunized, in the absence of adjuvant, with a BSA-dextran conjugate (BSA-dex), a persistent, high-titre anti-BSA IgG1 response was induced.	Dextromethorphan	65-68	LOC105243590	Mus musculus	128-132
7826826-0	1994	The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.	Dextromethorphan	68-84	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	12-18
7826826-2	1994	The enzyme kinetics of dextromethorphan O-demethylation in liver microsomes from three extensive metabolisers (EM) with respect to CYP2D6 indicated high (Km1 2.2-9.4 microM) and low (Km2 55.5-307.3 microM) affinity sites whereas microsomes from two poor metabolisers (PM) indicated a single site (Km 560 and 157 microM).	Dextromethorphan	23-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137
7826826-12	1994	Dextromethorphan and 3-methoxymorphinan are metabolised by the same P450 isoform, CYP2D6, whereas the N-demethylation reactions are not carried out by CYP2D6.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	82-88
8043020-4	1994	B-lymphoblastoid cells expressing CYP3A4 incubated with 0.4 mM dextromethorphan catalyzed the formation of 3-methoxymorphinan at a rate of 22 pmol product/mg protein/min.	Dextromethorphan	63-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
8013282-7	1994	For the CYP2D6-dependent O-demethylation of dextromethorphan, tropisetron and ondansetron were competitive inhibitors with Ki values of 14 and 29 microM, respectively.	Dextromethorphan	44-60	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	8-14
7693389-3	1993	Urinary metabolic ratios of hydrocodone/hydromorphone were highly correlated with O-demethylation ratios for dextromethorphan, an established marker drug of CYP2D6 activity (rs = 0.85; n = 18).	Dextromethorphan	109-125	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	157-163
8477651-10	1993	After 96 h of DEX treatment, there was also a significant decrease in adult hepatic CBG mRNA abundance.	Dextromethorphan	14-17	corticosteroid-binding globulin	Ovis aries	84-87
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	64-67	glutaminase	Rattus norvegicus	0-2
7680684-8	1993	Whereas IL-4 + IL-5 costimulated Ig isotype production by alpha delta-dex-activated cells, the further addition of LPS led to a marked ablation of the Ig secretory response indicating the cross-inhibitory effects of these two modes of B cell activation.	Dextromethorphan	70-73	interleukin 4	Mus musculus	8-12
7680684-8	1993	Whereas IL-4 + IL-5 costimulated Ig isotype production by alpha delta-dex-activated cells, the further addition of LPS led to a marked ablation of the Ig secretory response indicating the cross-inhibitory effects of these two modes of B cell activation.	Dextromethorphan	70-73	interleukin 5	Mus musculus	15-19
8447753-2	1993	Just before restoring circulation, we gave intravenous mannitol (an osmotic agent and free-radical scavenger), dextromethorphan (an N-methyl-D-aspartate receptor antagonist), or catalase (an antioxidant enzyme).	Dextromethorphan	111-127	catalase	Oryctolagus cuniculus	132-186
8452558-2	1993	The O-demethylation of dextromethorphan (DM) to dextrorphan (DR) is catalysed by the polymorphic CYP2D6 (cytochrome P4502D6) isozyme in man.	Dextromethorphan	23-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
8452558-2	1993	The O-demethylation of dextromethorphan (DM) to dextrorphan (DR) is catalysed by the polymorphic CYP2D6 (cytochrome P4502D6) isozyme in man.	Dextromethorphan	23-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	105-123
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	64-67	glutaminase	Rattus norvegicus	172-174
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	64-67	glutaminase	Rattus norvegicus	172-174
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	254-257	glutaminase	Rattus norvegicus	0-2
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	254-257	glutaminase	Rattus norvegicus	172-174
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	254-257	glutaminase	Rattus norvegicus	172-174
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	254-257	glutaminase	Rattus norvegicus	0-2
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	254-257	glutaminase	Rattus norvegicus	172-174
8418701-8	1993	GA activity was increased within 2 hours after a single dose of DEX, with a peak after 4 hours, Kinetic analysis at the 4-hour time point showed an increase in the maximum GA activity (maximal transport velocity [Vmax]: 619 +/- 107 nmol/mg protein/hr in DEX versus 380 +/- 53 nmol/mg protein/hr in CONT, p < 0.05), with no change in GA affinity (Michaelis constant [Km]: 2.28 +/- 0.39 mM in DEX versus 2.20 +/- 0.36 mM in CONT, p = NS).	Dextromethorphan	254-257	glutaminase	Rattus norvegicus	172-174
8418701-9	1993	Repeated doses of DEX resulted in a twofold increase in GA activity (550 +/- 125 nmol/mg protein/hr versus 1,175 +/- 40, p < 0.01).	Dextromethorphan	18-21	glutaminase	Rattus norvegicus	56-58
1384968-1	1992	The sensitivity of the human glucocorticoid receptor (hGR) gene to mutagenesis by the cancer chemotherapeutic drugs adriamycin, bleomycin, and chlorambucil was evaluated using glucocorticoid-sensitive (dexs) subclones of the human leukemic cell line CEM-C7.	Dextromethorphan	202-206	nuclear receptor subfamily 3 group C member 1	Homo sapiens	29-52
8448065-2	1993	In microsomes prepared from three human livers, methadone competitively inhibited the O-demethylation of dextromethorphan, a marker substrate for CYP2D6.	Dextromethorphan	105-121	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	146-152
1432700-1	1992	The polymorphism of dextromethorphan and encainide metabolism is genetically determined and is related to the activity of hepatic CYP2D6.	Dextromethorphan	20-36	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	130-136
8391148-6	1993	We hypothesize that ICV DEX reduces hypothalamic corticotropin releasing hormone (CRH) synthesis and/or release.	Dextromethorphan	24-27	corticotropin releasing hormone	Rattus norvegicus	49-80
8391148-6	1993	We hypothesize that ICV DEX reduces hypothalamic corticotropin releasing hormone (CRH) synthesis and/or release.	Dextromethorphan	24-27	corticotropin releasing hormone	Rattus norvegicus	82-85
28386740-5	1992	Addition of DEX reversed the rise in B-50/GAP-43 levels induced by either the change of medium or by NGF.	Dextromethorphan	12-15	growth associated protein 43	Rattus norvegicus	42-48
1432700-6	1992	Results showed that phenotype, either extensive or poor metabolizer, for CYP2D6-dependent metabolism could be identified from the dextromethorphan metabolic ratio calculated in urine, from the encainide metabolic ratio calculated in plasma and from the genotype.	Dextromethorphan	130-146	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	73-79
1394146-2	1992	Infection of these thymus-derived T-cell lines with a recombinant retrovirus encoding the human M(r) 26,000 Bcl-2 oncoprotein resulted in marked resistance to DEX-mediated cell death and DNA degradation into oligonucleosomal fragments, without interfering with the ability of dexamethasone to suppress cellular proliferation and without lowering levels of glucocorticoid receptors.	Dextromethorphan	159-162	B cell leukemia/lymphoma 2	Mus musculus	108-113
1611804-7	1992	Based on the brain/plasma ratio for dextromethorphan in rats, it is estimated that brain dextromethorphan concentrations of 1.0 to 10 micrograms/gm may be attainable in humans by inhibition of cytochrome P4502D6 activity with quinidine.	Dextromethorphan	89-105	cytochrome P450 2D6	Homo sapiens	193-211
1501111-8	1992	The DEX- and HC-induced depression of BLC could be described by an integrated pharmacokinetic-pharmacodynamic competitive-interaction model that assumes that both agonists act on the same receptor.	Dextromethorphan	4-7	C-X-C motif chemokine ligand 13	Homo sapiens	38-41
1355711-2	1992	Cytochrome CYP2D6 also plays a major role in dextromethorphan O-demethylation.	Dextromethorphan	45-61	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	11-17
1611804-0	1992	Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.	Dextromethorphan	0-16	cytochrome P450 2D6	Homo sapiens	106-124
1611804-3	1992	The purpose of this research was to determine whether quinidine (a selective inhibitor of cytochrome P4502D6) could improve dextromethorphan systemic delivery in patients with amyotrophic lateral sclerosis (a neurodegenerative disease).	Dextromethorphan	124-140	cytochrome P450 2D6	Homo sapiens	90-108
1545398-4	1992	Clozapine and its structural analog fluperlapine both bind to the active site of CYP2D6, as demonstrated by the competitive inhibition of dextromethorphan metabolism at inhibitor concentrations up to 40 microM.	Dextromethorphan	138-154	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	81-87
1787884-5	1991	Unlike levorphanol and other opiates, intrathecal administration of dextromethorphan (50-500 micrograms) blocked the C-fibre input and A beta response in parallel and was not reversed by naloxone.	Dextromethorphan	68-84	amyloid beta precursor protein	Rattus norvegicus	135-141
1306804-0	1992	Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies.	Dextromethorphan	40-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
1389999-5	1992	Addition of DEX reversed the rise in B-50/GAP-43 levels induced by either the change of medium or by NGF.	Dextromethorphan	12-15	growth associated protein 43	Rattus norvegicus	42-48
1722149-1	1991	The CYP2D6 protein is a polymorphic isoenzyme involved in the biotransformation of several drugs including the probe drug dextromethorphan.	Dextromethorphan	122-138	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
1722149-6	1991	The rise in CYP2D6 protein was associated with the developmental onset of dextromethorphan O-demethylation, but not N-demethylation, even if activity was lower in fetal than in neonatal and in adult liver microsomes.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	12-18
1714474-4	1991	We show that an IL-4-containing CD4+ T cell supernatant (Th2 SN) stimulates large increases in IgG1 and IgE production by LPS-activated B cells, but fails to stimulate detectable levels of IgE by alpha delta-dex-activated cells, despite inducing high levels of secreted IgM and IgG1.	Dextromethorphan	208-211	interleukin 4	Mus musculus	16-20
1913646-1	1991	To characterize the immunoreactive glucocorticoid receptor (GR) protein present in "receptorless" (r-) mutants isolated from the glucocorticoid-sensitive (dexs) human leukemic cell line CEM-C7, binding of [3H]dexamethasone was determined in extracts prepared from the sensitive cell line 6TG1.1 and the r- mutant ICR27TK.3 after gentle freeze-thaw lysis and low-speed centrifugation.	Dextromethorphan	155-159	nuclear receptor subfamily 3 group C member 1	Homo sapiens	35-58
1913646-1	1991	To characterize the immunoreactive glucocorticoid receptor (GR) protein present in "receptorless" (r-) mutants isolated from the glucocorticoid-sensitive (dexs) human leukemic cell line CEM-C7, binding of [3H]dexamethasone was determined in extracts prepared from the sensitive cell line 6TG1.1 and the r- mutant ICR27TK.3 after gentle freeze-thaw lysis and low-speed centrifugation.	Dextromethorphan	155-159	nuclear receptor subfamily 3 group C member 1	Homo sapiens	60-62
1796314-2	1991	After 3 h incubation the specific binding power with [3H] Dex was decreased by 23.3 +/- 10.0, 32.2 +/- 13.2 and 54.3 +/- 9.2% (P greater than 0.05, P greater than 0.05 and P less than 0.01 as compared with the control value of 100 in the absence of insulin) respectively in the presence of 20 mU/L (physiological testing concentration), 200 mU/L (physiological upper limit) and 2,000 mU/L (pharmacological concentration) insulin in the incubation medium.	Dextromethorphan	58-61	insulin	Homo sapiens	249-256
1796314-2	1991	After 3 h incubation the specific binding power with [3H] Dex was decreased by 23.3 +/- 10.0, 32.2 +/- 13.2 and 54.3 +/- 9.2% (P greater than 0.05, P greater than 0.05 and P less than 0.01 as compared with the control value of 100 in the absence of insulin) respectively in the presence of 20 mU/L (physiological testing concentration), 200 mU/L (physiological upper limit) and 2,000 mU/L (pharmacological concentration) insulin in the incubation medium.	Dextromethorphan	58-61	insulin	Homo sapiens	421-428
1703179-5	1991	Addition of IL-5 or IL-2 stimulated enhanced anti-TNP responses in the presence of TNP-Ficoll, or induced polyclonal Ig secretion in the presence of anti-delta-dex.	Dextromethorphan	160-163	interleukin 5	Homo sapiens	12-16
1955072-9	1991	Dex treatment resulted in inhibition of PRL mRNA and release despite parallel inhibition of GR mRNA by dex; these effects were enhanced by the presence of T3.	Dextromethorphan	0-3	prolactin	Rattus norvegicus	40-43
1855464-7	1991	The relative proportion of nuclear vs. cytoplasmic localized [3H]DEX-bound GR did not differ between control and CRF-treated cultures, indicating that CRF does not interfere with GR nuclear translocation.	Dextromethorphan	65-68	nuclear receptor subfamily 3, group C, member 1	Mus musculus	75-77
2022691-6	1991	The levels of alkaline phosphatase, osteopontin, and osteocalcin mRNAs in Dex/Dex/VitD3 cultures were comparable to those of 1,25-dihydroxyvitamin D3-treated ROS 17/2.8 osteosarcoma cells.	Dextromethorphan	74-77	bone gamma-carboxyglutamate protein	Rattus norvegicus	53-64
2379953-9	1990	Dex and Flu each inhibited (P less than 0.05) PAF-induced N-PMN aggregation at the highest dose, and A-PMN aggregation at the two higher doses.	Dextromethorphan	0-3	PCNA-associated factor	Bos taurus	46-49
1980647-3	1990	The [Ca2+]i response to NMDA was blocked or reversed by selective antagonists such as 2-amino-5-phosphonovalerate (APV), MK801 and ketamine, as well as by desmethylimipramine and dextromethorphan.	Dextromethorphan	179-195	carbonic anhydrase 2	Gallus gallus	5-8
2177986-4	1990	On the other hand, incubation with 10(-6) M Dex for 24 hr enhanced the syntheses of both transferrin and albumin.	Dextromethorphan	44-47	transferrin	Rattus norvegicus	89-100
2379953-11	1990	We compared the inhibition rate in both age groups and could demonstrate that Dex, Flu, and Flxin each at the highest dose, and PB at all doses used, inhibited PAF-induced aggregation less (P less than 0.05) in N-PMNs than in A-PMNs.	Dextromethorphan	78-81	PCNA-associated factor	Bos taurus	160-163
26640530-13	2015	In the DEX group compared with the control group, IL-1beta, IL-6 and CRP levels were markedly decreased at 6 h and 1 day after surgery (P<0.01).	Dextromethorphan	7-10	interleukin 1 beta	Homo sapiens	50-58
2076741-2	1990	Dextromethorphan and dextrorphan hemisuccinates were linked to bovine serum albumin and specific antisera against each immunogen were raised in rabbits.	Dextromethorphan	0-16	albumin	Oryctolagus cuniculus	70-83
33781345-3	2021	METHODS: In the in vitro study, we examined the effect of miR-133a antagomir on DEX-treated MSCs, including proliferation, apoptosis, osteoblast, and adipocyte differentiation, then, we explored the mechanism of these effects of miR-133a silencing through measuring the phosphorylation of ERK1/2 and its regulator FGFR1 via western blot and qRT-PCR.	Dextromethorphan	80-83	microRNA 133a-1	Rattus norvegicus	58-66
33781345-6	2021	The in vitro study showed that miR-133a antagomir significantly promoted cell proliferation, viability, and osteoblast differentiation and inhibited adipocyte differentiation in DEX-treated MSCs.	Dextromethorphan	178-181	microRNA 133a-1	Rattus norvegicus	31-39
33781345-7	2021	Furthermore, the expression of p-ERK1/2 and FGFR1 in DEX-treated MSCs was also upregulated by miR-133a antagomir.	Dextromethorphan	53-56	Fibroblast growth factor receptor 1	Rattus norvegicus	44-49
33781345-7	2021	Furthermore, the expression of p-ERK1/2 and FGFR1 in DEX-treated MSCs was also upregulated by miR-133a antagomir.	Dextromethorphan	53-56	microRNA 133a-1	Rattus norvegicus	94-102
26640530-13	2015	In the DEX group compared with the control group, IL-1beta, IL-6 and CRP levels were markedly decreased at 6 h and 1 day after surgery (P<0.01).	Dextromethorphan	7-10	interleukin 6	Homo sapiens	60-64
26640530-13	2015	In the DEX group compared with the control group, IL-1beta, IL-6 and CRP levels were markedly decreased at 6 h and 1 day after surgery (P<0.01).	Dextromethorphan	7-10	C-reactive protein	Homo sapiens	69-72
34943934-14	2021	CONCLUSIONS: GEN ameliorated Dex-induced accumulation of cholesterol and inhibition of cell differentiation by mediating the GLP-1R/ABCA1 axis in MC3T3-E1 cells.	Dextromethorphan	29-32	glucagon-like peptide 1 receptor	Mus musculus	125-131
34891063-4	2022	(PAH/DexS H) systems lead to linear growth, i.e. amounts deposited increase both for PAH and DexS H, while the PAH/DexS L pair generated zig-zag shaped asymmetric growth.	Dextromethorphan	115-119	alpha-2-glycoprotein 1, zinc-binding	Homo sapiens	141-144
34902439-2	2022	AIM: Based on the fact that (1) HNF4alpha is crucial for beta-cell proliferation, (2) DEX-induced IR promotes beta-cell mass expansion, and (3) the stimulation of beta-cell mass expansion may be an important target for DM therapies, we aimed to investigate whether DEX-induced proliferation of beta pancreatic cells is dependent on HNF4alpha.	Dextromethorphan	265-268	hepatic nuclear factor 4, alpha	Mus musculus	32-41
34902439-2	2022	AIM: Based on the fact that (1) HNF4alpha is crucial for beta-cell proliferation, (2) DEX-induced IR promotes beta-cell mass expansion, and (3) the stimulation of beta-cell mass expansion may be an important target for DM therapies, we aimed to investigate whether DEX-induced proliferation of beta pancreatic cells is dependent on HNF4alpha.	Dextromethorphan	265-268	hepatic nuclear factor 4, alpha	Mus musculus	332-341
34902439-7	2022	In addition, DEX-induced beta-cell mass expansion and an increase in the Ki67 immunostaining were observed only in WT mice, evidencing that IR-induced beta-cell mass expansion is dependent on HNF4alpha.	Dextromethorphan	13-16	antigen identified by monoclonal antibody Ki 67	Mus musculus	73-77
34902439-7	2022	In addition, DEX-induced beta-cell mass expansion and an increase in the Ki67 immunostaining were observed only in WT mice, evidencing that IR-induced beta-cell mass expansion is dependent on HNF4alpha.	Dextromethorphan	13-16	hepatic nuclear factor 4, alpha	Mus musculus	192-201
34902439-8	2022	Also, we observed that DEX-treatment, in an HNF4alpha-dependent way, promoted an increase in PDX1, PAX4 and NGN3 gene expression.	Dextromethorphan	23-26	hepatic nuclear factor 4, alpha	Mus musculus	44-53
34902439-8	2022	Also, we observed that DEX-treatment, in an HNF4alpha-dependent way, promoted an increase in PDX1, PAX4 and NGN3 gene expression.	Dextromethorphan	23-26	pancreatic and duodenal homeobox 1	Mus musculus	93-97
34902439-8	2022	Also, we observed that DEX-treatment, in an HNF4alpha-dependent way, promoted an increase in PDX1, PAX4 and NGN3 gene expression.	Dextromethorphan	23-26	paired box 4	Mus musculus	99-103
34902439-8	2022	Also, we observed that DEX-treatment, in an HNF4alpha-dependent way, promoted an increase in PDX1, PAX4 and NGN3 gene expression.	Dextromethorphan	23-26	neurogenin 3	Mus musculus	108-112
34902439-9	2022	CONCLUSIONS: Our results strongly suggest that DEX-induced IR promotes beta-cell mass expansion through processes of proliferation and neogenesis that depend on the HNF4alpha activity, pointing to HNF4alpha as a possible therapeutic target in DM treatment.	Dextromethorphan	47-50	hepatic nuclear factor 4, alpha	Mus musculus	165-174
34902439-9	2022	CONCLUSIONS: Our results strongly suggest that DEX-induced IR promotes beta-cell mass expansion through processes of proliferation and neogenesis that depend on the HNF4alpha activity, pointing to HNF4alpha as a possible therapeutic target in DM treatment.	Dextromethorphan	47-50	hepatic nuclear factor 4, alpha	Mus musculus	197-206
34715116-10	2022	ANGPTL8 was upregulated in the cAMP/Dex-induced hepatocyte gluconeogenesis model.	Dextromethorphan	36-39	angiopoietin-like 8	Mus musculus	0-7
34244776-5	2021	KEY FINDINGS: Data of the study suggested that treatment with ZMT alone and in combination with DMP (dextromethorphan) significantly (P < 0.01) decreases the escape latency in conditioned avoidance response (CAR) and transfer latency in elevated plus maze (EPM) as compared with negative control group.	Dextromethorphan	96-99	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	208-211
34244776-5	2021	KEY FINDINGS: Data of the study suggested that treatment with ZMT alone and in combination with DMP (dextromethorphan) significantly (P < 0.01) decreases the escape latency in conditioned avoidance response (CAR) and transfer latency in elevated plus maze (EPM) as compared with negative control group.	Dextromethorphan	101-117	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	208-211
34244776-8	2021	Histopathology study also suggested that the concentration of Abeta peptide decreases in the brain tissues in ZMT and ZMT + DMP-treated group than the negative control group.	Dextromethorphan	124-127	amyloid beta precursor protein	Rattus norvegicus	62-67
34943934-14	2021	CONCLUSIONS: GEN ameliorated Dex-induced accumulation of cholesterol and inhibition of cell differentiation by mediating the GLP-1R/ABCA1 axis in MC3T3-E1 cells.	Dextromethorphan	29-32	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	132-137
34740715-3	2021	In this study, increased phosphorylations of ERK/Akt and hyperlocomotion induced by DM (30mg/kg, i.p./day x 7) were significantly protected by the ouabain inhibitor rostafuroxin (ROSTA), suggesting that DM induces the manic potential.	Dextromethorphan	84-86	mitogen-activated protein kinase 1	Mus musculus	45-48
34740715-3	2021	In this study, increased phosphorylations of ERK/Akt and hyperlocomotion induced by DM (30mg/kg, i.p./day x 7) were significantly protected by the ouabain inhibitor rostafuroxin (ROSTA), suggesting that DM induces the manic potential.	Dextromethorphan	84-86	thymoma viral proto-oncogene 1	Mus musculus	49-52
34740715-10	2021	Our results suggest that ROSTA inhibits DM-induced manic potential by attenuating ERK/Akt activation, GluN2B/PKCdelta signalings, and Nrf2-dependent system.	Dextromethorphan	40-42	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	102-108
34740715-10	2021	Our results suggest that ROSTA inhibits DM-induced manic potential by attenuating ERK/Akt activation, GluN2B/PKCdelta signalings, and Nrf2-dependent system.	Dextromethorphan	40-42	protein kinase C, delta	Mus musculus	109-117
34740715-3	2021	In this study, increased phosphorylations of ERK/Akt and hyperlocomotion induced by DM (30mg/kg, i.p./day x 7) were significantly protected by the ouabain inhibitor rostafuroxin (ROSTA), suggesting that DM induces the manic potential.	Dextromethorphan	203-205	mitogen-activated protein kinase 1	Mus musculus	45-48
34740715-10	2021	Our results suggest that ROSTA inhibits DM-induced manic potential by attenuating ERK/Akt activation, GluN2B/PKCdelta signalings, and Nrf2-dependent system.	Dextromethorphan	40-42	nuclear factor, erythroid derived 2, like 2	Mus musculus	134-138
34740715-3	2021	In this study, increased phosphorylations of ERK/Akt and hyperlocomotion induced by DM (30mg/kg, i.p./day x 7) were significantly protected by the ouabain inhibitor rostafuroxin (ROSTA), suggesting that DM induces the manic potential.	Dextromethorphan	203-205	thymoma viral proto-oncogene 1	Mus musculus	49-52
34740715-7	2021	ROSTA, PKCdelta inhibitor rottlerin, and GluN2B inhibitor traxoprodil significantly attenuated DM-induced alterations in Nrf2-related redox parameters and locomotor activity induced by DM in wild-type mice.	Dextromethorphan	95-97	protein kinase C, delta	Mus musculus	7-15
34740715-7	2021	ROSTA, PKCdelta inhibitor rottlerin, and GluN2B inhibitor traxoprodil significantly attenuated DM-induced alterations in Nrf2-related redox parameters and locomotor activity induced by DM in wild-type mice.	Dextromethorphan	95-97	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	41-47
34740715-7	2021	ROSTA, PKCdelta inhibitor rottlerin, and GluN2B inhibitor traxoprodil significantly attenuated DM-induced alterations in Nrf2-related redox parameters and locomotor activity induced by DM in wild-type mice.	Dextromethorphan	95-97	nuclear factor, erythroid derived 2, like 2	Mus musculus	121-125
34740715-7	2021	ROSTA, PKCdelta inhibitor rottlerin, and GluN2B inhibitor traxoprodil significantly attenuated DM-induced alterations in Nrf2-related redox parameters and locomotor activity induced by DM in wild-type mice.	Dextromethorphan	185-187	protein kinase C, delta	Mus musculus	7-15
34740715-7	2021	ROSTA, PKCdelta inhibitor rottlerin, and GluN2B inhibitor traxoprodil significantly attenuated DM-induced alterations in Nrf2-related redox parameters and locomotor activity induced by DM in wild-type mice.	Dextromethorphan	185-187	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	41-47
34740715-7	2021	ROSTA, PKCdelta inhibitor rottlerin, and GluN2B inhibitor traxoprodil significantly attenuated DM-induced alterations in Nrf2-related redox parameters and locomotor activity induced by DM in wild-type mice.	Dextromethorphan	185-187	nuclear factor, erythroid derived 2, like 2	Mus musculus	121-125
34740715-10	2021	Our results suggest that ROSTA inhibits DM-induced manic potential by attenuating ERK/Akt activation, GluN2B/PKCdelta signalings, and Nrf2-dependent system.	Dextromethorphan	40-42	mitogen-activated protein kinase 1	Mus musculus	82-85
34740715-10	2021	Our results suggest that ROSTA inhibits DM-induced manic potential by attenuating ERK/Akt activation, GluN2B/PKCdelta signalings, and Nrf2-dependent system.	Dextromethorphan	40-42	thymoma viral proto-oncogene 1	Mus musculus	86-89
34310007-5	2021	Presently, we found that both mitophagy-related protein hypoxia-inducible factor-1alpha (HIF-1alpha) and BNIP3 were up-regulated in the hypoxic environment, and their expression was down-regulated when exposed to DEX.	Dextromethorphan	213-216	hypoxia inducible factor 1, alpha subunit	Mus musculus	89-99
34355409-2	2021	In the present study, the effects of age and gender on the CYP2D6 activity were evaluated using dextromethorphan as a probe drug in humans.	Dextromethorphan	96-112	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	59-65
34355409-5	2021	Dextromethorphan and its metabolite dextrorphan were measured using HPLC-fluorescence, and dextromethorphan metabolic ratio (MR, log (dextromethorphan/dextrorphan)) was used to evaluate the CYP2D6 activity.	Dextromethorphan	91-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	190-196
34355409-5	2021	Dextromethorphan and its metabolite dextrorphan were measured using HPLC-fluorescence, and dextromethorphan metabolic ratio (MR, log (dextromethorphan/dextrorphan)) was used to evaluate the CYP2D6 activity.	Dextromethorphan	134-150	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	190-196
34830120-5	2021	Furthermore, CRH/DEX tests show an increased sensitivity (hypersensitivity) of their feedback inhibition in the hypothalamic-pituitary-adrenal (HPA) axis.	Dextromethorphan	17-20	corticotropin releasing hormone	Mus musculus	13-16
34310007-5	2021	Presently, we found that both mitophagy-related protein hypoxia-inducible factor-1alpha (HIF-1alpha) and BNIP3 were up-regulated in the hypoxic environment, and their expression was down-regulated when exposed to DEX.	Dextromethorphan	213-216	BCL2/adenovirus E1B interacting protein 3	Mus musculus	105-110
34310007-6	2021	Besides, we demonstrated that overexpressing HIF-1alpha resisted DEX-induced apoptosis in a hypoxic environment.	Dextromethorphan	65-68	hypoxia inducible factor 1, alpha subunit	Mus musculus	45-55
34310007-7	2021	Here, we demonstrated that overexpression of HIF-1alpha, through its downstream marker BNIP3, reduced the suppression of DEX on mitophagy induced by hypoxia and protected bone cells from apoptosis.	Dextromethorphan	121-124	hypoxia inducible factor 1, alpha subunit	Mus musculus	45-55
34310007-7	2021	Here, we demonstrated that overexpression of HIF-1alpha, through its downstream marker BNIP3, reduced the suppression of DEX on mitophagy induced by hypoxia and protected bone cells from apoptosis.	Dextromethorphan	121-124	BCL2/adenovirus E1B interacting protein 3	Mus musculus	87-92
34716917-2	2022	As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP), our goal was to further assess the impact of rs5758550 on CYP2D6 activity toward two probe substrates, atomoxetine (ATX) and dextromethorphan (DM), using in vivo urinary metabolite (DM; n=188) and pharmacokinetic (ATX; n=70) and in vitro metabolite formation (ATX and DM; n=166) data.	Dextromethorphan	255-271	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	188-194
34569808-5	2021	The results support the hypothesis of the existence of substrate specificity of the CYP2D6*17-allele (higher debrisoquine clearance), a subtle effect of the CYP2D6*10-allele (lower dextromethorphan clearance) but no substrate-specific effect of the CYP2D6*2-allele.	Dextromethorphan	181-197	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	157-163
34716917-2	2022	As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP), our goal was to further assess the impact of rs5758550 on CYP2D6 activity toward two probe substrates, atomoxetine (ATX) and dextromethorphan (DM), using in vivo urinary metabolite (DM; n=188) and pharmacokinetic (ATX; n=70) and in vitro metabolite formation (ATX and DM; n=166) data.	Dextromethorphan	273-275	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	188-194
34575489-5	2021	The anti-inflammatory effect of MNP-Dex/PCA was associated with the reduction in the levels of ERK1/2 and p38-alpha mitogen-activated protein kinases (MAPKs) and NF-kB transcription factor.	Dextromethorphan	36-39	mitogen-activated protein kinase 3	Homo sapiens	95-101
34352333-8	2021	The largest variability in CYP activity was shown for CYP2D6 activity, after oral dosing of dextromethorphan, for which genetic polymorphisms are well characterised and constitute a significant source of variability.	Dextromethorphan	92-108	peptidylprolyl isomerase G	Homo sapiens	27-30
34352333-8	2021	The largest variability in CYP activity was shown for CYP2D6 activity, after oral dosing of dextromethorphan, for which genetic polymorphisms are well characterised and constitute a significant source of variability.	Dextromethorphan	92-108	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
34242672-0	2021	Ventral tegmental area serotonin 5-HT1A receptors and corticolimbic cFos/BDNF/GFAP signaling pathways mediate dextromethorphan/morphine anti-allodynia.	Dextromethorphan	110-126	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	68-72
34242672-0	2021	Ventral tegmental area serotonin 5-HT1A receptors and corticolimbic cFos/BDNF/GFAP signaling pathways mediate dextromethorphan/morphine anti-allodynia.	Dextromethorphan	110-126	brain-derived neurotrophic factor	Rattus norvegicus	73-77
34242672-0	2021	Ventral tegmental area serotonin 5-HT1A receptors and corticolimbic cFos/BDNF/GFAP signaling pathways mediate dextromethorphan/morphine anti-allodynia.	Dextromethorphan	110-126	glial fibrillary acidic protein	Rattus norvegicus	78-82
34242672-7	2021	Dextromethorphan/morphine-induced anti-allodynia was accompanied by the decrease of hippocampus/amygdala/PFC GFAP and amygdala cFos expressions.	Dextromethorphan	0-16	glial fibrillary acidic protein	Rattus norvegicus	109-113
34242672-7	2021	Dextromethorphan/morphine-induced anti-allodynia was accompanied by the decrease of hippocampus/amygdala/PFC GFAP and amygdala cFos expressions.	Dextromethorphan	0-16	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	127-131
34242672-8	2021	The PFC BDNF expression level was increased in dextromethorphan/morphine-treated rats.	Dextromethorphan	47-63	brain-derived neurotrophic factor	Rattus norvegicus	8-12
34242672-12	2021	(S)-WAY100135 plus dextromethorphan/morphine increased the hippocampal/amygdala and PFC levels of GFAP.	Dextromethorphan	19-35	glial fibrillary acidic protein	Rattus norvegicus	98-102
34097071-0	2021	The Cortisol and ACTH response to Dex/CRH testing in Women with and without Perimenopausal Depression.	Dextromethorphan	34-37	proopiomelanocortin	Homo sapiens	17-21
34097071-3	2021	OBJECTIVE: We examined HPA axis function in perimenopausal women with and without depression using the combined dexamethasone-CRH (Dex/CRH) test.	Dextromethorphan	131-134	corticotropin releasing hormone	Homo sapiens	126-129
34578717-6	2021	In addition, by further incorporating with DEX@PCNFs, the alkaline phosphatase (ALP) level and calcium deposition were a little higher based on pearl powder.	Dextromethorphan	43-46	alkaline phosphatase, placental	Homo sapiens	58-78
34578717-6	2021	In addition, by further incorporating with DEX@PCNFs, the alkaline phosphatase (ALP) level and calcium deposition were a little higher based on pearl powder.	Dextromethorphan	43-46	alkaline phosphatase, placental	Homo sapiens	80-83
34575489-5	2021	The anti-inflammatory effect of MNP-Dex/PCA was associated with the reduction in the levels of ERK1/2 and p38-alpha mitogen-activated protein kinases (MAPKs) and NF-kB transcription factor.	Dextromethorphan	36-39	mitogen-activated protein kinase 1	Homo sapiens	106-109
34090135-7	2021	RESULTS: We found an increased ACTH and cortisol response following the dex/CRH-test in patients that were weary of life.	Dextromethorphan	72-75	proopiomelanocortin	Homo sapiens	31-35
34090135-7	2021	RESULTS: We found an increased ACTH and cortisol response following the dex/CRH-test in patients that were weary of life.	Dextromethorphan	72-75	corticotropin releasing hormone	Homo sapiens	76-79
34302119-0	2021	Correction: Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.	Dextromethorphan	24-40	cholinergic receptor nicotinic alpha 7 subunit	Homo sapiens	114-120
34413386-5	2021	Translocation of GR from the cytosol into the nucleus following Dex treatment was confirmed by separating the cytosol and nuclear fractions and by immunofluorescence staining.	Dextromethorphan	64-67	nuclear receptor subfamily 3 group C member 1	Homo sapiens	17-19
34413386-6	2021	In ChIP assays, Dex induced GR binding to the Mlph promoter and we determined that Dex induced the GR binding motif on the Mlph promoter.	Dextromethorphan	16-19	melanophilin	Homo sapiens	46-50
34413386-6	2021	In ChIP assays, Dex induced GR binding to the Mlph promoter and we determined that Dex induced the GR binding motif on the Mlph promoter.	Dextromethorphan	83-86	nuclear receptor subfamily 3 group C member 1	Homo sapiens	99-101
34413386-6	2021	In ChIP assays, Dex induced GR binding to the Mlph promoter and we determined that Dex induced the GR binding motif on the Mlph promoter.	Dextromethorphan	83-86	melanophilin	Homo sapiens	123-127
34302119-0	2021	Correction: Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.	Dextromethorphan	24-40	Janus kinase 2	Homo sapiens	132-136
34302119-0	2021	Correction: Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.	Dextromethorphan	24-40	signal transducer and activator of transcription 3	Homo sapiens	137-142
34302119-0	2021	Correction: Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.	Dextromethorphan	24-40	SRY-box transcription factor 2	Homo sapiens	143-147
33060488-8	2021	In the IV-POS group, three patients were poor dextromethorphan (CYP2D6) metabolizers; in the POS-POS group, one was a poor mephenytoin (CYP2C19) metabolizer.	Dextromethorphan	46-62	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	64-70
34121856-8	2021	Moreover, the expressions of proinflammatory markers regulated by NF-kappaB were diminished in Dex + MPTP group.	Dextromethorphan	95-98	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	66-75
34336001-3	2021	Furthermore, dextromethorphan can inhibit the accumulation of GPR37 in the hippocampus of newborns caused by buprenorphine and is accompanied by the proapoptotic ER stress response that involves the procaspase-3/CHOP pathway.	Dextromethorphan	13-29	G protein-coupled receptor 37	Homo sapiens	62-67
34336001-3	2021	Furthermore, dextromethorphan can inhibit the accumulation of GPR37 in the hippocampus of newborns caused by buprenorphine and is accompanied by the proapoptotic ER stress response that involves the procaspase-3/CHOP pathway.	Dextromethorphan	13-29	caspase 3	Homo sapiens	199-211
34336001-3	2021	Furthermore, dextromethorphan can inhibit the accumulation of GPR37 in the hippocampus of newborns caused by buprenorphine and is accompanied by the proapoptotic ER stress response that involves the procaspase-3/CHOP pathway.	Dextromethorphan	13-29	DNA damage inducible transcript 3	Homo sapiens	212-216
34227748-8	2021	Results from screening FDA-approved drugs suggested that GluN1-M641I containing NMDARs are more sensitive to the NMDAR channel blockers memantine, ketamine, and dextromethorphan compared to the wild-type receptors.	Dextromethorphan	161-177	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	57-62
34540637-3	2021	Objectives: This study examined the effect of the non-competitive NMDAR antagonist dextromethorphan on partial sciatic nerve ligation (PSL)-induced neuropathic pain and the spinal expression of the glucocorticoid receptor (GR).	Dextromethorphan	83-99	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	66-71
34249943-3	2021	Here, we reported that there was an increase in ROS level and SENP3 expression in Dex-induced osteoporotic BM-MSCs, and enhanced adipogenesis and weakened osteogenesis in osteoporotic BM-MSCs might be caused by upregulated SENP3.	Dextromethorphan	82-85	SUMO specific peptidase 3	Homo sapiens	62-67
34249943-3	2021	Here, we reported that there was an increase in ROS level and SENP3 expression in Dex-induced osteoporotic BM-MSCs, and enhanced adipogenesis and weakened osteogenesis in osteoporotic BM-MSCs might be caused by upregulated SENP3.	Dextromethorphan	82-85	SUMO specific peptidase 3	Homo sapiens	223-228
34121856-10	2021	Hence, in this study, we provided insight on the effect of Dex in the inhibition of NF-kappaB1 regulated proinflammatory mediators to improve dopamine levels and reduce SNpc dopaminergic neuronal degeneration.	Dextromethorphan	59-62	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-94
34758716-2	2021	The triglyceride-glucose in-dex(TyG index) is considered as a novel marker of insulin resistance and can represent peripheral tissue insulin sensitivity.	Dextromethorphan	28-31	insulin	Homo sapiens	78-85
34821124-8	2021	RESULTS: The high-performance liquid chromatography (HPLC)-based dextromethorphan O-demethylase assay was established as CYP2D6 marker.	Dextromethorphan	65-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	121-127
34758716-2	2021	The triglyceride-glucose in-dex(TyG index) is considered as a novel marker of insulin resistance and can represent peripheral tissue insulin sensitivity.	Dextromethorphan	28-31	insulin	Homo sapiens	133-140
35171269-0	2022	Corrigendum to: The Cortisol and ACTH Response to Dex/CRH Testing in Women With and Without Perimenopausal Depression.	Dextromethorphan	50-53	proopiomelanocortin	Homo sapiens	33-37
35629363-9	2022	Additionally, DXM reduced the mRNA levels of the cytokines TNF-alpha, IL-6, IL-17A, and IL-22 in skin and the percentage of IL-17A and IL-22 producing T cell receptor gammadelta T cells (TCRgammadeltaT).	Dextromethorphan	14-17	tumor necrosis factor	Mus musculus	59-68
35629363-9	2022	Additionally, DXM reduced the mRNA levels of the cytokines TNF-alpha, IL-6, IL-17A, and IL-22 in skin and the percentage of IL-17A and IL-22 producing T cell receptor gammadelta T cells (TCRgammadeltaT).	Dextromethorphan	14-17	interleukin 6	Mus musculus	70-74
35629363-9	2022	Additionally, DXM reduced the mRNA levels of the cytokines TNF-alpha, IL-6, IL-17A, and IL-22 in skin and the percentage of IL-17A and IL-22 producing T cell receptor gammadelta T cells (TCRgammadeltaT).	Dextromethorphan	14-17	interleukin 17A	Mus musculus	76-82
35629363-9	2022	Additionally, DXM reduced the mRNA levels of the cytokines TNF-alpha, IL-6, IL-17A, and IL-22 in skin and the percentage of IL-17A and IL-22 producing T cell receptor gammadelta T cells (TCRgammadeltaT).	Dextromethorphan	14-17	interleukin 22	Mus musculus	88-93
35629363-9	2022	Additionally, DXM reduced the mRNA levels of the cytokines TNF-alpha, IL-6, IL-17A, and IL-22 in skin and the percentage of IL-17A and IL-22 producing T cell receptor gammadelta T cells (TCRgammadeltaT).	Dextromethorphan	14-17	interleukin 17A	Mus musculus	124-130
35629363-9	2022	Additionally, DXM reduced the mRNA levels of the cytokines TNF-alpha, IL-6, IL-17A, and IL-22 in skin and the percentage of IL-17A and IL-22 producing T cell receptor gammadelta T cells (TCRgammadeltaT).	Dextromethorphan	14-17	interleukin 22	Mus musculus	135-140
35257505-1	2022	This study provides a whole-body physiologically-based pharmacokinetic (PBPK) model of dextromethorphan and its metabolites dextrorphan and dextrorphan O-glucuronide for predicting the effects of cytochrome P450 2D6 (CYP2D6) drug-gene interactions (DGIs) on dextromethorphan pharmacokinetics (PK).	Dextromethorphan	87-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	196-215
35510347-3	2022	Besides, the noncovalent interaction mechanism between SPI and Dex is also unclear.	Dextromethorphan	63-66	chromogranin A	Homo sapiens	55-58
35510347-4	2022	Therefore, we fabricated SPI-Dex complexes and used them to stabilize HIPEs-loaded quercetin to explore the interaction mechanism between SPI and Dex and the effect of Dex concentration on the particle size, zeta-potential, microstructure, rheology, quercetin encapsulation efficiency, and gastrointestinal fate of the HIPEs.	Dextromethorphan	146-149	chromogranin A	Homo sapiens	138-141
35510347-5	2022	RESULTS: Spectral analysis (fourier transform infrared spectroscopy, ultraviolet spectroscopy, and fluorescence spectroscopy) results identified the formation of SPI-Dex complexes, and indicated that the addition of Dex changed the spatial structure of SPI, while thermodynamic analysis (DeltaH > 0, DeltaS > 0) showed that hydrophobic interactions were the main driving forces in the formation of SPI-Dex complexes.	Dextromethorphan	216-219	chromogranin A	Homo sapiens	162-165
35510347-5	2022	RESULTS: Spectral analysis (fourier transform infrared spectroscopy, ultraviolet spectroscopy, and fluorescence spectroscopy) results identified the formation of SPI-Dex complexes, and indicated that the addition of Dex changed the spatial structure of SPI, while thermodynamic analysis (DeltaH > 0, DeltaS > 0) showed that hydrophobic interactions were the main driving forces in the formation of SPI-Dex complexes.	Dextromethorphan	216-219	chromogranin A	Homo sapiens	253-256
35510347-5	2022	RESULTS: Spectral analysis (fourier transform infrared spectroscopy, ultraviolet spectroscopy, and fluorescence spectroscopy) results identified the formation of SPI-Dex complexes, and indicated that the addition of Dex changed the spatial structure of SPI, while thermodynamic analysis (DeltaH > 0, DeltaS > 0) showed that hydrophobic interactions were the main driving forces in the formation of SPI-Dex complexes.	Dextromethorphan	216-219	chromogranin A	Homo sapiens	398-401
35510347-6	2022	Compared with HIPEs stabilized by SPI, the SPI-Dex complex-stabilized HIPEs had smaller particles (3000.33 +- 201.22 nm) and higher zeta-potential (-21.73 +- 1.10 mV), apparent viscosities, modulus, and quercetin encapsulation efficiency (98.19+-0.14%).	Dextromethorphan	47-50	chromogranin A	Homo sapiens	43-46
35510347-7	2022	In addition, in vitro digestion revealed that SPI-Dex complex-stabilized HIPEs significantly reduced the release of free fatty acid and improved quercetin bioaccessibility.	Dextromethorphan	50-53	chromogranin A	Homo sapiens	46-49
35571112-4	2022	Furthermore, oral administration of dextromethorphan, an over-the-counter NMDA receptor antagonist, to diabetic patients in a small clinical trial showed improved glucose tolerance and increased insulin release.	Dextromethorphan	36-52	insulin	Homo sapiens	195-202
35624563-4	2022	In this work, we examined the chaperone activity of PLL-g-Dex to assist G-quadruplex-based fluorescent DNA biosensors for sensitive detection of VEGF.	Dextromethorphan	58-61	vascular endothelial growth factor A	Homo sapiens	145-149
35456223-11	2022	These 50 drugs were also found to be validated in different cancer cell lines, such as dasatinib, captopril, leflunomide, and dextromethorphan targeting SRC, MMP2, PTK2B, and RAC1 hub genes, respectively.	Dextromethorphan	126-142	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	153-156
35456223-11	2022	These 50 drugs were also found to be validated in different cancer cell lines, such as dasatinib, captopril, leflunomide, and dextromethorphan targeting SRC, MMP2, PTK2B, and RAC1 hub genes, respectively.	Dextromethorphan	126-142	matrix metallopeptidase 2	Homo sapiens	158-162
35456223-11	2022	These 50 drugs were also found to be validated in different cancer cell lines, such as dasatinib, captopril, leflunomide, and dextromethorphan targeting SRC, MMP2, PTK2B, and RAC1 hub genes, respectively.	Dextromethorphan	126-142	protein tyrosine kinase 2 beta	Homo sapiens	164-169
35456223-11	2022	These 50 drugs were also found to be validated in different cancer cell lines, such as dasatinib, captopril, leflunomide, and dextromethorphan targeting SRC, MMP2, PTK2B, and RAC1 hub genes, respectively.	Dextromethorphan	126-142	Rac family small GTPase 1	Homo sapiens	175-179
35257505-1	2022	This study provides a whole-body physiologically-based pharmacokinetic (PBPK) model of dextromethorphan and its metabolites dextrorphan and dextrorphan O-glucuronide for predicting the effects of cytochrome P450 2D6 (CYP2D6) drug-gene interactions (DGIs) on dextromethorphan pharmacokinetics (PK).	Dextromethorphan	87-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	217-223
35257505-2	2022	Moreover, the effect of interindividual variability (IIV) within CYP2D6 activity score groups on the PK of dextromethorphan and its metabolites was investigated.	Dextromethorphan	107-123	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
35119082-2	2022	7 on p. 323; specifically, while preparing the figure, the panels denoting the "CD31 DEXs-miRNA-194-3p inhibitor" and "VEGF-DEXs-blank" panels were imported incorrectly in Fig.	Dextromethorphan	85-89	platelet and endothelial cell adhesion molecule 1	Homo sapiens	80-84
35330172-18	2022	DEX decreased the levels of cytokines, including IL-6, IL-10, and TNF-alpha.	Dextromethorphan	0-3	interleukin 6	Rattus norvegicus	49-53
35330172-18	2022	DEX decreased the levels of cytokines, including IL-6, IL-10, and TNF-alpha.	Dextromethorphan	0-3	interleukin 10	Rattus norvegicus	55-60
35330172-18	2022	DEX decreased the levels of cytokines, including IL-6, IL-10, and TNF-alpha.	Dextromethorphan	0-3	tumor necrosis factor	Rattus norvegicus	66-75
2556654-2	1989	The effects of dextromethorphan were tested on the synaptic responses of the interconnections between Schaffer collaterals and CA1 pyramidal cells in hippocampal slices of the rat.	Dextromethorphan	15-31	carbonic anhydrase 1	Rattus norvegicus	127-130
35190765-6	2022	Overexpression of lncRNA FGD5-AS1 promoted cell proliferation and restrained apoptosis in Dex-treated hBMSCs.	Dextromethorphan	90-93	FYVE, RhoGEF and PH domain containing 5	Homo sapiens	25-29
35190765-6	2022	Overexpression of lncRNA FGD5-AS1 promoted cell proliferation and restrained apoptosis in Dex-treated hBMSCs.	Dextromethorphan	90-93	prostaglandin D2 receptor	Homo sapiens	30-33
35190765-9	2022	More importantly, miR-296-5p and STAT3 can affect the function of lncRNA FGD5-AS1 in Dex-treated hBMSCs.	Dextromethorphan	85-88	microRNA 296	Homo sapiens	18-25
35190765-9	2022	More importantly, miR-296-5p and STAT3 can affect the function of lncRNA FGD5-AS1 in Dex-treated hBMSCs.	Dextromethorphan	85-88	signal transducer and activator of transcription 3	Homo sapiens	33-38
35190765-9	2022	More importantly, miR-296-5p and STAT3 can affect the function of lncRNA FGD5-AS1 in Dex-treated hBMSCs.	Dextromethorphan	85-88	FYVE, RhoGEF and PH domain containing 5	Homo sapiens	73-77
35190765-9	2022	More importantly, miR-296-5p and STAT3 can affect the function of lncRNA FGD5-AS1 in Dex-treated hBMSCs.	Dextromethorphan	85-88	prostaglandin D2 receptor	Homo sapiens	78-81
35071218-7	2021	Moreover, we demonstrate that ACT-Dex NPs suppress keratinocyte proliferation more efficiently than neat ACT by enhancing the inhibitory effect on STAT3 phosphorylation.	Dextromethorphan	34-37	signal transducer and activator of transcription 3	Homo sapiens	147-152
35226290-7	2022	Primary and immortalized human cholangiocytes treated with NHs/dex show an increase in the functional marker expression of NHE1 cholangiocytes compared to control groups.	Dextromethorphan	63-66	solute carrier family 9 member A1	Homo sapiens	123-127
35327555-11	2022	Clinical trials demonstrated that several Sig-1R agonists (pridopidine, ANAVEX3-71, fluvoxamine, dextrometorphan) and their combinations have a neuroprotective effect and slow down the progression of distinct NDDs.	Dextromethorphan	97-112	sigma non-opioid intracellular receptor 1	Homo sapiens	42-48
35191764-11	2022	The Dex treatment significantly increased the expression levels of TGF-beta1, KL-6, and MMP-1.	Dextromethorphan	4-7	transforming growth factor, beta 1	Rattus norvegicus	67-76
35191764-11	2022	The Dex treatment significantly increased the expression levels of TGF-beta1, KL-6, and MMP-1.	Dextromethorphan	4-7	matrix metallopeptidase 1	Rattus norvegicus	88-93
35014636-0	2022	The regioselectivity of the interaction between dextromethorphan and CYP2D6.	Dextromethorphan	48-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
35014636-4	2022	Here, we construct four systems to explore the interaction between dextromethorphan (DM) and CYP2D6.	Dextromethorphan	67-83	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	93-99
35014636-4	2022	Here, we construct four systems to explore the interaction between dextromethorphan (DM) and CYP2D6.	Dextromethorphan	85-87	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	93-99
35014636-6	2022	Our results also indicate that the substrate concentration could mediate the binding mode between the substrate and CYP2D6 by decreasing the volume of the catalytic pocket, which is not conducive to the O-demethylation of DM but benefits the N-demethylation of DM.	Dextromethorphan	222-224	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	116-122
35014636-6	2022	Our results also indicate that the substrate concentration could mediate the binding mode between the substrate and CYP2D6 by decreasing the volume of the catalytic pocket, which is not conducive to the O-demethylation of DM but benefits the N-demethylation of DM.	Dextromethorphan	261-263	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	116-122
34994213-10	2022	RESULTS: Symptoms of AR significantly improved in the AR + Aba and AR + Dex groups compared with the AR group.	Dextromethorphan	72-75	ferredoxin reductase	Mus musculus	21-23
34994213-10	2022	RESULTS: Symptoms of AR significantly improved in the AR + Aba and AR + Dex groups compared with the AR group.	Dextromethorphan	72-75	ferredoxin reductase	Mus musculus	67-69
34994213-12	2022	Both the AR + Aba and AR + Dex groups showed a significant decrease in nasal T helper 2 cytokine levels, including interleukin (IL)-4, IL-5, IL-13 and T cell activation related IL-17A, and interferon gamma (IFN- gamma).	Dextromethorphan	27-30	interleukin 4	Mus musculus	115-133
34994213-12	2022	Both the AR + Aba and AR + Dex groups showed a significant decrease in nasal T helper 2 cytokine levels, including interleukin (IL)-4, IL-5, IL-13 and T cell activation related IL-17A, and interferon gamma (IFN- gamma).	Dextromethorphan	27-30	interleukin 5	Mus musculus	135-139
34994213-12	2022	Both the AR + Aba and AR + Dex groups showed a significant decrease in nasal T helper 2 cytokine levels, including interleukin (IL)-4, IL-5, IL-13 and T cell activation related IL-17A, and interferon gamma (IFN- gamma).	Dextromethorphan	27-30	interleukin 13	Mus musculus	141-146
34994213-12	2022	Both the AR + Aba and AR + Dex groups showed a significant decrease in nasal T helper 2 cytokine levels, including interleukin (IL)-4, IL-5, IL-13 and T cell activation related IL-17A, and interferon gamma (IFN- gamma).	Dextromethorphan	27-30	interleukin 17A	Mus musculus	177-183
34994213-12	2022	Both the AR + Aba and AR + Dex groups showed a significant decrease in nasal T helper 2 cytokine levels, including interleukin (IL)-4, IL-5, IL-13 and T cell activation related IL-17A, and interferon gamma (IFN- gamma).	Dextromethorphan	27-30	interferon gamma	Mus musculus	189-217
34994213-13	2022	Total immunoglobulin (Ig) E and OVA-specific IgG1 levels were also significantly lower in the AR + Aba and AR + Dex groups.	Dextromethorphan	112-115	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	32-35
2556654-6	1989	The data indicate that: (1) dextromethorphan has an influence on CA1 pyramidal cells, different from that of other opioids; (2) the reported antiepileptic effects of dextromethorphan do not involve the hippocampal area.	Dextromethorphan	28-44	carbonic anhydrase 1	Rattus norvegicus	65-68
2472228-7	1989	The rate of disappearance of the complexed drug from the circulation was markedly influenced by the molecular size of the carrier CM-dex, since the retained amount of drug was considerably higher with the T-40 and T-250 complexes than with the T-10 complex.	Dextromethorphan	133-136	transport and golgi organization 2	Mus musculus	244-248
2475649-4	1989	During Dextran infusion, peak R (cm/sec) increased (control; 53.5 +/- 7.5, Dex 100 ml; 57.8 +/- 10.0, p less than 0.05, Dex 200 ml; 60.4 +/- 10.6, p less than 0.01) as did IR1 (cm) (control; 3.2 +/- 1.1, Dex 100 ml; 3.8 +/- 1.0, p less than 0.01, Dex 200 ml; 4.2 +/- 1.3, p less than 0.01).	Dextromethorphan	7-10	nischarin	Homo sapiens	172-175
2481572-3	1989	DEX(10(-7) M) in DMEM supplemented with 5 per cent FCS, enhanced the IL-6 effect on the three positive acute phase proteins.	Dextromethorphan	0-3	interleukin 6	Mus musculus	69-73
2785553-6	1989	A decrease of the effect on either DN/IL-2R+ cells or CD4+ SP cells was selectively observed after long-term treatments with 17 beta-estradiol or DEX, respectively.	Dextromethorphan	146-149	interleukin 2 receptor subunit alpha	Homo sapiens	38-43
2785553-6	1989	A decrease of the effect on either DN/IL-2R+ cells or CD4+ SP cells was selectively observed after long-term treatments with 17 beta-estradiol or DEX, respectively.	Dextromethorphan	146-149	CD4 molecule	Homo sapiens	54-57
2910636-0	1989	Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-108
2970461-8	1988	ANF processing was also stimulated by the specific glucocorticoid receptor agonist RU 28362, and both DEX- and RU 28362-stimulated ANF processing was inhibited by the specific glucocorticoid receptor antagonist RU 38486.	Dextromethorphan	102-105	natriuretic peptide A	Homo sapiens	131-134
3155537-3	1985	Dex added at the beginning of the culture period inhibited, cell proliferation and IL 1/IL 2 synthesis, although not completely.	Dextromethorphan	0-3	interleukin 1 alpha	Homo sapiens	83-87
3024513-8	1986	DEX attenuated the vasopressin and ACTH responses to each infusion.	Dextromethorphan	0-3	proopiomelanocortin	Canis lupus familiaris	35-39
3011905-1	1986	Here we demonstrate that CsA and DEX, at concentrations that markedly inhibited PHA-induced proliferation and IL 2 mRNA accumulation, partially diminished the expression of receptors for IL 2 on PBMC.	Dextromethorphan	33-36	interleukin 2	Homo sapiens	110-114
3011905-1	1986	Here we demonstrate that CsA and DEX, at concentrations that markedly inhibited PHA-induced proliferation and IL 2 mRNA accumulation, partially diminished the expression of receptors for IL 2 on PBMC.	Dextromethorphan	33-36	interleukin 2	Homo sapiens	187-191
3011905-3	1986	Although both CsA and DEX inhibited IL 2 receptor expression by about 50%, only CsA blocked the PHA-mediated induction of IL 2 responsivity in PBMC cultures.	Dextromethorphan	22-25	interleukin 2	Homo sapiens	36-40
3011905-4	1986	These data provide evidence that 1) CsA and DEX suppress the proliferation of T lymphocytes through distinct (though perhaps overlapping) mechanisms, 2) CsA (but not DEX) blocks the PHA-mediated induction of signals necessary for T cells to become capable of proliferating in response to IL 2, and 3) T cells regulate the expression of their genes for IL 2 and IL 2 receptors, at least in part, through independent mechanisms.	Dextromethorphan	44-47	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	153-156
3153479-5	1987	Insulin (5 x 10(-9) M) alone had no significant effect on either hGH mRNA or protein, but blunted the effect of Dex.	Dextromethorphan	112-115	insulin	Homo sapiens	0-7
3153479-8	1987	Insulin alone or in combination with T3 or Dex was found to increase hGH mRNA levels in some cell lines and to decrease hGH mRNA levels in others; these effects were correlated strongly (r = 0.88; P less than 0.001) with the influence of insulin on the endogenous rat GH gene, implying that individual cellular differences can simultaneously affect the insulin responsiveness of both genes.	Dextromethorphan	43-46	insulin	Homo sapiens	238-245
3153479-8	1987	Insulin alone or in combination with T3 or Dex was found to increase hGH mRNA levels in some cell lines and to decrease hGH mRNA levels in others; these effects were correlated strongly (r = 0.88; P less than 0.001) with the influence of insulin on the endogenous rat GH gene, implying that individual cellular differences can simultaneously affect the insulin responsiveness of both genes.	Dextromethorphan	43-46	insulin	Homo sapiens	353-360
3504063-6	1987	Finally, the influence of DEX on aromatase in genital skin fibroblasts differs in some important respects from the pattern of control observed in adipose tissue stromal-vascular cells.	Dextromethorphan	26-29	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	33-42
2428915-7	1986	These findings suggest a model for the initiation of autoimmunity in MG. Antibodies made in response to DEX epitopes on the surface of certain bacteria would elicit the production of anti-Ids.	Dextromethorphan	104-107	iduronate 2-sulfatase	Homo sapiens	188-191
3155537-3	1985	Dex added at the beginning of the culture period inhibited, cell proliferation and IL 1/IL 2 synthesis, although not completely.	Dextromethorphan	0-3	interleukin 2	Homo sapiens	88-92
3155537-7	1985	Moreover, primed T lymphocytes treated with Dex in the presence of exogenous IL 2 enhanced the proliferative responses of fresh autologous PBMC stimulated by MPPS.	Dextromethorphan	44-47	interleukin 2	Homo sapiens	77-81
6195285-7	1983	The results show that IgA responses are epitope-related and selectively associated with anti-Dex antibodies: no IgA PFC are detected against a hapten coupled to Dex or proteins, while the enhanced levels of helper cell reactivity provided by protein carrier to Dex result in the appearance of IgG1 antibodies in addition to IgA.	Dextromethorphan	93-96	LOC105243590	Mus musculus	293-297
2579418-2	1985	This report shows that, in 8- to 10-month-old BALB/c mice immunized intraperitoneally with dextran B1355, approximately 75% of IgG3 anti-alpha (1----3) polyglucan (anti-dex) plaque-forming cells (PFC) detected in the spleen were identified as double-Ig class producers secreting simultaneously IgG3 and IgM antibodies with the same specificity for the dex epitope.	Dextromethorphan	91-94	Immunoglobulin heavy constant gamma 3	Mus musculus	127-131
2579418-2	1985	This report shows that, in 8- to 10-month-old BALB/c mice immunized intraperitoneally with dextran B1355, approximately 75% of IgG3 anti-alpha (1----3) polyglucan (anti-dex) plaque-forming cells (PFC) detected in the spleen were identified as double-Ig class producers secreting simultaneously IgG3 and IgM antibodies with the same specificity for the dex epitope.	Dextromethorphan	91-94	Immunoglobulin heavy constant gamma 3	Mus musculus	294-298
2579418-2	1985	This report shows that, in 8- to 10-month-old BALB/c mice immunized intraperitoneally with dextran B1355, approximately 75% of IgG3 anti-alpha (1----3) polyglucan (anti-dex) plaque-forming cells (PFC) detected in the spleen were identified as double-Ig class producers secreting simultaneously IgG3 and IgM antibodies with the same specificity for the dex epitope.	Dextromethorphan	91-94	immunoglobulin heavy constant mu	Mus musculus	303-306
6606667-4	1984	Endogenous IL 2 production was blocked in situ by pharmacologic concentration of DEX (100 to 1000 nM), resulting in an 80 to 90% reduction of thymidine uptake.	Dextromethorphan	81-84	interleukin 2	Homo sapiens	11-15
6606667-6	1984	The addition of IL 2-containing supernatants reversed this inhibitory effect of DEX by allowing the cells to synthesize more RNA (G1a-G1b transition).	Dextromethorphan	80-83	interleukin 2	Homo sapiens	16-20
6606667-9	1984	In these studies, IL 2-induced RNA synthesis, and subsequent proliferation of DEX-treated and PHA-stimulated cells was inhibited by anti-Tac.	Dextromethorphan	78-81	interleukin 2	Homo sapiens	18-22
7046471-8	1982	These results indicate that the elevation of blood pressure in DEX depends partially on the renin-angiotensin system.	Dextromethorphan	63-66	renin	Rattus norvegicus	92-97
34007314-3	2021	In the present study, the exact molecular mechanism underlying HMGB1-mediated drug resistance in MM was explored using three chemotherapy-resistant MM cells (RPMI8226/ADR, RPMI8226/BOR and RPMI8226/DEX) that were successfully established.	Dextromethorphan	198-201	high mobility group box 1	Homo sapiens	63-68
33862465-7	2021	Further, glucocorticoid (Dexamethasone, DEX) was found to sustain Klotho and miR-30a levels during PAN treatment in vitro.	Dextromethorphan	40-43	Klotho	Rattus norvegicus	66-72
33862465-7	2021	Further, glucocorticoid (Dexamethasone, DEX) was found to sustain Klotho and miR-30a levels during PAN treatment in vitro.	Dextromethorphan	40-43	microRNA 30a	Rattus norvegicus	77-84
33980953-5	2021	Dex was found to improve the nucleoplasmic accumulation of soluble Lamin A/C and was capable of managing the large chromatin Lamin A/C scaffolds contained complex, thus regulating epigenetics in treated cells.	Dextromethorphan	0-3	lamin A/C	Homo sapiens	67-76
34048989-4	2021	Besides, miR-155 mimic could abolish the protective effect of DEX on the hippocampal neurons under OGD/R.	Dextromethorphan	62-65	microRNA 155	Rattus norvegicus	9-16
34048989-5	2021	DEX, via down-regulating the expression of miR-155, could activate the ERK1/2 pathway, thereby mitigating the apoptosis and oxidative stress injury and increasing the MMP, thereby protecting hippocampal cells from OGD/R injury.	Dextromethorphan	0-3	microRNA 155	Rattus norvegicus	43-50
34048989-5	2021	DEX, via down-regulating the expression of miR-155, could activate the ERK1/2 pathway, thereby mitigating the apoptosis and oxidative stress injury and increasing the MMP, thereby protecting hippocampal cells from OGD/R injury.	Dextromethorphan	0-3	mitogen activated protein kinase 3	Rattus norvegicus	71-77
33913688-0	2021	Inhibition of the ERK1/2 Phosphorylation by Dextromethorphan Protects against Core Autistic Symptoms in VPA Induced Autistic Rats: In Silico and in Vivo Drug Repurposition Study.	Dextromethorphan	44-60	mitogen activated protein kinase 3	Rattus norvegicus	18-24
33913688-8	2021	The levels of various oxidative stress markers (GSH, SOD, catalase, MDA) and inflammatory markers (IL-1beta, IL-6, IL-10, TNF-alpha) were ameliorated by different doses of dextromethorphan.	Dextromethorphan	172-188	catalase	Rattus norvegicus	58-66
33913688-8	2021	The levels of various oxidative stress markers (GSH, SOD, catalase, MDA) and inflammatory markers (IL-1beta, IL-6, IL-10, TNF-alpha) were ameliorated by different doses of dextromethorphan.	Dextromethorphan	172-188	interleukin 1 alpha	Rattus norvegicus	99-107
33913688-8	2021	The levels of various oxidative stress markers (GSH, SOD, catalase, MDA) and inflammatory markers (IL-1beta, IL-6, IL-10, TNF-alpha) were ameliorated by different doses of dextromethorphan.	Dextromethorphan	172-188	interleukin 6	Rattus norvegicus	109-113
33913688-8	2021	The levels of various oxidative stress markers (GSH, SOD, catalase, MDA) and inflammatory markers (IL-1beta, IL-6, IL-10, TNF-alpha) were ameliorated by different doses of dextromethorphan.	Dextromethorphan	172-188	interleukin 10	Rattus norvegicus	115-120
33913688-8	2021	The levels of various oxidative stress markers (GSH, SOD, catalase, MDA) and inflammatory markers (IL-1beta, IL-6, IL-10, TNF-alpha) were ameliorated by different doses of dextromethorphan.	Dextromethorphan	172-188	tumor necrosis factor	Rattus norvegicus	122-131
33980953-5	2021	Dex was found to improve the nucleoplasmic accumulation of soluble Lamin A/C and was capable of managing the large chromatin Lamin A/C scaffolds contained complex, thus regulating epigenetics in treated cells.	Dextromethorphan	0-3	lamin A/C	Homo sapiens	125-134
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	150-153	Wnt family member 3A	Rattus norvegicus	62-67
33914271-9	2021	LY294002 attenuated the myocardial protective effect of DEX, indicating that Dex protected against cardiac I/R by activating the PI3K/Akt pathway.	Dextromethorphan	56-59	AKT serine/threonine kinase 1	Rattus norvegicus	134-137
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	Wnt family member 3A	Rattus norvegicus	62-65
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	Wnt family member 3A	Rattus norvegicus	62-67
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	catenin beta 1	Rattus norvegicus	88-100
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	Wnt family member 3A	Rattus norvegicus	62-65
33966704-1	2021	Objective To explore the effect of dexmedetomidine(Dex)on sevoflurane-induced cognitive impairment in neonatal rats through Wnt signaling pathway.	Dextromethorphan	51-54	Wnt family member 3A	Rattus norvegicus	124-127
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	Wnt family member 3A	Rattus norvegicus	62-67
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	150-153	catenin beta 1	Rattus norvegicus	88-100
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	150-153	Wnt family member 3A	Rattus norvegicus	62-65
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	Wnt family member 3A	Rattus norvegicus	62-67
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	catenin beta 1	Rattus norvegicus	88-100
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	Wnt family member 3A	Rattus norvegicus	62-65
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	catenin beta 1	Rattus norvegicus	88-100
33485995-1	2021	Dengue virus NS3 is a prototypical DEx(H/D) helicase that binds and hydrolyzes NTP to translocate along and unwind double-stranded nucleic acids.	Dextromethorphan	35-38	KRAS proto-oncogene, GTPase	Homo sapiens	13-16
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	Wnt family member 3A	Rattus norvegicus	62-67
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	catenin beta 1	Rattus norvegicus	88-100
33966704-4	2021	Compared with that in sevoflurane group,the protein levels of Wnt3a(t=6.410,P=0.003)and beta-catenin(t=4.640,P=0.015)were up-regulated in sevoflurane+Dex group.Compared with that in sevoflurane+Dex group,the protein expression of Wnt3a(t=6.360,P=0.003)and beta-catenin(t=4.640,P=0.016)was down-regulated in sevoflurane+Dex+Wnt inhibitor group.Compared with that in the control group,the expression(gray value)of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane group(t=11.280,P=0.002),sevoflurane+Dex group(t=7.080,P=0.002),and sevoflurane+Dex+Wnt inhibitor group(t=9.970,P=0.001)were down-regulated.Compared with that in the sevoflurane group,the expression of P(ser9)-GSK-3beta/GSK-3beta were up-regulated in sevoflurane+Dex group(t=8.310,P <0.001).Compared with that in sevoflurane+Dex group,the expression of P(ser9)-GSK-3beta/GSK-3beta in sevoflurane+Dex+Wnt inhibitor group was down-regulated(t=5.510,P=0.005).	Dextromethorphan	194-197	Wnt family member 3A	Rattus norvegicus	62-65
33966704-5	2021	Conclusion Dex can mediate Wnt/GSK-3beta/beta-catenin signaling pathway to inhibit sevoflurane-induced cognitive impairment in neonatal rats.	Dextromethorphan	11-14	Wnt family member 3A	Rattus norvegicus	27-30
33966704-5	2021	Conclusion Dex can mediate Wnt/GSK-3beta/beta-catenin signaling pathway to inhibit sevoflurane-induced cognitive impairment in neonatal rats.	Dextromethorphan	11-14	glycogen synthase kinase 3 alpha	Rattus norvegicus	31-40
33966704-5	2021	Conclusion Dex can mediate Wnt/GSK-3beta/beta-catenin signaling pathway to inhibit sevoflurane-induced cognitive impairment in neonatal rats.	Dextromethorphan	11-14	catenin beta 1	Rattus norvegicus	41-53
33831979-8	2021	RESULTS: The high-performance liquid chromatography (HPLC)-based dextromethorphan O-demethylase assay was established as CYP2D6 marker.	Dextromethorphan	65-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	121-127
33792897-4	2021	It was also possible to measure liver sEV-catalysed dextromethorphan (DEX) O-demethylation to dextrorphan (DXO), correlated with sEV CYP2D6 expression (r = 0.917, P = 0.0001; N = 10) and 3hr plasma DXO-to-DEX concentration ratio (r = 0.843, P = 0.002; N = 10), and show that CYP2D6 was not induced by RIF.	Dextromethorphan	52-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	133-139
33403748-9	2021	Among drugs interacting with hub genes in suicides we found MAOA inhibitors and dextromethorphan.	Dextromethorphan	80-96	ELAV like RNA binding protein 2	Homo sapiens	29-32
33403748-9	2021	Among drugs interacting with hub genes in suicides we found MAOA inhibitors and dextromethorphan.	Dextromethorphan	80-96	monoamine oxidase A	Homo sapiens	60-64
33792897-4	2021	It was also possible to measure liver sEV-catalysed dextromethorphan (DEX) O-demethylation to dextrorphan (DXO), correlated with sEV CYP2D6 expression (r = 0.917, P = 0.0001; N = 10) and 3hr plasma DXO-to-DEX concentration ratio (r = 0.843, P = 0.002; N = 10), and show that CYP2D6 was not induced by RIF.	Dextromethorphan	70-73	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	133-139
33792897-4	2021	It was also possible to measure liver sEV-catalysed dextromethorphan (DEX) O-demethylation to dextrorphan (DXO), correlated with sEV CYP2D6 expression (r = 0.917, P = 0.0001; N = 10) and 3hr plasma DXO-to-DEX concentration ratio (r = 0.843, P = 0.002; N = 10), and show that CYP2D6 was not induced by RIF.	Dextromethorphan	205-208	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	133-139
33558888-6	2021	CONCLUSION: Dex pretreatment protects against lipopolysaccharide induced actue liver injury via inhibiting the activation of the NLRP3 signaling pathway by upregulating the expression of Cav-1 downregulated by sepsis.	Dextromethorphan	12-15	NLR family, pyrin domain containing 3	Rattus norvegicus	129-134
33511783-5	2021	For a specification of the cortisol response to both conditions, subgroups of high- and low-cortisol responders to the TSST and the DEX-CRH test were formed.	Dextromethorphan	132-135	corticotropin releasing hormone	Homo sapiens	136-139
33511783-7	2021	This increase was 3 times greater in the TSST than the DEX-CRH test.	Dextromethorphan	55-58	corticotropin releasing hormone	Homo sapiens	59-62
33558888-6	2021	CONCLUSION: Dex pretreatment protects against lipopolysaccharide induced actue liver injury via inhibiting the activation of the NLRP3 signaling pathway by upregulating the expression of Cav-1 downregulated by sepsis.	Dextromethorphan	12-15	caveolin 1	Rattus norvegicus	187-192
33660202-12	2021	Treatment with the NMDA receptor antagonist dextromethorphan attenuated chronic IH-induced anxiety-like behavior and GluN2B expression.	Dextromethorphan	44-60	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	117-123
33786848-9	2021	Treatment with PPD, the GR agonist Dex and membrane impermeable GR agonist Dex-BSA in cultured microglia induces remarkable dynorphin A expression, which is totally blocked by pretreatment with Dex-21-mesylate.	Dextromethorphan	35-38	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	24-26
33376147-8	2021	Michaelis-Menten kinetic studies completed with purified enzyme in a reconstituted system showed overall reduced enzyme efficiency for metabolism of bufuralol and dextromethorphan by the Trp75Ala mutant compared to CYP2D6*1.	Dextromethorphan	163-179	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	215-221
33434947-2	2021	Since CYP2D6 prototypic substrates are positively charged, the aim of this study was to evaluate the organic cation membrane transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs) as potential contributors to the variability of CYP2D6 hydroxylation of the CYP2D6 drugs debrisoquine, dextromethorphan, diphenhydramine, perhexiline and sparteine.	Dextromethorphan	299-315	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	6-12
33434947-2	2021	Since CYP2D6 prototypic substrates are positively charged, the aim of this study was to evaluate the organic cation membrane transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs) as potential contributors to the variability of CYP2D6 hydroxylation of the CYP2D6 drugs debrisoquine, dextromethorphan, diphenhydramine, perhexiline and sparteine.	Dextromethorphan	299-315	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	244-250
33434947-2	2021	Since CYP2D6 prototypic substrates are positively charged, the aim of this study was to evaluate the organic cation membrane transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs) as potential contributors to the variability of CYP2D6 hydroxylation of the CYP2D6 drugs debrisoquine, dextromethorphan, diphenhydramine, perhexiline and sparteine.	Dextromethorphan	299-315	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	244-250
33434947-6	2021	KEY RESULTS: OCTs and MATE1 transport sparteine and debrisoquine with high affinity in vitro, but OCT- and MATE1-dependent transport of dextromethorphan, diphenhydramine and perhexiline was not detected.	Dextromethorphan	136-152	solute carrier family 47 member 1	Homo sapiens	107-112
33603170-6	2021	Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7.	Dextromethorphan	17-33	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	82-88
33603170-0	2021	Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.	Dextromethorphan	12-28	cholinergic receptor nicotinic alpha 7 subunit	Homo sapiens	102-108
33594318-5	2021	On the other hand, GR activation by its agonist DEX increased HIF1alpha protein through post-transcriptional mechanism.	Dextromethorphan	48-51	nuclear receptor subfamily 3, group C, member 1	Mus musculus	19-21
33603170-0	2021	Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.	Dextromethorphan	12-28	Janus kinase 2	Homo sapiens	120-124
33603170-0	2021	Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.	Dextromethorphan	12-28	signal transducer and activator of transcription 3	Homo sapiens	125-130
33603170-0	2021	Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.	Dextromethorphan	12-28	SRY-box transcription factor 2	Homo sapiens	131-135
33633357-5	2022	PLA/PEI-CPT-SUR-DEX-APT enhanced cellular uptake through receptor-mediated endocytosis followed by increased CPT accumulation, downregulation of survivin, and thereby 38% cell apoptosis.	Dextromethorphan	16-19	baculoviral IAP repeat-containing 5	Mus musculus	145-153
33688431-10	2021	DEX implants are a valuable option for treating DME, although they are usually seen as a second choice, particularly in those eyes that have an insufficient response to anti-VEGF.	Dextromethorphan	0-3	vascular endothelial growth factor A	Homo sapiens	174-178
33688431-11	2021	The new evidence suggested that, in eyes that did not adequately respond to anti-VEGF, switching to a DEX implant at the time to 3 monthly anti-VEGF injections provided better functional outcomes.	Dextromethorphan	102-105	vascular endothelial growth factor A	Homo sapiens	81-85
33688431-11	2021	The new evidence suggested that, in eyes that did not adequately respond to anti-VEGF, switching to a DEX implant at the time to 3 monthly anti-VEGF injections provided better functional outcomes.	Dextromethorphan	102-105	vascular endothelial growth factor A	Homo sapiens	144-148
33594318-5	2021	On the other hand, GR activation by its agonist DEX increased HIF1alpha protein through post-transcriptional mechanism.	Dextromethorphan	48-51	hypoxia inducible factor 1, alpha subunit	Mus musculus	62-71
33594318-6	2021	However, hypoxia and DEX show differential synergistic effects on HIF1alpha and GR.	Dextromethorphan	21-24	hypoxia inducible factor 1, alpha subunit	Mus musculus	66-75
33594318-6	2021	However, hypoxia and DEX show differential synergistic effects on HIF1alpha and GR.	Dextromethorphan	21-24	nuclear receptor subfamily 3, group C, member 1	Mus musculus	80-82
33613584-15	2020	DEX:IPT plants up-regulated phospholipase D and MAP-kinase 4.	Dextromethorphan	0-3	phospholipase D P1	Arabidopsis thaliana	28-43
33567340-5	2021	Treating wild type (WT) mice with DEX attenuated insulin activated Akt activity in liver, epididymal white adipose tissue and gastrocnemius muscle.	Dextromethorphan	34-37	thymoma viral proto-oncogene 1	Mus musculus	67-70
33567340-11	2021	Pik3r1 knockout also decreased basal protein synthesis rate (likely caused by lower 4E-BP1 phosphorylation at Thr37/Thr46) and curbed the ability of DEX to attenuate protein synthesis rate.	Dextromethorphan	149-152	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	0-6
33567340-12	2021	Finally, the ability of DEX to inhibit eIF2alpha phosphorylation and insulin-induced 4E-BP1 phosphorylation was reduced in MKO mice.	Dextromethorphan	24-27	eukaryotic translation initiation factor 2A	Mus musculus	39-48
33613584-15	2020	DEX:IPT plants up-regulated phospholipase D and MAP-kinase 4.	Dextromethorphan	0-3	MAP kinase 4	Arabidopsis thaliana	48-60
33542651-2	2021	Central sensitization and neuroinflammation have been forwarded as models of FM pathophysiology, both of which indicate dextromethorphan (DXM) as a potential treatment.	Dextromethorphan	120-136	fibromodulin	Homo sapiens	77-79
33542651-5	2021	This study evaluated the effectiveness of DXM in treating FM-associated symptoms.	Dextromethorphan	42-45	fibromodulin	Homo sapiens	58-60
33542651-2	2021	Central sensitization and neuroinflammation have been forwarded as models of FM pathophysiology, both of which indicate dextromethorphan (DXM) as a potential treatment.	Dextromethorphan	138-141	fibromodulin	Homo sapiens	77-79
33434210-16	2021	The TNF-alpha levels decreased significantly in the DEX-3 group on day 28 compared with the OA group.	Dextromethorphan	52-55	tumor necrosis factor	Rattus norvegicus	4-13
33553719-11	2021	The concentrations of TNF- , IL-6, and SAA were lower in the DEX group (P < 0.05).	Dextromethorphan	61-64	tumor necrosis factor	Bos taurus	22-25
33553719-11	2021	The concentrations of TNF- , IL-6, and SAA were lower in the DEX group (P < 0.05).	Dextromethorphan	61-64	interleukin 6	Bos taurus	29-33
33553719-11	2021	The concentrations of TNF- , IL-6, and SAA were lower in the DEX group (P < 0.05).	Dextromethorphan	61-64	serum amyloid A protein	Bos taurus	39-42
33639054-9	2021	Western blot, immunohistochemistry, and PCR results revealed that DEX promoted TLR4 expression and upregulated expression of the TLR4 downstream factors, HO-1 and NQO-1.	Dextromethorphan	66-69	toll-like receptor 4	Rattus norvegicus	79-83
33413642-9	2021	Overexpression of NORAD improved DEX-induced inhibition of proliferation and differentiation, and promotion of apoptosis in hBMSCs, while knockdown of NORAD led to the opposite results.	Dextromethorphan	33-36	non-coding RNA activated by DNA damage	Homo sapiens	18-23
33413642-10	2021	Moreover, NORAD improved DEX-induced inhibition of proliferation and differentiation, and promotion of apoptosis by regulation of miR-26a-5p in hBMSCs.	Dextromethorphan	25-28	non-coding RNA activated by DNA damage	Homo sapiens	10-15
33413642-12	2021	NORAD improved DEX-induced inhibition of proliferation and differentiation, and promotion of apoptosis by regulation of miR-26a-5p in hBMSCs.	Dextromethorphan	15-18	non-coding RNA activated by DNA damage	Homo sapiens	0-5
33406583-11	2021	The PLGA-DEX NPs (0.1 mg/kg) significantly reduced macroscopic and histopathological scores, decreased MDA, TNF-alpha and IL-1beta levels, immunostaining for NF-kappaB, COX-2, TGF-beta, and suppressed NF-kappaB p65 mRNA expression, but increased GILZ and MKP1 expression.	Dextromethorphan	9-12	tumor necrosis factor	Homo sapiens	108-117
33406583-11	2021	The PLGA-DEX NPs (0.1 mg/kg) significantly reduced macroscopic and histopathological scores, decreased MDA, TNF-alpha and IL-1beta levels, immunostaining for NF-kappaB, COX-2, TGF-beta, and suppressed NF-kappaB p65 mRNA expression, but increased GILZ and MKP1 expression.	Dextromethorphan	9-12	interleukin 1 alpha	Homo sapiens	122-130
33406583-11	2021	The PLGA-DEX NPs (0.1 mg/kg) significantly reduced macroscopic and histopathological scores, decreased MDA, TNF-alpha and IL-1beta levels, immunostaining for NF-kappaB, COX-2, TGF-beta, and suppressed NF-kappaB p65 mRNA expression, but increased GILZ and MKP1 expression.	Dextromethorphan	9-12	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	169-174
33406583-11	2021	The PLGA-DEX NPs (0.1 mg/kg) significantly reduced macroscopic and histopathological scores, decreased MDA, TNF-alpha and IL-1beta levels, immunostaining for NF-kappaB, COX-2, TGF-beta, and suppressed NF-kappaB p65 mRNA expression, but increased GILZ and MKP1 expression.	Dextromethorphan	9-12	transforming growth factor alpha	Homo sapiens	176-184
33406583-11	2021	The PLGA-DEX NPs (0.1 mg/kg) significantly reduced macroscopic and histopathological scores, decreased MDA, TNF-alpha and IL-1beta levels, immunostaining for NF-kappaB, COX-2, TGF-beta, and suppressed NF-kappaB p65 mRNA expression, but increased GILZ and MKP1 expression.	Dextromethorphan	9-12	RELA proto-oncogene, NF-kB subunit	Homo sapiens	201-214
33406583-11	2021	The PLGA-DEX NPs (0.1 mg/kg) significantly reduced macroscopic and histopathological scores, decreased MDA, TNF-alpha and IL-1beta levels, immunostaining for NF-kappaB, COX-2, TGF-beta, and suppressed NF-kappaB p65 mRNA expression, but increased GILZ and MKP1 expression.	Dextromethorphan	9-12	TSC22 domain family member 3	Homo sapiens	246-250
33406583-11	2021	The PLGA-DEX NPs (0.1 mg/kg) significantly reduced macroscopic and histopathological scores, decreased MDA, TNF-alpha and IL-1beta levels, immunostaining for NF-kappaB, COX-2, TGF-beta, and suppressed NF-kappaB p65 mRNA expression, but increased GILZ and MKP1 expression.	Dextromethorphan	9-12	dual specificity phosphatase 1	Homo sapiens	255-259
33639054-9	2021	Western blot, immunohistochemistry, and PCR results revealed that DEX promoted TLR4 expression and upregulated expression of the TLR4 downstream factors, HO-1 and NQO-1.	Dextromethorphan	66-69	toll-like receptor 4	Rattus norvegicus	129-133
33639054-9	2021	Western blot, immunohistochemistry, and PCR results revealed that DEX promoted TLR4 expression and upregulated expression of the TLR4 downstream factors, HO-1 and NQO-1.	Dextromethorphan	66-69	heme oxygenase 1	Rattus norvegicus	154-158
33639054-9	2021	Western blot, immunohistochemistry, and PCR results revealed that DEX promoted TLR4 expression and upregulated expression of the TLR4 downstream factors, HO-1 and NQO-1.	Dextromethorphan	66-69	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	163-168
33639054-10	2021	Furthermore, DEX treatment markedly prevented the downregulation of inflammatory response factors, TNF-alpha, IL-1beta and NF-kappaB, and IL-6.	Dextromethorphan	13-16	tumor necrosis factor	Rattus norvegicus	99-108
33639054-10	2021	Furthermore, DEX treatment markedly prevented the downregulation of inflammatory response factors, TNF-alpha, IL-1beta and NF-kappaB, and IL-6.	Dextromethorphan	13-16	interleukin 1 alpha	Rattus norvegicus	110-118
33639054-10	2021	Furthermore, DEX treatment markedly prevented the downregulation of inflammatory response factors, TNF-alpha, IL-1beta and NF-kappaB, and IL-6.	Dextromethorphan	13-16	interleukin 6	Rattus norvegicus	138-142
33376453-0	2020	Dextromethorphan Suppresses Lipopolysaccharide-Induced Epigenetic Histone Regulation in the Tumor Necrosis Factor-alpha Expression in Primary Rat Microglia.	Dextromethorphan	0-16	tumor necrosis factor	Rattus norvegicus	92-119
33416108-9	2021	It was observed that, compared with the control group, DEXs from the MI group significantly upregulated the expression of VEGF in CMECs, enhanced tube formation by CMECs, and upregulated the expression of VEGF and CD31 in the infarcted myocardium of MI model mice.	Dextromethorphan	55-59	vascular endothelial growth factor A	Mus musculus	122-126
33416108-9	2021	It was observed that, compared with the control group, DEXs from the MI group significantly upregulated the expression of VEGF in CMECs, enhanced tube formation by CMECs, and upregulated the expression of VEGF and CD31 in the infarcted myocardium of MI model mice.	Dextromethorphan	55-59	vascular endothelial growth factor A	Mus musculus	205-209
33416108-9	2021	It was observed that, compared with the control group, DEXs from the MI group significantly upregulated the expression of VEGF in CMECs, enhanced tube formation by CMECs, and upregulated the expression of VEGF and CD31 in the infarcted myocardium of MI model mice.	Dextromethorphan	55-59	platelet/endothelial cell adhesion molecule 1	Mus musculus	214-218
32965508-5	2020	To explore the potential mechanisms of biased binding and activity of the two drugs, haloperidol and dextromethorphan towards NSP6, we herein utilized molecular docking-based molecular dynamics simulation studies.	Dextromethorphan	101-117	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	126-130
32378154-2	2020	Considering the importance of metabolic enzymes" activities on the efficacy and safety of medicines, the changes in liver enzymatic activity of CYP2D1 and its related hepatic clearance, by using Dextromethorphan as probe in the animal model of type I and type II diabetes, before and after treatment, was assessed in this study.	Dextromethorphan	195-211	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	144-150
32378154-5	2020	In day 21, rats were subjected to liver perfusion by Krebs-Henseleit buffer containing Dextromethorphan as CYP2D1 probe.	Dextromethorphan	87-103	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	107-113
33200000-10	2020	In addition, the expression levels of IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 were decreased in the Dex, Eto and Dex-Eto groups, compared with the model group.	Dextromethorphan	123-126	interleukin 17A	Rattus norvegicus	38-44
33200000-10	2020	In addition, the expression levels of IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 were decreased in the Dex, Eto and Dex-Eto groups, compared with the model group.	Dextromethorphan	123-126	tumor necrosis factor	Rattus norvegicus	57-66
33200000-10	2020	In addition, the expression levels of IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 were decreased in the Dex, Eto and Dex-Eto groups, compared with the model group.	Dextromethorphan	123-126	interleukin 6	Rattus norvegicus	68-72
33200000-10	2020	In addition, the expression levels of IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 were decreased in the Dex, Eto and Dex-Eto groups, compared with the model group.	Dextromethorphan	123-126	interleukin 1 alpha	Rattus norvegicus	74-82
33200000-10	2020	In addition, the expression levels of IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 were decreased in the Dex, Eto and Dex-Eto groups, compared with the model group.	Dextromethorphan	136-139	interleukin 17A	Rattus norvegicus	38-44
33200000-10	2020	In addition, the expression levels of IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 were decreased in the Dex, Eto and Dex-Eto groups, compared with the model group.	Dextromethorphan	136-139	tumor necrosis factor	Rattus norvegicus	57-66
33200000-10	2020	In addition, the expression levels of IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 were decreased in the Dex, Eto and Dex-Eto groups, compared with the model group.	Dextromethorphan	136-139	interleukin 6	Rattus norvegicus	68-72
33200000-10	2020	In addition, the expression levels of IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 were decreased in the Dex, Eto and Dex-Eto groups, compared with the model group.	Dextromethorphan	136-139	interleukin 1 alpha	Rattus norvegicus	74-82
33200000-11	2020	Among the Dex, Eto and Dex-Eto groups, the escape latency and swimming distance in the Dex-Eto group were the shortest, the number of times of crossing the platform and the target quadrant residence time were the highest, and IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 expression levels were the lowest.	Dextromethorphan	23-26	interleukin 17A	Rattus norvegicus	226-232
33200000-11	2020	Among the Dex, Eto and Dex-Eto groups, the escape latency and swimming distance in the Dex-Eto group were the shortest, the number of times of crossing the platform and the target quadrant residence time were the highest, and IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 expression levels were the lowest.	Dextromethorphan	23-26	tumor necrosis factor	Rattus norvegicus	245-254
33200000-11	2020	Among the Dex, Eto and Dex-Eto groups, the escape latency and swimming distance in the Dex-Eto group were the shortest, the number of times of crossing the platform and the target quadrant residence time were the highest, and IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 expression levels were the lowest.	Dextromethorphan	23-26	interleukin 6	Rattus norvegicus	256-260
33200000-11	2020	Among the Dex, Eto and Dex-Eto groups, the escape latency and swimming distance in the Dex-Eto group were the shortest, the number of times of crossing the platform and the target quadrant residence time were the highest, and IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 expression levels were the lowest.	Dextromethorphan	23-26	interleukin 1 alpha	Rattus norvegicus	262-270
33200000-11	2020	Among the Dex, Eto and Dex-Eto groups, the escape latency and swimming distance in the Dex-Eto group were the shortest, the number of times of crossing the platform and the target quadrant residence time were the highest, and IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 expression levels were the lowest.	Dextromethorphan	23-26	interleukin 17A	Rattus norvegicus	226-232
33200000-11	2020	Among the Dex, Eto and Dex-Eto groups, the escape latency and swimming distance in the Dex-Eto group were the shortest, the number of times of crossing the platform and the target quadrant residence time were the highest, and IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 expression levels were the lowest.	Dextromethorphan	23-26	tumor necrosis factor	Rattus norvegicus	245-254
33200000-11	2020	Among the Dex, Eto and Dex-Eto groups, the escape latency and swimming distance in the Dex-Eto group were the shortest, the number of times of crossing the platform and the target quadrant residence time were the highest, and IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 expression levels were the lowest.	Dextromethorphan	23-26	interleukin 6	Rattus norvegicus	256-260
33200000-11	2020	Among the Dex, Eto and Dex-Eto groups, the escape latency and swimming distance in the Dex-Eto group were the shortest, the number of times of crossing the platform and the target quadrant residence time were the highest, and IL-17A, S-100beta, TNF-alpha, IL-6, IL-1beta and NF-kappaB p65 expression levels were the lowest.	Dextromethorphan	23-26	interleukin 1 alpha	Rattus norvegicus	262-270
32965508-0	2020	Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis.	Dextromethorphan	37-53	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	89-93
32965508-6	2020	Our extensive analysis of the protein-drug interactions, structural and conformational dynamics, residual frustrations, and molecular switches of NSP6-drug complexes indicates that dextromethorphan binding leads to structural destabilization and increase in conformational dynamics and energetic frustrations.	Dextromethorphan	181-197	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	146-150
32965508-11	2020	Dextromethorphan, agonist of sigma receptors, binding leads to overall destabilization of NSP6.	Dextromethorphan	0-16	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	90-94
33204294-7	2020	Western blot showed that Dex could inhibit the expression of the col I and III as well as alpha-SMA (all P < 0.05) and enhance the expression of apoptosis-related factors including cleaved caspase-3 and cleaved caspase-9 (all P < 0.05).	Dextromethorphan	25-28	caspase 3	Homo sapiens	189-198
32647098-8	2020	Peak intraocular DEX levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after administration.	Dextromethorphan	17-20	LAP	Homo sapiens	41-44
32647098-10	2020	Intravitreal DEX/LAP delivery extended higher vitreous DEX levels up to week 24 (466.32 +- 311.15 ng/g).	Dextromethorphan	55-58	LAP	Homo sapiens	17-20
33204294-7	2020	Western blot showed that Dex could inhibit the expression of the col I and III as well as alpha-SMA (all P < 0.05) and enhance the expression of apoptosis-related factors including cleaved caspase-3 and cleaved caspase-9 (all P < 0.05).	Dextromethorphan	25-28	caspase 9	Homo sapiens	211-220
33204294-8	2020	Besides, Dex could also inhibit the activation of the PI3K/AKT signaling pathway (all P < 0.05), thus affecting cell function, while Berb treatment significantly reversed the expression of those above proteins (all P < 0.05).	Dextromethorphan	9-12	AKT serine/threonine kinase 1	Homo sapiens	59-62
33204294-9	2020	Conclusion: Berb attenuated DEX induced reduction of proliferation and migration, oxidative stress, and apoptosis of tendon cells by activating the PI3K/AKT signaling pathway and regulated the expression of phenotype related biomarkers in tendon cells.	Dextromethorphan	28-31	AKT serine/threonine kinase 1	Homo sapiens	153-156
32806259-5	2020	Osteoblasts grown on CHI-coated Dex-filled TNTs surfaces displayed higher alkaline phosphatase (ALP) and mineralization, which was consistent with qRT-PCR analysis of osteoblastic genes including collagen type I (Col I), osteocalcin (OCN), osteopontin (OPN) and runt related transcription factor 2 (Runx2).	Dextromethorphan	32-35	bone gamma-carboxyglutamate protein 2	Mus musculus	221-232
33520876-5	2020	On day 21, rats were subjected to liver perfusion using Krebs-Henseleit buffer containing dextromethorphan as a CYP2D1 probe.	Dextromethorphan	90-106	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	112-118
32806259-5	2020	Osteoblasts grown on CHI-coated Dex-filled TNTs surfaces displayed higher alkaline phosphatase (ALP) and mineralization, which was consistent with qRT-PCR analysis of osteoblastic genes including collagen type I (Col I), osteocalcin (OCN), osteopontin (OPN) and runt related transcription factor 2 (Runx2).	Dextromethorphan	32-35	bone gamma-carboxyglutamate protein 2	Mus musculus	234-237
32806259-5	2020	Osteoblasts grown on CHI-coated Dex-filled TNTs surfaces displayed higher alkaline phosphatase (ALP) and mineralization, which was consistent with qRT-PCR analysis of osteoblastic genes including collagen type I (Col I), osteocalcin (OCN), osteopontin (OPN) and runt related transcription factor 2 (Runx2).	Dextromethorphan	32-35	secreted phosphoprotein 1	Mus musculus	240-251
32806259-5	2020	Osteoblasts grown on CHI-coated Dex-filled TNTs surfaces displayed higher alkaline phosphatase (ALP) and mineralization, which was consistent with qRT-PCR analysis of osteoblastic genes including collagen type I (Col I), osteocalcin (OCN), osteopontin (OPN) and runt related transcription factor 2 (Runx2).	Dextromethorphan	32-35	secreted phosphoprotein 1	Mus musculus	253-256
32806259-5	2020	Osteoblasts grown on CHI-coated Dex-filled TNTs surfaces displayed higher alkaline phosphatase (ALP) and mineralization, which was consistent with qRT-PCR analysis of osteoblastic genes including collagen type I (Col I), osteocalcin (OCN), osteopontin (OPN) and runt related transcription factor 2 (Runx2).	Dextromethorphan	32-35	runt related transcription factor 2	Mus musculus	262-297
32806259-5	2020	Osteoblasts grown on CHI-coated Dex-filled TNTs surfaces displayed higher alkaline phosphatase (ALP) and mineralization, which was consistent with qRT-PCR analysis of osteoblastic genes including collagen type I (Col I), osteocalcin (OCN), osteopontin (OPN) and runt related transcription factor 2 (Runx2).	Dextromethorphan	32-35	runt related transcription factor 2	Mus musculus	299-304
32806259-6	2020	In contrast, protein levels of nitric oxide (NO) and proinflammatory cytokines (TNF-alpha and IL-1beta) from macrophages on Dex-filled TNTs, CHI-coated TNTs and CHI-coated Dex-filled TNTs were significantly lower, especially on CHI-coated Dex-filled TNTs surfaces compared to levels on titanium and TNTs.	Dextromethorphan	124-127	tumor necrosis factor	Mus musculus	80-89
32806259-6	2020	In contrast, protein levels of nitric oxide (NO) and proinflammatory cytokines (TNF-alpha and IL-1beta) from macrophages on Dex-filled TNTs, CHI-coated TNTs and CHI-coated Dex-filled TNTs were significantly lower, especially on CHI-coated Dex-filled TNTs surfaces compared to levels on titanium and TNTs.	Dextromethorphan	124-127	interleukin 1 alpha	Mus musculus	94-102
32907546-6	2020	Chronic RF was introduced by sublethal ischemia-reperfusion injury in mice, and NMDAR inhibitor dextromethorphan hydrobromide (DXM) was administered orally.	Dextromethorphan	96-125	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	80-85
33193079-16	2020	DXM (100 microM) efficiently diminished [Ca2+]c in stimulated human CHI islet cell clusters as well as in stimulated SUR1-/- islet cell clusters.	Dextromethorphan	0-3	ATP binding cassette subfamily C member 8	Homo sapiens	117-121
33193079-19	2020	Targeting KCa3.1 channels by channel openers or L-type Ca2+ channels by DXM or simvastatin might be valuable approaches for treatment of CHI caused by mutations of KATP channels not sensitive to KATP channel openers.	Dextromethorphan	72-75	potassium calcium-activated channel subfamily N member 4	Homo sapiens	10-16
33009922-3	2020	Herein, this study aimed to investigate whether Mettl3 knockdown inhibits the secretion and activity of donor Dex, thereby inhibiting donor Dex-mediated immune rejection.	Dextromethorphan	110-113	methyltransferase like 3	Mus musculus	48-54
33009922-3	2020	Herein, this study aimed to investigate whether Mettl3 knockdown inhibits the secretion and activity of donor Dex, thereby inhibiting donor Dex-mediated immune rejection.	Dextromethorphan	140-143	methyltransferase like 3	Mus musculus	48-54
33009922-7	2020	In summary, Mettl3 knockdown inhibits the immune rejection of Dex in a mouse cardiac allograft model.	Dextromethorphan	62-65	methyltransferase like 3	Mus musculus	12-18
32665318-9	2020	In islets of KATP channel-deficient SUR1 knockout mice the elevating effects of 100 microM DXM on [Ca2+]c and insulin release were completely lost.	Dextromethorphan	91-94	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	Mus musculus	36-40
33134765-10	2020	FPG-Dex (P = 0.007) was an independent predictor of incident prediabetes in a multivariate model that included age, race, gender, BMI, waist circumference, FPG, insulin sensitivity, and secretion.	Dextromethorphan	4-7	insulin	Homo sapiens	161-168
33000187-8	2020	Both MK2206 and DEX treatment in TDI-induced mice resulted not only in the attenuation of AKT phosphorylation, but also reductions in neutrophil, eosinophil and lymphocyte counts in the lungs of mice in the asthma group.	Dextromethorphan	16-19	thymoma viral proto-oncogene 1	Mus musculus	90-93
33000187-9	2020	Consistently, increases in the levels of the inflammatory cytokines IL-4, -5, -6 and -13 analyzed in BALF, and serum IgE in the TDI group were demonstrated to be attenuated in the TDI + MK2206 and TDI + DEX groups.	Dextromethorphan	203-206	interleukin 4	Mus musculus	68-88
32691726-5	2020	MATERIALS AND METHODS: The enzymatic activity of several CYP2D6 genetic variants; i.e., CYP2D6.1 (wild type), CYP2D6.2, CYP2D6.10, and CYP2D6.39, was assessed by examining the O-demethylation of dextromethorphan.	Dextromethorphan	195-211	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	57-63
32691726-6	2020	RESULTS AND CONCLUSION: The intrinsic clearance of dextromethorphan (Vmax/Km) for CYP2D6.2, CYP2D6.10, and CYP2D6.39 were 0.565-, 0.0376-, and 0.470-fold of that for wild type, respectively.	Dextromethorphan	51-67	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	82-88
32691726-6	2020	RESULTS AND CONCLUSION: The intrinsic clearance of dextromethorphan (Vmax/Km) for CYP2D6.2, CYP2D6.10, and CYP2D6.39 were 0.565-, 0.0376-, and 0.470-fold of that for wild type, respectively.	Dextromethorphan	51-67	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-98
32691726-6	2020	RESULTS AND CONCLUSION: The intrinsic clearance of dextromethorphan (Vmax/Km) for CYP2D6.2, CYP2D6.10, and CYP2D6.39 were 0.565-, 0.0376-, and 0.470-fold of that for wild type, respectively.	Dextromethorphan	51-67	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-98
32755625-9	2020	Although dextromethorphan is considered a noncompetitive NMDA receptor antagonist, dextromethorphan binds to several monoaminergic receptors (SERT and NET) and likely produces the antidepressant-like effects through these receptors similar to traditional antidepressant drugs.	Dextromethorphan	83-99	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	142-146
32813313-3	2020	ENDOss also correlated significantly with CYP2D6 genotype (activity score) and CYP2D6 phenotype (dextromethorphan test).	Dextromethorphan	97-113	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
32813313-3	2020	ENDOss also correlated significantly with CYP2D6 genotype (activity score) and CYP2D6 phenotype (dextromethorphan test).	Dextromethorphan	97-113	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
32829248-7	2020	In the following study, we found that 10-6 mol/L Dex significantly inhibited proliferation, arrested cell cycle at the G1 phase, increased caspase-3 activity, induced apoptosis and impeded the migration of hBMSCs, while downregulation of the expression of LINC00473 produced results that were in line with the results of the microarray analysis in a time-dependent manner.	Dextromethorphan	49-52	caspase 3	Homo sapiens	139-148
32829248-7	2020	In the following study, we found that 10-6 mol/L Dex significantly inhibited proliferation, arrested cell cycle at the G1 phase, increased caspase-3 activity, induced apoptosis and impeded the migration of hBMSCs, while downregulation of the expression of LINC00473 produced results that were in line with the results of the microarray analysis in a time-dependent manner.	Dextromethorphan	49-52	long intergenic non-protein coding RNA 473	Homo sapiens	256-265
32829248-8	2020	Interestingly, upregulation of LINC00473 attenuated the negative effects caused by 10-6 mol/L Dex on hBMSCs, except for cell cycle arrest.	Dextromethorphan	94-97	long intergenic non-protein coding RNA 473	Homo sapiens	31-40
32829248-10	2020	Collectively, our data revealed that LINC00473 attenuated apoptosis, promoted the proliferation and migration of Dex-induced hBMSCs, which are not involved in interference with the cell cycle of hBMSCs.	Dextromethorphan	113-116	long intergenic non-protein coding RNA 473	Homo sapiens	37-46
33062149-5	2020	Mechanistically, PAC neutralized Dex-induced damage in the osteoblasts by activating the Nrf2 pathway, since silencing Nrf2 partly eliminated the protective effects of PAC.	Dextromethorphan	33-36	NFE2 like bZIP transcription factor 2	Rattus norvegicus	89-93
33062149-6	2020	Furthermore, PAC injection restored bone mass and promoted the expression of Nrf2 in the distal femur of Dex-treated osteoporotic rats.	Dextromethorphan	105-108	NFE2 like bZIP transcription factor 2	Rattus norvegicus	77-81
33062149-7	2020	In summary, PAC protect osteoblasts against Dex-induced oxidative stress and mitochondrial dysfunction via the Nrf2 pathway activation and may be a promising drug for treating GIOP.	Dextromethorphan	44-47	NFE2 like bZIP transcription factor 2	Rattus norvegicus	111-115
32907546-6	2020	Chronic RF was introduced by sublethal ischemia-reperfusion injury in mice, and NMDAR inhibitor dextromethorphan hydrobromide (DXM) was administered orally.	Dextromethorphan	127-130	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	80-85
32778146-9	2020	CRP and procalcitonin levels were lower in the DEX vs. non-DEX group during the 14-day treatment period [CRP-range, 5.6-20.3 vs. 8.3-21.1 mg/dL (P = 0.03); procalcitonin-range, 1.2-37.4 vs. 1.7-52.9 ng/mL (P = 0.04)].	Dextromethorphan	47-50	C-reactive protein	Homo sapiens	0-3
33061795-3	2020	Our present results indicate that dexamethasone(DEX) increased FoxO3a expression in PC12 and hypothalamic neuronal cultures in correlation to reduced expression of NPW, a process that could be blocked by GR2 antagonist.	Dextromethorphan	48-51	forkhead box O3	Rattus norvegicus	63-69
33061795-3	2020	Our present results indicate that dexamethasone(DEX) increased FoxO3a expression in PC12 and hypothalamic neuronal cultures in correlation to reduced expression of NPW, a process that could be blocked by GR2 antagonist.	Dextromethorphan	48-51	neuropeptide W	Rattus norvegicus	164-167
33061795-4	2020	DEX restrained the phosphorylation of Akt and FoxO3a, but not ERK1/2 phosphorylation, resulting with FoxO3a nuclear localization.	Dextromethorphan	0-3	AKT serine/threonine kinase 1	Rattus norvegicus	38-41
33061795-4	2020	DEX restrained the phosphorylation of Akt and FoxO3a, but not ERK1/2 phosphorylation, resulting with FoxO3a nuclear localization.	Dextromethorphan	0-3	forkhead box O3	Rattus norvegicus	46-52
33061795-4	2020	DEX restrained the phosphorylation of Akt and FoxO3a, but not ERK1/2 phosphorylation, resulting with FoxO3a nuclear localization.	Dextromethorphan	0-3	forkhead box O3	Rattus norvegicus	101-107
32473248-6	2020	KEY FINDINGS: Rats born to DEX-treated mothers exhibited increased pancreatic alpha-cell mass, circulating glucagon levels and Gcg, Pax6, MafB and Nkx2.2 expression.	Dextromethorphan	27-30	glucagon	Rattus norvegicus	107-115
32925968-11	2020	Both CN dose treatments lowered IL-1beta significantly better than DXM Interestingly, DXM and CN treatments both exhibited the upregulation of the anti-inflammatory cytokines IL-2 and 4.	Dextromethorphan	86-89	interleukin 1 alpha	Rattus norvegicus	32-40
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	interleukin 1 alpha	Rattus norvegicus	142-150
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	interleukin 18	Rattus norvegicus	152-157
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	NLR family, pyrin domain containing 3	Rattus norvegicus	264-269
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	PYD and CARD domain containing	Rattus norvegicus	271-274
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	caspase 1	Rattus norvegicus	279-288
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	interleukin 1 alpha	Rattus norvegicus	142-150
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	interleukin 18	Rattus norvegicus	152-157
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	NLR family, pyrin domain containing 3	Rattus norvegicus	264-269
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	PYD and CARD domain containing	Rattus norvegicus	271-274
32787359-8	2020	when compared with Group H, which were decreased significantly in Group DEX (P<0.05), and the total protein level in BALF and the contents of IL-1beta, IL-18 in serum and BALF of Group DEX were reduced markedly (P<0.05), Besides the mRNA and protein expression of NLRP3, ASC and caspase-1 in lung tissue of Group DEX were lowered dramatically (P<0.05).	Dextromethorphan	185-188	caspase 1	Rattus norvegicus	279-288
32787359-9	2020	However, mRNA and protein expression of NLRC3 in lung tissue of Group DEX were up-regulated observably (P<0.05).	Dextromethorphan	70-73	NLR family, CARD domain containing 3	Rattus norvegicus	40-45
32473248-6	2020	KEY FINDINGS: Rats born to DEX-treated mothers exhibited increased pancreatic alpha-cell mass, circulating glucagon levels and Gcg, Pax6, MafB and Nkx2.2 expression.	Dextromethorphan	27-30	glucagon	Rattus norvegicus	127-130
32473248-6	2020	KEY FINDINGS: Rats born to DEX-treated mothers exhibited increased pancreatic alpha-cell mass, circulating glucagon levels and Gcg, Pax6, MafB and Nkx2.2 expression.	Dextromethorphan	27-30	paired box 6	Rattus norvegicus	132-136
32473248-6	2020	KEY FINDINGS: Rats born to DEX-treated mothers exhibited increased pancreatic alpha-cell mass, circulating glucagon levels and Gcg, Pax6, MafB and Nkx2.2 expression.	Dextromethorphan	27-30	MAF bZIP transcription factor B	Rattus norvegicus	138-142
32473248-6	2020	KEY FINDINGS: Rats born to DEX-treated mothers exhibited increased pancreatic alpha-cell mass, circulating glucagon levels and Gcg, Pax6, MafB and Nkx2.2 expression.	Dextromethorphan	27-30	NK2 homeobox 2	Rattus norvegicus	147-153
32778146-9	2020	CRP and procalcitonin levels were lower in the DEX vs. non-DEX group during the 14-day treatment period [CRP-range, 5.6-20.3 vs. 8.3-21.1 mg/dL (P = 0.03); procalcitonin-range, 1.2-37.4 vs. 1.7-52.9 ng/mL (P = 0.04)].	Dextromethorphan	47-50	C-reactive protein	Homo sapiens	105-108
32778146-10	2020	Albumin levels were higher in the DEX group (range, 2.3-2.6 g/dL) than in the non-DEX group (range, 2.1-2.7 g/dL; P = 0.01).	Dextromethorphan	34-37	albumin	Homo sapiens	0-7
32778146-10	2020	Albumin levels were higher in the DEX group (range, 2.3-2.6 g/dL) than in the non-DEX group (range, 2.1-2.7 g/dL; P = 0.01).	Dextromethorphan	82-85	albumin	Homo sapiens	0-7
32521774-3	2020	Recently, de novo expression of connexin43 and connexin45 hemichannels (Cx43 HCs and Cx45 HCs, respectively) has been proposed to play a critical role in the mechanism underlying myofiber atrophy induced by dexamethasone (Dex: a synthetic glucocorticoid), but their involvement in specific muscle changes promoted by Dex remains poorly understood.	Dextromethorphan	222-225	gap junction protein, alpha 1	Mus musculus	32-42
32562787-8	2020	Moreover, these JAK inhibitors reduced the expression of markers such as CXCL13, MARCO and SOCS3 in alternatively activated macrophages induced by IL-10 and dexamethasone (M2c+dex) or IL-10 alone (M2c MDM).	Dextromethorphan	157-160	C-X-C motif chemokine ligand 13	Homo sapiens	73-79
32562787-8	2020	Moreover, these JAK inhibitors reduced the expression of markers such as CXCL13, MARCO and SOCS3 in alternatively activated macrophages induced by IL-10 and dexamethasone (M2c+dex) or IL-10 alone (M2c MDM).	Dextromethorphan	157-160	suppressor of cytokine signaling 3	Homo sapiens	91-96
32557706-8	2020	Wherease CYP2D-catalyzed dextromethorphan O-deethylation decreased in a dose- and time-dependent manner in vivo.	Dextromethorphan	25-41	cytochrome P450, 2d region	Mus musculus	9-14
32334136-1	2020	Beta-cyclodextrin (beta-CD) is an oligosaccharide commonly used to improve the aqueous solubility of lipophilic drugs (e.g., dexamethasone, DEX).	Dextromethorphan	140-143	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	19-26
32334136-2	2020	Here we present the development of a drug delivery system to provide sustained release of DEX by beta-CD-inclusion complex (IC) to amplify the mineralization capacity of stem cells from human-extracted deciduous teeth (SHEDs) as a potential direct pulp capping strategy.	Dextromethorphan	90-93	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	97-104
32334136-3	2020	First, IC of DEX (DEX-CD-IC) was synthesized with beta-CD.	Dextromethorphan	13-16	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	50-57
32521774-3	2020	Recently, de novo expression of connexin43 and connexin45 hemichannels (Cx43 HCs and Cx45 HCs, respectively) has been proposed to play a critical role in the mechanism underlying myofiber atrophy induced by dexamethasone (Dex: a synthetic glucocorticoid), but their involvement in specific muscle changes promoted by Dex remains poorly understood.	Dextromethorphan	222-225	gap junction protein, gamma 1	Mus musculus	47-57
32521774-3	2020	Recently, de novo expression of connexin43 and connexin45 hemichannels (Cx43 HCs and Cx45 HCs, respectively) has been proposed to play a critical role in the mechanism underlying myofiber atrophy induced by dexamethasone (Dex: a synthetic glucocorticoid), but their involvement in specific muscle changes promoted by Dex remains poorly understood.	Dextromethorphan	222-225	gap junction protein, alpha 3	Mus musculus	72-76
32521774-3	2020	Recently, de novo expression of connexin43 and connexin45 hemichannels (Cx43 HCs and Cx45 HCs, respectively) has been proposed to play a critical role in the mechanism underlying myofiber atrophy induced by dexamethasone (Dex: a synthetic glucocorticoid), but their involvement in specific muscle changes promoted by Dex remains poorly understood.	Dextromethorphan	222-225	gap junction protein, gamma 1	Mus musculus	85-89
32521774-3	2020	Recently, de novo expression of connexin43 and connexin45 hemichannels (Cx43 HCs and Cx45 HCs, respectively) has been proposed to play a critical role in the mechanism underlying myofiber atrophy induced by dexamethasone (Dex: a synthetic glucocorticoid), but their involvement in specific muscle changes promoted by Dex remains poorly understood.	Dextromethorphan	317-320	gap junction protein, alpha 1	Mus musculus	32-42
32521774-3	2020	Recently, de novo expression of connexin43 and connexin45 hemichannels (Cx43 HCs and Cx45 HCs, respectively) has been proposed to play a critical role in the mechanism underlying myofiber atrophy induced by dexamethasone (Dex: a synthetic glucocorticoid), but their involvement in specific muscle changes promoted by Dex remains poorly understood.	Dextromethorphan	317-320	gap junction protein, gamma 1	Mus musculus	47-57
32521774-3	2020	Recently, de novo expression of connexin43 and connexin45 hemichannels (Cx43 HCs and Cx45 HCs, respectively) has been proposed to play a critical role in the mechanism underlying myofiber atrophy induced by dexamethasone (Dex: a synthetic glucocorticoid), but their involvement in specific muscle changes promoted by Dex remains poorly understood.	Dextromethorphan	317-320	gap junction protein, alpha 3	Mus musculus	72-76
32521774-3	2020	Recently, de novo expression of connexin43 and connexin45 hemichannels (Cx43 HCs and Cx45 HCs, respectively) has been proposed to play a critical role in the mechanism underlying myofiber atrophy induced by dexamethasone (Dex: a synthetic glucocorticoid), but their involvement in specific muscle changes promoted by Dex remains poorly understood.	Dextromethorphan	317-320	gap junction protein, gamma 1	Mus musculus	85-89
32521774-5	2020	In the present work, a 7-day Dex treatment in adult mice was found to induce weight loss and skeletal muscle changes including expression of functional Cx43/Cx45 HCs, elevated atrogin immunoreactivity, atrophy, oxidative stress and mitochondrial dysfunction.	Dextromethorphan	29-32	gap junction protein, alpha 3	Mus musculus	152-156
32139118-8	2020	Moreover, chromatin immunoprecipitation analyses demonstrated that MLL2 could co-occupy glucocorticoid response elements (GREs) of GR target genes along with GR following Dex stimulation.	Dextromethorphan	171-174	lysine methyltransferase 2D	Homo sapiens	67-71
32477139-10	2020	IL-6 (P < 0.001) levels were lower in the DEX group at T1, and TNF-alpha (P = 0.003) levels were lower in the DEX group at T1 and T3, but IL-1beta levels were similar between the two groups.	Dextromethorphan	42-45	interleukin 6	Homo sapiens	0-4
32477139-10	2020	IL-6 (P < 0.001) levels were lower in the DEX group at T1, and TNF-alpha (P = 0.003) levels were lower in the DEX group at T1 and T3, but IL-1beta levels were similar between the two groups.	Dextromethorphan	110-113	tumor necrosis factor	Homo sapiens	63-72
32139118-9	2020	Finally, the FAIRE-qPCR results illustrated that MLL2 is pivotal in establishing chromatin structure accessibility at the GREs of ARPE-19 specific genes in the presence of Dex.	Dextromethorphan	172-175	lysine methyltransferase 2D	Homo sapiens	49-53
31814297-2	2020	This study aimed at evaluating its effect on CYP2D6 and CYP2C19 activities in submitting psychiatric patients to phenotyping with dextromethorphan and mephenytoin, respectively, substrates of these enzymes, before and during a treatment with perazine.	Dextromethorphan	130-146	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	45-51
31814297-2	2020	This study aimed at evaluating its effect on CYP2D6 and CYP2C19 activities in submitting psychiatric patients to phenotyping with dextromethorphan and mephenytoin, respectively, substrates of these enzymes, before and during a treatment with perazine.	Dextromethorphan	130-146	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	56-63
32351722-4	2020	Treatment with DEX implant was started either as first-line therapy in pseudophakic patients and in patients with cardiovascular comorbidities or as second-line therapy in patients refractory to the inhibitor of the vascular endothelial growth factor (anti-VEGF) therapy.	Dextromethorphan	15-18	vascular endothelial growth factor A	Homo sapiens	216-250
32351722-4	2020	Treatment with DEX implant was started either as first-line therapy in pseudophakic patients and in patients with cardiovascular comorbidities or as second-line therapy in patients refractory to the inhibitor of the vascular endothelial growth factor (anti-VEGF) therapy.	Dextromethorphan	15-18	vascular endothelial growth factor A	Homo sapiens	257-261
32214297-12	2020	A significant decrease of interleukin (IL)-1 beta, IL-6, tumor necrosis factor (TNF)-alpha, and increased CD4+ and CD4+/CD8+ were observed in the DEX group compared with the SUF group at 24 and 48 hours after surgery (P < 0.05).	Dextromethorphan	146-149	interleukin 1 alpha	Homo sapiens	26-49
32226020-9	2020	Conversely, TG explants from uninfected mice or mice latently infected with a LAT-/- mutant increased the number of beta-catenin+ TG neurons in the presence of DEX relative to samples not treated with DEX.	Dextromethorphan	160-163	catenin (cadherin associated protein), beta 1	Mus musculus	116-128
32398952-5	2020	Results indicated that this 1393@MBG scaffold could effectively load and controlled release BMP-2, DNA and DEX, which can be applied for orthopedic treatment.	Dextromethorphan	107-110	bone morphogenetic protein 2	Rattus norvegicus	92-97
32398952-6	2020	The in vitro study showed that the DEX loaded 1393@MBG exhibited excellent antibacterial ability, which was evaluated by Staphylococcus aureus (S. aureus), and the BMP-2 loaded 1393@MBG can improve the alkaline phosphatase (ALP) activity and upregulate the expression of osteogenesis-related genes (OCN and RUNX2) of human bone mesenchymal stem cells (hBMSCs).	Dextromethorphan	35-38	bone morphogenetic protein 2	Rattus norvegicus	164-169
32398952-6	2020	The in vitro study showed that the DEX loaded 1393@MBG exhibited excellent antibacterial ability, which was evaluated by Staphylococcus aureus (S. aureus), and the BMP-2 loaded 1393@MBG can improve the alkaline phosphatase (ALP) activity and upregulate the expression of osteogenesis-related genes (OCN and RUNX2) of human bone mesenchymal stem cells (hBMSCs).	Dextromethorphan	35-38	AT695_RS04080	Staphylococcus aureus	202-222
32398952-6	2020	The in vitro study showed that the DEX loaded 1393@MBG exhibited excellent antibacterial ability, which was evaluated by Staphylococcus aureus (S. aureus), and the BMP-2 loaded 1393@MBG can improve the alkaline phosphatase (ALP) activity and upregulate the expression of osteogenesis-related genes (OCN and RUNX2) of human bone mesenchymal stem cells (hBMSCs).	Dextromethorphan	35-38	AT695_RS04080	Staphylococcus aureus	224-227
32145512-12	2020	Finally, in vivo PPARgamma inhibition in macrophages by siRNA significantly increased liver IR injury and intrahepatic inflammation in mice from the Dex group, with no significant effect in the VEH group.	Dextromethorphan	149-152	peroxisome proliferator activated receptor gamma	Mus musculus	17-26
32050158-5	2020	Therefore, the aim of this study was to develop, validate and optimize a simplified assay for the probe drugs caffeine (metabolized by CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9), dextromethorphan (CYP2D6), midazolam (CYP3A4) and their respective enzyme-specific metabolites in small volumes (100 muL) of human plasma, that addresses the issues noted.	Dextromethorphan	185-201	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	176-182
32214297-12	2020	A significant decrease of interleukin (IL)-1 beta, IL-6, tumor necrosis factor (TNF)-alpha, and increased CD4+ and CD4+/CD8+ were observed in the DEX group compared with the SUF group at 24 and 48 hours after surgery (P < 0.05).	Dextromethorphan	146-149	interleukin 6	Homo sapiens	51-55
32214297-12	2020	A significant decrease of interleukin (IL)-1 beta, IL-6, tumor necrosis factor (TNF)-alpha, and increased CD4+ and CD4+/CD8+ were observed in the DEX group compared with the SUF group at 24 and 48 hours after surgery (P < 0.05).	Dextromethorphan	146-149	tumor necrosis factor	Homo sapiens	57-90
32214297-12	2020	A significant decrease of interleukin (IL)-1 beta, IL-6, tumor necrosis factor (TNF)-alpha, and increased CD4+ and CD4+/CD8+ were observed in the DEX group compared with the SUF group at 24 and 48 hours after surgery (P < 0.05).	Dextromethorphan	146-149	CD4 molecule	Homo sapiens	106-109
32214297-12	2020	A significant decrease of interleukin (IL)-1 beta, IL-6, tumor necrosis factor (TNF)-alpha, and increased CD4+ and CD4+/CD8+ were observed in the DEX group compared with the SUF group at 24 and 48 hours after surgery (P < 0.05).	Dextromethorphan	146-149	CD4 molecule	Homo sapiens	115-118
32214297-12	2020	A significant decrease of interleukin (IL)-1 beta, IL-6, tumor necrosis factor (TNF)-alpha, and increased CD4+ and CD4+/CD8+ were observed in the DEX group compared with the SUF group at 24 and 48 hours after surgery (P < 0.05).	Dextromethorphan	146-149	CD8a molecule	Homo sapiens	120-123
31648367-4	2020	EXPERIMENTAL APPROACH: Dextromethorphan (DEX) metabolism to dextrorphan (DOR) was used to measure CYP2D activity and to characterize propranolol inhibition in vitro and in vivo.	Dextromethorphan	23-39	cytochrome P450, 2d region	Mus musculus	98-103
32179326-6	2020	We previously reported that dextromethorphan (DM), another sigma-1R agonist with a different structure, had similar effects.	Dextromethorphan	28-44	sigma non-opioid intracellular receptor 1	Homo sapiens	59-67
32179326-6	2020	We previously reported that dextromethorphan (DM), another sigma-1R agonist with a different structure, had similar effects.	Dextromethorphan	46-48	sigma non-opioid intracellular receptor 1	Homo sapiens	59-67
31744669-0	2020	Validation of a sensitive UHPLC-MS/MS method for cytochrome P450 probe substrates caffeine, tolbutamide, dextromethorphan, and alprazolam in human serum reveals drug contamination of serum used for research.	Dextromethorphan	105-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
31648367-4	2020	EXPERIMENTAL APPROACH: Dextromethorphan (DEX) metabolism to dextrorphan (DOR) was used to measure CYP2D activity and to characterize propranolol inhibition in vitro and in vivo.	Dextromethorphan	41-44	cytochrome P450, 2d region	Mus musculus	98-103
33693436-6	2020	For this study, GR was determined by the concentration of dexamethasone required for 50% inhibition (Dex IC50) of the cytokine tumor-necrosis factor alpha (TNF-alpha) release in vitro in response to a standard dose of lipopolysaccharide.	Dextromethorphan	101-104	tumor necrosis factor	Homo sapiens	156-165
32037159-0	2020	CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity.	Dextromethorphan	136-154	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
32037159-3	2020	Given the scarceness of CYP2D6 related data in these populations, the purpose of this study was to perform a pharmacogenomic analysis of the Kenyan and Ni-Vanuatu population and ultimately characterize the enzymatic properties of eight novel CYP2D6 variant proteins expressed in 293FT cells in vitro using dextromethorphan as a substrate.	Dextromethorphan	306-322	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	242-248
31276199-3	2020	Moreover, a RNA aptamer against a cancer stem cell (CSC) marker, CD133 was covalently attached to the carboxyl groups of DEX to produce a CD133-PCAD-DMSN@DOX.	Dextromethorphan	121-124	prominin 1	Homo sapiens	65-70
31276199-3	2020	Moreover, a RNA aptamer against a cancer stem cell (CSC) marker, CD133 was covalently attached to the carboxyl groups of DEX to produce a CD133-PCAD-DMSN@DOX.	Dextromethorphan	121-124	prominin 1	Homo sapiens	138-143
31653394-6	2020	Opioids that are good inhibitors of SERT (tramadol, dextromethorphan, methadone, and meperidine) are most frequently associated with serotonin toxicity.	Dextromethorphan	52-68	solute carrier family 6 member 4	Homo sapiens	36-40
32090096-4	2020	Treatment of IL-1beta-stimulated tenocytes with DEX/PMSs suppressed the mRNA levels for COX-2, IL-1beta, IL-6, and TNF-alpha.	Dextromethorphan	48-51	interleukin 1 alpha	Rattus norvegicus	13-21
32090096-4	2020	Treatment of IL-1beta-stimulated tenocytes with DEX/PMSs suppressed the mRNA levels for COX-2, IL-1beta, IL-6, and TNF-alpha.	Dextromethorphan	48-51	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	88-93
32090096-4	2020	Treatment of IL-1beta-stimulated tenocytes with DEX/PMSs suppressed the mRNA levels for COX-2, IL-1beta, IL-6, and TNF-alpha.	Dextromethorphan	48-51	interleukin 1 alpha	Rattus norvegicus	95-103
32090096-4	2020	Treatment of IL-1beta-stimulated tenocytes with DEX/PMSs suppressed the mRNA levels for COX-2, IL-1beta, IL-6, and TNF-alpha.	Dextromethorphan	48-51	interleukin 6	Rattus norvegicus	105-109
32090096-4	2020	Treatment of IL-1beta-stimulated tenocytes with DEX/PMSs suppressed the mRNA levels for COX-2, IL-1beta, IL-6, and TNF-alpha.	Dextromethorphan	48-51	tumor necrosis factor	Rattus norvegicus	115-124
32090096-5	2020	The intratendinous injection of DEX/PMSs into Achilles tendinitis rats both decreased the mRNA levels for these cytokines and increased mRNA levels for anti-inflammatory cytokines IL-4 and IL-10 in tendon tissues.	Dextromethorphan	32-35	interleukin 4	Rattus norvegicus	180-184
32090096-5	2020	The intratendinous injection of DEX/PMSs into Achilles tendinitis rats both decreased the mRNA levels for these cytokines and increased mRNA levels for anti-inflammatory cytokines IL-4 and IL-10 in tendon tissues.	Dextromethorphan	32-35	interleukin 10	Rattus norvegicus	189-194
30957437-3	2020	In this study, we designed nanoparticles comprising dexamethasone-conjugated polyethylenimine (DEX PEI) complexed with minicircle plasmid (MC) harboring SOX duo (SOX-9, -6) and ANGPTL4 small hairpin RNA (shANG) [MC SOX9/6/shANG] in the expectation that transfection of these nanoparticles would enhance chondrogenesis of stem cells and suppress inflammation in OA.	Dextromethorphan	95-98	SRY-box transcription factor 9	Rattus norvegicus	162-167
32727269-10	2020	In Bara-C spleens only ara-C/dex decreased dCK activity (32%).	Dextromethorphan	29-32	sticky	Drosophila melanogaster	43-46
31637538-7	2019	The inhibition kinetics of CYP2D6-mediated dextromethorphan O-demethylation were analyzed in human hepatic microsomes, with SNO found to be ~ 19-fold more active than SOR (Kis 1.8 +- 0.3 muM and 34 +- 11 muM, respectively).	Dextromethorphan	43-61	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	27-33
31587004-11	2020	Pan inhibitions of WZ35 on rat CYP3A2, CYP2B1, CYP2C11, CYP2D1, and -CYP2E1 were observed by detecting probe substrates (midazolam, bupropion, tolbutamide, dextromethorphan, chlorzoxazone) and metabolites accordingly.	Dextromethorphan	156-172	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	69-75
31784596-8	2019	Drug treatment did not reverse ozone-induced ventillatory changes, however, lung effects (protein and albumin leakage, inflammation, and IL-6 increase) were exacerbated by CLEN and CLEN + DEX pre-treatment in a dose-dependent manner (CLEN > CLEN + DEX).	Dextromethorphan	188-191	interleukin 6	Rattus norvegicus	137-141
31679515-8	2019	RESULTS: We confirmed the effects of statin-Dex in inducing Foxp3+ nTreg cells and found that both statin-Dex and DMSO-Dex could upregulate CD40 but only statin-Dex increased Aire expression in thymic stromal cells in vivo.	Dextromethorphan	44-47	forkhead box P3	Rattus norvegicus	60-65
31679515-8	2019	RESULTS: We confirmed the effects of statin-Dex in inducing Foxp3+ nTreg cells and found that both statin-Dex and DMSO-Dex could upregulate CD40 but only statin-Dex increased Aire expression in thymic stromal cells in vivo.	Dextromethorphan	106-109	forkhead box P3	Rattus norvegicus	60-65
31679515-8	2019	RESULTS: We confirmed the effects of statin-Dex in inducing Foxp3+ nTreg cells and found that both statin-Dex and DMSO-Dex could upregulate CD40 but only statin-Dex increased Aire expression in thymic stromal cells in vivo.	Dextromethorphan	106-109	autoimmune regulator	Rattus norvegicus	175-179
31679515-8	2019	RESULTS: We confirmed the effects of statin-Dex in inducing Foxp3+ nTreg cells and found that both statin-Dex and DMSO-Dex could upregulate CD40 but only statin-Dex increased Aire expression in thymic stromal cells in vivo.	Dextromethorphan	106-109	forkhead box P3	Rattus norvegicus	60-65
31679515-8	2019	RESULTS: We confirmed the effects of statin-Dex in inducing Foxp3+ nTreg cells and found that both statin-Dex and DMSO-Dex could upregulate CD40 but only statin-Dex increased Aire expression in thymic stromal cells in vivo.	Dextromethorphan	106-109	autoimmune regulator	Rattus norvegicus	175-179
31679515-9	2019	Furthermore, we found that the role of statin-Dex and DMSO-Dex in the induction of Foxp3+ nTreg cells was dependent on epithelial cells in vitro.	Dextromethorphan	46-49	forkhead box P3	Rattus norvegicus	83-88
31679515-10	2019	CONCLUSIONS: We demonstrated that statin-Dex increased expression of Aire in the thymus, which may further promote the Foxp3 expression in the thymus.	Dextromethorphan	41-44	autoimmune regulator	Rattus norvegicus	69-73
31679515-10	2019	CONCLUSIONS: We demonstrated that statin-Dex increased expression of Aire in the thymus, which may further promote the Foxp3 expression in the thymus.	Dextromethorphan	41-44	forkhead box P3	Rattus norvegicus	119-124
31307858-6	2019	Taken together, most studies of antidepressants find that they are associated with a reduction in both basal and post-dexamethasone-CRH (DEX/CRH) cortisol, although some report no change.	Dextromethorphan	137-140	corticotropin releasing hormone	Homo sapiens	132-135
31307858-7	2019	Similarly, antipsychotics, both typical and atypical, are found to reduce basal and DEX/CRH cortisol levels in most studies.	Dextromethorphan	84-87	corticotropin releasing hormone	Homo sapiens	88-91
31491406-6	2019	This animal study demonstrated that DXM significantly attenuated 6-OHDA-induced DAT and SERT loss, correlating to rotational behaviors.	Dextromethorphan	36-39	solute carrier family 6 member 3	Rattus norvegicus	80-83
31637538-7	2019	The inhibition kinetics of CYP2D6-mediated dextromethorphan O-demethylation were analyzed in human hepatic microsomes, with SNO found to be ~ 19-fold more active than SOR (Kis 1.8 +- 0.3 muM and 34 +- 11 muM, respectively).	Dextromethorphan	43-61	strawberry notch homolog 1	Homo sapiens	124-127
30825074-5	2019	Typical probe substrates were used as follows-midazolam for CYP3A2/3A4, dextromethorphan for CYP2D1/2D6, tolbutamide for CYP2C9/2C11, and bupropion for CYP2B1/2B6.	Dextromethorphan	72-88	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	93-103
31571814-5	2019	FAc demonstrated sustained, stable and predictable effects on BCVA and CFT over 24 months and also improved BCVA and decreased CFT in a cohort of DME eyes that was refractory to DEX over 6 months.	Dextromethorphan	178-181	FA complementation group C	Homo sapiens	0-3
31268632-2	2019	Following the development of a new duloxetine model and optimization of a paroxetine model, the effect of genetic polymorphisms on CYP2D6-mediated intrinsic clearances of dextromethorphan, duloxetine, and paroxetine was estimated from rich pharmacokinetic profiles in activity score (AS)1 and AS2 subjects.	Dextromethorphan	171-187	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137
31254953-8	2019	Our results show that DEX pretreatment significantly decreased lung Wet-to-Dry weight (W/D) ratio and MPO activity and ameliorated LPS induced lung histopathological alterations.	Dextromethorphan	22-25	myeloperoxidase	Rattus norvegicus	102-105
31254953-9	2019	In addition, we confirmed that DEX can increased the phosphorylation of STAT3 and GSK-3beta, and inhibit the phosphorylation of nuclear factor-kappaB (NF-kappaB) p65 in the inflammatory response induced by LPS.	Dextromethorphan	31-34	signal transducer and activator of transcription 3	Rattus norvegicus	72-77
31254953-9	2019	In addition, we confirmed that DEX can increased the phosphorylation of STAT3 and GSK-3beta, and inhibit the phosphorylation of nuclear factor-kappaB (NF-kappaB) p65 in the inflammatory response induced by LPS.	Dextromethorphan	31-34	glycogen synthase kinase 3 alpha	Rattus norvegicus	82-91
31254953-9	2019	In addition, we confirmed that DEX can increased the phosphorylation of STAT3 and GSK-3beta, and inhibit the phosphorylation of nuclear factor-kappaB (NF-kappaB) p65 in the inflammatory response induced by LPS.	Dextromethorphan	31-34	synaptotagmin 1	Rattus norvegicus	162-165
31254953-12	2019	In summary, our data demonstrated that DEX can ameliorate ALI induced by LPS through GSK-3beta/STAT3-NF-kappaB pathway.	Dextromethorphan	39-42	glycogen synthase kinase 3 alpha	Rattus norvegicus	85-94
31254953-12	2019	In summary, our data demonstrated that DEX can ameliorate ALI induced by LPS through GSK-3beta/STAT3-NF-kappaB pathway.	Dextromethorphan	39-42	signal transducer and activator of transcription 3	Rattus norvegicus	95-100
31153898-7	2019	SERT density in DXM-treated rats was significantly higher than that in non-DXM-treated rats.	Dextromethorphan	16-19	solute carrier family 6 member 4	Rattus norvegicus	0-4
31153898-7	2019	SERT density in DXM-treated rats was significantly higher than that in non-DXM-treated rats.	Dextromethorphan	75-78	solute carrier family 6 member 4	Rattus norvegicus	0-4
31153898-8	2019	Because prophylactic medication restored the NMDA-inhibited neurite length of serotonergic neurons and presented SERT density, DXM could be a potential agent in alleviating NIHL.	Dextromethorphan	127-130	solute carrier family 6 member 4	Rattus norvegicus	113-117
31239454-8	2019	Furthermore, the results indicate that coumarin (CYP2A), midazolam (CYP3A), tolbutamide (CYP2C), and dextromethorphan (CYP2D) are as selective for porcine as for human CYP450.	Dextromethorphan	101-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	119-124
31367254-9	2019	Results: Proteomic analysis revealed distinct integrin expression patterns on the MV-DEX surface, in which the integrin alphaLbeta2 (LFA-1) and alpha4beta1 (VAL-4) enabled them to adhere to the inflamed kidney.	Dextromethorphan	85-88	integrin alpha L	Mus musculus	133-138
30898674-0	2019	The blockade of 5-HT1A receptors in the ventral tegmental area inhibited morphine/dextromethorphan-induced analgesia in pain rat models.	Dextromethorphan	82-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	16-22
30898674-1	2019	The aim of the present study was to determine the involvement of the VTA 5-HT1A receptors in analgesia induced by the co-administration of morphine and dextromethorphan (DM).	Dextromethorphan	152-168	5-hydroxytryptamine receptor 1A	Rattus norvegicus	73-79
30790719-4	2019	The liver mRNA levels of fatty acid transport protein (FATP-1), farnesoid X receptor (FXR), AMPK alpha 1 subunit (AMPKalpha1), and glucocorticoid receptor were significantly upregulated in DEX-treated broilers; the gene expression of liver cholesterol 7 alpha-hydroxylase (CYP7A1) was significantly downregulated.	Dextromethorphan	189-192	cytochrome P450 family 7 subfamily A member 1	Gallus gallus	240-271
31171009-3	2019	The image of CD4+CD25+ T cells of the statin-Dex group was unintentionally replaced with the image of CD4+CD25+ T cells from the control group.	Dextromethorphan	45-48	CD4 molecule	Homo sapiens	13-16
31171009-3	2019	The image of CD4+CD25+ T cells of the statin-Dex group was unintentionally replaced with the image of CD4+CD25+ T cells from the control group.	Dextromethorphan	45-48	CD4 molecule	Homo sapiens	102-105
30790719-4	2019	The liver mRNA levels of fatty acid transport protein (FATP-1), farnesoid X receptor (FXR), AMPK alpha 1 subunit (AMPKalpha1), and glucocorticoid receptor were significantly upregulated in DEX-treated broilers; the gene expression of liver cholesterol 7 alpha-hydroxylase (CYP7A1) was significantly downregulated.	Dextromethorphan	189-192	cytochrome P450 family 7 subfamily A member 1	Gallus gallus	273-279
30790719-5	2019	The protein level of liver CYP7A1 was significantly decreased by DEX treatment at both 24 and 72 h, while the protein level of p-AMPK/ t-AMPK stayed unchanged.	Dextromethorphan	65-68	cytochrome P450 family 7 subfamily A member 1	Gallus gallus	27-33
30790719-6	2019	In the in vitro cultured hepatocytes, compound C pretreatment blocked the increase in CYP7A1 protein level by DEX and significantly suppressed FATP-1, SREBP-1c, FXR, and CYP7A1 gene expression stimulated by DEX.	Dextromethorphan	110-113	cytochrome P450 family 7 subfamily A member 1	Gallus gallus	86-92
31164617-3	2019	The metabolic rates of caffeine, dextromethorphan, midazolam, omeprazole, and Losartan to the CYP-specific metabolites are validated measures of in vivo CYP 1A2, 2D6, 3A4, 2C19, and 2C9 activities, respectively.	Dextromethorphan	33-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
32186002-2	2019	Dex) on allergic rhinitis (AR) by injecting dexamethasone into the Zusanli (ST 36) acupoint.	Dextromethorphan	0-3	ferredoxin reductase	Mus musculus	27-29
32186002-16	2019	Dex significantly reduced the rubbing score, spleen weight, serum IgE, and serum histamine in OVA-sensitized mice.	Dextromethorphan	0-3	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	94-97
32186002-18	2019	Dex significantly decreased the serum levels of inflammatory cytokines (thymic stromal lymphopoietin and tumor ne- crosis factor-alpha) in OVA-sensitized mice.	Dextromethorphan	0-3	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	139-142
32186002-22	2019	Dex effectively attenuated the expression of caspase-1 and receptorinteractingprotein-2 in nasal mucosal tissue.	Dextromethorphan	0-3	caspase 1	Mus musculus	45-54
30851701-10	2019	The expression of IL-10 increased in the Der p1-DC/AR group to a level similar to that observed in the Dex/AR group.	Dextromethorphan	103-106	interleukin 10	Mus musculus	18-23
30822415-5	2019	Here, we report that subpico- and micromolar doses of dextromethorphan showed comparable efficacy in protecting mice from lipopolysaccharide/d-galactosamine (LPS/GalN)-induced hepatotoxicity and mortality.	Dextromethorphan	54-70	galanin and GMAP prepropeptide	Mus musculus	162-166
31050723-9	2019	Both TM tissue in eyes of DEX-treated GRdim mice and cultured TM cells isolated from GRdim mice had reduced or no change in the expression of fibronectin, myocilin, collagen type I, and alpha-smooth muscle actin (alpha-SMA).	Dextromethorphan	26-29	actin alpha 2, smooth muscle, aorta	Mus musculus	213-222
31145307-11	2019	Although mean CMT in the anti-VEGF group was not significantly lower than that in the DEX group at 6 months (MD = 55.53, P = .07), the mean CMT change from baseline achieved by the anti-VEGF treatment was significantly superior to that obtained with DEX (MD = 75.53, P = .0002).	Dextromethorphan	250-253	vascular endothelial growth factor A	Homo sapiens	186-190
30822415-7	2019	Our results showed that dextromethorphan at subpicomolar doses promoted survival rate in LPS/GalN-injected mice.	Dextromethorphan	24-40	galanin and GMAP prepropeptide	Mus musculus	93-97
30822415-8	2019	Ultralow dose dextromethorphan also significantly reduced serum alanine aminotransferase activity, TNF-alpha level and liver cell damage of endotoxemia mice.	Dextromethorphan	14-30	tumor necrosis factor	Mus musculus	99-108
30822415-9	2019	Mechanistic studies using primary liver Kupffer cell cultures revealed that subpicomolar concentrations of dextromethorphan reduced the NADPH oxidase-generated superoxide free radicals from Kupffer cells, which in turn reduced the elevation of its downstream reactive oxygen species (iROS) to relieve the oxidative stress and decreased TNF-alpha production in Kupffer cells.	Dextromethorphan	107-123	tumor necrosis factor	Mus musculus	336-345
30887238-1	2019	A physiologically based pharmacokinetic (PBPK) model was used to simulate the impact of elevated levels of interleukin (IL)-6 on the exposure of several orally administered cytochrome P450 (CYP) probe substrates (caffeine, S-warfarin, omeprazole, dextromethorphan, midazolam, and simvastatin).	Dextromethorphan	247-263	interleukin 6	Homo sapiens	107-125
30827503-14	2019	Knockdown of GSK3beta by siRNA in primary osteoblast cells attenuated DEX-induced apoptosis and loss of mitochondrial transmembrane potential (Deltapsim).	Dextromethorphan	70-73	glycogen synthase kinase 3 beta	Rattus norvegicus	13-21
30933261-10	2019	Conclusions: Even though visual acuity response and anatomic effect are not always correlated in DME, we found that baseline elevated MCP-1 AH levels and DRT pattern were biomarkers that predicted a future favorable anatomic response to DEX.	Dextromethorphan	237-240	C-C motif chemokine ligand 2	Homo sapiens	134-139
30867526-5	2019	And in cAMP and DEX induced T2D zebrafish model, CA reduced glycogen degradation and increased glucose consumption by regulating some key enzymes in carbon metabolism including GLUT1, GLUT2, GLUT3, LDHA, LDHB, GP, G6Pase, GYS1, and PFKFB3.	Dextromethorphan	16-19	solute carrier family 2 member 1a	Danio rerio	177-182
30967782-7	2019	The results showed that Escin combined with low-dose Dex significantly decreased arthritic index, serum IL-6 and TNF-alpha levels, reduced paw swelling, and ameliorated the joint pathology and immune organ pathology.	Dextromethorphan	53-56	interleukin 6	Rattus norvegicus	104-108
30967782-7	2019	The results showed that Escin combined with low-dose Dex significantly decreased arthritic index, serum IL-6 and TNF-alpha levels, reduced paw swelling, and ameliorated the joint pathology and immune organ pathology.	Dextromethorphan	53-56	tumor necrosis factor	Rattus norvegicus	113-122
30867526-5	2019	And in cAMP and DEX induced T2D zebrafish model, CA reduced glycogen degradation and increased glucose consumption by regulating some key enzymes in carbon metabolism including GLUT1, GLUT2, GLUT3, LDHA, LDHB, GP, G6Pase, GYS1, and PFKFB3.	Dextromethorphan	16-19	solute carrier family 2 member 2	Danio rerio	184-189
30867526-5	2019	And in cAMP and DEX induced T2D zebrafish model, CA reduced glycogen degradation and increased glucose consumption by regulating some key enzymes in carbon metabolism including GLUT1, GLUT2, GLUT3, LDHA, LDHB, GP, G6Pase, GYS1, and PFKFB3.	Dextromethorphan	16-19	lactate dehydrogenase A4	Danio rerio	198-202
30867526-5	2019	And in cAMP and DEX induced T2D zebrafish model, CA reduced glycogen degradation and increased glucose consumption by regulating some key enzymes in carbon metabolism including GLUT1, GLUT2, GLUT3, LDHA, LDHB, GP, G6Pase, GYS1, and PFKFB3.	Dextromethorphan	16-19	lactate dehydrogenase Ba	Danio rerio	204-208
30867526-5	2019	And in cAMP and DEX induced T2D zebrafish model, CA reduced glycogen degradation and increased glucose consumption by regulating some key enzymes in carbon metabolism including GLUT1, GLUT2, GLUT3, LDHA, LDHB, GP, G6Pase, GYS1, and PFKFB3.	Dextromethorphan	16-19	glycogen synthase 1 (muscle)	Danio rerio	222-226
30867526-5	2019	And in cAMP and DEX induced T2D zebrafish model, CA reduced glycogen degradation and increased glucose consumption by regulating some key enzymes in carbon metabolism including GLUT1, GLUT2, GLUT3, LDHA, LDHB, GP, G6Pase, GYS1, and PFKFB3.	Dextromethorphan	16-19	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Danio rerio	232-238
30842914-2	2019	Dextromethorphan is extensively metabolized via cytochrome P450 (CYP) 2D6, and its half-life in extensive metabolizers is 2 to 4 hours.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-73
30828084-10	2019	RESULTS The levels of serum IgE and IgG in BLA- or Dex- treated mice were significantly reduced compared to those in the asthma (AS) group (P&lt;0.01), whereas the levels of cytokines IL-4, TNF-alpha, and MCP-1 were significantly decreased (P&lt;0.01).	Dextromethorphan	51-54	interleukin 4	Mus musculus	184-188
30828084-10	2019	RESULTS The levels of serum IgE and IgG in BLA- or Dex- treated mice were significantly reduced compared to those in the asthma (AS) group (P&lt;0.01), whereas the levels of cytokines IL-4, TNF-alpha, and MCP-1 were significantly decreased (P&lt;0.01).	Dextromethorphan	51-54	tumor necrosis factor	Mus musculus	190-199
30828084-10	2019	RESULTS The levels of serum IgE and IgG in BLA- or Dex- treated mice were significantly reduced compared to those in the asthma (AS) group (P&lt;0.01), whereas the levels of cytokines IL-4, TNF-alpha, and MCP-1 were significantly decreased (P&lt;0.01).	Dextromethorphan	51-54	mast cell protease 1	Mus musculus	205-210
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	sirtuin 1	Sus scrofa	41-50
30192434-3	2019	The aim of this study was to investigate the effect of CYP2D6 genotype on the inhibition of dextromethorphan O-demethylation by duloxetine and paroxetine in human liver microsomes (HLMs).	Dextromethorphan	92-108	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	sirtuin 1	Sus scrofa	52-57
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	patatin like phospholipase domain containing 2	Sus scrofa	91-118
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	patatin like phospholipase domain containing 2	Sus scrofa	120-124
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	lipase E, hormone sensitive type	Sus scrofa	130-154
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	lipase E, hormone sensitive type	Sus scrofa	156-159
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	peroxisome proliferator activated receptor gamma	Sus scrofa	261-309
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	peroxisome proliferator activated receptor gamma	Sus scrofa	311-321
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	CCAAT enhancer binding protein alpha	Sus scrofa	324-360
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	CCAAT enhancer binding protein alpha	Sus scrofa	362-373
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	fatty acid synthase	Sus scrofa	379-398
30394333-4	2019	Moreover, 10-6 M Dex obviously decreased sirtuin 1 (SIRT1) and its related lipolysis genes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) mRNA expression and enzyme activity, while significantly increased expression of adipogenesis genes peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT/enhancer binding protein-alpha (C/EBP-alpha) and fatty acid synthase (FAS).	Dextromethorphan	17-20	fatty acid synthase	Sus scrofa	400-403
30657579-13	2019	In contrast, dexmedetomidine pretreatment decreased the expression levels of IL-6, TNF-alpha, IL-10, and IL-1in the Dex group.	Dextromethorphan	116-119	interleukin 6	Rattus norvegicus	77-81
30657579-13	2019	In contrast, dexmedetomidine pretreatment decreased the expression levels of IL-6, TNF-alpha, IL-10, and IL-1in the Dex group.	Dextromethorphan	116-119	tumor necrosis factor	Rattus norvegicus	83-92
30657579-13	2019	In contrast, dexmedetomidine pretreatment decreased the expression levels of IL-6, TNF-alpha, IL-10, and IL-1in the Dex group.	Dextromethorphan	116-119	interleukin 10	Rattus norvegicus	94-99
30657579-14	2019	Also, the activities of MDA and MPO in lung tissues of rats in the IR group significantly increased after lung ischemia-reperfusion injury, whereas dexmedetomidine pretreatment reversed the elevated activities of MDA and MPO in the Dex group.	Dextromethorphan	232-235	myeloperoxidase	Rattus norvegicus	221-224
30657579-16	2019	In addition, dexmedetomidine pretreatment increased the expression levels of HIF-1alpha, p-Akt and HIF- in the Dex group when compared to those in the IR group.	Dextromethorphan	111-114	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	77-87
30657579-16	2019	In addition, dexmedetomidine pretreatment increased the expression levels of HIF-1alpha, p-Akt and HIF- in the Dex group when compared to those in the IR group.	Dextromethorphan	111-114	AKT serine/threonine kinase 1	Rattus norvegicus	91-94
30581478-11	2018	Dex and CRT treatments had significantly stimulated the growth and reduced the apoptosis of PMECs (all p &lt; 0.05 or 0.01) and alleviated the TNF-alpha-induced cell injury.	Dextromethorphan	0-3	tumor necrosis factor	Rattus norvegicus	143-152
30326290-0	2018	Medial Prefrontal Cortical Cannabinoid CB1 Receptors Mediate Morphine-Dextromethorphan Cross State-Dependent Memory: The Involvement of BDNF/cFOS Signaling Pathways.	Dextromethorphan	70-86	cannabinoid receptor 1	Rattus norvegicus	39-42
29874682-1	2019	- How CYP2D6 Metabolizing Activity Can Result in Dextromethorphan Intoxication.	Dextromethorphan	49-65	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	6-12
30137570-6	2018	Reduced FtsHi5 expression in DEX-induced RNAi transgenic plants produced a similar growth phenotype with pr1 (ftsHi5-1).	Dextromethorphan	29-32	pathogenesis-related protein 1	Arabidopsis thaliana	105-108
30581478-12	2018	The expression of Claudin-5 and ZO-1 in Dex and all 3 CRT groups was markedly increased compared with TNF-a group (all p &lt; 0.05 or 0.01).	Dextromethorphan	40-43	claudin 5	Rattus norvegicus	18-27
30581478-12	2018	The expression of Claudin-5 and ZO-1 in Dex and all 3 CRT groups was markedly increased compared with TNF-a group (all p &lt; 0.05 or 0.01).	Dextromethorphan	40-43	tight junction protein 1	Rattus norvegicus	32-36
30219715-4	2018	In individual HLMs with variable CYP2D6 activities, a significant correlation was observed between celecoxib hydroxylation and CYP2D6-selective dextromethorphan O-demethylation when CYP2C9 and CYP3A4 activities were suppressed (r = 0.97, P &lt; 0.0001).	Dextromethorphan	144-160	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	33-39
29882961-7	2018	Those with co-ingestion of another CYP2D6-dependent drug were 9.49 (95% confidence interval (CI): 1.54-186.41; P = 0.01) times more likely to have genotype-phenotype discordance based upon the 3 hours dextrophan/dextromethorphan (DX/DM) ratio.	Dextromethorphan	212-228	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	35-41
30581701-5	2018	The activated ALP subsequently catalyzes the dephosphorylation (activation) of Dex phosphate, a pro-drug of Dex, and expedites the release of Dex from hydrogels to further promote hMSC osteogenesis.	Dextromethorphan	79-82	alkaline phosphatase, placental	Homo sapiens	14-17
30581701-5	2018	The activated ALP subsequently catalyzes the dephosphorylation (activation) of Dex phosphate, a pro-drug of Dex, and expedites the release of Dex from hydrogels to further promote hMSC osteogenesis.	Dextromethorphan	108-111	alkaline phosphatase, placental	Homo sapiens	14-17
30219715-4	2018	In individual HLMs with variable CYP2D6 activities, a significant correlation was observed between celecoxib hydroxylation and CYP2D6-selective dextromethorphan O-demethylation when CYP2C9 and CYP3A4 activities were suppressed (r = 0.97, P &lt; 0.0001).	Dextromethorphan	144-160	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	127-133
30219715-4	2018	In individual HLMs with variable CYP2D6 activities, a significant correlation was observed between celecoxib hydroxylation and CYP2D6-selective dextromethorphan O-demethylation when CYP2C9 and CYP3A4 activities were suppressed (r = 0.97, P &lt; 0.0001).	Dextromethorphan	144-160	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	182-188
29784728-0	2018	CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.	Dextromethorphan	149-165	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
29777869-12	2018	Pro-inflammatory gene expression levels of MMP9, IL6, IL8, and TNFalpha were significantly decreased in the D-Dex group compared to the Free-Dex and saline group.	Dextromethorphan	110-113	matrix metalloproteinase-9	Oryctolagus cuniculus	43-47
29777869-12	2018	Pro-inflammatory gene expression levels of MMP9, IL6, IL8, and TNFalpha were significantly decreased in the D-Dex group compared to the Free-Dex and saline group.	Dextromethorphan	110-113	interleukin-6	Oryctolagus cuniculus	49-52
29777869-12	2018	Pro-inflammatory gene expression levels of MMP9, IL6, IL8, and TNFalpha were significantly decreased in the D-Dex group compared to the Free-Dex and saline group.	Dextromethorphan	110-113	interleukin-8	Oryctolagus cuniculus	54-57
29777869-12	2018	Pro-inflammatory gene expression levels of MMP9, IL6, IL8, and TNFalpha were significantly decreased in the D-Dex group compared to the Free-Dex and saline group.	Dextromethorphan	110-113	tumor necrosis factor	Oryctolagus cuniculus	63-71
29916050-6	2018	In studies with human SERT-transfected human HEK293 cells, the synthetic opioids tramadol, meperidine, methadone, tapentadol, and dextromethorphan inhibited SERT, but fentanyl and a number of phenanthrenes including morphine and hydromorphone did not.	Dextromethorphan	130-146	solute carrier family 6 member 4	Homo sapiens	22-26
29916050-6	2018	In studies with human SERT-transfected human HEK293 cells, the synthetic opioids tramadol, meperidine, methadone, tapentadol, and dextromethorphan inhibited SERT, but fentanyl and a number of phenanthrenes including morphine and hydromorphone did not.	Dextromethorphan	130-146	solute carrier family 6 member 4	Homo sapiens	157-161
29468562-0	2018	PKCdelta Knockout Mice Are Protected from Dextromethorphan-Induced Serotonergic Behaviors in Mice: Involvements of Downregulation of 5-HT1A Receptor and Upregulation of Nrf2-Dependent GSH Synthesis.	Dextromethorphan	42-58	protein kinase C, delta	Mus musculus	0-8
29468562-2	2018	We firstly observed that the activation of 5-HT1A receptor, but not 5-HT2A receptor, contributed to DM-induced serotonergic behaviors in mice.	Dextromethorphan	100-102	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	43-58
29468562-6	2018	More importantly, 5-HT1A receptor co-immunoprecipitated PKCdelta in the presence of DM.	Dextromethorphan	84-86	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	18-33
29468562-6	2018	More importantly, 5-HT1A receptor co-immunoprecipitated PKCdelta in the presence of DM.	Dextromethorphan	84-86	protein kinase C, delta	Mus musculus	56-64
29468562-8	2018	Treatment with DM resulted in an initial increase in nuclear factor erythroid-2-related factor 2 (Nrf2) nuclear translocation and DNA-binding activity, gamma-glutamylcysteine (GCL) mRNA expression, and glutathione (GSH) level.	Dextromethorphan	15-17	nuclear factor, erythroid derived 2, like 2	Mus musculus	53-96
29468562-8	2018	Treatment with DM resulted in an initial increase in nuclear factor erythroid-2-related factor 2 (Nrf2) nuclear translocation and DNA-binding activity, gamma-glutamylcysteine (GCL) mRNA expression, and glutathione (GSH) level.	Dextromethorphan	15-17	nuclear factor, erythroid derived 2, like 2	Mus musculus	98-102
29468562-8	2018	Treatment with DM resulted in an initial increase in nuclear factor erythroid-2-related factor 2 (Nrf2) nuclear translocation and DNA-binding activity, gamma-glutamylcysteine (GCL) mRNA expression, and glutathione (GSH) level.	Dextromethorphan	15-17	germ cell-less, spermatogenesis associated 1	Mus musculus	176-179
29468562-12	2018	Our results suggest that interaction between 5-HT1A receptor and PKCdelta is critical for inducing DM-induced serotonergic behaviors and that inhibition of PKCdelta attenuates the serotonergic behaviors via downregulation of 5-HT1A receptor and upregulation of Nrf2-dependent GSH synthesis.	Dextromethorphan	99-101	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	45-60
29468562-12	2018	Our results suggest that interaction between 5-HT1A receptor and PKCdelta is critical for inducing DM-induced serotonergic behaviors and that inhibition of PKCdelta attenuates the serotonergic behaviors via downregulation of 5-HT1A receptor and upregulation of Nrf2-dependent GSH synthesis.	Dextromethorphan	99-101	protein kinase C, delta	Mus musculus	65-73
29468562-12	2018	Our results suggest that interaction between 5-HT1A receptor and PKCdelta is critical for inducing DM-induced serotonergic behaviors and that inhibition of PKCdelta attenuates the serotonergic behaviors via downregulation of 5-HT1A receptor and upregulation of Nrf2-dependent GSH synthesis.	Dextromethorphan	99-101	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	225-240
29468562-12	2018	Our results suggest that interaction between 5-HT1A receptor and PKCdelta is critical for inducing DM-induced serotonergic behaviors and that inhibition of PKCdelta attenuates the serotonergic behaviors via downregulation of 5-HT1A receptor and upregulation of Nrf2-dependent GSH synthesis.	Dextromethorphan	99-101	nuclear factor, erythroid derived 2, like 2	Mus musculus	261-265
30252871-9	2018	Histological findings and a significant drop in several markers of inflammation (p65 nuclear translocation, mRNA expressions of TNF-alpha, IL-1beta, IL-6) showed that DEX treatment reversed cholestasis-induced inflammation, and similar results have been obtained with oxidative stress markers.	Dextromethorphan	167-170	synaptotagmin 1	Rattus norvegicus	81-84
30252871-9	2018	Histological findings and a significant drop in several markers of inflammation (p65 nuclear translocation, mRNA expressions of TNF-alpha, IL-1beta, IL-6) showed that DEX treatment reversed cholestasis-induced inflammation, and similar results have been obtained with oxidative stress markers.	Dextromethorphan	167-170	tumor necrosis factor	Rattus norvegicus	128-137
30252871-9	2018	Histological findings and a significant drop in several markers of inflammation (p65 nuclear translocation, mRNA expressions of TNF-alpha, IL-1beta, IL-6) showed that DEX treatment reversed cholestasis-induced inflammation, and similar results have been obtained with oxidative stress markers.	Dextromethorphan	167-170	interleukin 1 beta	Rattus norvegicus	139-147
30252871-9	2018	Histological findings and a significant drop in several markers of inflammation (p65 nuclear translocation, mRNA expressions of TNF-alpha, IL-1beta, IL-6) showed that DEX treatment reversed cholestasis-induced inflammation, and similar results have been obtained with oxidative stress markers.	Dextromethorphan	167-170	interleukin 6	Rattus norvegicus	149-153
30252871-10	2018	The nuclear expression of p65 and CAR were inversely correlated, with the latter increasing significantly after DEX treatment (p&lt;0.01 vs vehicle).	Dextromethorphan	112-115	synaptotagmin 1	Rattus norvegicus	26-29
30252871-10	2018	The nuclear expression of p65 and CAR were inversely correlated, with the latter increasing significantly after DEX treatment (p&lt;0.01 vs vehicle).	Dextromethorphan	112-115	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	34-37
30252871-13	2018	In conclusion, DEX reduces inflammation and oxidative stress in BDL rats, and probably CAR is responsible for this effect.	Dextromethorphan	15-18	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	87-90
30078531-10	2018	Dogs in the DEX group had significant lower HR (p &lt; 0.01) and fR (p &lt; 0.01), higher SAP (p &lt; 0.01) and DAP (p &lt; 0.01) at all time points, and higher MAP (p &lt; 0.01) during the first 15 minutes following drug injection in comparison with the ACE group.	Dextromethorphan	12-15	death-associated protein 1	Canis lupus familiaris	112-115
30078531-10	2018	Dogs in the DEX group had significant lower HR (p &lt; 0.01) and fR (p &lt; 0.01), higher SAP (p &lt; 0.01) and DAP (p &lt; 0.01) at all time points, and higher MAP (p &lt; 0.01) during the first 15 minutes following drug injection in comparison with the ACE group.	Dextromethorphan	12-15	angiotensin I converting enzyme	Canis lupus familiaris	255-258
30106963-8	2018	RESULTS: The 72-hour morphine consumption was lower in the DEX group than in the CTRL group (median 39.0 mg [interquartile range 37.3, 41.0] in the DEX group vs. 49.0 mg [45.5, 50.0] in the CTRL group; median difference -9.0 mg [95% CI -10.0, -6.0], P &lt; 0.001).	Dextromethorphan	59-62	chymotrypsin like	Homo sapiens	190-194
29277297-13	2018	MMP-9 concentrations in the Dex-Iso group were lower than the Iso group at T3 and T4.	Dextromethorphan	28-31	matrix metallopeptidase 9	Homo sapiens	0-5
29499586-5	2018	Using DEX to mimic stress conditions, it was shown that the gene expression pattern of FKBP5, CREB, GRIK4, VEGF, NET, and ARRB2 in SH-SY5Y cells is time- and treatment-dependent.	Dextromethorphan	6-9	FKBP prolyl isomerase 5	Homo sapiens	87-92
29499586-5	2018	Using DEX to mimic stress conditions, it was shown that the gene expression pattern of FKBP5, CREB, GRIK4, VEGF, NET, and ARRB2 in SH-SY5Y cells is time- and treatment-dependent.	Dextromethorphan	6-9	cAMP responsive element binding protein 1	Homo sapiens	94-98
29499586-5	2018	Using DEX to mimic stress conditions, it was shown that the gene expression pattern of FKBP5, CREB, GRIK4, VEGF, NET, and ARRB2 in SH-SY5Y cells is time- and treatment-dependent.	Dextromethorphan	6-9	glutamate ionotropic receptor kainate type subunit 4	Homo sapiens	100-105
29499586-5	2018	Using DEX to mimic stress conditions, it was shown that the gene expression pattern of FKBP5, CREB, GRIK4, VEGF, NET, and ARRB2 in SH-SY5Y cells is time- and treatment-dependent.	Dextromethorphan	6-9	vascular endothelial growth factor A	Homo sapiens	107-111
29499586-5	2018	Using DEX to mimic stress conditions, it was shown that the gene expression pattern of FKBP5, CREB, GRIK4, VEGF, NET, and ARRB2 in SH-SY5Y cells is time- and treatment-dependent.	Dextromethorphan	6-9	solute carrier family 6 member 2	Homo sapiens	113-116
29499586-5	2018	Using DEX to mimic stress conditions, it was shown that the gene expression pattern of FKBP5, CREB, GRIK4, VEGF, NET, and ARRB2 in SH-SY5Y cells is time- and treatment-dependent.	Dextromethorphan	6-9	arrestin beta 2	Homo sapiens	122-127
29499586-6	2018	Most pronounced effects were observed for FKBP5: after 6 h of co-incubation, only STW3-VI could reverse the DEX-induced increase in FKBP5 expression, and after 48 h, citalopram, miquelianin, and hyperforin also reversed the glucocorticoid-induced increase in FKBP5 mRNA expression.	Dextromethorphan	108-111	FKBP prolyl isomerase 5	Homo sapiens	132-137
29499586-6	2018	Most pronounced effects were observed for FKBP5: after 6 h of co-incubation, only STW3-VI could reverse the DEX-induced increase in FKBP5 expression, and after 48 h, citalopram, miquelianin, and hyperforin also reversed the glucocorticoid-induced increase in FKBP5 mRNA expression.	Dextromethorphan	108-111	FKBP prolyl isomerase 5	Homo sapiens	132-137
29719052-7	2018	Dextromethorphan O-demethylation, which is catalysed mainly by CYP2D6, was decreased by 40% in the presence of SO-SWCNT.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	63-69
29989011-2	2018	The inhibition of CYP enzymatic activities by TQ was evaluated by incubating typical substrates (phenacetin for CYP1A2, tolbutamide for CYP2C9, dextromethorphan for CYP2D6, and testosterone for CYP3A4) with human liver microsomes and NADPH in the absence or presence of TQ (1, 10 and 100 microM).	Dextromethorphan	144-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
29927470-1	2018	BACKGROUND AND OBJECTIVE: Dexamethasone intravitreal implant (DEX) (Ozurdex; Allergan plc, Dublin, Ireland) is approved for the treatment of diabetic macular edema (DME).	Dextromethorphan	62-65	heparan sulfate proteoglycan 2	Homo sapiens	86-89
28287112-4	2018	Pharmacological modulation of GR by its agonist (dexamethasone, Dex) protects IMH mice against inflammatory injury.	Dextromethorphan	64-67	nuclear receptor subfamily 3, group C, member 1	Mus musculus	30-32
29950233-7	2018	The expression of IL-21 mRNA and the secretion of IL-21 obviously decreased after DEX intervention, but increased after AG490 blocking(P&lt;0.01).	Dextromethorphan	82-85	interleukin 21	Homo sapiens	18-23
29950233-7	2018	The expression of IL-21 mRNA and the secretion of IL-21 obviously decreased after DEX intervention, but increased after AG490 blocking(P&lt;0.01).	Dextromethorphan	82-85	interleukin 21	Homo sapiens	50-55
28992584-8	2018	Furthermore, the effects of prenatal DEX exposure and swimming exercise on depression were associated with OGT-related mitochondrial motility, including PINK1/Parkin pathway and AKT/GSK3beta pathway.	Dextromethorphan	37-40	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	107-110
29675422-8	2018	The upregulation of bone sialoprotein (BSP), ALP, and osteopontin (OPN) in Dex challenged cells was completely inhibited by SB202190.	Dextromethorphan	75-78	secreted phosphoprotein 1	Mus musculus	54-65
29675422-8	2018	The upregulation of bone sialoprotein (BSP), ALP, and osteopontin (OPN) in Dex challenged cells was completely inhibited by SB202190.	Dextromethorphan	75-78	secreted phosphoprotein 1	Mus musculus	67-70
29210063-7	2018	KEY RESULTS: Dextromethorphan, l(R)-methadone, racemic methadone, pethidine, tramadol and tapentadol inhibited the SERT at or close to observed drug plasma or estimated brain concentrations in patients.	Dextromethorphan	13-29	solute carrier family 6 member 4	Homo sapiens	115-119
29210063-14	2018	SERT inhibition by tramadol, tapentadol, methadone, dextromethorphan and pethidine may contribute to the serotonin syndrome.	Dextromethorphan	52-68	solute carrier family 6 member 4	Homo sapiens	0-4
29534535-6	2018	DXM significantly restored tumor necrosis factor-alpha (TNF-alpha)-mediated reduction of collagen II and decreased TNF-alpha-induced MMP-13 production.	Dextromethorphan	0-3	tumor necrosis factor	Homo sapiens	27-54
29534535-6	2018	DXM significantly restored tumor necrosis factor-alpha (TNF-alpha)-mediated reduction of collagen II and decreased TNF-alpha-induced MMP-13 production.	Dextromethorphan	0-3	tumor necrosis factor	Homo sapiens	56-65
29534535-6	2018	DXM significantly restored tumor necrosis factor-alpha (TNF-alpha)-mediated reduction of collagen II and decreased TNF-alpha-induced MMP-13 production.	Dextromethorphan	0-3	tumor necrosis factor	Homo sapiens	115-124
29534535-6	2018	DXM significantly restored tumor necrosis factor-alpha (TNF-alpha)-mediated reduction of collagen II and decreased TNF-alpha-induced MMP-13 production.	Dextromethorphan	0-3	matrix metallopeptidase 13	Homo sapiens	133-139
29534535-7	2018	To inhibit the synthesis of MMP-13, DXM blocked TNF-alpha downstream signaling, including I kappa B kinase (IKK)alpha/beta-IkappaBalpha-nuclear factor-kappaB (NF-kappaB) and c-Jun N-terminal kinase (JNK)-activator protein-1 (AP-1) activation.	Dextromethorphan	36-39	matrix metallopeptidase 13	Homo sapiens	28-34
29534535-7	2018	To inhibit the synthesis of MMP-13, DXM blocked TNF-alpha downstream signaling, including I kappa B kinase (IKK)alpha/beta-IkappaBalpha-nuclear factor-kappaB (NF-kappaB) and c-Jun N-terminal kinase (JNK)-activator protein-1 (AP-1) activation.	Dextromethorphan	36-39	tumor necrosis factor	Homo sapiens	48-57
29534535-7	2018	To inhibit the synthesis of MMP-13, DXM blocked TNF-alpha downstream signaling, including I kappa B kinase (IKK)alpha/beta-IkappaBalpha-nuclear factor-kappaB (NF-kappaB) and c-Jun N-terminal kinase (JNK)-activator protein-1 (AP-1) activation.	Dextromethorphan	36-39	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	90-117
28389999-17	2018	Comparing with the blank group, BrdU+/DEX+ fluorescence intensity significantly enhanced in the miR-21 mimics and si-PDCD4 groups and significantly reduced in the miR-21 inhibitor group.	Dextromethorphan	38-41	microRNA 21	Rattus norvegicus	96-102
28389999-17	2018	Comparing with the blank group, BrdU+/DEX+ fluorescence intensity significantly enhanced in the miR-21 mimics and si-PDCD4 groups and significantly reduced in the miR-21 inhibitor group.	Dextromethorphan	38-41	programmed cell death 4	Rattus norvegicus	117-122
28389999-17	2018	Comparing with the blank group, BrdU+/DEX+ fluorescence intensity significantly enhanced in the miR-21 mimics and si-PDCD4 groups and significantly reduced in the miR-21 inhibitor group.	Dextromethorphan	38-41	microRNA 21	Rattus norvegicus	163-169
28992584-8	2018	Furthermore, the effects of prenatal DEX exposure and swimming exercise on depression were associated with OGT-related mitochondrial motility, including PINK1/Parkin pathway and AKT/GSK3beta pathway.	Dextromethorphan	37-40	PTEN induced kinase 1	Homo sapiens	153-158
28992584-8	2018	Furthermore, the effects of prenatal DEX exposure and swimming exercise on depression were associated with OGT-related mitochondrial motility, including PINK1/Parkin pathway and AKT/GSK3beta pathway.	Dextromethorphan	37-40	AKT serine/threonine kinase 1	Homo sapiens	178-181
28992584-8	2018	Furthermore, the effects of prenatal DEX exposure and swimming exercise on depression were associated with OGT-related mitochondrial motility, including PINK1/Parkin pathway and AKT/GSK3beta pathway.	Dextromethorphan	37-40	glycogen synthase kinase 3 beta	Homo sapiens	182-190
29290897-6	2018	Compared with the CLP group, the DEX groups exhibited decreased HLA-DR levels (Pgroup=0.0202) and increased IL-6 production, which was increased at 3 h (P= 0.0113) and was then attenuated at 5 h; additionally, the DEX groups exhibited decreased HR (P&lt;0.001) while maintaining MAP (Pgroup=0.1238), and remarkably improving lactate (P&lt;0.0001).	Dextromethorphan	33-36	interleukin 6	Rattus norvegicus	108-112
29621784-16	2018	Finally, the inhibition of HSP70, PI3K and mTOR completely abolished the effect of DEXs on naive T cells.	Dextromethorphan	83-87	heat shock protein 1B	Mus musculus	27-32
29621784-16	2018	Finally, the inhibition of HSP70, PI3K and mTOR completely abolished the effect of DEXs on naive T cells.	Dextromethorphan	83-87	mechanistic target of rapamycin kinase	Mus musculus	43-47
29621784-18	2018	DEXs transported HSP70 into naive T cells and stimulated the PI3K/mTOR axis to modulate the balance between Tregs and Th17 cells and protect the liver from IR injury.	Dextromethorphan	0-4	heat shock protein 1B	Mus musculus	17-22
29621784-18	2018	DEXs transported HSP70 into naive T cells and stimulated the PI3K/mTOR axis to modulate the balance between Tregs and Th17 cells and protect the liver from IR injury.	Dextromethorphan	0-4	mechanistic target of rapamycin kinase	Mus musculus	66-70
29402873-8	2018	CONCLUSION: Repeated intravitreal DEX injections with average intervals of 4 months are valuable in patients with DME refractory to anti-VEGF therapy.	Dextromethorphan	34-37	vascular endothelial growth factor A	Homo sapiens	137-141
29311514-5	2018	From taste sensor measurements, diphenidol, haloperidol, diphenhydramine, dextromethorphan and papaverine, all ligands of hTAS2R 10 and/or hTAS2R14, were predicted to express strong bitterness, surpassing that of quinine.	Dextromethorphan	74-90	taste 2 receptor member 10	Homo sapiens	122-131
29311514-5	2018	From taste sensor measurements, diphenidol, haloperidol, diphenhydramine, dextromethorphan and papaverine, all ligands of hTAS2R 10 and/or hTAS2R14, were predicted to express strong bitterness, surpassing that of quinine.	Dextromethorphan	74-90	taste 2 receptor member 14	Homo sapiens	139-147
29203387-6	2017	In conclusion, the AIF activated Nrf2 signaling pathway was observed to suppress Dex-induced ROS production in osteoblastic and osteocytic cells, which may explain its anti-osteoporotic effects against dexamethasone-induced osteoporosis.	Dextromethorphan	81-84	NFE2 like bZIP transcription factor 2	Rattus norvegicus	33-37
28449367-5	2017	CYP2D6 inhibition potency and reversibility was assessed using dextromethorphan.	Dextromethorphan	63-79	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
27832523-11	2017	Graphical Abstract Possible molecular pathways of involvement of DEX in cerebral ischemia-induced apoptosis, oxidative stress, and calcium accumulation through TRPA1, TRPM2 and TRPV1 in the hippocampus and DRG neurons of rats.	Dextromethorphan	65-68	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	160-165
27832523-11	2017	Graphical Abstract Possible molecular pathways of involvement of DEX in cerebral ischemia-induced apoptosis, oxidative stress, and calcium accumulation through TRPA1, TRPM2 and TRPV1 in the hippocampus and DRG neurons of rats.	Dextromethorphan	65-68	transient receptor potential cation channel, subfamily M, member 2	Rattus norvegicus	167-172
27832523-11	2017	Graphical Abstract Possible molecular pathways of involvement of DEX in cerebral ischemia-induced apoptosis, oxidative stress, and calcium accumulation through TRPA1, TRPM2 and TRPV1 in the hippocampus and DRG neurons of rats.	Dextromethorphan	65-68	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	177-182
29218102-7	2017	In the LPS-treated mice, the levels of NF-kappab p65, Caspase-3, Caspase-8, Bax, p53, IL-6, IL-1beta, TNF-alpha and p-STAT3 were significantly increased, while alpha7nAChR level was decreased significantly (P &lt; 0.01); DEX alone had no impact on the expression of these proteins but significantly up-regulated the expression of these genes except alpha7nAChR when used jointly with BT (P &lt; 0.01).	Dextromethorphan	221-224	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	39-48
29218102-8	2017	It is clear that DEX can alleviate heart injury, while alpha7nAChR-specific blocker BT is antagonistic against the anti-inflammatory effect of DEX on sepsis in mice.	Dextromethorphan	143-146	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	55-66
28739134-6	2017	With regard to EEG indicators, DXM administration reduced visually "evoked" (30Hz to 50Hz) and "induced" occipital gamma-band activity (70Hz to 100Hz), which was partly compensated by additional MAST exposure.	Dextromethorphan	31-34	SPG21 abhydrolase domain containing, maspardin	Homo sapiens	195-199
28501709-7	2017	Moreover, the administration by Dex supramolecular hydrogel exhibited a comparable anti-inflammatory efficacy to native Dex solution on an experimental autoimmune uveitis (EAU) model induced in Lewis rats with IRBP peptide and the therapeutic efficacy had in a dosage-dependent manner.	Dextromethorphan	32-35	retinol binding protein 3	Rattus norvegicus	210-214
28786716-2	2017	The objective was to determine CYP2D6 phenotype in Yoruba Nigerians using dextromethorphan (DEX).	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	31-37
28786716-2	2017	The objective was to determine CYP2D6 phenotype in Yoruba Nigerians using dextromethorphan (DEX).	Dextromethorphan	92-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	31-37
28900117-3	2017	Herein, we found that DXM treatment attenuated arthritis severity and proinflammatory cytokine expression levels, including TNF-alpha, IL-6, and IL-17A, in paw tissues of CIA mice.	Dextromethorphan	22-25	tumor necrosis factor	Mus musculus	124-133
28900117-3	2017	Herein, we found that DXM treatment attenuated arthritis severity and proinflammatory cytokine expression levels, including TNF-alpha, IL-6, and IL-17A, in paw tissues of CIA mice.	Dextromethorphan	22-25	interleukin 6	Mus musculus	135-139
28900117-3	2017	Herein, we found that DXM treatment attenuated arthritis severity and proinflammatory cytokine expression levels, including TNF-alpha, IL-6, and IL-17A, in paw tissues of CIA mice.	Dextromethorphan	22-25	interleukin 17A	Mus musculus	145-151
28900117-3	2017	Herein, we found that DXM treatment attenuated arthritis severity and proinflammatory cytokine expression levels, including TNF-alpha, IL-6, and IL-17A, in paw tissues of CIA mice.	Dextromethorphan	22-25	nuclear receptor coactivator 5	Mus musculus	171-174
28900117-4	2017	DXM treatment also reduced serum TNF-alpha, IL-6, and IL-17A levels of CIA mice and patients with RA.	Dextromethorphan	0-3	tumor necrosis factor	Mus musculus	33-42
28900117-4	2017	DXM treatment also reduced serum TNF-alpha, IL-6, and IL-17A levels of CIA mice and patients with RA.	Dextromethorphan	0-3	interleukin 6	Mus musculus	44-48
28900117-4	2017	DXM treatment also reduced serum TNF-alpha, IL-6, and IL-17A levels of CIA mice and patients with RA.	Dextromethorphan	0-3	interleukin 17A	Mus musculus	54-60
28900117-4	2017	DXM treatment also reduced serum TNF-alpha, IL-6, and IL-17A levels of CIA mice and patients with RA.	Dextromethorphan	0-3	nuclear receptor coactivator 5	Mus musculus	71-74
28900117-5	2017	DXM further decreased the production of anti-CII IgG, IFN-gamma, and IL-17A in collagen-reactive CD4+ T cells extracted from the lymph nodes of CIA mice.	Dextromethorphan	0-3	interferon gamma	Mus musculus	54-63
28900117-5	2017	DXM further decreased the production of anti-CII IgG, IFN-gamma, and IL-17A in collagen-reactive CD4+ T cells extracted from the lymph nodes of CIA mice.	Dextromethorphan	0-3	interleukin 17A	Mus musculus	69-75
28900117-5	2017	DXM further decreased the production of anti-CII IgG, IFN-gamma, and IL-17A in collagen-reactive CD4+ T cells extracted from the lymph nodes of CIA mice.	Dextromethorphan	0-3	nuclear receptor coactivator 5	Mus musculus	144-147
28900117-7	2017	In conclusion, our results showed that DXM attenuated arthritis symptoms in CIA mice and significantly reduced proinflammatory cytokines in patients with RA, suggesting that it can be used as an anti-arthritic agent.	Dextromethorphan	39-42	nuclear receptor coactivator 5	Mus musculus	76-79
32095466-1	2017	This study focused on the role of cytochrome P450 2D6 (CYP2D6) genotypes to predict phenotypes in the metabolism of dextromethorphan.	Dextromethorphan	116-132	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	34-53
28724622-6	2017	Using DEX-inducible MYB26 lines and overexpression in the various mutant backgrounds, we have shown that MYB26 up-regulates both NST1 and NST2 expression.	Dextromethorphan	6-9	N-deacetylase and N-sulfotransferase 1	Homo sapiens	129-133
32095466-1	2017	This study focused on the role of cytochrome P450 2D6 (CYP2D6) genotypes to predict phenotypes in the metabolism of dextromethorphan.	Dextromethorphan	116-132	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
28705835-10	2017	shRNA-mediated knockdown of one such gene, claudin-7, in HUVEC resulted in decreased TEER and increased adiponectin flux, confirming the functional significance of Dex-induced changes in its expression.	Dextromethorphan	164-167	claudin 7	Rattus norvegicus	43-52
28724622-6	2017	Using DEX-inducible MYB26 lines and overexpression in the various mutant backgrounds, we have shown that MYB26 up-regulates both NST1 and NST2 expression.	Dextromethorphan	6-9	N-deacetylase and N-sulfotransferase 2	Homo sapiens	138-142
28605710-4	2017	The present results showed that chronic DEX exposure significantly increased LDH release and apoptosis, decreased MAP2 and GR expression in hippocampal neurons.	Dextromethorphan	40-43	microtubule associated protein 2	Homo sapiens	114-118
28605710-5	2017	DEX (5muMu) exposure for 3d significantly increased the expression of NLRP-1, ASC, caspase-1 and IL-1beta in the hippocampal neurons and the release of IL-1beta and IL-18 in the supernatants.	Dextromethorphan	0-3	NLR family pyrin domain containing 1	Homo sapiens	70-76
28605710-5	2017	DEX (5muMu) exposure for 3d significantly increased the expression of NLRP-1, ASC, caspase-1 and IL-1beta in the hippocampal neurons and the release of IL-1beta and IL-18 in the supernatants.	Dextromethorphan	0-3	PYD and CARD domain containing	Homo sapiens	78-81
28605710-5	2017	DEX (5muMu) exposure for 3d significantly increased the expression of NLRP-1, ASC, caspase-1 and IL-1beta in the hippocampal neurons and the release of IL-1beta and IL-18 in the supernatants.	Dextromethorphan	0-3	caspase 1	Homo sapiens	83-92
28605710-5	2017	DEX (5muMu) exposure for 3d significantly increased the expression of NLRP-1, ASC, caspase-1 and IL-1beta in the hippocampal neurons and the release of IL-1beta and IL-18 in the supernatants.	Dextromethorphan	0-3	interleukin 1 alpha	Homo sapiens	97-105
28605710-5	2017	DEX (5muMu) exposure for 3d significantly increased the expression of NLRP-1, ASC, caspase-1 and IL-1beta in the hippocampal neurons and the release of IL-1beta and IL-18 in the supernatants.	Dextromethorphan	0-3	interleukin 1 alpha	Homo sapiens	152-160
28605710-5	2017	DEX (5muMu) exposure for 3d significantly increased the expression of NLRP-1, ASC, caspase-1 and IL-1beta in the hippocampal neurons and the release of IL-1beta and IL-18 in the supernatants.	Dextromethorphan	0-3	interleukin 18	Homo sapiens	165-170
28605710-6	2017	Moreover, DEX (1, 5muMu) treatment for 3d significantly increased the expression of NF-kappaB in hippocampal neurons.	Dextromethorphan	10-13	nuclear factor kappa B subunit 1	Homo sapiens	84-93
28705835-10	2017	shRNA-mediated knockdown of one such gene, claudin-7, in HUVEC resulted in decreased TEER and increased adiponectin flux, confirming the functional significance of Dex-induced changes in its expression.	Dextromethorphan	164-167	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	104-115
28251369-7	2017	All groups had robust cortisol and ACTH response to DEX/CRH and cortisol response to TSST.	Dextromethorphan	52-55	proopiomelanocortin	Homo sapiens	35-39
28377308-4	2017	We found that Dex induced TLR2 expression mainly in undifferentiated and less in calcium-induced differentiated keratinocytes but not in HaCaT cells or fibroblasts, however, Dex reduced TLR1/6 expression.	Dextromethorphan	14-17	toll like receptor 2	Homo sapiens	26-30
28377308-4	2017	We found that Dex induced TLR2 expression mainly in undifferentiated and less in calcium-induced differentiated keratinocytes but not in HaCaT cells or fibroblasts, however, Dex reduced TLR1/6 expression.	Dextromethorphan	14-17	toll like receptor 1	Homo sapiens	186-190
28377308-4	2017	We found that Dex induced TLR2 expression mainly in undifferentiated and less in calcium-induced differentiated keratinocytes but not in HaCaT cells or fibroblasts, however, Dex reduced TLR1/6 expression.	Dextromethorphan	174-177	toll like receptor 1	Homo sapiens	186-190
28377308-5	2017	Stimulation with Dex under inflammatory conditions further increased TLR2 but not TLR1 or TLR6 levels in keratinocytes.	Dextromethorphan	17-20	toll like receptor 2	Homo sapiens	69-73
28377308-5	2017	Stimulation with Dex under inflammatory conditions further increased TLR2 but not TLR1 or TLR6 levels in keratinocytes.	Dextromethorphan	17-20	toll like receptor 6	Homo sapiens	90-94
28763903-6	2017	In contrast, the IC50-Dex of RXM+ 10%CSE group [(4.94+-1.62)x10(-8)] was significantly higher than that of control group [(1.75+-0.77)x10(-8)], but lower than that of 10%CSE group [(2.92+-0.78)x10(-7)] (both P&lt;0.01).	Dextromethorphan	22-25	choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity)	Homo sapiens	37-40
28408351-3	2017	In the present study, inhibition of HSP90 activity by 17-Demethoxy-17-allyaminogeldanmycin (17-AAG) or knockdown of HSP90 expression by siRNAs attenuated dexamethasone(Dex)-induced GR nuclear accumulation and transcriptional output of GR signaling, whereas overexpression of HSP90alpha or HSP90beta enhanced GR transactivity in C3H10T1/2 cells.	Dextromethorphan	168-171	heat shock protein, 3	Mus musculus	36-41
28408351-3	2017	In the present study, inhibition of HSP90 activity by 17-Demethoxy-17-allyaminogeldanmycin (17-AAG) or knockdown of HSP90 expression by siRNAs attenuated dexamethasone(Dex)-induced GR nuclear accumulation and transcriptional output of GR signaling, whereas overexpression of HSP90alpha or HSP90beta enhanced GR transactivity in C3H10T1/2 cells.	Dextromethorphan	168-171	heat shock protein, 3	Mus musculus	116-121
29926585-7	2017	Compared with I/R Atip Dex+Atip group, the levels of W/D TLW,IL-1beta and TNF-alpha in Dex group were lower (P&lt;0.05), the structure damages of lung tissues observed under light microscopy and electron microscope in Dex group were slighter.	Dextromethorphan	87-90	interleukin 1 beta	Rattus norvegicus	61-69
27317395-5	2017	METHODS: Metabolism data for tramadol and for the probe substrates midazolam (CYP3A4) and dextromethorphan (CYP2D6) were gathered in human liver microsomes (HLM) and recombinant human enzyme systems (rhCYP).	Dextromethorphan	90-106	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	108-114
28626102-9	2017	Compared with the control group, the levels of cTnI, NT-proBNP and hs-CRP were significantly decreased in the Dex group (P&lt;0.05).	Dextromethorphan	110-113	troponin I3, cardiac type	Homo sapiens	47-51
29926585-7	2017	Compared with I/R Atip Dex+Atip group, the levels of W/D TLW,IL-1beta and TNF-alpha in Dex group were lower (P&lt;0.05), the structure damages of lung tissues observed under light microscopy and electron microscope in Dex group were slighter.	Dextromethorphan	87-90	tumor necrosis factor	Rattus norvegicus	74-83
29926585-7	2017	Compared with I/R Atip Dex+Atip group, the levels of W/D TLW,IL-1beta and TNF-alpha in Dex group were lower (P&lt;0.05), the structure damages of lung tissues observed under light microscopy and electron microscope in Dex group were slighter.	Dextromethorphan	23-26	interleukin 1 beta	Rattus norvegicus	61-69
29926585-7	2017	Compared with I/R Atip Dex+Atip group, the levels of W/D TLW,IL-1beta and TNF-alpha in Dex group were lower (P&lt;0.05), the structure damages of lung tissues observed under light microscopy and electron microscope in Dex group were slighter.	Dextromethorphan	87-90	interleukin 1 beta	Rattus norvegicus	61-69
29926585-7	2017	Compared with I/R Atip Dex+Atip group, the levels of W/D TLW,IL-1beta and TNF-alpha in Dex group were lower (P&lt;0.05), the structure damages of lung tissues observed under light microscopy and electron microscope in Dex group were slighter.	Dextromethorphan	87-90	tumor necrosis factor	Rattus norvegicus	74-83
28288109-3	2017	To identify a MRGPRX2 probe, we first screened 5,695 small molecules and found that many opioid compounds activated MRGPRX2, including (-)- and (+)-morphine, hydrocodone, sinomenine, dextromethorphan, and the prodynorphin-derived peptides dynorphin A, dynorphin B, and alpha- and beta-neoendorphin.	Dextromethorphan	183-199	MAS related GPR family member X2	Homo sapiens	14-21
28254952-7	2017	Finally, the biologic miR-34a agent had no significant effects on the PK of cocktail drugs but caused a marginal (45%-48%) increase in systemic exposure to midazolam, phenacetin, and dextromethorphan in mice.	Dextromethorphan	183-199	microRNA 34a	Mus musculus	22-29
28254952-8	2017	In vitro validation of these data suggested that miR-34a slightly attenuated intrinsic clearance of dextromethorphan.	Dextromethorphan	100-116	microRNA 34a	Mus musculus	49-56
28153746-8	2017	DXM injection prevented the Ovx-induced reduction of osteocalcin expression and significantly upregulated CTX-1 expression.	Dextromethorphan	0-3	bone gamma-carboxyglutamate protein	Rattus norvegicus	53-64
29926648-7	2017	Compared with I/R group, NS groups and DA group, the concentrations of IL-1beta and TNF-alpha in Dex group were significantly lower(P&lt;0.05)and the structure damages of renal tissues observed under electron microscope in Dex group were slighter.	Dextromethorphan	97-100	interleukin 1 beta	Mus musculus	71-79
29926648-7	2017	Compared with I/R group, NS groups and DA group, the concentrations of IL-1beta and TNF-alpha in Dex group were significantly lower(P&lt;0.05)and the structure damages of renal tissues observed under electron microscope in Dex group were slighter.	Dextromethorphan	97-100	tumor necrosis factor	Mus musculus	84-93
29926648-7	2017	Compared with I/R group, NS groups and DA group, the concentrations of IL-1beta and TNF-alpha in Dex group were significantly lower(P&lt;0.05)and the structure damages of renal tissues observed under electron microscope in Dex group were slighter.	Dextromethorphan	223-226	tumor necrosis factor	Mus musculus	84-93
28290770-0	2017	In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report.	Dextromethorphan	57-73	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	28-34
28290770-3	2017	The father presented with intermediate metabolism when challenged with the CYP2D6 probe drug dextromethorphan (DM/dextrorphan [DX] = 0.0839).	Dextromethorphan	93-109	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	75-81
28211700-3	2017	Herein, the genotype of CYP2D6 was determined along with the absolute content of CYP2D6 and microsomal protein per gram of liver in human liver microsomes, the molecular, cellular (microsomal, tissue, organ), and organismal phenotype of CYP2D6 determined; the effect of genotype on each phenotype of CYP2D6-mediated dextromethorphan clearance (CL) was delineated, and the overall genotype-phenotype relationship for CYP2D6 was charted.	Dextromethorphan	316-332	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
28096434-8	2017	Mean fiber CSA, myonuclei/myofiber and Pax7+ nuclei/myofiber ratios were reduced in DEX compared to those in CON and PF muscles; CSA/myonucleus, BrdU+/total myonuclei and BrdU+ myonuclei/Pax7+ nuclei were similar among groups.	Dextromethorphan	84-87	paired box 7	Rattus norvegicus	39-43
29931930-10	2017	AET group showed a significantly reduced role on insulin resistance in-dex.	Dextromethorphan	71-74	insulin	Homo sapiens	49-56
27930497-0	2017	The COMT Val158Met Polymorphism Is Associated With Response to Add-on Dextromethorphan Treatment in Bipolar Disorder.	Dextromethorphan	70-86	catechol-O-methyltransferase	Homo sapiens	4-8
27930497-9	2017	FINDINGS/RESULTS: When stratified by the COMT Val158Met genotypes, significantly greater decreases in Hamilton Depression Rating Scale scores were found in the VPA + DM (30 mg/d) group in patients with the Val/Met genotype (P = 0.008).	Dextromethorphan	166-168	catechol-O-methyltransferase	Homo sapiens	41-45
27930497-10	2017	CONCLUSIONS: We conclude that the COMT Val158Met polymorphism may influence responses to DM (30 mg/d) by decreasing depressive symptoms in BD patients.	Dextromethorphan	89-91	catechol-O-methyltransferase	Homo sapiens	34-38
27836773-5	2017	MECs cultured with PRL, EGF and dexamethasone (DEX: glucocorticoid analog) developed the beta-casein secretion pathway.	Dextromethorphan	47-50	prolactin	Homo sapiens	19-22
27836773-9	2017	DEX also up-regulated the expression of SNARE proteins, such as SNAP-23, VAMP-8 and Syntaxin-12.	Dextromethorphan	0-3	synaptosome associated protein 23	Homo sapiens	64-71
27836773-9	2017	DEX also up-regulated the expression of SNARE proteins, such as SNAP-23, VAMP-8 and Syntaxin-12.	Dextromethorphan	0-3	vesicle associated membrane protein 8	Homo sapiens	73-79
27836773-9	2017	DEX also up-regulated the expression of SNARE proteins, such as SNAP-23, VAMP-8 and Syntaxin-12.	Dextromethorphan	0-3	syntaxin 12	Homo sapiens	84-95
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	Dextromethorphan	135-151	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27867000-10	2017	Interestingly, intra-CA1 microinjection of ACPA (0.5-1ng/rat) improved the amnesic effect of dextromethorphan /morphine combination.	Dextromethorphan	93-109	carbonic anhydrase 1	Rattus norvegicus	21-24
27867000-11	2017	The microinjection of AM251 into the CA1 region enhanced the response of the combination of dextromethorphan /morphine in inducing amnesia.	Dextromethorphan	92-108	carbonic anhydrase 1	Rattus norvegicus	37-40
27867000-12	2017	Moreover, Intra-CA1 microinjection of AM251 inhibited the improving effect of ACPA on dextromethorphan /morphine-induced amnesia.	Dextromethorphan	86-102	carbonic anhydrase 1	Rattus norvegicus	16-19
27867000-14	2017	Thus, it can be concluded that the dorsal hippocampal endocannabinoid system, via CB1 receptor-dependent mechanism, may be involved in morphine/dextromethorphan -induced amnesia.	Dextromethorphan	144-160	cannabinoid receptor 1	Rattus norvegicus	82-85
27791398-9	2017	Both DEX-treated groups displayed severely altered expression patterns of the core clock genes Bmal1 and Per2 in the liver and in fat.	Dextromethorphan	5-8	aryl hydrocarbon receptor nuclear translocator-like	Rattus norvegicus	95-100
27791398-9	2017	Both DEX-treated groups displayed severely altered expression patterns of the core clock genes Bmal1 and Per2 in the liver and in fat.	Dextromethorphan	5-8	period circadian regulator 2	Rattus norvegicus	105-109
27791398-10	2017	In addition, the expression of glutamate aspartate transporter, glial fibrillary acidic protein and glutamate transporter-1, astrocyte-related genes important for maintaining nervous system functions, was drastically decreased in the hippocampus of DEX-treated rats, especially when DEX was given at ZT0.	Dextromethorphan	249-252	solute carrier family 1 member 3	Rattus norvegicus	31-62
27791398-10	2017	In addition, the expression of glutamate aspartate transporter, glial fibrillary acidic protein and glutamate transporter-1, astrocyte-related genes important for maintaining nervous system functions, was drastically decreased in the hippocampus of DEX-treated rats, especially when DEX was given at ZT0.	Dextromethorphan	249-252	solute carrier family 1 member 2	Rattus norvegicus	100-123
27791398-10	2017	In addition, the expression of glutamate aspartate transporter, glial fibrillary acidic protein and glutamate transporter-1, astrocyte-related genes important for maintaining nervous system functions, was drastically decreased in the hippocampus of DEX-treated rats, especially when DEX was given at ZT0.	Dextromethorphan	283-286	solute carrier family 1 member 3	Rattus norvegicus	31-62
27452504-7	2016	On the other hand, we found that ATF4 might inhibit the transcription of Srebp1c through TRB3, which is repressed by IBMX and DEX during early adipogenesis.	Dextromethorphan	126-129	activating transcription factor 4	Homo sapiens	33-37
28523069-6	2017	Chromatin immunoprecipitation analysis demonstrated that GR repress AHR recruitment and chromatin accessibility response to TCDD + Dex treatment leading to repression of AHR target genes.	Dextromethorphan	131-134	nuclear receptor subfamily 3 group C member 1	Homo sapiens	57-59
28523069-6	2017	Chromatin immunoprecipitation analysis demonstrated that GR repress AHR recruitment and chromatin accessibility response to TCDD + Dex treatment leading to repression of AHR target genes.	Dextromethorphan	131-134	aryl hydrocarbon receptor	Homo sapiens	68-71
28523069-6	2017	Chromatin immunoprecipitation analysis demonstrated that GR repress AHR recruitment and chromatin accessibility response to TCDD + Dex treatment leading to repression of AHR target genes.	Dextromethorphan	131-134	aryl hydrocarbon receptor	Homo sapiens	170-173
28523069-9	2017	Coimmunoprecipitation assay revealed that AHR is associated with GR in ARPE-19 cells and the interaction is enhanced by the addition of TCDD and Dex.	Dextromethorphan	145-148	aryl hydrocarbon receptor	Homo sapiens	42-45
27998873-6	2016	Urine protein was obviously reduced in DEX group with comparable p-AKT/AKT ratio and Bad mRNA expression level with those in the control group (P&gt;0.05).	Dextromethorphan	39-42	AKT serine/threonine kinase 1	Rattus norvegicus	67-70
27998873-6	2016	Urine protein was obviously reduced in DEX group with comparable p-AKT/AKT ratio and Bad mRNA expression level with those in the control group (P&gt;0.05).	Dextromethorphan	39-42	AKT serine/threonine kinase 1	Rattus norvegicus	71-74
27557631-7	2016	The treatment with TGF-beta1, even when combined with Dex, decreased the viability and cell growth when compared with the positive control.	Dextromethorphan	54-57	transforming growth factor, beta 1	Rattus norvegicus	19-28
28704069-4	2017	Here, we characterized the peripheral clock gene synchronization in Clock/Clock mice by daily injections of a synthetic glucocorticoid (dexamethasone, DEX) by monitoring in vivo PER2::LUCIFERASE bioluminescence.	Dextromethorphan	151-154	circadian locomotor output cycles kaput	Mus musculus	38-43
28704069-4	2017	Here, we characterized the peripheral clock gene synchronization in Clock/Clock mice by daily injections of a synthetic glucocorticoid (dexamethasone, DEX) by monitoring in vivo PER2::LUCIFERASE bioluminescence.	Dextromethorphan	151-154	circadian locomotor output cycles kaput	Mus musculus	68-73
28704069-4	2017	Here, we characterized the peripheral clock gene synchronization in Clock/Clock mice by daily injections of a synthetic glucocorticoid (dexamethasone, DEX) by monitoring in vivo PER2::LUCIFERASE bioluminescence.	Dextromethorphan	151-154	circadian locomotor output cycles kaput	Mus musculus	74-79
28704069-4	2017	Here, we characterized the peripheral clock gene synchronization in Clock/Clock mice by daily injections of a synthetic glucocorticoid (dexamethasone, DEX) by monitoring in vivo PER2::LUCIFERASE bioluminescence.	Dextromethorphan	151-154	period circadian clock 2	Mus musculus	178-182
28704069-8	2017	The Clock/Clock mice synchronized to the 30-h T-cycle stimulation, which suggested that the peripheral clocks in the Clock/Clock mice had increased synchronizing ability upon DEX stimulation, to that of circadian and hour-glass type oscillations, because of weak internal clock oscillators.	Dextromethorphan	175-178	circadian locomotor output cycles kaput	Mus musculus	4-9
28704069-8	2017	The Clock/Clock mice synchronized to the 30-h T-cycle stimulation, which suggested that the peripheral clocks in the Clock/Clock mice had increased synchronizing ability upon DEX stimulation, to that of circadian and hour-glass type oscillations, because of weak internal clock oscillators.	Dextromethorphan	175-178	circadian locomotor output cycles kaput	Mus musculus	10-15
28704069-8	2017	The Clock/Clock mice synchronized to the 30-h T-cycle stimulation, which suggested that the peripheral clocks in the Clock/Clock mice had increased synchronizing ability upon DEX stimulation, to that of circadian and hour-glass type oscillations, because of weak internal clock oscillators.	Dextromethorphan	175-178	circadian locomotor output cycles kaput	Mus musculus	10-15
28704069-8	2017	The Clock/Clock mice synchronized to the 30-h T-cycle stimulation, which suggested that the peripheral clocks in the Clock/Clock mice had increased synchronizing ability upon DEX stimulation, to that of circadian and hour-glass type oscillations, because of weak internal clock oscillators.	Dextromethorphan	175-178	circadian locomotor output cycles kaput	Mus musculus	10-15
28704069-8	2017	The Clock/Clock mice synchronized to the 30-h T-cycle stimulation, which suggested that the peripheral clocks in the Clock/Clock mice had increased synchronizing ability upon DEX stimulation, to that of circadian and hour-glass type oscillations, because of weak internal clock oscillators.	Dextromethorphan	175-178	circadian locomotor output cycles kaput	Mus musculus	103-108
28523069-9	2017	Coimmunoprecipitation assay revealed that AHR is associated with GR in ARPE-19 cells and the interaction is enhanced by the addition of TCDD and Dex.	Dextromethorphan	145-148	nuclear receptor subfamily 3 group C member 1	Homo sapiens	65-67
28271978-4	2017	Thus, the present study evaluated, using dextromethorphan as a phenotyping probe, the relationship between CYP2D6 phenotype and CYP2D6 genotype, especially for the ultrarapid metabolizer (UM) phenotype.	Dextromethorphan	41-57	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	128-134
27802180-9	2016	The up-regulated miR-146a expression with agomir contributed to the differentiation of Th17 and Treg in ITP patients.Moreover, miR-146a was increased in the presence of DEX in PBMCs of ITP patients in vitro.Our study represents the abnormal expression profile of immune-related miRNAs in ITP patients, and miR-146a may be involved in Tregs differentiation and function.	Dextromethorphan	169-172	microRNA 146a	Homo sapiens	17-25
27802180-9	2016	The up-regulated miR-146a expression with agomir contributed to the differentiation of Th17 and Treg in ITP patients.Moreover, miR-146a was increased in the presence of DEX in PBMCs of ITP patients in vitro.Our study represents the abnormal expression profile of immune-related miRNAs in ITP patients, and miR-146a may be involved in Tregs differentiation and function.	Dextromethorphan	169-172	microRNA 146a	Homo sapiens	127-135
27802180-9	2016	The up-regulated miR-146a expression with agomir contributed to the differentiation of Th17 and Treg in ITP patients.Moreover, miR-146a was increased in the presence of DEX in PBMCs of ITP patients in vitro.Our study represents the abnormal expression profile of immune-related miRNAs in ITP patients, and miR-146a may be involved in Tregs differentiation and function.	Dextromethorphan	169-172	microRNA 146a	Homo sapiens	127-135
27452504-7	2016	On the other hand, we found that ATF4 might inhibit the transcription of Srebp1c through TRB3, which is repressed by IBMX and DEX during early adipogenesis.	Dextromethorphan	126-129	sterol regulatory element binding transcription factor 1	Homo sapiens	73-80
27452504-7	2016	On the other hand, we found that ATF4 might inhibit the transcription of Srebp1c through TRB3, which is repressed by IBMX and DEX during early adipogenesis.	Dextromethorphan	126-129	tribbles pseudokinase 3	Homo sapiens	89-93
27543351-4	2016	To further understand the properties of this unique polymer, we encapsulated a model drug resiquimod, which is a toll-like receptor (TLR) 7/8 agonist, into Ace-DEX MPs of different polymer CAC and dextran MW.	Dextromethorphan	160-163	angiotensin I converting enzyme	Homo sapiens	156-159
27580115-1	2016	OBJECTIVE To characterize polymorphisms of the gene for cytochrome P450 isozyme 2D50 (CYP2D50) and the disposition of 2 CYP2D50 probe drugs, dextromethorphan and debrisoquine, in horses.	Dextromethorphan	141-157	cytochrome P450 family 2 subfamily D member 50	Equus caballus	56-84
27523466-8	2016	DEX increased Ang1 and decreased Ang2, indicating that the balance of Ang1/Ang2 may be important in determining functional changes in REC under high glucose conditions.	Dextromethorphan	0-3	angiopoietin 1	Homo sapiens	14-18
27523466-8	2016	DEX increased Ang1 and decreased Ang2, indicating that the balance of Ang1/Ang2 may be important in determining functional changes in REC under high glucose conditions.	Dextromethorphan	0-3	angiopoietin 2	Homo sapiens	33-37
27523466-8	2016	DEX increased Ang1 and decreased Ang2, indicating that the balance of Ang1/Ang2 may be important in determining functional changes in REC under high glucose conditions.	Dextromethorphan	0-3	angiopoietin 1	Homo sapiens	70-74
27523466-8	2016	DEX increased Ang1 and decreased Ang2, indicating that the balance of Ang1/Ang2 may be important in determining functional changes in REC under high glucose conditions.	Dextromethorphan	0-3	angiopoietin 2	Homo sapiens	75-79
27580401-3	2016	In this proof-of-concept study, behavioral and biochemical analyses were carried out to evaluate the potential involvement of brain-derived neurotrophic factor (BDNF) in the antidepressant-like effects of DM in mice, with comparisons to ketamine and imipramine.	Dextromethorphan	205-207	brain derived neurotrophic factor	Mus musculus	126-159
27580401-3	2016	In this proof-of-concept study, behavioral and biochemical analyses were carried out to evaluate the potential involvement of brain-derived neurotrophic factor (BDNF) in the antidepressant-like effects of DM in mice, with comparisons to ketamine and imipramine.	Dextromethorphan	205-207	brain derived neurotrophic factor	Mus musculus	161-165
27136042-6	2016	On the basis of its turn-on fluorescence response, PhO-dex-GO was able to report kinetic and thermodynamic parameters involving a maximum velocity, a Michaelis constant, and an inhibition dissociation constant for AChE activity and inhibition.	Dextromethorphan	55-58	acetylcholinesterase (Cartwright blood group)	Homo sapiens	214-218
27023460-3	2016	In this study, we investigated the pharmacokinetic interaction between Zuojin Pill and the sensitive CYP2D6 probe dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.	Dextromethorphan	114-130	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	101-107
27023460-9	2016	CONCLUSION: These data demonstrated that administration of Zuojin Pill inhibited moderately CYP2D6-mediated metabolism of dextromethorphan in healthy volunteers.	Dextromethorphan	122-138	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-98
27196001-10	2016	In cells with silenced beclin-1 (BCN1), required for autophagosome formation, the synergy of DEX and SEL was markedly reduced.	Dextromethorphan	93-96	beclin 1	Homo sapiens	23-31
27196001-10	2016	In cells with silenced beclin-1 (BCN1), required for autophagosome formation, the synergy of DEX and SEL was markedly reduced.	Dextromethorphan	93-96	beclin 1	Homo sapiens	33-37
27142940-12	2016	Dex and Cort induced expression of only one of the three Tdo2 transcripts (Tdo2-FL) in OHSCs.	Dextromethorphan	0-3	tryptophan 2,3-dioxygenase	Mus musculus	75-79
26709018-5	2016	PCR and PLS-2 models were established for simultaneous determination of the studied drugs in the range of 3.00-15.00, 1.00-13.00, 4.00-12.00, 1.50-9.50, and 4.00-12.00 mug mL(-1) for IMP, CIPRO, DEX, PAR and CIL, respectively, by using eighteen mixtures as calibration set and seven mixtures as validation set.	Dextromethorphan	195-198	lymphocyte cytosolic protein 1	Homo sapiens	8-13
26387777-0	2016	Fluorescent bovine serum albumin interacting with the antitussive quencher dextromethorphan: a spectroscopic insight.	Dextromethorphan	75-91	albumin	Homo sapiens	19-32
26387777-1	2016	The interaction of dextromethorphan hydrobromide (DXM) with bovine serum albumin (BSA) is studied by using fluorescence spectra, UV-vis absorption, synchronous fluorescence spectra (SFS), 3D fluorescence spectra, Fourier transform infrared (FTIR) spectroscopy and circular dichroism under simulated physiological conditions.	Dextromethorphan	19-48	albumin	Homo sapiens	67-80
26387777-1	2016	The interaction of dextromethorphan hydrobromide (DXM) with bovine serum albumin (BSA) is studied by using fluorescence spectra, UV-vis absorption, synchronous fluorescence spectra (SFS), 3D fluorescence spectra, Fourier transform infrared (FTIR) spectroscopy and circular dichroism under simulated physiological conditions.	Dextromethorphan	50-53	albumin	Homo sapiens	67-80
27228512-8	2016	Lower shivering cessation time (P &lt; 0.001) and higher response rate (P &lt; 0.01) were observed in DEX I and II groups compared with DEX III and meperidine groups, with a nonsignificant difference between DEX I and II groups.	Dextromethorphan	102-105	Dexi homolog	Homo sapiens	208-220
26840181-3	2016	The observed in vitro GR activity ranged from 39 to 155 ng dexamethasone-equivalent/L (ng Dex-EQ/L) in the secondary effluents of four wastewater treatment plants.	Dextromethorphan	90-93	nuclear receptor subfamily 3 group C member 1	Homo sapiens	22-24
29931886-1	2016	OBJECTIVE: To explore the role of Nrf2/ARE pathway in skeletal muscle ischemia/reperfusion(I/R) injury preconditioning by dexmedetomidine(DEX).	Dextromethorphan	138-141	NFE2 like bZIP transcription factor 2	Rattus norvegicus	34-38
29931886-11	2016	The levels of wet/dry MDA LDH CK were significantly lower(P&lt;0.05) yet the levels of SOD and Nrf2/HO-1 were significantly higher(P&lt;0.05) in DEX group than those in I/R group.	Dextromethorphan	145-148	NFE2 like bZIP transcription factor 2	Rattus norvegicus	95-99
29931886-11	2016	The levels of wet/dry MDA LDH CK were significantly lower(P&lt;0.05) yet the levels of SOD and Nrf2/HO-1 were significantly higher(P&lt;0.05) in DEX group than those in I/R group.	Dextromethorphan	145-148	heme oxygenase 1	Rattus norvegicus	100-104
29931886-13	2016	CONCLUSIONS: Nrf2 protein was expressed in skeletal muscle of rat and DEX could promote its level in nucleus by alpha-adrenergic receptor.	Dextromethorphan	70-73	NFE2 like bZIP transcription factor 2	Rattus norvegicus	13-17
27033569-10	2016	The HO-1 mRNA level before the stimulation was 1.000, and 17.264+-4.275 after the stimulation of 1 ng/ml IL-17A (U=0, P&lt;0.05), 19.128+-4.605 after the stimulation of 10 ng/ml IL-17A (U=0, P&lt;0.05), but was significantly suppressed after stimulation with glucocorticoids (dexamethasone, DEX).	Dextromethorphan	291-294	heme oxygenase 1	Homo sapiens	4-8
26310775-0	2016	Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms In Vitro.	Dextromethorphan	89-105	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	20-26
26310775-9	2016	The remaining 22 variants exhibited significantly decreased intrinsic clearance values for bufuralol 1"-hydroxylation and 20 variants showed significantly lower intrinsic clearance values for dextromethorphan O-demethylation than those of the wild-type CYP2D6.1.	Dextromethorphan	192-208	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	253-259
26212138-8	2016	Stepwise linear regression analysis showed F-DEX% was significantly related to HbA1c level (beta=- 0.328, p=0.007) after adjusting for other covariates (age, BMI, waist circumference, SBP, TC, TG, and HOMA-IR).	Dextromethorphan	45-48	selenium binding protein 1	Homo sapiens	184-187
27582327-8	2016	The activities of cytochrome P450 (CYP) 1A2, CYP2D6, CYP3A, xanthine oxidase (XO) and N-acetyltransferase 2 (NAT2) were assessed based on the urinary metabolic indices of caffeine and dextromethorphan, and the urinary excretion ratio of 6beta-hydroxycortisol to cortisol.	Dextromethorphan	184-200	N-acetyltransferase 2	Homo sapiens	109-113
26892731-11	2016	Cynomolgus monkey CYP2D17 and Japanese monkey 2D29 metabolize bufuralol and dextromethorphan.	Dextromethorphan	76-92	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	18-25
26892731-12	2016	CYP2D17 metabolizes bufuralol and dextromethorphan, whereas CYP2D29 metabolizes bufuralol and debrisoquine.	Dextromethorphan	34-50	cytochrome P450 family 2 subfamily D member 6	Macaca fascicularis	0-7
26452722-11	2016	Similarly, quinidine-mediated CYP2D6 inhibition reduced clearance of dextromethorphan and desipramine by 71 and 22%, respectively.	Dextromethorphan	69-85	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	30-36
26362564-0	2016	Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.	Dextromethorphan	11-27	insulin	Homo sapiens	80-87
26597400-3	2015	METHODS: The (13)C-dextromethorphan breath test (DM-BT) was used to determine CYP2D6 phenotype using (13)C-dextromethorphan ((13)C-DM) as a probe.	Dextromethorphan	19-35	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
26756383-8	2016	CONCLUSIONS: In patients with macula oedema secondary to RVO, the switch from bevacizumab to IVI-DEX seems more beneficial in terms of short-term VA and long-term reduction of CMT than the DEX anti-VEGF agent sequence.	Dextromethorphan	97-100	vascular endothelial growth factor A	Homo sapiens	198-202
29693982-1	2016	The aim of the paper was to studyfrequency of laboratory determinationsand toxicological informationrelated to over-the-counter drugs(OTC): paracetamol (acetaminophen),salicylates and dextromethorphan.The research was based on data fromToxicological Laboratory and PoisonInformation Center UJ CM in Krakowin years 2010-2015.Paracetamol was determined averagely102 times a year, more than50% (57 cases) were positive withconfirmation of poisoning.	Dextromethorphan	184-200	ornithine transcarbamylase	Homo sapiens	134-137
26597400-3	2015	METHODS: The (13)C-dextromethorphan breath test (DM-BT) was used to determine CYP2D6 phenotype using (13)C-dextromethorphan ((13)C-DM) as a probe.	Dextromethorphan	19-35	B cell receptor associated protein 31	Homo sapiens	129-133
26597400-3	2015	METHODS: The (13)C-dextromethorphan breath test (DM-BT) was used to determine CYP2D6 phenotype using (13)C-dextromethorphan ((13)C-DM) as a probe.	Dextromethorphan	49-51	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
26597400-3	2015	METHODS: The (13)C-dextromethorphan breath test (DM-BT) was used to determine CYP2D6 phenotype using (13)C-dextromethorphan ((13)C-DM) as a probe.	Dextromethorphan	49-51	B cell receptor associated protein 31	Homo sapiens	129-133
26323097-7	2015	By silencing GILZ, we next demonstrated that GILZ is necessary for Dex induced apoptosis while triggering an imbalance between anti- and pro-apoptotic Bcl-2 proteins.	Dextromethorphan	67-70	TSC22 domain family member 3	Homo sapiens	45-49
26519345-11	2015	CONCLUSIONS: DEX 0.7 significantly improved visual and anatomic outcomes in patients with DME previously treated with laser, intravitreal anti-vascular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these therapies.	Dextromethorphan	13-16	vascular endothelial growth factor A	Homo sapiens	143-177
26343594-0	2015	ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan.	Dextromethorphan	117-133	aldehyde dehydrogenase 2 family member	Homo sapiens	0-5
26779334-13	2015	The anti-CD163-dex group showed increased blood levels of albumin and alanine aminotransferase and a diminished inflammatory response in terms of significantly reduced haptoglobin, alpha2-macroglobulin and Interleukine-6.	Dextromethorphan	15-18	haptoglobin	Rattus norvegicus	168-179
26779334-13	2015	The anti-CD163-dex group showed increased blood levels of albumin and alanine aminotransferase and a diminished inflammatory response in terms of significantly reduced haptoglobin, alpha2-macroglobulin and Interleukine-6.	Dextromethorphan	15-18	alpha-2-macroglobulin	Rattus norvegicus	181-201
26636519-6	2015	CONCLUSIONS: Large dose of DEX (10-6 mol/l) up-regulated the expression of MR and GR in the reduction of the contrast exactly.	Dextromethorphan	27-30	nuclear receptor subfamily 3 group C member 2	Homo sapiens	75-77
26636519-6	2015	CONCLUSIONS: Large dose of DEX (10-6 mol/l) up-regulated the expression of MR and GR in the reduction of the contrast exactly.	Dextromethorphan	27-30	nuclear receptor subfamily 3 group C member 1	Homo sapiens	82-84
26517722-12	2015	P38 inhibitor significantly enhanced DEX suppression of LPS-induced IL-8 mRNA by PBMC of steroid resistant asthmatics.	Dextromethorphan	37-40	mitogen-activated protein kinase 14	Homo sapiens	0-3
26517722-12	2015	P38 inhibitor significantly enhanced DEX suppression of LPS-induced IL-8 mRNA by PBMC of steroid resistant asthmatics.	Dextromethorphan	37-40	C-X-C motif chemokine ligand 8	Homo sapiens	68-72
26053620-6	2015	RESULTS AND CONCLUSION: Masseter muscle weight in the DEX-treated group was significantly lower than that in the Control group, as expected, but co-treatment with CB suppressed the DEX-induced masseter muscle atrophy, concomitantly with inhibition of fast-to-slow MHC isoforms transition.	Dextromethorphan	54-57	major histocompatibility complex, class I, C	Homo sapiens	264-267
26195224-4	2015	In a competitive inhibition study, the metabolic activity of the CYP2D6 was assessed based on their demethylation of dextromethorphan in the presence or absence of TER, and the time-dependency of the inhibitory effects were examined by preincubating the enzymes with TER.	Dextromethorphan	117-133	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
26004528-3	2015	Inhibition studies showed appropriate sigma1 receptor pharmacology, including higher affinity for (+)-N-allylnormetazocine with respect to the (-)-enantiomer, and positive allosteric modulation of dextromethorphan binding by phenytoin.	Dextromethorphan	197-213	sigma non-opioid intracellular receptor 1	Mus musculus	38-53
26004528-7	2015	In vivo, dextromethorphan inhibited the specific binding of a radioiodinated sigma1 receptor ligand in lung with an ED50 of 1.2mumol/kg, a value near the recommended dosage for the drug as a cough suppressant.	Dextromethorphan	9-25	sigma non-opioid intracellular receptor 1	Mus musculus	77-92
25370709-11	2015	ZOL&amp;DEX treatment suppressed the levels of RANKL and IL-17, but induced an upregulation of osteoprotegerin and FAM20C in both bones.	Dextromethorphan	8-11	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	47-52
25370709-11	2015	ZOL&amp;DEX treatment suppressed the levels of RANKL and IL-17, but induced an upregulation of osteoprotegerin and FAM20C in both bones.	Dextromethorphan	8-11	interleukin 17A	Mus musculus	57-62
25370709-11	2015	ZOL&amp;DEX treatment suppressed the levels of RANKL and IL-17, but induced an upregulation of osteoprotegerin and FAM20C in both bones.	Dextromethorphan	8-11	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	95-110
25370709-11	2015	ZOL&amp;DEX treatment suppressed the levels of RANKL and IL-17, but induced an upregulation of osteoprotegerin and FAM20C in both bones.	Dextromethorphan	8-11	FAM20C, golgi associated secretory pathway kinase	Mus musculus	115-121
25682269-2	2015	CYP2D44 is expressed in cynomolgus macaque liver and encodes a functional drug metabolizing enzyme, metabolizing typical human CYP2D substrates such as bufuralol and dextromethorphan.	Dextromethorphan	166-182	cytochrome P450 family 2 subfamily D member 8	Macaca fascicularis	0-7
25682269-2	2015	CYP2D44 is expressed in cynomolgus macaque liver and encodes a functional drug metabolizing enzyme, metabolizing typical human CYP2D substrates such as bufuralol and dextromethorphan.	Dextromethorphan	166-182	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-5
26084330-6	2015	Moreover, the inhibited expression of Dex/cAMP-induced PEPCK mRNA by insulin was enhanced by the L-Cit treatment.	Dextromethorphan	38-41	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	55-60
26053620-7	2015	Activation of the Akt/mTOR pathway in masseter muscle of the DEX-treated group was significantly inhibited compared to that of the Control group, and CB suppressed this inhibition.	Dextromethorphan	61-64	AKT serine/threonine kinase 1	Homo sapiens	18-21
26053620-7	2015	Activation of the Akt/mTOR pathway in masseter muscle of the DEX-treated group was significantly inhibited compared to that of the Control group, and CB suppressed this inhibition.	Dextromethorphan	61-64	mechanistic target of rapamycin kinase	Homo sapiens	22-26
26053620-8	2015	DEX also suppressed expression of IGF1 (positive regulator of muscle growth), and CB attenuated this inhibition.	Dextromethorphan	0-3	insulin like growth factor 1	Homo sapiens	34-38
26053620-11	2015	These results indicate that CB antagonizes DEX-induced muscle atrophy and fast-to-slow MHC isoform transition via modulation of Akt/mTOR activity and IGF1 expression.	Dextromethorphan	43-46	AKT serine/threonine kinase 1	Homo sapiens	128-131
26053620-11	2015	These results indicate that CB antagonizes DEX-induced muscle atrophy and fast-to-slow MHC isoform transition via modulation of Akt/mTOR activity and IGF1 expression.	Dextromethorphan	43-46	mechanistic target of rapamycin kinase	Homo sapiens	132-136
26053620-11	2015	These results indicate that CB antagonizes DEX-induced muscle atrophy and fast-to-slow MHC isoform transition via modulation of Akt/mTOR activity and IGF1 expression.	Dextromethorphan	43-46	insulin like growth factor 1	Homo sapiens	150-154
25681130-11	2015	Beagle dogs treated intravenously with dextromethorphan (2 mg/ml) after pretreatment with GFA injection showed reduced CYP2D metabolic activity, with the Cmax of dextrorphan being one-third that of the saline-treated group and area under the plasma concentration-time curve half that of the saline-treated group.	Dextromethorphan	39-55	cytochrome P450 2D15	Canis lupus familiaris	119-124
26514007-34	2015	DEX significantly increased the expression of Foxp3 mRNA (P&lt;0.	Dextromethorphan	0-3	forkhead box P3	Mus musculus	46-51
26514007-36	2015	CONCLUSION: DEX reduce upper airway allergic inflammation effectively, which may be mediated by promoting the expression of Foxp3 and inducing the amplification of Tregs in vivo.	Dextromethorphan	12-15	forkhead box P3	Mus musculus	124-129
25681130-4	2015	We characterized the potency and specificity of GFA CYP2D inhibition based on dextromethorphan O-demethylation, a CYP2D6 probe substrate of activity in human, mouse, rat, dog, and monkey liver microsomes.	Dextromethorphan	78-94	cytochrome P450 2D15	Canis lupus familiaris	52-57
25613226-6	2015	Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORgammat+ T cells and elevation of CD4+Foxp3+ T cells in BALF.	Dextromethorphan	49-52	CD4 antigen	Mus musculus	118-121
25613226-6	2015	Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORgammat+ T cells and elevation of CD4+Foxp3+ T cells in BALF.	Dextromethorphan	49-52	CD4 antigen	Mus musculus	158-161
25613226-6	2015	Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORgammat+ T cells and elevation of CD4+Foxp3+ T cells in BALF.	Dextromethorphan	49-52	forkhead box P3	Mus musculus	162-167
25613226-7	2015	Furthermore, icariin or DEX caused a significant reduction in IL-6, IL-17 and TGF-beta level in BALF.	Dextromethorphan	24-27	interleukin 6	Mus musculus	62-66
25613226-7	2015	Furthermore, icariin or DEX caused a significant reduction in IL-6, IL-17 and TGF-beta level in BALF.	Dextromethorphan	24-27	interleukin 17A	Mus musculus	68-73
25613226-7	2015	Furthermore, icariin or DEX caused a significant reduction in IL-6, IL-17 and TGF-beta level in BALF.	Dextromethorphan	24-27	transforming growth factor, beta 1	Mus musculus	78-86
25613226-9	2015	Western blot assay found that icariin or DEX suppressed RORgammat and promoted Foxp3 expression in the lung tissue.	Dextromethorphan	41-44	forkhead box P3	Mus musculus	79-84
25613226-10	2015	qPCR analysis revealed that icariin and DEX resulted in a notable decrease in RORgammat and increase in Foxp3 mRNA expression in isolated spleen CD4+ T cell.	Dextromethorphan	40-43	forkhead box P3	Mus musculus	104-109
25613226-10	2015	qPCR analysis revealed that icariin and DEX resulted in a notable decrease in RORgammat and increase in Foxp3 mRNA expression in isolated spleen CD4+ T cell.	Dextromethorphan	40-43	CD4 antigen	Mus musculus	145-148
25970334-8	2015	At 24 h post-IR urine lipocalin-2 (mug/mL) was higher (P&lt;0.05) in VPA, Dex and Vehicle groups (9.61-11.36) compared to naive group (0.67+-0.29); also, kidney injury molecule-1 (KIM-1; ng/mL) was higher (P&lt;0.05) in VPA, Dex and Vehicle groups (13.7-18.7) compared to naive group (1.7+-1.9).	Dextromethorphan	74-77	lipocalin 2	Rattus norvegicus	22-33
25689493-4	2015	Regarding the DEX-induced atrophy of C2C12 myotubes, N-myristoylated Cblin was more effective than Cblin for inhibiting the DEX-induced decreases in C2C12 myotube diameter and IRS-1 degradation.	Dextromethorphan	124-127	insulin receptor substrate 1	Mus musculus	176-181
25824679-0	2015	Diabetes: Dextromethorphan stimulates insulin secretion from pancreatic beta cells--a new role for an old drug?	Dextromethorphan	10-26	insulin	Homo sapiens	38-45
25891764-1	2015	In a previous study, we found that the CYP2D6 phenotype determined by (13)C-dextromethorphan breath test (DM-BT) might be used to predict tamoxifen treatment outcome in breast cancer patients in the adjuvant setting.	Dextromethorphan	76-92	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
25625352-13	2015	BSYQF and DEX treatment resulted in an obvious elevation in CD4(+)Foxp3(+) T cells in BALF and spleen (p&lt;0.05).	Dextromethorphan	10-13	CD4 antigen	Mus musculus	60-63
25625352-13	2015	BSYQF and DEX treatment resulted in an obvious elevation in CD4(+)Foxp3(+) T cells in BALF and spleen (p&lt;0.05).	Dextromethorphan	10-13	forkhead box P3	Mus musculus	66-71
25624460-4	2015	Here, we show that MERTK is highly expressed on dex-induced human tol-DCs and participates in their tolerogenic effect.	Dextromethorphan	48-51	MER proto-oncogene, tyrosine kinase	Homo sapiens	19-24
25774850-5	2015	We also noticed that, in vivo, the NMDAR antagonist dextromethorphan (DXM) enhanced glucose tolerance in mice, and that in vitro dextrorphan, the main metabolite of DXM, amplified the stimulatory effect of exendin-4 on GSIS.	Dextromethorphan	52-68	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	35-40
25774850-5	2015	We also noticed that, in vivo, the NMDAR antagonist dextromethorphan (DXM) enhanced glucose tolerance in mice, and that in vitro dextrorphan, the main metabolite of DXM, amplified the stimulatory effect of exendin-4 on GSIS.	Dextromethorphan	70-73	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	35-40
25774850-5	2015	We also noticed that, in vivo, the NMDAR antagonist dextromethorphan (DXM) enhanced glucose tolerance in mice, and that in vitro dextrorphan, the main metabolite of DXM, amplified the stimulatory effect of exendin-4 on GSIS.	Dextromethorphan	165-168	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	35-40
25689493-7	2015	Finally, we demonstrated that N-myristoylated Cblin prevented the wet weight loss, IRS-1 degradation, and MAFbx/atrogin-1 and MuRF-1 expression in gastrocnemius muscle of DEX-treated mice approximately fourfold more effectively than Cblin.	Dextromethorphan	171-174	F-box protein 32	Mus musculus	106-111
25689493-7	2015	Finally, we demonstrated that N-myristoylated Cblin prevented the wet weight loss, IRS-1 degradation, and MAFbx/atrogin-1 and MuRF-1 expression in gastrocnemius muscle of DEX-treated mice approximately fourfold more effectively than Cblin.	Dextromethorphan	171-174	F-box protein 32	Mus musculus	112-121
25689493-7	2015	Finally, we demonstrated that N-myristoylated Cblin prevented the wet weight loss, IRS-1 degradation, and MAFbx/atrogin-1 and MuRF-1 expression in gastrocnemius muscle of DEX-treated mice approximately fourfold more effectively than Cblin.	Dextromethorphan	171-174	tripartite motif-containing 63	Mus musculus	126-132
26226765-4	2015	After the oral administration with FZHY, normal rats given phenacetin, omeprazole, tolbutamide and dextromethorphan showed increase in AUC(0-t) and decrease in CL to varying degrees, indicating that FZHY obviously inhibited the activities of CYP1A2, CYP2C9, CYP2C19 and CYP2D6 in normal rats, but with no obvious effect on the activity of CYP3A4.	Dextromethorphan	99-115	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	242-248
25512021-4	2015	Dex reveals its anti-inflammatory effect by reducing endogenous prostaglandin E2 (PGE2) formation and by suppressing the inducible enzymes cyclooxygenase 2 and microsomal PGE2 synthase 1.	Dextromethorphan	0-3	prostaglandin-endoperoxide synthase 2	Homo sapiens	139-155
26226765-4	2015	After the oral administration with FZHY, normal rats given phenacetin, omeprazole, tolbutamide and dextromethorphan showed increase in AUC(0-t) and decrease in CL to varying degrees, indicating that FZHY obviously inhibited the activities of CYP1A2, CYP2C9, CYP2C19 and CYP2D6 in normal rats, but with no obvious effect on the activity of CYP3A4.	Dextromethorphan	99-115	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	270-276
25619394-5	2015	The metabolism of testosterone (TEST, 10 mumol/L) and dextromethorphan (DEM, 1 mumol/L), the two typical substrates for CYP3A4 and CYP2D6, in the cells was examined in the presence of different agents.	Dextromethorphan	54-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
26118111-3	2015	Tolbutamide, chlorzoxazone, theophylline, midazolam, omeprazole and dextromethorphan were chosen as probe substrates of CYP2C6, CYP2E1, CYP1A2, CYP3A2, CYP2D1 and CYP2D2 of rats.	Dextromethorphan	68-84	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	120-126
25619394-5	2015	The metabolism of testosterone (TEST, 10 mumol/L) and dextromethorphan (DEM, 1 mumol/L), the two typical substrates for CYP3A4 and CYP2D6, in the cells was examined in the presence of different agents.	Dextromethorphan	54-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137
25619394-5	2015	The metabolism of testosterone (TEST, 10 mumol/L) and dextromethorphan (DEM, 1 mumol/L), the two typical substrates for CYP3A4 and CYP2D6, in the cells was examined in the presence of different agents.	Dextromethorphan	72-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
25619394-5	2015	The metabolism of testosterone (TEST, 10 mumol/L) and dextromethorphan (DEM, 1 mumol/L), the two typical substrates for CYP3A4 and CYP2D6, in the cells was examined in the presence of different agents.	Dextromethorphan	72-75	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137
25464883-4	2014	The compounds, similarly as dextromethorphan, interact with the middle portion of alpha3beta4 nAChR ion channel.	Dextromethorphan	28-44	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	94-99
25324279-7	2015	The closest prediction was obtained for CYP3A (simvastatin) DDI when the competitive inhibition from both AMIO and MDEA was considered, for CYP2D6 (dextromethorphan) DDI when the competitive inhibition from AMIO and the competitive plus time-dependent inhibition from MDEA were incorporated, and for CYP2C9 (warfarin) DDI when the competitive plus time-dependent inhibition from AMIO and the competitive inhibition from MDEA were considered.	Dextromethorphan	148-164	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	140-146
25324279-7	2015	The closest prediction was obtained for CYP3A (simvastatin) DDI when the competitive inhibition from both AMIO and MDEA was considered, for CYP2D6 (dextromethorphan) DDI when the competitive inhibition from AMIO and the competitive plus time-dependent inhibition from MDEA were incorporated, and for CYP2C9 (warfarin) DDI when the competitive plus time-dependent inhibition from AMIO and the competitive inhibition from MDEA were considered.	Dextromethorphan	148-164	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	300-306
25256150-10	2015	Moreover, COG and Dex significantly suppressed the production of TNF-alpha, IL-1beta, and IL-6 in serum.	Dextromethorphan	18-21	tumor necrosis factor	Rattus norvegicus	65-74
25256150-10	2015	Moreover, COG and Dex significantly suppressed the production of TNF-alpha, IL-1beta, and IL-6 in serum.	Dextromethorphan	18-21	interleukin 1 beta	Rattus norvegicus	76-84
25256150-10	2015	Moreover, COG and Dex significantly suppressed the production of TNF-alpha, IL-1beta, and IL-6 in serum.	Dextromethorphan	18-21	interleukin 6	Rattus norvegicus	90-94
25256150-11	2015	HE staining study demonstrated that COG and Dex significantly suppressed pathological changes of joints tissues; TUNEL assay demonstrated that COG and Dex induced apoptosis of AA via regulation of the protein expression of Bcl-2 and Bax.	Dextromethorphan	151-154	BCL2, apoptosis regulator	Rattus norvegicus	223-228
25256150-11	2015	HE staining study demonstrated that COG and Dex significantly suppressed pathological changes of joints tissues; TUNEL assay demonstrated that COG and Dex induced apoptosis of AA via regulation of the protein expression of Bcl-2 and Bax.	Dextromethorphan	151-154	BCL2 associated X, apoptosis regulator	Rattus norvegicus	233-236
25268311-9	2015	The phosphorylation of protein kinase B (PKB) at ser(473) decreased by 44%, whereas, the phosphorylation of insulin receptor substrate (IRS)-1 at ser(307) increased by 93% in the adipose tissue of the DEX rats after an oral bolus of glucose (P&lt;0.05).	Dextromethorphan	201-204	insulin receptor substrate 1	Rattus norvegicus	108-142
25268311-10	2015	The basal phosphorylation of c-jun-N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B (IKKbeta) proteins was reduced by 46% and 58%, respectively, in the adipose tissue of the DEX rats (P&lt;0.05).	Dextromethorphan	189-192	mitogen-activated protein kinase 8	Rattus norvegicus	54-57
25268311-10	2015	The basal phosphorylation of c-jun-N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B (IKKbeta) proteins was reduced by 46% and 58%, respectively, in the adipose tissue of the DEX rats (P&lt;0.05).	Dextromethorphan	189-192	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	100-107
25622744-13	2014	Monocytes TLR4 expression was lower in group Pre-Dex at T(3)-T(5) (P &lt; 0.05).	Dextromethorphan	49-52	toll like receptor 4	Homo sapiens	10-14
24702319-4	2014	Dextromethorphan and memantine have been administered to animals after spinal nerve ligation (SNL) to evaluate their antinociceptive/cognitive effects and associated molecular events, including the phosphorylation of several tyrosine (pTyr(1336), pTyr(1472)) residues in the NR2B NMDAR subunit.	Dextromethorphan	0-16	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	275-279
24702319-12	2014	Dextromethorphan, but not memantine, reversed neuropathic pain (NP) symptoms, restored spatial memory integrity and decreased the expression of pTyr(1336)NR2B.	Dextromethorphan	0-16	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	154-158
24702319-13	2014	Following postoperative administration of dextromethorphan, this study has demonstrated for the first time a concordance between behaviour, cognitive function and molecular events via pTyr(1336)NR2B for neuropathic pain alleviation.	Dextromethorphan	42-58	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	194-198
24948701-4	2014	In Dex-treated allograft recipient mice, CD11b(+)Gr1(+) MDSCs prolonged graft survival and acted as functional suppressive immune modulators that resulted in fewer IFN-gamma-producing Th1 cells and a greater number of IL-4-producing Th2 cells.	Dextromethorphan	3-6	integrin alpha M	Mus musculus	41-46
25561870-2	2014	Dextromethorphan (DEX) was used as a marker to assess metabolic activities of these enzymes, based on its CYP2D6 and CYP3A4 mediated metabolism to dextrorphan (DOR) and 3-methoxymorphinan (3-MM), respectively.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	106-112
25561870-2	2014	Dextromethorphan (DEX) was used as a marker to assess metabolic activities of these enzymes, based on its CYP2D6 and CYP3A4 mediated metabolism to dextrorphan (DOR) and 3-methoxymorphinan (3-MM), respectively.	Dextromethorphan	0-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
25561870-2	2014	Dextromethorphan (DEX) was used as a marker to assess metabolic activities of these enzymes, based on its CYP2D6 and CYP3A4 mediated metabolism to dextrorphan (DOR) and 3-methoxymorphinan (3-MM), respectively.	Dextromethorphan	18-21	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	106-112
25561870-2	2014	Dextromethorphan (DEX) was used as a marker to assess metabolic activities of these enzymes, based on its CYP2D6 and CYP3A4 mediated metabolism to dextrorphan (DOR) and 3-methoxymorphinan (3-MM), respectively.	Dextromethorphan	18-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
25132247-8	2014	In addition, the Dex group had lower serum CK-MB, IL-6, cTnI and GP-BB concentrations than the control group (P &lt; 0.05).	Dextromethorphan	17-20	interleukin 6	Homo sapiens	50-54
25132247-8	2014	In addition, the Dex group had lower serum CK-MB, IL-6, cTnI and GP-BB concentrations than the control group (P &lt; 0.05).	Dextromethorphan	17-20	troponin I3, cardiac type	Homo sapiens	56-60
25132247-8	2014	In addition, the Dex group had lower serum CK-MB, IL-6, cTnI and GP-BB concentrations than the control group (P &lt; 0.05).	Dextromethorphan	17-20	glycogen phosphorylase B	Homo sapiens	65-70
24948701-4	2014	In Dex-treated allograft recipient mice, CD11b(+)Gr1(+) MDSCs prolonged graft survival and acted as functional suppressive immune modulators that resulted in fewer IFN-gamma-producing Th1 cells and a greater number of IL-4-producing Th2 cells.	Dextromethorphan	3-6	interferon gamma	Mus musculus	164-173
24948701-4	2014	In Dex-treated allograft recipient mice, CD11b(+)Gr1(+) MDSCs prolonged graft survival and acted as functional suppressive immune modulators that resulted in fewer IFN-gamma-producing Th1 cells and a greater number of IL-4-producing Th2 cells.	Dextromethorphan	3-6	negative elongation factor complex member C/D, Th1l	Mus musculus	184-187
24948701-4	2014	In Dex-treated allograft recipient mice, CD11b(+)Gr1(+) MDSCs prolonged graft survival and acted as functional suppressive immune modulators that resulted in fewer IFN-gamma-producing Th1 cells and a greater number of IL-4-producing Th2 cells.	Dextromethorphan	3-6	interleukin 4	Mus musculus	218-222
24948701-4	2014	In Dex-treated allograft recipient mice, CD11b(+)Gr1(+) MDSCs prolonged graft survival and acted as functional suppressive immune modulators that resulted in fewer IFN-gamma-producing Th1 cells and a greater number of IL-4-producing Th2 cells.	Dextromethorphan	3-6	heart and neural crest derivatives expressed 2	Mus musculus	233-236
24948701-5	2014	In agreement, Dex-treated MDSCs promoted reciprocal differentiation between Th1 and Th2 in vivo.	Dextromethorphan	14-17	negative elongation factor complex member C/D, Th1l	Mus musculus	76-79
24948701-5	2014	In agreement, Dex-treated MDSCs promoted reciprocal differentiation between Th1 and Th2 in vivo.	Dextromethorphan	14-17	heart and neural crest derivatives expressed 2	Mus musculus	84-87
24948701-7	2014	The blocking of GR with RU486 significantly diminished the expression of CXCR2 and the recruitment of CD11b(+)Gr1(+) MDSCs, thereby recovering the increased MDSC-suppressive activity induced by Dex.	Dextromethorphan	194-197	chemokine (C-X-C motif) receptor 2	Mus musculus	73-78
24948701-7	2014	The blocking of GR with RU486 significantly diminished the expression of CXCR2 and the recruitment of CD11b(+)Gr1(+) MDSCs, thereby recovering the increased MDSC-suppressive activity induced by Dex.	Dextromethorphan	194-197	integrin alpha M	Mus musculus	102-107
25335188-7	2014	C/EBPbeta, but not HNF3alpha, was identified as an important mediator of DEX-mediated inhibition of Cbg promoter activity by using specific deletion and mutant promoter reporter constructs of Cbg.	Dextromethorphan	73-76	CCAAT enhancer binding protein beta	Homo sapiens	0-9
25335188-7	2014	C/EBPbeta, but not HNF3alpha, was identified as an important mediator of DEX-mediated inhibition of Cbg promoter activity by using specific deletion and mutant promoter reporter constructs of Cbg.	Dextromethorphan	73-76	serpin family A member 6	Homo sapiens	100-103
25335188-7	2014	C/EBPbeta, but not HNF3alpha, was identified as an important mediator of DEX-mediated inhibition of Cbg promoter activity by using specific deletion and mutant promoter reporter constructs of Cbg.	Dextromethorphan	73-76	serpin family A member 6	Homo sapiens	192-195
25335188-8	2014	Furthermore, knockdown of C/EBPbeta protein expression reduced DEX-induced repression of CBG mRNA, confirming C/EBPbeta"s involvement in GC-mediated CBG repression.	Dextromethorphan	63-66	CCAAT enhancer binding protein beta	Homo sapiens	26-35
25335188-8	2014	Furthermore, knockdown of C/EBPbeta protein expression reduced DEX-induced repression of CBG mRNA, confirming C/EBPbeta"s involvement in GC-mediated CBG repression.	Dextromethorphan	63-66	serpin family A member 6	Homo sapiens	89-92
25335188-8	2014	Furthermore, knockdown of C/EBPbeta protein expression reduced DEX-induced repression of CBG mRNA, confirming C/EBPbeta"s involvement in GC-mediated CBG repression.	Dextromethorphan	63-66	serpin family A member 6	Homo sapiens	149-152
25335188-9	2014	Chromatin immunoprecipitation (ChIP) after DEX treatment indicated increased co-recruitment of C/EBPbeta and GR to the Cbg promoter, while C/EBPbeta knockdown prevented GR recruitment.	Dextromethorphan	43-46	CCAAT enhancer binding protein beta	Homo sapiens	95-104
25335188-9	2014	Chromatin immunoprecipitation (ChIP) after DEX treatment indicated increased co-recruitment of C/EBPbeta and GR to the Cbg promoter, while C/EBPbeta knockdown prevented GR recruitment.	Dextromethorphan	43-46	nuclear receptor subfamily 3 group C member 1	Homo sapiens	109-111
25335188-9	2014	Chromatin immunoprecipitation (ChIP) after DEX treatment indicated increased co-recruitment of C/EBPbeta and GR to the Cbg promoter, while C/EBPbeta knockdown prevented GR recruitment.	Dextromethorphan	43-46	serpin family A member 6	Homo sapiens	119-122
25335188-10	2014	Together, the results suggest that DEX repression of CBG involves tethering of the GR to C/EBPbeta.	Dextromethorphan	35-38	serpin family A member 6	Homo sapiens	53-56
25335188-10	2014	Together, the results suggest that DEX repression of CBG involves tethering of the GR to C/EBPbeta.	Dextromethorphan	35-38	CCAAT enhancer binding protein beta	Homo sapiens	89-98
24995583-5	2014	We found that HAB mice respond with significantly reduced corticosterone (CORT) secretion to an acute stressful stimulus and a blunted response in the Dex/CRH test compared to NAB and LAB mice.	Dextromethorphan	151-154	corticotropin releasing hormone	Mus musculus	155-158
25340739-7	2014	Previously in site-directed mutational studies, we have characterized the response of T2R1 to dextromethorphan, therefore, T2R1 was selected for further analysis in this study.	Dextromethorphan	94-110	taste 2 receptor member 1	Homo sapiens	86-90
25340739-7	2014	Previously in site-directed mutational studies, we have characterized the response of T2R1 to dextromethorphan, therefore, T2R1 was selected for further analysis in this study.	Dextromethorphan	94-110	taste 2 receptor member 1	Homo sapiens	123-127
25340739-8	2014	Knockdown with T2R1 specific shRNA decreased mRNA levels, protein levels and dextromethorphan-induced calcium responses in pulmonary artery smooth muscle cells by up to 50%.	Dextromethorphan	77-93	taste 2 receptor member 1	Homo sapiens	15-19
25340739-11	2014	This study shows that dextromethorphan, acting through T2R1, causes vasoconstrictor responses in the pulmonary circuit and relaxation in the airways.	Dextromethorphan	22-38	taste 2 receptor member 1	Homo sapiens	55-59
25036266-7	2014	Chloroquine, denatonium, dextromethorphan, noscapine and quinine, agonists for TAS2R3, TAS2R4, TAS2R10 and TAS2R14, induced strong endothelium-independent relaxations (responses between 82-96% of maximal relaxations) in phenylephrine pre-contracted guinea-pig aorta that persisted in the presence of L-type Ca2+ and KCa1.1-channel blockers.	Dextromethorphan	25-41	taste 2 receptor member 3	Homo sapiens	79-85
25036266-7	2014	Chloroquine, denatonium, dextromethorphan, noscapine and quinine, agonists for TAS2R3, TAS2R4, TAS2R10 and TAS2R14, induced strong endothelium-independent relaxations (responses between 82-96% of maximal relaxations) in phenylephrine pre-contracted guinea-pig aorta that persisted in the presence of L-type Ca2+ and KCa1.1-channel blockers.	Dextromethorphan	25-41	taste 2 receptor member 4	Homo sapiens	87-93
25036266-7	2014	Chloroquine, denatonium, dextromethorphan, noscapine and quinine, agonists for TAS2R3, TAS2R4, TAS2R10 and TAS2R14, induced strong endothelium-independent relaxations (responses between 82-96% of maximal relaxations) in phenylephrine pre-contracted guinea-pig aorta that persisted in the presence of L-type Ca2+ and KCa1.1-channel blockers.	Dextromethorphan	25-41	taste 2 receptor member 10	Homo sapiens	95-102
25036266-7	2014	Chloroquine, denatonium, dextromethorphan, noscapine and quinine, agonists for TAS2R3, TAS2R4, TAS2R10 and TAS2R14, induced strong endothelium-independent relaxations (responses between 82-96% of maximal relaxations) in phenylephrine pre-contracted guinea-pig aorta that persisted in the presence of L-type Ca2+ and KCa1.1-channel blockers.	Dextromethorphan	25-41	taste 2 receptor member 14	Homo sapiens	107-114
29403890-2	2014	This method employed a cocktail of six probe substrates (i.e., phenacetin, amodiaquine, diclofenac, S-mephenytoin, dextromethorphan and midazolam for CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4, respectively) as well as individual prototypical inhibitors of the six CYP enzymes in human liver microsomes under optimized incubation conditions.	Dextromethorphan	115-131	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	150-156
24697814-5	2014	METHODS: We assessed the CYP2D6 and CYP3A metabolic phenotypes in 40 breast cancer patients on tamoxifen treatment with a single dose of dextromethorphan as a dual phenotypic probe for CYP2D6 and CYP3A.	Dextromethorphan	137-153	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	25-31
24697814-8	2014	In the final model for tamoxifen, the dextromethorphan derived metabolic phenotypes for CYP2D6 as well as CYP3A significantly (P &lt; 0.0001) explained 54% of the observed variability in endoxifen formation (inter-individual variability reduced from 55% to 25%).	Dextromethorphan	38-54	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-94
24985704-2	2014	Cynomolgus CYP2D17, highly homologous to human CYP2D6, metabolizes human CYP2D6 substrates such as bufuralol and dextromethorphan, and the gene is expressed predominantly in liver.	Dextromethorphan	113-129	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
24985704-2	2014	Cynomolgus CYP2D17, highly homologous to human CYP2D6, metabolizes human CYP2D6 substrates such as bufuralol and dextromethorphan, and the gene is expressed predominantly in liver.	Dextromethorphan	113-129	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	73-79
24747158-12	2014	CONCLUSIONS: A sensitive method for determination of dextromethorphan and its metabolite in plasma samples was developed and successfully applied, providing evidence of the impact that CYP2D6 inhibitors have on the enzyme"s metabolic capacity.	Dextromethorphan	53-69	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	185-191
25019304-6	2014	In vivo studies in mice showed that: i) ICAM-NG accumulates in mouse lungs (~120% ID/g vs ~15% ID/g of IgG-NG); and, ii) DEX encapsulated in ICAM-NG, but not in IgG-NG practically blocks LPS-induced overexpression of pro-inflammatory cell adhesion molecules including ICAM-1 in the pulmonary inflammation.	Dextromethorphan	121-124	intercellular adhesion molecule 1	Mus musculus	268-274
24685436-11	2014	The glucose+dex arm highlighted a CCK1-receptor dependent increase in BOLD signal only in the motor cortex.	Dextromethorphan	12-15	C-C motif chemokine ligand 28	Homo sapiens	34-38
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Dextromethorphan	27-29	cytochrome P450 2D6	Homo sapiens	45-64
24961510-5	2014	We demonstrate this possibility by using a BV-2 microglia culture model in which reactive oxygen species (ROS) and inducible nitric oxide synthase (iNOS) expression was attenuated in response to DEX released from EMF-stimulated Ppy.	Dextromethorphan	195-198	nitric oxide synthase 2	Homo sapiens	115-146
24961510-5	2014	We demonstrate this possibility by using a BV-2 microglia culture model in which reactive oxygen species (ROS) and inducible nitric oxide synthase (iNOS) expression was attenuated in response to DEX released from EMF-stimulated Ppy.	Dextromethorphan	195-198	nitric oxide synthase 2	Homo sapiens	148-152
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Dextromethorphan	98-114	cytochrome P450 2D6	Homo sapiens	45-64
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Dextromethorphan	172-188	cytochrome P450 2D6	Homo sapiens	45-64
24558046-5	2014	We found that the SGK-1 gene is up-regulated by Dex and GnRH alone, whereas a combination of both ligands resulted in a synergistic increase in SGK-1 mRNA levels.	Dextromethorphan	48-51	serum/glucocorticoid regulated kinase 1	Mus musculus	18-23
24987171-2	2014	This study aimed at finding the prevalence of CYP2D6 polymorphisms using dextromethorphan as a probe drug.	Dextromethorphan	73-89	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
24940027-8	2014	Importantly, the number of apoptotic cells, ACs and PL, FITC-dex extravasation, and thickness increased in the retinas of the diabetic and Cx43 siRNA-treated rats compared to those of the control rats.	Dextromethorphan	61-64	gap junction protein, alpha 1	Rattus norvegicus	139-143
24682508-6	2014	Furthermore, CYP2D6 metabolic activity was determined in a subset of 50 patients by assessing dextromethorphan/dextrorphan urinary excretion ratios.	Dextromethorphan	94-110	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
24558046-7	2014	Interestingly, although several GR cofactors are differentially recruited to the SGK-1 promoter in the presence of Dex and GnRH, GR levels remain unchanged compared with Dex treatment alone, suggesting that lipid raft association of the GR has a role in enhancing its transcriptional output in the nucleus.	Dextromethorphan	115-118	nuclear receptor subfamily 3, group C, member 1	Mus musculus	32-34
24558046-7	2014	Interestingly, although several GR cofactors are differentially recruited to the SGK-1 promoter in the presence of Dex and GnRH, GR levels remain unchanged compared with Dex treatment alone, suggesting that lipid raft association of the GR has a role in enhancing its transcriptional output in the nucleus.	Dextromethorphan	115-118	serum/glucocorticoid regulated kinase 1	Mus musculus	81-86
24558046-8	2014	Finally, we show that Dex plus GnRH synergistically inhibit cell proliferation in a manner dependent on SGK-1 and Flot-1.	Dextromethorphan	22-25	serum/glucocorticoid regulated kinase 1	Mus musculus	104-109
24558046-8	2014	Finally, we show that Dex plus GnRH synergistically inhibit cell proliferation in a manner dependent on SGK-1 and Flot-1.	Dextromethorphan	22-25	flotillin 1	Mus musculus	114-120
24705399-6	2014	Treatment of the DEX rats with a glucagon receptor antagonist normalized their blood glucose level.	Dextromethorphan	17-20	glucagon receptor	Rattus norvegicus	33-50
24406217-4	2014	MGlu-Dex-modified liposomes were taken up efficiently by dendritic cells and delivered entrapped ovalbumin (OVA) molecules into the cytosol.	Dextromethorphan	5-8	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	97-106
24705399-9	2014	Additionally, insulin secretion in the presence of glucagon was augmented in the islets of the DEX rats, which was most likely due to their higher glucagon receptor content.	Dextromethorphan	95-98	glucagon receptor	Rattus norvegicus	147-164
24126150-3	2014	Therefore, the objective of this study was to examine the inhibitory effect of an exogenous GC (dexamethasone, DEX) on leptin- and lipopolysaccharide (LPS)-induced IL-6 production by peripheral blood mononuclear cells (PBMCs) ex vivo in obese subjects compared to normal-weight subjects.	Dextromethorphan	111-114	interleukin 6	Homo sapiens	164-168
24587167-7	2014	Finally, saturation binding assays were performed to assess the manner in which dextromethorphan interacts at the sigma1 receptor.	Dextromethorphan	80-96	sigma non-opioid intracellular receptor 1	Mus musculus	114-129
24587167-8	2014	Our results revealed dextromethorphan displays antidepressant-like effects in the forced swim test that can be attenuated by pretreatment with sigma1 receptor antagonists, with BD1063 causing a shift to the right in the dextromethorphan dose response curve.	Dextromethorphan	21-37	sigma non-opioid intracellular receptor 1	Mus musculus	143-158
24587167-8	2014	Our results revealed dextromethorphan displays antidepressant-like effects in the forced swim test that can be attenuated by pretreatment with sigma1 receptor antagonists, with BD1063 causing a shift to the right in the dextromethorphan dose response curve.	Dextromethorphan	220-236	sigma non-opioid intracellular receptor 1	Mus musculus	143-158
24587916-3	2014	In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.	Dextromethorphan	116-119	lactotransferrin	Rattus norvegicus	71-73
24587916-11	2014	LF lowered (P &lt; 0.01) and dose dependently prevented (P &lt; 0.001) Dex-induced hypertension.	Dextromethorphan	71-74	lactotransferrin	Rattus norvegicus	0-2
24587916-13	2014	Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.	Dextromethorphan	124-127	lactotransferrin	Rattus norvegicus	26-28
24126150-9	2014	The suppressive effect of DEX on leptin- and LPS-induced IL-6 production (IC50) was not different between the two groups.	Dextromethorphan	26-29	interleukin 6	Homo sapiens	57-61
24433504-16	2014	Compared with DEX positive medicine control, anti-IL-1beta scfv/TNFRI appeared more beneficial in treatment of CIA mice.	Dextromethorphan	14-17	interleukin 1 beta	Mus musculus	50-58
24433504-16	2014	Compared with DEX positive medicine control, anti-IL-1beta scfv/TNFRI appeared more beneficial in treatment of CIA mice.	Dextromethorphan	14-17	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	64-69
24167220-3	2014	Sarpogrelate potently and selectively inhibited CYP2D6-mediated dextromethorphan O-demethylation with an IC50 (Ki) value of 3.05 muM (1.24 muM), in a competitive manner.	Dextromethorphan	64-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
23985325-7	2014	In a pediatric cohort of 164 individuals, rs16947 alone (minor haplotype frequency 28%) was associated with reduced CYP2D6 metabolic activity (measured as dextromethorphan/metabolite ratios), whereas rs5758550/rs133333 alone (frequency 3%) resulted in increased CYP2D6 activity, while haplotypes containing both rs16947 and rs5758550/rs133333 were similar to the wild-type.	Dextromethorphan	155-171	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	116-122
24711855-3	2014	Dextromethorphan was used as a common marker for measuring metabolic activity of CYP2D6 and CYP3A4 enzymes.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	81-87
24711855-3	2014	Dextromethorphan was used as a common marker for measuring metabolic activity of CYP2D6 and CYP3A4 enzymes.	Dextromethorphan	0-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
23943595-4	2014	Dex inhibited a RUNX2 reporter gene and attenuated locus-dependently RUNX2-driven expression of several endogenous target genes.	Dextromethorphan	0-3	RUNX family transcription factor 2	Homo sapiens	16-21
23943595-4	2014	Dex inhibited a RUNX2 reporter gene and attenuated locus-dependently RUNX2-driven expression of several endogenous target genes.	Dextromethorphan	0-3	RUNX family transcription factor 2	Homo sapiens	69-74
23835282-3	2013	Hyperoside strongly inhibited CYP2D6-catalyzed dextromethorphan O-demethylation, with IC50 values of 1.2 and 0.81 muM after 0 and 15 min of preincubation, and a Ki value of 2.01 muM in HLMs, respectively.	Dextromethorphan	47-63	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	30-36
24772975-10	2013	Dex in low dose (0.1 microM) caused a decrease in CHOP expression in HEp2 cells and an increase in Grp78 expression, in particular.	Dextromethorphan	0-3	DNA damage inducible transcript 3	Homo sapiens	50-54
24772975-10	2013	Dex in low dose (0.1 microM) caused a decrease in CHOP expression in HEp2 cells and an increase in Grp78 expression, in particular.	Dextromethorphan	0-3	heat shock protein family A (Hsp70) member 5	Homo sapiens	99-104
24269965-4	2014	(20mg/kg) or intra-CA1 (0.5 and 1 mug/mouse) administration of DM induced amnesia in a dose-dependent manner.	Dextromethorphan	63-65	carbonic anhydrase 1	Mus musculus	19-22
24269965-10	2014	(20mg/kg) or intra-CA1 administration of DM (1 mug/mouse) was restored in mice receiving pre-test i.p.	Dextromethorphan	41-43	carbonic anhydrase 1	Mus musculus	19-22
23881421-2	2013	To determine the clinical effect of GSE on CYP2D6, the pharmacokinetic interaction between GSE and the sensitive CYP2D6 probe dextromethorphan in healthy adult volunteers was examined.	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	113-119
23881421-12	2013	The results of this clinical study indicate that GSE appears to be safe to combine with drugs extensively metabolized by CYP2D6, such as dextromethorphan and tamoxifen.	Dextromethorphan	137-153	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	121-127
24013574-3	2013	METHODS: This study evaluated the effects of co-administration of panobinostat with a sensitive CYP2D6 substrate, dextromethorphan (DM), in patients with advanced cancer who have functional CYP2D6 genes.	Dextromethorphan	114-130	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	96-102
24013574-3	2013	METHODS: This study evaluated the effects of co-administration of panobinostat with a sensitive CYP2D6 substrate, dextromethorphan (DM), in patients with advanced cancer who have functional CYP2D6 genes.	Dextromethorphan	114-130	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	190-196
23835282-6	2013	Furthermore, hyperoside decreased CYP2D6-catalyzed dextromethorphan O-demethylation activity of human recombinant cDNA-expressed CYP2D6, with an IC50 value of 3.87 muM.	Dextromethorphan	51-67	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	34-40
23835282-6	2013	Furthermore, hyperoside decreased CYP2D6-catalyzed dextromethorphan O-demethylation activity of human recombinant cDNA-expressed CYP2D6, with an IC50 value of 3.87 muM.	Dextromethorphan	51-67	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	129-135
23951228-3	2013	When transgenic seeds germinated on medium containing 30 microM DEX, LEC1 transgenic seedlings were ivory and fleshy, with unexpanded cotyledons, stubby hypocotyls, short roots and no obvious callus formation at the shoot meristem position.	Dextromethorphan	64-67	Histone superfamily protein	Arabidopsis thaliana	69-73
23951228-10	2013	Ectopi c expression of LEC2 induced large number of somatic embryo formation and shoot regeneration but 20 d DEX induction of LEC1 is not sufficient to induce somatic embryogenesis and shoot formation.	Dextromethorphan	109-112	Histone superfamily protein	Arabidopsis thaliana	126-130
23400250-0	2013	Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-kappaB activation.	Dextromethorphan	0-16	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	68-73
23359530-8	2013	Treatment of the cell cultures with 1,25(OH)2 D3 /Dex, however, significantly increased ALP activity and BGLAP messenger RNA levels.	Dextromethorphan	50-53	alkaline phosphatase, placental	Homo sapiens	88-91
23359530-8	2013	Treatment of the cell cultures with 1,25(OH)2 D3 /Dex, however, significantly increased ALP activity and BGLAP messenger RNA levels.	Dextromethorphan	50-53	bone gamma-carboxyglutamate protein	Homo sapiens	105-110
23400250-2	2013	Here, we report that DXM inhibits the receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis and bone resorption by abrogating the activation of NF-kappaB signalling in vitro.	Dextromethorphan	21-24	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	38-89
23400250-2	2013	Here, we report that DXM inhibits the receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis and bone resorption by abrogating the activation of NF-kappaB signalling in vitro.	Dextromethorphan	21-24	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	91-96
23400250-13	2013	RESULTS: DXM inhibited RANKL-induced osteoclastogenesis.	Dextromethorphan	9-12	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	23-28
23640538-7	2013	Caspase-3/7 activity (msi) of HTM cells exposed to Dex 2, 1 or 0.5 mg/ml was 21068 +- 2498 (P &lt; 0.001), 26994 +- 3104 (P &lt; 0.001) and 20416 +- 1150 (P &lt; 0.001) compared to untreated HTM cells 1148 +- 803.	Dextromethorphan	51-54	caspase 3	Homo sapiens	0-9
23903683-9	2013	The combination of 2% HS+0.1 microM Dex+10 ng/mL HGF+20 ng/mL FGF4 induced the highest ALB-GLuc activity.	Dextromethorphan	36-39	albumin	Mus musculus	87-90
23903683-9	2013	The combination of 2% HS+0.1 microM Dex+10 ng/mL HGF+20 ng/mL FGF4 induced the highest ALB-GLuc activity.	Dextromethorphan	36-39	glucosidase, beta, acid	Mus musculus	91-95
23640538-8	2013	Caspase-9 activity (msi) of HTM cells after exposure to Dex 2, 1 or 0.5 mg/ml was 14188 +- 1203 (P &lt; 0.001), 13256 +- 1564 (P &lt; 0.001) and 15041 +- 1584 (P &lt; 0.001) compared to untreated HTM cells 1748 +- 524.	Dextromethorphan	56-59	caspase 9	Homo sapiens	0-9
23458730-2	2013	In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats.	Dextromethorphan	88-104	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	148-153
24466755-7	2013	In the same conditions Dex in a wide range of concentrations (10(-5)-10(-7) M) and Est (10(-6) and 10(-7) M) activate U2af1l4 gene expression that probably leads to "surrogate memory T cells" formation.	Dextromethorphan	23-26	U2 small nuclear RNA auxiliary factor 1 like 4	Homo sapiens	118-125
23493285-7	2013	Dex-resistant HUVECs have a stronger interaction of glucocorticoid receptor with the proteasomal recruiting protein, BCL2-associated athanogene 1 (BAG1), as shown by immunoprecipitation assays.	Dextromethorphan	0-3	BAG cochaperone 1	Homo sapiens	117-145
23493285-7	2013	Dex-resistant HUVECs have a stronger interaction of glucocorticoid receptor with the proteasomal recruiting protein, BCL2-associated athanogene 1 (BAG1), as shown by immunoprecipitation assays.	Dextromethorphan	0-3	BAG cochaperone 1	Homo sapiens	147-151
23493285-8	2013	Silencing BAG1 expression increased Dex-sensitivity in resistant HUVECs, whereas BAG1 overexpression decreased Dex-sensitivity in sensitive HUVECs.	Dextromethorphan	36-40	BAG cochaperone 1	Homo sapiens	10-14
23493285-8	2013	Silencing BAG1 expression increased Dex-sensitivity in resistant HUVECs, whereas BAG1 overexpression decreased Dex-sensitivity in sensitive HUVECs.	Dextromethorphan	111-115	BAG cochaperone 1	Homo sapiens	81-85
23493285-9	2013	Finally, Dex-resistant HUVECs presented higher BAG1 expression than Dex-sensitive HUVECs.	Dextromethorphan	9-12	BAG cochaperone 1	Homo sapiens	47-51
23493285-10	2013	CONCLUSIONS: In vitro endothelial sensitivity to Dex varies within individuals and is inversely proportional to BAG1 protein expression and glucocorticoid receptor protein turnover.	Dextromethorphan	49-52	BAG cochaperone 1	Homo sapiens	112-116
23802435-4	2013	The substrates used in this study were phenacetin (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19) and dextromethorphan (CYP2D6).	Dextromethorphan	107-123	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	125-131
23458730-2	2013	In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats.	Dextromethorphan	106-109	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	148-153
23458730-10	2013	Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities.	Dextromethorphan	80-83	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	175-180
23355638-5	2013	For verification, the disposition of CYP1A2-metabolized drug theophylline (THEO) and CYP2D6-metabolized drugs paroxetine (PAR), dextromethorphan (DEX), and clonidine (CLO) during pregnancy was predicted.	Dextromethorphan	146-149	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	85-91
23665933-4	2013	Individual differences in CYP2D6-dependent dextromethorphan O-demethylation activities in liver microsomes from Caucasians were not affected by either the CYP3A4*1/*22 or CYP3A5*1/*3 genotype.	Dextromethorphan	43-59	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	26-32
23522153-6	2013	Administration of expanding CD34+ cells was associated with increased lung growth and, in animals treated with DEX-exposed cells, enhanced alveolar septation.	Dextromethorphan	111-114	CD34 molecule	Homo sapiens	28-32
23100173-4	2013	METHODS: CYP2D6 extensive metabolism was determined upon appropriate dextromethorphan/dextrorphan (DM/DX) urinary excretion ratios (&lt;=0.30).	Dextromethorphan	69-85	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	9-15
23100173-4	2013	METHODS: CYP2D6 extensive metabolism was determined upon appropriate dextromethorphan/dextrorphan (DM/DX) urinary excretion ratios (&lt;=0.30).	Dextromethorphan	99-101	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	9-15
23140507-1	2013	OBJECTIVE: This study examines the effect of Dextromethorphan (d-3-methoxy-17-methylmorphinan; DXM), a commonly used cough-suppressing drug, on the expression of VCAM-1 and ICAM-1 in human umbilical vein endothelial cells (HUVECs) stimulated with lipopolysaccharide (LPS).	Dextromethorphan	45-61	vascular cell adhesion molecule 1	Homo sapiens	162-168
23140507-1	2013	OBJECTIVE: This study examines the effect of Dextromethorphan (d-3-methoxy-17-methylmorphinan; DXM), a commonly used cough-suppressing drug, on the expression of VCAM-1 and ICAM-1 in human umbilical vein endothelial cells (HUVECs) stimulated with lipopolysaccharide (LPS).	Dextromethorphan	45-61	intercellular adhesion molecule 1	Homo sapiens	173-179
23140507-1	2013	OBJECTIVE: This study examines the effect of Dextromethorphan (d-3-methoxy-17-methylmorphinan; DXM), a commonly used cough-suppressing drug, on the expression of VCAM-1 and ICAM-1 in human umbilical vein endothelial cells (HUVECs) stimulated with lipopolysaccharide (LPS).	Dextromethorphan	95-98	vascular cell adhesion molecule 1	Homo sapiens	162-168
23140507-1	2013	OBJECTIVE: This study examines the effect of Dextromethorphan (d-3-methoxy-17-methylmorphinan; DXM), a commonly used cough-suppressing drug, on the expression of VCAM-1 and ICAM-1 in human umbilical vein endothelial cells (HUVECs) stimulated with lipopolysaccharide (LPS).	Dextromethorphan	95-98	intercellular adhesion molecule 1	Homo sapiens	173-179
23140507-5	2013	Furthermore, treatment of HUVECs with DXM can significantly decrease LPS-induced expression of ICAM-1 and VCAM-1.	Dextromethorphan	38-41	intercellular adhesion molecule 1	Homo sapiens	95-101
23140507-5	2013	Furthermore, treatment of HUVECs with DXM can significantly decrease LPS-induced expression of ICAM-1 and VCAM-1.	Dextromethorphan	38-41	vascular cell adhesion molecule 1	Homo sapiens	106-112
23140507-6	2013	DXM abrogated LPS-induced phosphorylation of ERK and Akt.	Dextromethorphan	0-3	mitogen-activated protein kinase 1	Homo sapiens	45-48
23140507-6	2013	DXM abrogated LPS-induced phosphorylation of ERK and Akt.	Dextromethorphan	0-3	AKT serine/threonine kinase 1	Homo sapiens	53-56
23140507-7	2013	The translocation of early growth response gene-1 (Egr-1), a downstream transcription factor involved in the mitogen-activated kinase (MEK)-ERK signaling pathway, was suppressed by DXM treatment.	Dextromethorphan	181-184	early growth response 1	Homo sapiens	21-56
23140507-7	2013	The translocation of early growth response gene-1 (Egr-1), a downstream transcription factor involved in the mitogen-activated kinase (MEK)-ERK signaling pathway, was suppressed by DXM treatment.	Dextromethorphan	181-184	mitogen-activated protein kinase 1	Homo sapiens	140-143
23140507-8	2013	Furthermore, DXM inhibited LPS-induced IkappaBalpha degradation and nuclear translocation of p65.	Dextromethorphan	13-16	NFKB inhibitor alpha	Homo sapiens	39-51
23140507-8	2013	Furthermore, DXM inhibited LPS-induced IkappaBalpha degradation and nuclear translocation of p65.	Dextromethorphan	13-16	RELA proto-oncogene, NF-kB subunit	Homo sapiens	93-96
23140507-9	2013	CONCLUSIONS: Dextromethorphan inhibits the adhesive capacity of HUVECs by reducing the LPS-induced ICAM-1 and VCAM-1 expression via the suppression of the ERK, Akt, and NF-kappaB signaling pathways.	Dextromethorphan	13-29	intercellular adhesion molecule 1	Homo sapiens	99-105
23140507-9	2013	CONCLUSIONS: Dextromethorphan inhibits the adhesive capacity of HUVECs by reducing the LPS-induced ICAM-1 and VCAM-1 expression via the suppression of the ERK, Akt, and NF-kappaB signaling pathways.	Dextromethorphan	13-29	vascular cell adhesion molecule 1	Homo sapiens	110-116
23140507-9	2013	CONCLUSIONS: Dextromethorphan inhibits the adhesive capacity of HUVECs by reducing the LPS-induced ICAM-1 and VCAM-1 expression via the suppression of the ERK, Akt, and NF-kappaB signaling pathways.	Dextromethorphan	13-29	mitogen-activated protein kinase 1	Homo sapiens	155-158
23140507-9	2013	CONCLUSIONS: Dextromethorphan inhibits the adhesive capacity of HUVECs by reducing the LPS-induced ICAM-1 and VCAM-1 expression via the suppression of the ERK, Akt, and NF-kappaB signaling pathways.	Dextromethorphan	13-29	AKT serine/threonine kinase 1	Homo sapiens	160-163
23150428-5	2013	In agreement with the increased Cyp2d mRNA, Cyp2d-mediated dextrorphan formation from dextromethorphan was increased 2.7-fold (P &lt; 0.05) on GD19 (56.8+-39.4 pmol/min/mg protein) when compared with the non-pregnant controls (20.8+-11.2 pmol/min/mg protein).	Dextromethorphan	86-102	cytochrome P450, 2d region	Mus musculus	44-49
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dextromethorphan	60-63	interleukin 17A	Homo sapiens	0-4
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dextromethorphan	60-63	interleukin 23 subunit alpha	Homo sapiens	6-11
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dextromethorphan	60-63	interleukin 2	Homo sapiens	16-19
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dextromethorphan	60-63	interleukin 17A	Homo sapiens	119-125
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dextromethorphan	60-63	interleukin 23 subunit alpha	Homo sapiens	140-145
23160983-7	2013	IL17, IL-23 and IL2 + 4 stimulations significantly hampered Dexamethasone-inhibition of proliferation (Dex EC(50) for: IL-17A + F = 251 nM; IL-23 = 435 nM; IL2 + 4 = 950 nM; Medium = 90 nM).	Dextromethorphan	60-63	interleukin 2	Homo sapiens	156-159
23160983-8	2013	IL2 + 4 and IL17A + F but not IL-23, significantly hampered Dexamethasone-induced apoptosis (1400 and 320 nM Dex, respectively).	Dextromethorphan	60-63	interleukin 2	Homo sapiens	0-3
23160983-8	2013	IL2 + 4 and IL17A + F but not IL-23, significantly hampered Dexamethasone-induced apoptosis (1400 and 320 nM Dex, respectively).	Dextromethorphan	60-63	interleukin 17A	Homo sapiens	12-17
23160983-9	2013	Dexamethasone"s trans-activation of GILZ and trans-repression of NF-kB-driven IL-6 expression were both inhibited by IL2 + 4; IL17 + IL23 antagonized Dex trans-repression in PBMC from asthmatics.	Dextromethorphan	0-3	TSC22 domain family member 3	Homo sapiens	36-40
23160983-9	2013	Dexamethasone"s trans-activation of GILZ and trans-repression of NF-kB-driven IL-6 expression were both inhibited by IL2 + 4; IL17 + IL23 antagonized Dex trans-repression in PBMC from asthmatics.	Dextromethorphan	0-3	interleukin 2	Homo sapiens	117-120
23160983-9	2013	Dexamethasone"s trans-activation of GILZ and trans-repression of NF-kB-driven IL-6 expression were both inhibited by IL2 + 4; IL17 + IL23 antagonized Dex trans-repression in PBMC from asthmatics.	Dextromethorphan	0-3	interleukin 17A	Homo sapiens	126-130
23160983-9	2013	Dexamethasone"s trans-activation of GILZ and trans-repression of NF-kB-driven IL-6 expression were both inhibited by IL2 + 4; IL17 + IL23 antagonized Dex trans-repression in PBMC from asthmatics.	Dextromethorphan	0-3	interleukin 23 subunit alpha	Homo sapiens	133-137
23064959-1	2013	PURPOSE: To assess the effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan HBr (CYP2D6 substrate) and theophylline (CYP1A2 substrate) in patients with metastatic castration-resistant prostate cancer (mCRPC).	Dextromethorphan	96-116	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	118-124
23064959-11	2013	CONCLUSION: Abiraterone acetate plus prednisone increased the exposure of dextromethorphan, suggesting a need for caution when coadministrating with known CYP2D6 substrates.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	155-161
23781253-6	2013	Therefore, DXM abrogated the ability of LPS-stimulated DCs to induce Ag-specific T-cell activation, as determined by their decreased proliferation and IFN- gamma secretion in mixed leukocyte cultures.	Dextromethorphan	11-14	interferon gamma	Homo sapiens	151-161
23781253-7	2013	Moreover, the inhibition of LPS-induced MAPK activation and NF- kappa B translocation may contribute to the suppressive effect of DXM on BMDCs.	Dextromethorphan	130-133	nuclear factor kappa B subunit 1	Homo sapiens	60-71
23781253-8	2013	Remarkably, DXM decreased the LPS-induced surface expression of CD80, CD83, and HLA-DR and the secretion of IL-6 and IL-12 in human monocyte-derived dendritic cells (MDDCs).	Dextromethorphan	12-15	CD80 molecule	Homo sapiens	64-68
23781253-8	2013	Remarkably, DXM decreased the LPS-induced surface expression of CD80, CD83, and HLA-DR and the secretion of IL-6 and IL-12 in human monocyte-derived dendritic cells (MDDCs).	Dextromethorphan	12-15	CD83 molecule	Homo sapiens	70-74
23781253-8	2013	Remarkably, DXM decreased the LPS-induced surface expression of CD80, CD83, and HLA-DR and the secretion of IL-6 and IL-12 in human monocyte-derived dendritic cells (MDDCs).	Dextromethorphan	12-15	interleukin 6	Homo sapiens	108-112
23665933-5	2013	Liver microsomes genotyped as CYP3A4*1/*22 (n = 4) showed significantly lower CYP3A-dependent dextromethorphan N-demethylation, midazolam 1"-hydroxylation, and testosterone 6beta-hydroxylation activities, as well as lower expression levels of CYP3A protein (28% of control), compared with those of the CYP3A4*1/*1 group (n = 19).	Dextromethorphan	94-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
23665933-5	2013	Liver microsomes genotyped as CYP3A4*1/*22 (n = 4) showed significantly lower CYP3A-dependent dextromethorphan N-demethylation, midazolam 1"-hydroxylation, and testosterone 6beta-hydroxylation activities, as well as lower expression levels of CYP3A protein (28% of control), compared with those of the CYP3A4*1/*1 group (n = 19).	Dextromethorphan	94-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35
23665933-5	2013	Liver microsomes genotyped as CYP3A4*1/*22 (n = 4) showed significantly lower CYP3A-dependent dextromethorphan N-demethylation, midazolam 1"-hydroxylation, and testosterone 6beta-hydroxylation activities, as well as lower expression levels of CYP3A protein (28% of control), compared with those of the CYP3A4*1/*1 group (n = 19).	Dextromethorphan	94-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-83
23340533-0	2013	Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.	Dextromethorphan	93-109	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
22771763-2	2012	We have previously shown that dextromethorphan, a low-affinity NMDAR antagonist with anti-inflammatory properties, is neuroprotective against neonatal excitotoxic brain injury.	Dextromethorphan	30-46	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	63-68
23340533-11	2013	CONCLUSION: CYP2D6 inhibition by quinidine influenced the pre-emptive analgesic effectiveness of DM confirming that CYP2D6 phenotypic switch increases the neuromodulatory effect of oral dextromethorphan.	Dextromethorphan	186-202	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	12-18
23340533-11	2013	CONCLUSION: CYP2D6 inhibition by quinidine influenced the pre-emptive analgesic effectiveness of DM confirming that CYP2D6 phenotypic switch increases the neuromodulatory effect of oral dextromethorphan.	Dextromethorphan	186-202	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	116-122
22861201-3	2012	However, amantadine and dextromethorphan are also thought to block serotonin (5-HT) uptake and cause 5-HT overflow, leading to stimulation of 5-HT(1A)  receptors, which has been shown to reduce LID.	Dextromethorphan	24-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-149
22861201-9	2012	We conclude that the anti-dyskinetic effect of amantadine is partially dependent on NMDA antagonism, while dextromethorphan suppresses AIMs via indirect 5-HT(1A)  agonism.	Dextromethorphan	107-123	5-hydroxytryptamine receptor 1A	Rattus norvegicus	153-160
22503138-7	2012	RESULTS: Severe fatigue 6 months after deployment was independently associated with low DEX-sensitivity of monocyte TNF-alpha production before deployment.	Dextromethorphan	88-91	tumor necrosis factor	Homo sapiens	116-125
22990619-6	2012	Chronic heroin-use-induced TNF-alpha and IL-8 levels were significantly (p &lt; 0.05) attenuated in patients treated for 12 weeks with add-on dextromethorphan.	Dextromethorphan	142-158	tumor necrosis factor	Homo sapiens	27-36
22990619-6	2012	Chronic heroin-use-induced TNF-alpha and IL-8 levels were significantly (p &lt; 0.05) attenuated in patients treated for 12 weeks with add-on dextromethorphan.	Dextromethorphan	142-158	C-X-C motif chemokine ligand 8	Homo sapiens	41-45
22771763-3	2012	Of interest, dextromethorphan is also a sigma-1 receptor (sigma1R) agonist.	Dextromethorphan	13-29	sigma non-opioid intracellular receptor 1	Mus musculus	40-56
22771763-3	2012	Of interest, dextromethorphan is also a sigma-1 receptor (sigma1R) agonist.	Dextromethorphan	13-29	sigma non-opioid intracellular receptor 1	Mus musculus	58-65
22451032-11	2012	The bioavailability of dextromethorphan (CYP2D6 and CYP3A4 substrates) was shown to be unaffected by TCZ treatment.	Dextromethorphan	23-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	41-47
23064078-6	2012	3 mg of DEX, the mean NRS was improved to 2.	Dextromethorphan	8-11	sphingolipid transporter 1 (putative)	Homo sapiens	22-25
22548589-0	2012	Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.	Dextromethorphan	6-22	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
22626647-5	2012	DEX-treated females of P45-50 had delayed vaginal opening, and irregular estrus cycles and lower GnRH expression in the preoptic area (POA) when compared with age-matched controls.	Dextromethorphan	0-3	gonadotropin releasing hormone 1	Mus musculus	97-101
22626647-6	2012	The expression levels of GPR147 and GPR74 mRNA in the POA increased significantly in DEX-treated female mice of P21 and P45-50 compared to controls.	Dextromethorphan	85-88	neuropeptide FF receptor 1	Mus musculus	25-31
22626647-6	2012	The expression levels of GPR147 and GPR74 mRNA in the POA increased significantly in DEX-treated female mice of P21 and P45-50 compared to controls.	Dextromethorphan	85-88	neuropeptide FF receptor 2	Mus musculus	36-41
22626647-9	2012	Taken together, the results show that the delayed pubertal onset could be due to the inhibition of GnRH gene expression after neonatal DEX treatment, which may be accounted for in part by the inhibitory signals from the up-regulated GnIH-GnIH receptor pathway to the POA.	Dextromethorphan	135-138	gonadotropin releasing hormone 1	Mus musculus	99-103
21885687-1	2012	In this study, the authors developed a phenotyping method for CYP1A2, 2C9, 2C19, 2D6, and 3A4 using a cocktail of 100 mg caffeine, 125 mg tolbutamide, 20 mg omeprazole, 30 mg dextromethorphan, and 2 mg midazolam.	Dextromethorphan	175-191	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	62-68
22548589-2	2012	Dextromethorphan-to-dextrorphan metabolic ratio (MR(DEM/DOR)) is well established as a marker of CYP2D6 metabolizer status.	Dextromethorphan	0-16	tumor protein p53 inducible nuclear protein 2	Homo sapiens	56-59
22548589-2	2012	Dextromethorphan-to-dextrorphan metabolic ratio (MR(DEM/DOR)) is well established as a marker of CYP2D6 metabolizer status.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
22548589-4	2012	This study addressed whether CYP2D6 phenotyping using molar metabolic ratio of dextromethorphan to dextrorphan (MR(DEM/DOR)) in serum is usable and reliable in clinical practice as urinary MR(DEM/DOR).	Dextromethorphan	79-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	29-35
22548589-14	2012	Our CYP2D6 phenotyping using serum dextromethorphan/dextrorphan molar ratio appears reliable but requires independent validation.	Dextromethorphan	35-51	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Dextromethorphan	125-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
22039821-10	2012	Furthermore, the CDOCKER algorithm was further applied to study the impact of mutations of 28 active site residues (mostly non-conserved) of CYP2D6 on substrate binding modes using five probe substrates including bufuralol, debrisoquine, dextromethorphan, sparteine, and tramadol.	Dextromethorphan	238-254	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	141-147
22326841-0	2012	The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder.	Dextromethorphan	58-74	dopamine receptor D2	Homo sapiens	4-8
22326841-0	2012	The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder.	Dextromethorphan	58-74	ankyrin repeat and kinase domain containing 1	Homo sapiens	9-14
22762141-5	2012	CYP2D6 activity was measured by a specific substrate using the dextromethorphan/dextrorphan metabolic ratio to classify patients into four activity phenotypes.	Dextromethorphan	63-79	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
22777153-7	2012	CYP2D6 phenotyping was performed by the determination of dextromethorphan (DMT) and dextrorphan (DTF) by high-performance liquid chromatography with fluorescence detection at plasma collected 3 hours after oral administration of 33 mg of DMF.	Dextromethorphan	57-73	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
22777153-7	2012	CYP2D6 phenotyping was performed by the determination of dextromethorphan (DMT) and dextrorphan (DTF) by high-performance liquid chromatography with fluorescence detection at plasma collected 3 hours after oral administration of 33 mg of DMF.	Dextromethorphan	75-78	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
22651995-5	2012	The calibration curve was linear over the range from 0.2 to 200 ng mL-1 for dextromethorphan and doxylamine and 0.05 to 10 ng mL-1 for dextrorphan.	Dextromethorphan	76-92	L1 cell adhesion molecule	Mus musculus	67-71
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Dextromethorphan	125-141	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	57-63
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Dextromethorphan	125-141	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-152
23983359-5	2012	In the experiment using model rats with pelvic inflammation, we found that the serum levels of IL-6, IL-8 and TNF-alpha in PV and DEX group were all significantly lower than those of the CON group, and the serum levels of IL-6 and IL-8 in PV group were significantly lower than those of the DEX group.	Dextromethorphan	130-133	interleukin 6	Rattus norvegicus	95-99
23983359-5	2012	In the experiment using model rats with pelvic inflammation, we found that the serum levels of IL-6, IL-8 and TNF-alpha in PV and DEX group were all significantly lower than those of the CON group, and the serum levels of IL-6 and IL-8 in PV group were significantly lower than those of the DEX group.	Dextromethorphan	130-133	tumor necrosis factor	Rattus norvegicus	110-119
23983359-5	2012	In the experiment using model rats with pelvic inflammation, we found that the serum levels of IL-6, IL-8 and TNF-alpha in PV and DEX group were all significantly lower than those of the CON group, and the serum levels of IL-6 and IL-8 in PV group were significantly lower than those of the DEX group.	Dextromethorphan	130-133	interleukin 6	Rattus norvegicus	222-226
22422635-14	2012	Clobazam increased dextromethorphan (CYP2D6) AUC(0- )  by 95% and C(max)  by 59%.	Dextromethorphan	19-35	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	37-43
21842479-2	2012	Recombinant human CYP3A4 and CYP2D6 enzymes were used and the activities were expressed by the metabolism of testosterone and dextromethorphan with ketoconazole and quinidine as positive inhibitor controls, respectively.	Dextromethorphan	126-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
22305191-7	2012	Metabolism of dextromethorphan to dextrorphan (CYP2D6-mediated) and chlorzoxazone to 6-hydroxychlorzoxazone (CYP2E1-mediated) was only minimally inhibited by PSP, with IC(20) values at 15.6muM and 11.9muM, respectively.	Dextromethorphan	14-30	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
22305191-7	2012	Metabolism of dextromethorphan to dextrorphan (CYP2D6-mediated) and chlorzoxazone to 6-hydroxychlorzoxazone (CYP2E1-mediated) was only minimally inhibited by PSP, with IC(20) values at 15.6muM and 11.9muM, respectively.	Dextromethorphan	14-30	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	109-115
21842479-2	2012	Recombinant human CYP3A4 and CYP2D6 enzymes were used and the activities were expressed by the metabolism of testosterone and dextromethorphan with ketoconazole and quinidine as positive inhibitor controls, respectively.	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	29-35
22553469-0	2012	The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.	Dextromethorphan	64-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	28-34
22553469-3	2012	We investigated the relationship of CYP2D6 genotypes to the metabolism of dextromethorphan (DM), which is frequently used as a surrogate marker for the formation of endoxifen.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
22553469-3	2012	We investigated the relationship of CYP2D6 genotypes to the metabolism of dextromethorphan (DM), which is frequently used as a surrogate marker for the formation of endoxifen.	Dextromethorphan	92-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
22536436-9	2012	If so, we examined whether the DEX-induced tau phosphorylation and mu-calpain activation mediate the DEX-induced inhibition on the insulin-stimulated Akt phosphorylation.	Dextromethorphan	31-34	insulin	Homo sapiens	131-138
22277677-2	2012	Dextromethorphan (DM) is a well-known probe drug for CYP2D6 and metabolic ratio (MR) is often used to measure the enzyme activity in vivo.	Dextromethorphan	0-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	53-59
23185487-6	2012	In addition, overexpression of RCAN1 rendered cells more sensitive to DEX.	Dextromethorphan	70-73	regulator of calcineurin 1	Homo sapiens	31-36
21976621-4	2012	The inhibition profiles of 20 known inhibitors of CYP2D6 were characterized in vitro against four clinically relevant CYP2D6 substrates (desipramine, dextromethorphan, metoprolol, and thioridazine) and bufuralol.	Dextromethorphan	150-166	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	50-56
21976621-10	2012	Similar to the in vitro results, dextromethorphan exhibited the highest sensitivity to CYP2D6 inhibition in vivo.	Dextromethorphan	33-49	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	87-93
21976621-11	2012	Finally, the magnitude of in vivo CYP2D6 DDIs caused by quinidine was predicted using desipramine, dextromethorphan, and metoprolol.	Dextromethorphan	99-115	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	34-40
23139844-7	2012	The sigma-1 receptor agonists Dextromethorphan (DM) and 1,3-di-o-tolyl-guanidine (DTG) also inhibited Na(V)1.2 currents through a sigma-1 receptor-independent pathway.	Dextromethorphan	30-46	immunoglobulin lambda variable 2-8	Homo sapiens	102-110
22536436-12	2012	Finally, both LiCl pre-treatment and calpain inhibition prevented the DEX-induced inhibition on the insulin-stimulated Akt phosphorylation.	Dextromethorphan	70-73	insulin	Homo sapiens	100-107
22536436-12	2012	Finally, both LiCl pre-treatment and calpain inhibition prevented the DEX-induced inhibition on the insulin-stimulated Akt phosphorylation.	Dextromethorphan	70-73	AKT serine/threonine kinase 1	Homo sapiens	119-122
22536436-13	2012	In conclusion, our study suggests that the tau phosphorylation and mu-calpain activation mediate the DEX-induced inhibition on the insulin-stimulated Akt phosphorylation.	Dextromethorphan	101-104	insulin	Homo sapiens	131-138
22536436-9	2012	If so, we examined whether the DEX-induced tau phosphorylation and mu-calpain activation mediate the DEX-induced inhibition on the insulin-stimulated Akt phosphorylation.	Dextromethorphan	101-104	insulin	Homo sapiens	131-138
22536436-13	2012	In conclusion, our study suggests that the tau phosphorylation and mu-calpain activation mediate the DEX-induced inhibition on the insulin-stimulated Akt phosphorylation.	Dextromethorphan	101-104	AKT serine/threonine kinase 1	Homo sapiens	150-153
22536436-9	2012	If so, we examined whether the DEX-induced tau phosphorylation and mu-calpain activation mediate the DEX-induced inhibition on the insulin-stimulated Akt phosphorylation.	Dextromethorphan	101-104	AKT serine/threonine kinase 1	Homo sapiens	150-153
22295073-9	2012	In addition, NR3C1 promoter methylation was linked to attenuated cortisol responses to the Dex/CRH test (p&lt;.05).	Dextromethorphan	91-94	nuclear receptor subfamily 3 group C member 1	Homo sapiens	13-18
20697841-4	2011	The significant up-regulation of BIM in CEM-C7 cells induced by DEX was also observed, but no up-regulation of BIM was detected in DEX-induced CEM-C1 cells.	Dextromethorphan	64-67	BCL2 like 11	Homo sapiens	33-36
21641725-3	2012	It was hypothesized that high levels of childhood trauma would be associated with blunted cortisol and adrenocorticotropin releasing hormone (ACTH) response to the combined dexamethasone(DEX)/CRH test in adults meeting general DSM-IV criteria for personality disorder.	Dextromethorphan	187-190	proopiomelanocortin	Homo sapiens	142-146
21641725-6	2012	RESULTS: As hypothesized, high CTQ score was associated with a blunted cortisol and ACTH response to DEX/CRH challenge.	Dextromethorphan	101-104	proopiomelanocortin	Homo sapiens	84-88
21641725-6	2012	RESULTS: As hypothesized, high CTQ score was associated with a blunted cortisol and ACTH response to DEX/CRH challenge.	Dextromethorphan	101-104	corticotropin releasing hormone	Homo sapiens	105-108
21641725-7	2012	Indices of cortisol and ACTH response (peak level and area under the curve (AUC)) to DEX/CRH were in turn significantly negatively correlated with CSF CRH concentration.	Dextromethorphan	85-88	proopiomelanocortin	Homo sapiens	24-28
21641725-7	2012	Indices of cortisol and ACTH response (peak level and area under the curve (AUC)) to DEX/CRH were in turn significantly negatively correlated with CSF CRH concentration.	Dextromethorphan	85-88	corticotropin releasing hormone	Homo sapiens	89-92
21641725-7	2012	Indices of cortisol and ACTH response (peak level and area under the curve (AUC)) to DEX/CRH were in turn significantly negatively correlated with CSF CRH concentration.	Dextromethorphan	85-88	corticotropin releasing hormone	Homo sapiens	151-154
21641725-8	2012	CONCLUSION: Childhood trauma in adults with personality disorder is associated with blunted cortisol and ACTH secretion following DEX/CRH challenge.	Dextromethorphan	130-133	proopiomelanocortin	Homo sapiens	105-109
21898343-7	2011	Membrane-bound GR-expressing monocytes were treated with DEX, DEX-BSA, or BSA.	Dextromethorphan	57-60	grainyhead like transcription factor 1	Mus musculus	15-17
20697841-5	2011	When treated with DEX plus RU486, a glucocorticoid receptor blocker, the apoptosis and BIM expression of CEM-C7 cells were canceled.	Dextromethorphan	18-21	BCL2 like 11	Homo sapiens	87-90
21911248-6	2011	Further, IL-18BPa/Fc enhanced dexamethason(DEX) reduction of PHA-induced IFN-gamma production by an additional 38.9%(DEX 20 nmol/l) and 49.9%(DEX 50 nmol/l) in ITP patients.	Dextromethorphan	117-120	interleukin 18 binding protein	Homo sapiens	9-17
22001938-5	2011	Enzyme activities were examined using high performance liquid chromatography (HPLC) assays with probe substrates dextromethorphan and testosterone for CYP2D6 and CYP3A4, respectively.	Dextromethorphan	113-129	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	151-157
22001938-5	2011	Enzyme activities were examined using high performance liquid chromatography (HPLC) assays with probe substrates dextromethorphan and testosterone for CYP2D6 and CYP3A4, respectively.	Dextromethorphan	113-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	162-168
21911248-6	2011	Further, IL-18BPa/Fc enhanced dexamethason(DEX) reduction of PHA-induced IFN-gamma production by an additional 38.9%(DEX 20 nmol/l) and 49.9%(DEX 50 nmol/l) in ITP patients.	Dextromethorphan	43-46	interleukin 18 binding protein	Homo sapiens	9-17
21849623-11	2011	CYP2D and CYP3A4 contents were significantly correlated with typical reactions of human CYP2D (bufuralol 1"-hydroxylation and dextromethorphan O-deethylation) and CYP3A (midazolam 1"-hydroxylation and 4-hydroxylation).	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-5
21911248-6	2011	Further, IL-18BPa/Fc enhanced dexamethason(DEX) reduction of PHA-induced IFN-gamma production by an additional 38.9%(DEX 20 nmol/l) and 49.9%(DEX 50 nmol/l) in ITP patients.	Dextromethorphan	43-46	interferon gamma	Homo sapiens	73-82
21911248-6	2011	Further, IL-18BPa/Fc enhanced dexamethason(DEX) reduction of PHA-induced IFN-gamma production by an additional 38.9%(DEX 20 nmol/l) and 49.9%(DEX 50 nmol/l) in ITP patients.	Dextromethorphan	117-120	interleukin 18 binding protein	Homo sapiens	9-17
21849623-11	2011	CYP2D and CYP3A4 contents were significantly correlated with typical reactions of human CYP2D (bufuralol 1"-hydroxylation and dextromethorphan O-deethylation) and CYP3A (midazolam 1"-hydroxylation and 4-hydroxylation).	Dextromethorphan	126-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
21849623-11	2011	CYP2D and CYP3A4 contents were significantly correlated with typical reactions of human CYP2D (bufuralol 1"-hydroxylation and dextromethorphan O-deethylation) and CYP3A (midazolam 1"-hydroxylation and 4-hydroxylation).	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-93
21849623-11	2011	CYP2D and CYP3A4 contents were significantly correlated with typical reactions of human CYP2D (bufuralol 1"-hydroxylation and dextromethorphan O-deethylation) and CYP3A (midazolam 1"-hydroxylation and 4-hydroxylation).	Dextromethorphan	126-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-15
21704706-0	2011	Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord.	Dextromethorphan	9-25	cytochrome b-245 beta chain	Homo sapiens	102-106
21704706-5	2011	Interestingly, a minor late attenuation by low dose DM treatment was seen in severe EAE that was characterized by a chronic disease course and a massive spinal cord infiltration of CD45(+) cells including T-lymphocytes, macrophages and neutrophils.	Dextromethorphan	52-54	protein tyrosine phosphatase receptor type C	Homo sapiens	181-185
21320758-0	2011	Low doses of dextromethorphan attenuate morphine-induced rewarding via the sigma-1 receptor at ventral tegmental area in rats.	Dextromethorphan	13-29	sigma non-opioid intracellular receptor 1	Rattus norvegicus	75-91
21910912-14	2011	Dex-IC50 increased 10-fold when the dose response effect of DEX was evaluated with glucose in ARH &amp;&amp; and MC/Car cells CONCLUSIONS: Our study shows for the first time that glucose or DEX regulates important components of ROS production through TXNIP modulation or direct interference with TRX activity in MM cells.	Dextromethorphan	0-3	low density lipoprotein receptor adaptor protein 1	Homo sapiens	94-97
21910912-14	2011	Dex-IC50 increased 10-fold when the dose response effect of DEX was evaluated with glucose in ARH &amp;&amp; and MC/Car cells CONCLUSIONS: Our study shows for the first time that glucose or DEX regulates important components of ROS production through TXNIP modulation or direct interference with TRX activity in MM cells.	Dextromethorphan	0-3	thioredoxin interacting protein	Homo sapiens	251-256
21910912-14	2011	Dex-IC50 increased 10-fold when the dose response effect of DEX was evaluated with glucose in ARH &amp;&amp; and MC/Car cells CONCLUSIONS: Our study shows for the first time that glucose or DEX regulates important components of ROS production through TXNIP modulation or direct interference with TRX activity in MM cells.	Dextromethorphan	0-3	thioredoxin	Homo sapiens	296-299
21320758-10	2011	Our findings suggest that the activation of the sigma-1 receptor at the VTA may be involved in the mechanism of low doses of DM in inhibiting the morphine rewarding effect and the possibility of using extremely low doses of DM in treatment of opioid addiction in clinics.	Dextromethorphan	125-127	sigma non-opioid intracellular receptor 1	Rattus norvegicus	48-64
21320758-10	2011	Our findings suggest that the activation of the sigma-1 receptor at the VTA may be involved in the mechanism of low doses of DM in inhibiting the morphine rewarding effect and the possibility of using extremely low doses of DM in treatment of opioid addiction in clinics.	Dextromethorphan	224-226	sigma non-opioid intracellular receptor 1	Rattus norvegicus	48-64
21463644-9	2011	Although co-treatment with Dex (10(-7)M) reduced the TSA effect on mRNA levels, it failed to reduce promoter activity; however co-transfection of HDAC1 but not 3 restored Dex inhibition.	Dextromethorphan	171-174	histone deacetylase 1	Homo sapiens	146-151
21029370-10	2011	Obestatin treatment in combination with IBMX and DEX showed to regulate the expression of C/EBPalpha, C/EBPbeta, C/EBPdelta and PPARgamma promoting adipogenesis.	Dextromethorphan	49-52	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	90-100
21029370-10	2011	Obestatin treatment in combination with IBMX and DEX showed to regulate the expression of C/EBPalpha, C/EBPbeta, C/EBPdelta and PPARgamma promoting adipogenesis.	Dextromethorphan	49-52	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	102-111
21029370-10	2011	Obestatin treatment in combination with IBMX and DEX showed to regulate the expression of C/EBPalpha, C/EBPbeta, C/EBPdelta and PPARgamma promoting adipogenesis.	Dextromethorphan	49-52	CCAAT/enhancer binding protein (C/EBP), delta	Mus musculus	113-123
21029370-10	2011	Obestatin treatment in combination with IBMX and DEX showed to regulate the expression of C/EBPalpha, C/EBPbeta, C/EBPdelta and PPARgamma promoting adipogenesis.	Dextromethorphan	49-52	peroxisome proliferator activated receptor gamma	Mus musculus	128-137
21724913-8	2011	Dex selectively upregulated Kir4.1 (not AQP4) in healthy and inflamed retinas, whereas TA induced AQP4 (not Kir4.1) downregulation in normal retina and upregulation in EIU.	Dextromethorphan	0-3	potassium inwardly-rectifying channel, subfamily J, member 10	Rattus norvegicus	28-34
21463644-11	2011	Dex led to increased HDAC1 but not HDAC3 occupancy.	Dextromethorphan	0-3	histone deacetylase 1	Homo sapiens	21-26
21803659-6	2011	CYP2D6 phenotype was determined by analysis of the urinary concentrations of the probe drug dextromethorphan and its primary metabolite dextrorphan after ingestion of 30 mg of dextromethorphan.	Dextromethorphan	92-108	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
21768449-4	2011	In this pharmacokinetic study, we investigated the value of dextromethorphan, a known probe drug for both CYP2D6 and CYP3A enzymatic activity, as a potential phenotyping probe for tamoxifen pharmacokinetics.	Dextromethorphan	60-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	106-112
21768449-4	2011	In this pharmacokinetic study, we investigated the value of dextromethorphan, a known probe drug for both CYP2D6 and CYP3A enzymatic activity, as a potential phenotyping probe for tamoxifen pharmacokinetics.	Dextromethorphan	60-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-122
21768449-10	2011	In a single patient using the potent CYP2D6 inhibitor paroxetine, the low endoxifen concentration was accurately predicted by dextromethorphan exposure.	Dextromethorphan	126-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	37-43
21803659-6	2011	CYP2D6 phenotype was determined by analysis of the urinary concentrations of the probe drug dextromethorphan and its primary metabolite dextrorphan after ingestion of 30 mg of dextromethorphan.	Dextromethorphan	176-192	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
21391981-8	2011	KEY RESULTS: Dex-liposomes attenuated granulocyte infiltration and IL-6 mRNA expression after LV(T) -ventilation, but not after HV(T) -ventilation.	Dextromethorphan	13-16	interleukin 6	Mus musculus	67-71
21867481-4	2011	For each experiment, we generate IC(50) values for up to 344 compounds and positive controls for five major CYP isoforms (probe substrate): CYP1A2 (phenacetin), CYP2C9 ((S)-warfarin), CYP2C19 ((S)-mephenytoin), CYP2D6 (dextromethorphan), and CYP3A4/5 (testosterone and midazolam).	Dextromethorphan	219-235	peptidylprolyl isomerase G	Homo sapiens	108-111
22007516-3	2011	A HPLC-MS method was applied to determine the metabolites formation of six CYP450s probe substrates (phenacetin-CYP1A2, dextromethorphan-CYP2D2, diclofenac sodium-CYP2C6, mephenytoin-CYP2C11, chlorzoxazone-CYP2E1 and midazolam-CYP3A1/2) in rat liver microsomal incubations.	Dextromethorphan	120-136	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	137-143
21391981-9	2011	Dex-liposomes also down-regulated mRNA expression of IL-1beta and KC, but not of CCL2 (MCP-1) in lungs of LV(T) and HV(T) -ventilated mice.	Dextromethorphan	0-3	interleukin 1 beta	Mus musculus	53-61
21476614-4	2011	Dextromethorphan/quinidine 20 mg/10 mg twice daily was associated with a significantly greater decrease in the rate of pseudobulbar affect episodes per day (primary endpoint) than placebo in the 12-week, randomized, double-blind, placebo-controlled, multicentre STAR trial (Safety, Tolerability, And efficacy Results trial of AVP-923 in PBA [pseudobulbar affect]) involving patients with pseudobulbar affect and ALS or multiple sclerosis.	Dextromethorphan	0-16	steroidogenic acute regulatory protein	Homo sapiens	262-266
21365364-2	2011	In vitro probe-based high performance liquid chromatography assays were developed to determine CYP2C9-dependent tolbutamide methylhydroxylation, CYP2D6-dependent dextromethorphan O-demethylation and CYP3A4-dependent testosterone 6beta-hydroxylation activities in the presence and absence of AP extracts and andrographolide.	Dextromethorphan	162-178	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	145-151
21447389-4	2011	This was done by using human substrates of CYP3A4 (verapamil and testosterone), CYP2C9 (diclofenac) and CYP2D6 (dextromethorphan).	Dextromethorphan	112-128	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	104-110
21476614-7	2011	The drug has been shown to cause dosage-dependent corrected QT interval (QTc) prolongation; however, in the STAR trial, dextromethorphan/quinidine 20 mg/10 mg twice daily appeared to be well tolerated with regard to QTc prolongation.	Dextromethorphan	120-136	steroidogenic acute regulatory protein	Homo sapiens	108-112
21294661-5	2011	DEX treatment significantly (P &lt; 0.05) increased plasma level of insulin in either the fed or fasting state, whereas plasma glucose level was only increased in the fed state.	Dextromethorphan	0-3	insulin	Gallus gallus	68-75
21456632-3	2011	This study assessed the inhibition and recovery half-life of CYP2D6 and CYP3A4 activity in female subjects by administering the probe drug dextromethorphan before and repeatedly after MDMA administration.	Dextromethorphan	139-155	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
21456632-3	2011	This study assessed the inhibition and recovery half-life of CYP2D6 and CYP3A4 activity in female subjects by administering the probe drug dextromethorphan before and repeatedly after MDMA administration.	Dextromethorphan	139-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
21294661-6	2011	In fasted chickens, DEX treatment significantly (P &lt; 0.01) upregulated the hepatic mRNA levels of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS).	Dextromethorphan	20-23	fatty acid synthase	Gallus gallus	134-153
21294661-6	2011	In fasted chickens, DEX treatment significantly (P &lt; 0.01) upregulated the hepatic mRNA levels of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS).	Dextromethorphan	20-23	fatty acid synthase	Gallus gallus	155-158
21294661-8	2011	In cultured primary hepatocytes, combined DEX and insulin significantly upregulated the transcription of the genes for FAS (1.34-fold) and malic enzyme (1.72-fold).	Dextromethorphan	42-45	fatty acid synthase	Gallus gallus	119-122
21294661-9	2011	By contrast, the expression of sterol response element-binding protein-1 (SREBP-1) was significantly upregulated by insulin (1.67-fold) regardless of DEX.	Dextromethorphan	150-153	sterol regulatory element binding transcription factor 1	Gallus gallus	31-72
21294661-9	2011	By contrast, the expression of sterol response element-binding protein-1 (SREBP-1) was significantly upregulated by insulin (1.67-fold) regardless of DEX.	Dextromethorphan	150-153	sterol regulatory element binding transcription factor 1	Gallus gallus	74-81
24024018-3	2011	The aim of this study was to identify the CYP2D6 oxidation phenotype with dextromethorphan (DEX) as a probe drug in Mazandarani ethnic group among Iranian population.	Dextromethorphan	74-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
21444768-0	2011	Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450.	Dextromethorphan	85-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130
24024018-3	2011	The aim of this study was to identify the CYP2D6 oxidation phenotype with dextromethorphan (DEX) as a probe drug in Mazandarani ethnic group among Iranian population.	Dextromethorphan	92-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
21225543-9	2011	The alterations observed in DEX-3 rats were more pronounced in DEX-5 rats, which also exhibited a higher content of islet Cdk4 and Cd2 proteins, compared to the CTL group (p&lt;0.05).	Dextromethorphan	28-31	cyclin-dependent kinase 4	Rattus norvegicus	122-126
21225543-9	2011	The alterations observed in DEX-3 rats were more pronounced in DEX-5 rats, which also exhibited a higher content of islet Cdk4 and Cd2 proteins, compared to the CTL group (p&lt;0.05).	Dextromethorphan	28-31	Cd2 molecule	Rattus norvegicus	131-134